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ABSTRACT	  
COPD	  is	  a	  severe	  chronic	  and	  complex	  airway	  disease	  that	  represents	  a	  major	  financial	  burden	  
on	   the	  healthcare	  and	  economic	   system.	  Environmental	   risk	   factors	   such	  as	   cigarette	   smoke	  
have	  been	  associated	  with	  the	  predisposition	  to	  COPD.	  Other	  factors	  such	  as	  exposure	  to	  viral	  
pathogens	  can	  exacerbate	  airway	  inflammation	  and	  tissue	  destruction	  generated	  by	  recruited	  
neutrophils,	   culminating	   in	  altered	  epithelial	   cell	   responses	   in	  COPD.	  This	   thesis	   investigated	  
the	  physiological	  role	  of	  Pellino-­‐1,	  an	  E3-­‐ubiquitin	  ligase,	  and	  its	  regulation	  in	  human	  primary	  
bronchial	  epithelial	  cells	  (HBEpCs)	  in	  response	  to	  viral	  infection. 
The	   viral	   mimic	   poly(I:C)	   increased	   Pellino-­‐1	   protein	   and	   gene	   expression	   in	   HBEpCs.	   In	  
addition,	  Pellino-­‐1	  gene	  expression	  was	  significantly	  increased	  by	  RV-­‐16	  and	  RV-­‐1B	  infection	  in	  
primary	  bronchial	  epithelial	  cells	  from	  COPD	  patients.	  Pellino-­‐1	  knockdown	  in	  HBEpCs	  led	  to	  a	  
reduction	   in	   NF-­‐κB	   regulated	   cytokines	   CXCL8,	   IL-­‐1α	   and	   β	   gene	   expression	   and	   release	   of	  
CXCL8	  in	  response	  to	  poly(I:C)	  while	  having	  no	  measurable	  effect	  on	  IFNβ	  mRNA	  expression.	  	  
Furthermore,	   the	   transient	   knockdown	   of	   Pellino-­‐1	   resulted	   in	   the	   decrease	   in	   IKKα/β	  
phosphorylation.	   The	   role	   for	   Pellino-­‐1	   in	   the	   non-­‐canonical	   NF-­‐κB	   pathway	   was	   also	  
investigated	  and	  while	  Pellino-­‐1	  knockdown	  did	  not	  alter	  the	  expression	  of	  the	  non-­‐canonical	  
NF-­‐κB	  precursor	  protein	  NFKB1	  following	  poly(I:C)	  stimulation,	  NFKB2	  protein	  expression	  was	  
suppressed.	  In	  contrast	  to	  Pellino-­‐1	  knockdown,	  the	  transient	  knockdown	  of	  NFKB2	  resulted	  in	  
significant	  increase	  in	  CXCL8	  mRNA	  and	  protein	  expression	  and	  in	  turn	  did	  not	  regulate	  Pellino-­‐
1	   mRNA	   expression	   to	   poly(I:C).	   These	   data	   suggest	   that	   following	   viral	   infection	   in	   airway	  
epithelial	   cells,	   TLR3	   activation	   culminates	   in	   the	   up-­‐regulation	   of	   Pellino-­‐1	   leading	   to	   an	  
increase	  in	  NFKB2	  expression,	  resulting	  in	  the	  suppression	  of	  NF-­‐κB	  specific	  gene	  transcription.	  	  
In	  addition	  to	  activating	  non-­‐canonical	  NF-­‐κB,	  NFKB1	  regulates	  the	  activation	  of	  ERK	  signalling	  
via	   MEK1.	   Treatment	   of	   HBEpCs	   with	   MEK1	   inhibitors,	   PD98059	   and	   U0126,	   resulted	   in	   a	  
significant	   reduction	   in	  Pellino-­‐1	  protein	  and	  gene	  expression	  which	   led	   to	   the	  suggestion	  of	  
ERK	  as	  a	  potential	  Pellino-­‐1	  regulator.	  
Proteomics	   analysis	   of	   primary	   epithelial	   cells	   obtained	   from	   COPD	   patient	   airways	   further	  
identified	  a	  potential	  novel	  mechanism	  of	  action	  for	  Pellino-­‐1	  in	  the	  NF-­‐κB	  signalling	  pathway,	  
wherein	  it	  Pellino-­‐1	  may	  inhibit	  A20’s	  negative	  regulatory	  role	  or	  its	  adaptor	  proteins	  TNIP1	  or	  
TAX1BP.	   Taken	   in	   combination	   these	   data	   support	   Pellino-­‐1	   as	   a	   potential	   target	   to	   down-­‐
regulate	  neutrophilic	  inflammation	  whilst	  retaining	  antiviral	  immunity	  by	  selectively	  mediating	  
the	   TLR3	   TRIF-­‐dependent	   NF-­‐κB/MAPK	   pathway	   and	   not	   TLR3-­‐mediated	   IRF3	   and	   IFNβ	  
activation.	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  pulmonary	  disease	  
CSE	  	   Cigarette	  smoke	  extract	  
CXCL8	   Interleukin	  8	  
DAMP	  	   Damage	  associated	  molecular	  pattern	  
DCs	  	   Dendritic	  cells	  
DD	  	   Death	  domain	  
DMEM	  	   Dulbecco's	  modified	  eagle	  medium	  
DNA	  	   Deoxyribonucleic	  acid	  
dsRNA	  	   Double-­‐stranded	  RNA	  
ECL	  	   Enhanced	  chemiluminescence	  
ECM	  	   Extracellular	  matrix	  
ELISA	  	   Enzyme-­‐linked	  immunosorbent	  assay	  
ER	  	   Endoplasmic	  reticulum	  
ERK	   Extracellular	  signal-­‐regulated	  kinases	  
FADD	  	   Fas-­‐associated	  death	  domain	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FAM	   6-­‐carboxyfluorescein	  
FCS	   Foetal	  calf	  serum	  
FHA	  	   Forkhead-­‐associated	  domain	  
GFP	  	   Green	  fluorescent	  protein	  
GOLD	  	   Global	  initiative	  for	  obstructive	  lung	  disease	  
GRR	   Glycine-­‐rich	  region	  
HBECs	  	   Human	  bronchial	  epithelial	  cells	  
HBEpC	   Human	  bronchial	  epithelial	  primary	  cell	  
HBSS	  	   Hank’s	  buffered	  salt	  solution	  
HEK293	  	   Human	  embryonic	  kidney	  293	  cells	  
HeLa	  	   Human	  cervical	  epithelial	  cell	  line	  
HEPES	  	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  
HMGB1	  	   High-­‐mobility	  group	  box	  1	  
HRP	  	   Horseradish	  peroxidase	  
HSV	  	   Herpes	  simplex	  virus	  
ICAM-­‐1	   Intercellular	  adhesion	  molecule	  1	  
ICS	  	   Inhaled	  corticosteroid	  
IFN	   Interferon	  
Ig	  	   Immunoglobulin	  
IKK	   Iκb	  kinase	  
IL-­‐1	   Interleukin	  1	  
IL-­‐1R	  	   Interleukin	  1	  receptor	  
IL-­‐1RA	   Il-­‐1	  receptor	  antagonist	  
IL-­‐1RAcP	  	   Il-­‐1	  receptor	  accessory	  protein	  
IL-­‐6	   Interleukin	  6	  
IP-­‐10	  	   Interferon	  gamma-­‐induced	  protein	  10	  
IRAK	  	   IL-­‐1R	  associated	  kinase	  
IRF	  	   Interferon	  regulatory	  factor	  
ISG	   Interferon-­‐stimulated	  gene	  
ISGF3	  	   IFN-­‐stimulated	  gene	  factor	  3	  
IκB	  	   Inhibitory	  κB	  
JAK	   Janus	  kinase	  
JNK	  	   C-­‐jun	  n-­‐terminal	  kinases	  
Kd	   Dissociation	  constant	  
KD	   Kinase	  domain	  
LDLR	  	   Low-­‐density	  lipoprotein	  receptor	  
LPS	   Lipopolysaccharide	  
LRR	  	   Leucine-­‐rich	  repeat	  
LTβR	   Lymphotoxin-­‐b	  receptor	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MAPK	   Mitogen	  activated	  protein	  kinase	  
MAVS	  	   Mitochondrial	  antiviral	  signaling	  protein	  
MCP-­‐1	   Monocyte	  chemoattractant	  protein	  1	  
MDA5	   Melanoma	  differentiation-­‐associated	  gene	  5	  
MEFs	   Mouse	  embryonic	  fibroblasts	  
MMP	  	   Matrix	  metalloproteinase	  
MOI	  	   Multiplicity	  of	  infection	  
MyD88	  	   Myeloid	  differentiation	  factor	  88	  
NE	  	   Neutrophil	  elastase	  
NEMO	  	   NF-­‐κB-­‐essential	  modulator	  
NF-­‐κB	  	   Nuclear	  factor	  kappa	  B	  
NIK	  	   NF-­‐κb-­‐inducing	  kinase	  
NLR	   Nod-­‐like	  receptor	  
NLS	  	   Nuclear	  location	  sequence	  
NOD	   Nucleotide-­‐binding	  oligomerization	  domain	  
OD	  	   Optical	  density	  
p.i.	  	   Post-­‐infection	  
PAMP	  	   Pathogen	  associated	  molecular	  pattern	  
PBMCs	  	   Peripheral	  blood	  mononuclear	  cells	  
PCR	  	   Polymerase	  chain	  reaction	  
PE	  	   Phosphatidylethanolamine	  
PMSF	  	   Phenylmethanesulfonylfluoride	  
Poly(I:C)	  	   Polyinosinic:polycytidylic	  acid	  
PPP	  	   Platelet	  poor	  plasma	  
PRR	  	   Pattern	  recognition	  receptor	  
qPCR	  	   Quantitative	  PCR	  
RANK	   Receptor	  activator	  for	  NF-­‐κB	  	  
RANTES	  	   Regulated	  upon	  activation	  in	  normal	  t-­‐cells,	  expressed	  and	  secreted	  
RHD	  	   Rel	  homology	  domain	  
RIG-­‐I	  	   Retinoic	  acid-­‐inducible	  gene-­‐I	  
RING	  	   Really	  interesting	  new	  gene	  
RIP1	  	   Receptor-­‐interacting	  protein	  1	  
RLR	  	   Rig-­‐I-­‐like	  receptor	  
RNA	  	   Ribonucleic	  acid	  
ROS	  	   Reactive	  oxygen	  species	  
rpm	  	   Repetitions	  per	  minute	  
RSV	  	   Respiratory	  syncytial	  virus	  
RT-­‐PCR	  	   Reverse	  transcription	  polymerase	  chain	  reaction	  
RV	  	   Rhinovirus	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SAPK	  	   Stress-­‐activated	  protein	  kinase	  
SDS-­‐PAGE	  	   Sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  
Ser	  	   Serine	  
SeV	  	   Sendai	  virus	  
shRNA	  	   Short	  hairpin	  RNA	  
siRNA	  	   Small	  interfering	  RNA	  
ssRNA	  	   Single-­‐stranded	  RNA	  
STAT	  	   Signal	  transducer	  and	  activator	  of	  transcription	  
TAB	  	   TAK1	  binding	  protein	  
TAD	  	   Transactivating	  domain	  
TAK1	   TGF-­‐β-­‐activated	  kinase	  1	  
TAMRA	  	   Tetramethylrhodamine	  
TANK	   TRAF-­‐family	  member	  associated	  NF-­‐κB	  activator	  	  
TBK1	  	   TANK	  binding	  kinase	  1	  
TEMED	  	   Tetramethylethylenediamine	  
TGF-­‐β	  	   Transforming	  growth	  factor-­‐beta	  
TIR	  	   TLR/IL-­‐1R	  
TLR	   Toll-­‐like	  receptor	  
TNF	  	   Tumour	  necrosis	  factor	  
TNFAIP3	   Tumor	  necrosis	  factor,	  alpha-­‐induced	  protein	  3	  	  
TRADD	  	   TNF	  receptor-­‐associated	  death	  domain	  
TRAF	  	   TNF	  receptor-­‐associated	  factor	  
TRIF	  	   TIR-­‐domain-­‐containing	  adaptor	  protein	  inducing	  ifn-­‐β	  
TWEAK	  	   TNF-­‐like	  weak	  inducer	  of	  apoptosis	  
UTR	  	   Untranslated	  region	  
UV	  	   Ultraviolet	  light	  
w/v	  	   Weight/volume	  ratio	  
WHO	  	   World	  health	  organisation	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CHAPTER	  1	  -­‐	  INTRODUCTION	  
1.1	  Chronic	  Obstructive	  Pulmonary	  Disease	  (COPD)	  
	  
COPD	   is	  a	  complex	  airway	   inflammatory	  disease	  that	   involves	  a	  multitude	  of	  cell	   types,	  both	  
inflammatory	   and	   structural,	   in	   its	   pathophysiology.	   The	   disease	   is	   characterized	   by	   the	  
obstruction	  of	  airflow	  that	  is	  not	  fully	  reversible	  (Pauwels	  et	  al.,	  2001).	  COPD	  mainly	  consists	  of	  
two	  conditions	  of	  the	  lung,	  chronic	  obstructive	  bronchitis	  and	  emphysema.	  Whilst	  obstructive	  
bronchitis	  causes	  fibrosis	  due	  to	  inflammation	  of	  the	  bronchioles,	  leading	  to	  an	  impediment	  of	  
small	  airways,	  emphysema	  on	   the	  other	  hand,	   triggers	   the	  enlargement	  of	  airspaces	  causing	  
the	   loss	   of	   lung	   elasticity	   ultimately	   resulting	   in	   the	   closure	   of	   small	   airways	   (Barnes,	   2004,	  
2008b).	  
	  
The	  World	   Health	   Organisation	   (WHO)	   estimated	   that	   COPD	  would	   become	   the	   third	  most	  
common	  cause	  of	  death	  and	  fifth	  most	  common	  cause	  of	  disability	  worldwide	  by	  2020	  (Lopez	  
and	  Murray,	  1998).	  WHO	  has	  since	  predicted	  that	  COPD	  will	  rise	  from	  its	  current	  fifth	  place	  in	  
the	  table	  of	  most	  common	  causes	  of	  death,	  to	  the	  fourth	  by	  2030	  (Mathers	  and	  Loncar,	  2006).	  
This	  highlights	  the	  importance	  of	  further	  elucidation	  of	  the	  underlying	  cellular	  and	  molecular	  
mechanisms	  involved	  in	  the	  pathogenesis	  of	  this	  complex	  disease.	  
	  
1.2	  Cells	  involved	  in	  COPD	  
	  
There	   are	   many	   cell	   types	   involved	   in	   this	   complex	   inflammatory	   disease.	   These	   vary	   from	  
structural	   cells	   such	   as	   epithelial	   and	   endothelial	   cells	   to	   the	   abnormally	   high	   numbers	   of	  
infiltrating	  inflammatory	  cells	  including	  monocytes,	  macrophages	  and	  neutrophils.	  	  
	  
Human	   airways	   are	   constantly	   bombarded	   with	   foreign	   and	   invading	   pathogens	   viruses,	  
bacteria	   and	   environmental	   toxins	   such	   as	   cigarette	   smoke.	   The	   respiratory	   mucociliary	  
epithelium	   provides	   a	   physical	   barrier,	   in	   the	   form	   of	   mucus,	   wherein	   beating	   cilia	   propel	  
mucus-­‐trapped	  debris	  away	  from	  the	  respiratory	  system	  (Braiman	  and	  Priel,	  2008).	  Epithelial	  
lining	   fluid	   surrounding	   airway	   epithelial	   cells	   also	   contain	   a	   multitude	   of	   glycoproteins,	  
proteins	   and	   molecules	   such	   as	   lysozymes,	   lactoferrins	   and	   defensins	   responsible	   for	   the	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effective	   neutralising	   of	   microbial	   contaminants	   (Diamond	   et	   al.,	   2000).	   	   In	   the	   airways	   of	  
patients	   with	   COPD,	   epithelial	   cells	   show	   a	   hyper-­‐proliferative	   phenotype	   resulting	   in	  
squamous	   metaplasia	   (Demoly	   et	   al.,	   1994).	   The	   underlying	   processes	   and	   growth	   factors	  
involved	   in	   these	   changes	   remain	   unclear.	   For	   instance	   expression	   of	   the	   receptor	   for	  
advanced	   glycation	   end	   products	   (RAGE)	   and	   its	   binding	   partner	   high-­‐mobility	   group	   box	   1	  
(HMGB1),	  a	  nuclear	  protein	  that	  is	  released	  during	  inflammation	  and	  repair	  and	  interacts	  with	  
pro-­‐inflammatory	  cytokines	  are	  increased	  in	  airway	  epithelium	  of	  patients	  with	  COPD	  (Ferhani	  
et	  al.,	  2010).	  However,	  when	  these	  structural	  cells	  encounter	  certain	  inflammatory	  stimuli	  this	  
can	  lead	  to	  the	  expression	  of	  adhesion	  molecules	  on	  endothelial	  cells,	  the	  release	  of	  reactive	  
oxygen	   species,	   proteolytic	   enzymes	   and	   the	   synthesis	   of	   a	   variety	   of	   cytokines	   and	  
chemokines	   including	   IL-­‐6,	   TNFα,	   IL-­‐1β	   and	   the	   neutrophil	   chemoattractant	   IL-­‐8/CXCL8	  
resulting	   in	   the	  recruitment	  and	  activation	  of	   inflammatory	  cells	  as	  seen	   in	   the	  disease	  state	  
(Brusselle	  et	  al.,	  2011;	  Cromwell	  et	  al.,	  1992).	  	  
	  
Neutrophils	  are	  the	  most	  abundant	  granulocyte	  in	  the	  human	  circulation	  (Bainton	  et	  al.,	  1971).	  
These	  short-­‐lived	  polymorphonuclear	  cells	  are	  among	  the	  first	  recruited	  immune	  cells	  to	  a	  site	  
of	   injury	  or	   infection.	  Neutrophils	   limit	   infection	  by	  engulfing	  pathogens	   into	  the	  phagosome	  
wherein	  noxious	  agents	  such	  as	  reactive	  oxygen	  species	  and	  hydrolytic	  enzymes	  are	  released	  
through	   the	   activity	   of	   the	   NADPH	   oxidase,	   or	   respiratory	   burst	   	   (Leto	   and	   Geiszt,	   2006).	  
Intracellular	  granulocytes	  then	  release	  potent	  antimicrobial	  peptides	  and	  proteolytic	  enzymes	  
into	  the	  phagosome	  such	  as	  cathepsin	  G,	  defensins,	  protinase-­‐3	  and	  bactericidal	  permeability-­‐
increasing	   (BPI)	   protein	   resulting	   in	   the	   effective	   killing	   and	   digestion	   of	   microorganisms	  
(Borregaard	   et	   al.,	   2007).	   These	   cells	   also	   release	   matrix	   metalloproteinases	   (MMP)-­‐8	   and	  
MMP-­‐9	   as	   well	   as	   reactive	   oxygen	   species	   (ROS),	   which	   may	   contribute	   to	   alveolar	   wall	  
destruction	  (emphysema)	  seen	  in	  COPD	  pathogenesis	  (Barnes,	  2004;	  Nadel,	  2000).	  Neutrophils	  
also	  contribute	  to	  the	  recruitment	  of	  other	   immune	  cells	   through	  the	  release	  of	  chemokines	  
and	   ultimately	   assist	   in	   mounting	   an	   adaptive	   immune	   response	   (Parker	   et	   al.,	   2005).	  
Normally,	   neutrophils	   undergo	   spontaneous	   apoptotic	   cell	   death	   within	   a	   day	   of	   entering	  
circulation,	   however	   in	   the	   presence	   of	   infection	   or	   inflammation,	   their	   life	   span	   can	   be	  
prolonged	  by	  several	  days	  to	  aid	  in	  pathogen	  clearance	  through	  the	  actions	  of	  cytokines	  such	  
as	   granulocyte-­‐macrophage	   colony	   stimulating	   factor	   (GM-­‐CSF)	   and	   granulocyte	   colony	  
stimulating	   factor	   (G-­‐CSF)	   (Mantovani	   et	   al.,	   2011).	   Like	  many	   other	   types	   of	   inflammatory	  
cells,	  increased	  numbers	  of	  neutrophils	  are	  found	  in	  COPD	  patient	  airways	  and	  their	  numbers	  
in	  turn	  correlate	  with	  decreased	  lung	  function	  (Lacoste	  et	  al.,	  1993;	  Stanescu	  et	  al.,	  1996).	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In	  contrast	  to	  neutrophils,	  macrophages	  are	  long-­‐lived	  immune	  cells	  that	  can	  reside	  in	  tissues	  
providing	  homeostasis	   through	   the	   removal	  of	   circulating	  old	   red	  blood	  cells,	  necrotic	   tissue	  
and	  toxic	  agents	  (Gordon	  and	  Taylor,	  2005).	  Macrophages	  mature	  from	  circulating	  monocytes	  
produced	   in	   the	   bone	   marrow.	   In	   the	   airway,	   alveolar	   macrophages	   migrate	   into	   the	  
interstitium	   and	   alveoli	   and	   can	   also	   be	   found	   within	   the	   epithelial	   lining	   fluid	   serving	   as	  
sentinel	   cells	   for	   the	   immune	   response	   against	   inhaled	   pathogens	   and	   toxins.	   Alveolar	  
macrophages	  are	  one	  of	  the	  main	  types	  of	  inflammatory	  cells	  involved	  in	  COPD.	  	  They	  produce	  
a	  plethora	  of	  proteases	   including	  MMP-­‐2,	  MMP-­‐9,	  MMP-­‐12,	  cathepsins	  K,	  L	  and	  S	  associated	  
with	   the	   activation	   of	   inflammatory	  mediators	   and	   onset	   of	   emphysema	   (Di	   Stefano	   et	   al.,	  
1998;	   Tetley,	   2002).	   In	   addition,	   alveolar	   macrophages	   are	   involved	   in	   the	   increased	  
production	   of	   proinflammatory	   cytokines	   such	   as	   IL-­‐1β,	   IL-­‐6,	   IP-­‐10	   and	   TNFα.	  Macrophages	  
collected	   from	   COPD	   patient	   sputum	   show	   increased	   NF-­‐κB	   activation,	   which	   is	   further	  
enhanced	   during	   exacerbations	   (Caramori	   et	   al.,	   2003).	   Bronchoalveolar	   lavage	   (BAL)	   fluid,	  
sputum	   and	   lung	   parenchyma	   analysis	   of	   COPD	   patients	   showed	   a	   5-­‐	   to	   10-­‐fold	   increase	   in	  
numbers	  of	  macrophages	  in	  the	  airways	  when	  compared	  to	  healthy	  controls	  (Retamales	  et	  al.,	  
2001;	  Tetley,	  2002).	  The	  increase	  in	  numbers	  of	  sequestered	  macrophages	  suggests	  a	  pivotal	  
role	   for	   macrophages	   in	   disease	   progression.	   In	   support	   of	   this,	   a	   direct	   correlation	   exists	  
between	  macrophage	  numbers	  in	  alveolar	  walls	  and	  the	  severity	  of	  emphysema	  experience	  by	  
COPD	  patients	  (Ohnishi	  et	  al.,	  1998).	  	  	  
	  
This	  increase	  in	  macrophage	  numbers	  occurs	  following	  the	  recruitment	  of	  monocytes	  from	  the	  
circulation	   in	   response	   to	   the	  production	  of	  CCL2	   also	   known	  as	  monocyte	   chemoattractant	  
protein	  (MCP)-­‐1	  (de	  Boer	  et	  al.,	  2000).	  Human	  monocytes	  can	  be	  sub-­‐categorised	  on	  the	  basis	  
of	   their	   chemokine	   receptor	   expression	   and	   specific	   identifying	   surface	   molecules,	   namely	  
CD14	   and	   CD16	   expression	   (Geissmann	   et	   al.,	   2003;	   Ziegler-­‐Heitbrock,	   2007).	   Classical	   or	  
CD14++CD16–	  monocytes	   are	   the	  most	   prevalent	  monocyte	   subset	   in	   the	   human	   blood	   and	  
express	   high	   surface	   levels	   of	   CC-­‐chemokine	   receptor	   2	   (CCR2)	   but	   low	   levels	   of	   CX3C-­‐
chemokine	  receptor	  1	  (CX3CR1)	  (Ziegler-­‐Heitbrock	  et	  al.,	  2010).	  In	  contrast,	  CD16+	  monocytes	  
population	  can	  be	  further	  sub-­‐divided	  by	  the	  non-­‐classical	  or	  CD14+CD16++	  monocytes	  and	  the	  
intermediate	  or	  CD14++CD16+	  monocytes	  and	  consist	  of	  high	  surface	  levels	  of	  C	  X3CR1	  but	  low	  
levels	  of	  CCR2	  (Belge	  et	  al.,	  2002;	  Grage-­‐Griebenow	  et	  al.,	  2001;	  Ziegler-­‐Heitbrock	  et	  al.,	  2010).	  
In	   an	   inflammatory	   disease	   state	   the	   balance	   between	   recruited	   monocytes	   and	   resident	  
macrophages	   is	   shifted	   and	   results	   in	   monocytes	   outnumbering	   macrophages	   (Maus	   et	   al.,	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2006).	  Whilst	  monocytes	  are	  believed	  to	  be	  more	  pro-­‐inflammatory	  than	  macrophages	  in	  that	  
they	  produce	  higher	  levels	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IL-­‐1β,	  they	  however	  display	  
less	  phagocytic	  capabilities	  than	  resident	  macrophages	  (Netea	  et	  al.,	  2009).	  	  
Small	   airway	   biopsies	   from	   COPD	   patients	   present	   with	   a	   surge	   of	   leukocyte	   infiltration	  
consisting	  of	  monocytes	  and	  neutrophils.	  These	  changes	  coupled	  with	  fibrosis-­‐induced	  airway	  
remodelling	   cause	   the	   progressive	   and	   irreversible	   narrowing	   of	   the	   airway	   that	   are	   the	  
hallmarks	  of	  COPD	  (Hogg	  et	  al.,	  2004).	  
	  
Fibrosis	  of	  the	  small	  airways	  in	  COPD	  patients	  is	  often	  a	  result	  of	  uncontrolled	  proliferation	  of	  
fibroblasts.	   Fibroblasts	  are	   structural	   cells	   closely	  apposed	   to	   the	  epithelium	  or	  endothelium	  
with	   an	   essential	   role	   in	   tissue	   repair	   and	   injury	   responses	   through	   the	   production	   and	  
homeostasis	  of	  extracellular	  matrix	  (ECM)	  proteins	  (reviewed	  in	  (Araya	  and	  Nishimura,	  2010)).	  
Furthermore,	   fibroblasts	   contribute	   to	   tissue	  architecture	  and	  matrix	   turnover	   rates	   through	  
MMPs	   and	   their	   inhibitors,	   tissue	   inhibitor	   of	   metalloprotinases	   (TIMPs)	   generation.	   The	  
production	  of	  essential	  ECM	  such	  as	  fibronectin,	  decorin,	  perlecan	  and	  versican	  is	  disregulated	  
in	  COPD	  patients	  contributing	  to	  the	  fibrotic	  phenotype	  associated	  with	  the	  disease	  (Hallgren	  
et	   al.,	   2010;	   Noordhoek	   et	   al.,	   2005).	   Evidence	   also	   supports	   a	   role	   for	   fibroblasts	   in	  
inflammatory	   response	   through	   the	   secretion	   of	   several	   cytokines	   in	   addition	   to	   direct	  
interaction	  with	  inflammatory	  cells	  (reviewed	  in	  (Buckley	  et	  al.,	  2001)).	  
 
	  The	   complex	   communication	   between	   these	   structural	   and	   inflammatory	   cells	   result	   in	   the	  
release	   of	   lipid	   mediators,	   reactive	   oxygen	   species,	   peptide	   mediators,	   chemokines	   and	  
cytokines	  capable	  of	  ultimately	  destroying	  the	  lung	  tissue	  and	  leading	  to	  the	  pathogenesis	  of	  
the	   disease	   (Barnes,	   2004;	   Shapiro,	   1999).	   Research	   into	   the	   mechanisms	   behind	   this	  
communication	  will	  be	   invaluable	   in	  developing	  a	  better	  understanding	  of	  COPD	  and	   lead	  to	  




Cytokines	   are	   small	   non-­‐structural	   intercellular	   signalling	   proteins	   ranging	   from	   8-­‐30	   kDa	   in	  
mass.	  Cytokines	  have	  roles	  in	  most	  biological	  processes	  including	  immunity	  and	  inflammation	  
and	   can	   act	   across	   a	   spectrum	   of	   distances	   to	   include	   autocrine,	   paracrine	   and	   endocrine	  
	   20	  
ranges	   (Cannon,	   2000).	   The	   family	   of	   cytokines	   encompasses	   interleukins,	   chemokines,	  
interferons,	  mesenchymal	  growth	  factors,	   tumour	  necrosis	   factors	  and	  adipokines	   (Dinarello,	  
2007).	  	  
	  
Abnormalities	  in	  cytokine	  production,	  their	  receptors	  or	  their	  signalling	  pathways	  can	  result	  in	  
the	  evolution	  of	  a	  wide	  variety	  of	  diseases	  such	  as	  COPD	  and	  asthma.	  Cytokines	  play	  a	  key	  role	  
in	   orchestrating	   the	   chronic	   inflammation	   of	   COPD	   through	   the	   recruitment,	   activation,	   and	  
increased	  survival	  of	  multiple	  inflammatory	  cells	  in	  the	  respiratory	  tract	  with	  over	  50	  cytokines	  
identified	   in	   COPD	   (Barnes,	   2008a)	   (see	   section	   1.2.1).	   The	   cytokines	   that	   are	   frequently	  
referred	   to	   throughout	   this	   thesis,	   due	   to	   their	   predominant	   roles	   in	   inflammation	  and	   viral	  
infection,	  are	  individually	  described	  below.	  
	  
1.2.1.1	  Interleukin-­‐1	  (IL-­‐1)	  
	  
The	  IL-­‐1	  family	  is	  composed	  of	  11	  members	  including	  agonistic	  and	  antagonistic	  molecules	  and	  
receptors	   (Reviewed	   by	   (Dinarello,	   1996,	   2011)).	   This	   section	   focuses	   on	   the	   originally	  
identified	  agonistic	  members,	  IL-­‐1α	  and	  IL-­‐1β,	  and	  the	  physiological	  inhibitor	  of	  IL-­‐1	  termed	  IL-­‐
1	  receptor	  antagonist	  (IL-­‐1Ra).	  
	  
Multiple	  cell	  types	  produce	  and	  secrete	  IL-­‐1α,	  IL-­‐1β,	  and	  IL-­‐1Ra	  upon	  inflammatory	  activation,	  
IL-­‐1	   is	   also	   a	   classic	   NF-­‐κB	   target	   (see	   section	   1.6.1.1).	   IL-­‐1α	   and	   IL-­‐1β	   are	   synthesized	   as	  
precursors	  of	  31	  kDa	  followed	  by	  protease	  cleavage	  to	  their	  active	  17	  kDa	  forms.	  
	  
IL-­‐1α	   is	   a	   ubiquitously	   expressed	   intracellular	   protein	   rarely	   secreted	   by	   living	   cells	   with	   its	  
release	  often	  associated	  with	  necrotic	  death.	  Under	  normal	  cellular	  conditions,	  IL-­‐1α	  precursor	  
is	   sequestered	   in	   the	  cytoplasm	  by	   IL-­‐1	   receptor	   type	  2	   (IL-­‐1R2)	  preventing	   it	   from	  protease	  
cleavage	  and	  IL-­‐1	  receptor	  type	  1	  (IL-­‐R1)	  activation	  (Di	  Paolo	  and	  Shayakhmetov,	  2013;	  Zheng	  
et	   al.,	   2013).	   However,	   following	   inflammatory	   activation,	   IL-­‐1R2	   is	   cleaved	   by	   caspase-­‐1,	  
freeing	  IL-­‐1α	  precursor	  to	  be	  cleaved	  by	  calpain,	  a	  calcium-­‐dependent	  non-­‐lysosomal	  cysteine	  
protease,	  generating	   its	  17	  kDa	  mature	   form	  which	  can	  be	  secreted	   from	  cells	   (Zheng	  et	  al.,	  
2013).	  	  
	  
IL-­‐1β	   is	   released	   in	   response	   to	   injury	   or	   inflammatory	   signals.	   It	   is	   largely	   produced	   by	  
immune	  cells	  including	  monocytes,	  macrophages,	  dendritic	  cells,	  B	  cells	  and	  NK	  cells	  although	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epithelial	  and	  endothelial	  cells	  have	  also	  been	  implicated	  in	  IL-­‐1β	  production	  (Cannon,	  2000).	  
IL-­‐1β	   precursor	   is	   biologically	   inactive	   and	   requires	   cleavage	   by	   the	   cysteine	   protease	   IL-­‐1β-­‐
converting	   enzyme	   (caspase-­‐1)	   in	   the	   cytoplasm	   on	   the	   inflammasome	   platform	   (Dinarello,	  
2009).	  Alternatively,	  the	  IL-­‐1β	  precursor	  can	  also	  be	  cleaved	  at	  distinct	  sites	   into	   its	  secreted	  
biologically	   active	   form	   by	   neutrophil	   proteases	   including	   caspase-­‐8,	   cathepsin	   G	   (CG),	  
neutrophil	  elastase	  (NE),	  and	  proteinase	  3	  (PR3)	  as	  well	  as	  mast	  cell	  proteases	  granzyme	  and	  
chymase	  (Hazuda	  et	  al.,	  1990;	  Irmler	  et	  al.,	  1995;	  Maelfait	  et	  al.,	  2008;	  Mizutani	  et	  al.,	  1991).	  	  
	  
An	   extensive	   list	   of	   agonists	   are	   involved	   in	   IL-­‐1β	   secretion,	   including	   bacterial	   and	   viral	  
pathogens	  through	  TLR	  signalling.	  IL-­‐1	  also	  induces	  its	  own	  production	  in	  monocytes	  (Dinarello	  
et	  al.,	  1987).	  IL-­‐1β	  is	  also	  a	  potent	  pyrogen	  (Murakami	  et	  al.,	  1990)	  and	  is	  involved	  in	  recruiting	  
circulating	  leukocytes	  to	  inflamed	  tissue	  as	  well	  as	  stimulating	  neutrophilia.	  	  
	  
In	  order	  to	  transduce	  a	  signal	  both	  extracellular	  IL-­‐1α,	  active	  or	  precursor	  form,	  and	  mature	  IL-­‐
1β	   activate	   the	  membrane	  bound	  receptor	   IL-­‐1R1.	  This	   leads	   to	   recruitment	  of	   IL-­‐1	   receptor	  
accessory	   protein	   (IL-­‐1RAcP).	   The	   TIR	   domains	   formed	   from	   the	   heterodimerisation	   of	   the	  
receptor	  and	  accessory	  protein	   results	   in	  MyD88	   recruitment.	  This	   leads	   to	   the	  activation	  of	  
IRAKs,	  which	   leads	   to	   the	   subsequent	   interaction	  with	  TRAF6.	   Following	  a	   sequence	  of	   both	  
phosphorylation	  and	  ubiquitination	  events,	  NF-­‐κB	  and	   the	   JNK	  and	  p38	  MAPK	  pathways	  are	  
activated	  leading	  to	  the	  expression	  of	  IL-­‐1	  target	  genes	  such	  as	  IL-­‐6,	  TNFα,	  IL-­‐8/CXCL8,	  MCP-­‐1,	  
COX-­‐2,	   IκBα,	   IL-­‐1α	   and	   IL-­‐1β	   through	   transcriptional	   and	   post-­‐transcriptional	   mechanisms	  
(Dinarello,	  2009).	  
	  
IL-­‐1Ra	  is	  a	  receptor	  antagonist	  consisting	  of	  two	  structural	  variants,	  one	  a	  secretory	  molecule,	  
the	  other	  an	  intracellular	  molecule	  with	  three	  isoforms	  (icILIRa1,	  2	  and	  3)	  (Akdis	  et	  al.,	  2011;	  
Arend	   and	   Guthridge,	   2000).	   IL-­‐1Ra’s	   role	   is	   to	   counter	   the	   effects	   of	   IL-­‐1	   function	   and	  
neutralise	  the	  proinflammatory	  function	  of	  IL-­‐1β	  by	  competing	  for	  IL-­‐1R1	  cell	  surface	  receptors	  
and	  preventing	   their	   intracellular	   responses	  by	  preventing	   recruitment	  of	   IL-­‐1RAcP	   (Akdis	   et	  
al.,	   2011;	   Arend,	   1993).	   Following	   viral	   infection,	   AMs	   and	   PBMCs	   from	  patients	  with	   COPD	  
show	   release	   of	   IL-­‐1β	  while	   the	   release	   of	   IL-­‐1RA	  was	   diminished	   resulting	   in	   a	   significantly	  
higher	  IL-­‐1β/IL-­‐1RA	  ratio	  when	  compared	  to	  healthy	  controls	  (Rupp	  et	  al.,	  2003).	  
	  
1.2.1.2	  Interleukin-­‐8	  (IL-­‐8)	  or	  CXCL8	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IL-­‐8,	  also	  known	  as	  CXCL8,	  is	  a	  member	  of	  the	  CXC	  chemokine	  family.	  IL-­‐8/CXCL8	  is	  expressed	  
in	  response	  to	   inflammatory	  stimuli	  and	  is	  a	  classic	  NF-­‐κB/MAPK	  target	  (see	  section	  1.6.1.1).	  
High	   levels	   of	   IL-­‐8/CXCL8	   are	   often	   observed	   in	   association	   with	   chronic	   and	   acute	  
inflammatory	   conditions	   such	   as	   COPD	   and	   correlate	  with	   tissue	   neutrophil	   infiltration	   (see	  
section	  1.2).	  	  
	  
IL-­‐8/CXCL8	  is	  a	  potent	  neutrophil	  chemotactic	  factor	  and	  activator	  secreted	  by	  a	  number	  of	  cell	  
types	   including	  monocytes,	  macrophages,	   neutrophils,	   fibroblasts,	   endothelial	   and	   epithelial	  
cells.	   IL-­‐8/CXCL8	   cDNA	   is	   transcribed	   as	   a	   99-­‐amino	   acid	   precursor	   protein,	   which	   can	   be	  
cleaved	   to	   yield	   predominantly	   77-­‐	   or	   72-­‐amino	   acid	   mature	   proteins,	   which	   can	   undergo	  
further	  processing	  resulting	  in	  truncation	  analogues	  of	  different	  sizes	  (77-­‐,	  72-­‐,	  71-­‐,	  70-­‐	  and	  69-­‐	  
residue	  proteins)	   (Matsushima	  et	  al.,	  1988;	  Mukaida,	  2003).	  Fibroblasts	  and	  endothelial	  cells	  
predominantly	  produce	  the	  77-­‐amino	  acid	  variant	  of	  IL-­‐8/CXCL8	  whilst	  leukocytes	  release	  72-­‐	  
and	   69-­‐	   amino	   acid	   forms.	   While	   all	   forms	   of	   IL-­‐8/CXCL8	   have	   neutrophil	   chemoattractant	  
activities,	  77-­‐	  amino	  acid	  variant	  appears	  to	  be	  essential	  for	  neutrophil	  adhesion	  to	  endothelial	  
cells	  before	  transmigration	  (Huber	  et	  al.,	  1991;	  Mukaida,	  2003;	  Murphy	  and	  Tiffany,	  1991).	  
	  
The	   effects	   of	   IL-­‐8/CXCL8	   are	  mediated	   through	   the	   receptors	   CXCR1	   and	  CXCR2,	  which	   are	  
present	  on	  a	   variety	  of	   cell	   types	   including	  non-­‐haematopoeitic	   cells	   such	  as	   epithelial	   cells,	  
however	   they	   are	   predominantly	   present	   on	   myeloid	   lineage	   cells	   such	   as	   monocytes	   and	  
mature	  polymorphonuclear	  cells	  (Holmes	  et	  al.,	  1991;	  Stillie	  et	  al.,	  2009).	  IL-­‐8/CXCL8	  signalling	  
through	   CXCR1	   and	   CXCR2	   is	   responsible	   for	   neutrophil	   antimicrobial	   activity	   including	  
chemotaxis	  (predominantly	  through	  CXCR1),	  degranulation	  and	  oxidative	  burst	  (Hammond	  et	  
al.,	  1995;	  Stillie	  et	  al.,	  2009).	  
	  
1.2.1.3	  Interferon	  (IFN)	  
	  
IFNs	  are	  a	  group	  of	  secreted	  cytokines	  that	  act	  as	  antiviral	  agents	  extensively	  studied	  for	  their	  
crucial	   role	   in	   immunity.	   IFNs	  are	  multi-­‐functional	   cytokines	   that	  bridge	   innate	  and	  adaptive	  
immunity	  and	  play	  important	  roles	  in	  the	  host	  response	  to	  pathogens,	  immunomodulation	  and	  
haematopoietic	   development	   (Mamane	   et	   al.,	   1999).	   IFNs	   have	   been	   categorized	   into	   three	  
groups	   based	   on	   amino	   acid	   sequence	   and	   receptor	   recognition,	   known	   as	   Type	   I,	   II	   and	   III	  
(Reviewed	  by	  (Randall	  and	  Goodbourn,	  2008)).	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Type	  I	   IFNs	  comprise	  of	  a	   large	  group	  of	  genes	   including	   IFN-­‐α/β	  and	  other	   less	  well	  defined	  
members	  such	  as	   IFNω	  –ε	  –τ	  -­‐δ	  and	  –κ.	   IFNα,	  composed	  of	  13	  subfamily	  genes,	  and	  a	  single	  
IFNβ,	  all	  of	  which	  are	  located	  in	  one	  locus	  on	  the	  same	  chromosome	  and	  are	  induced	  directly	  
in	  response	  to	  viral	  infection	  (Taniguchi	  et	  al.,	  1980;	  van	  Boxel-­‐Dezaire	  et	  al.,	  2006;	  Weissmann	  
and	  Weber,	  1986).	  A	  mutation	  in	  the	  type	  I	  IFN	  receptor	  gene	  of	  mice	  results	  in	  elimination	  of	  
antiviral	  responses	  highlighting	  the	  essential	  role	  of	  IFNα	  and	  IFNβ	  in	  viral	  defence	  (Hwang	  et	  
al.,	   1995).	   pDCs	   are	   the	  main	   Type	   I	   IFNs	   producing	   cells,	   however	   they	   can	   be	   released	   by	  
most	   cells.	   IFNα	   and	   IFNβ	   can	   regulate	   their	   own	   production	   and	   have	   two	  main	   forms	   of	  
action,	   either	   by	   direct	   inhibition	   of	   viral	   replication	   by	   blocking	   viral	   entry	   into	   the	   cell,	  
cleavage	  of	  RNA,	  or	  prevention	  of	  viral	  translation,	  or	  indirectly	  through	  the	  initiation	  of	  innate	  
and	  adaptive	  immune	  responses	  (Jacobs	  and	  Langland,	  1996;	  Sen,	  2001).	  Virally	  infected	  host	  
cells	   lead	  to	  the	  induction	  of	  type	  I	   IFNs,	  which	  require	  the	  assembly	  of	  complexes	  known	  as	  
enhanceosomes,	  composed	  of	  transcription	  factors	  such	  as	  NF-­‐κB,	  AP-­‐1,	   IRF-­‐3	  and	   IRF-­‐7	  that	  
recruit	  transcriptional	  machinery	  to	  the	  IFNβ	  promoter	  region	  (Honda	  et	  al.,	  2006;	  Maniatis	  et	  
al.,	  1998).	  
 
Type	  II	   IFN	  has	  a	  single	  member	  known	  as	   IFN-­‐γ	  and	   is	  a	  TH1	  cytokine	   inducible	  by	  activated	  
immune	  cells	  such	  as	  T	  cells	  and	  natural	  killer	  (NK)	  cells,	  rather	  than	  in	  direct	  response	  to	  viral	  
infection	  and	  will	  therefore	  not	  be	  reviewed	  in	  this	  section	  (Schreiber	  and	  Farrar,	  1993).	  	  	  
	  
The	  most	  recently	  discovered	  of	  the	  IFNs	  are	  the	  type	  III	  IFNs	  or	  IFN-­‐λ.	  Their	  production	  occurs	  
in	  a	  wide	  range	  of	  cell	  types	  including	  epithelial,	   lymphoid	  and	  myeloid	  cells.	  There	  are	  three	  
isoforms	  of	   IFN-­‐λ,	   IFNλ1	  –λ2	  and	  –λ3	  and	  unlike	   type	   I	   IFNs,	   IFN-­‐λ	   displays	   an	   IFN-­‐inducible	  
nature,	  allowing	   ISGF3	  and	   IRF-­‐1	   to	   regulate	   its	   induction	   (Ank	  et	  al.,	   2006).	   In	  addition,	   IFN	  
type	  III	  family	  present	  with	  IRF	  and	  NF-­‐κB	  binding	  sites	  at	  their	  promoters.	  IFNλ1	  is	  regulated	  
similarly	  to	  IFNβ	  through	  virus	  activated	  IRF3	  and	  NF-­‐κB,	  whilst	  IFNλ2	  and	  IFNλ3	  are	  regulated	  
by	  IRF7	  and	  thus	  resemble	  IFNα	  (Onoguchi	  et	  al.,	  2007).	  
	  
The	   initiation	   of	   the	   transcription	   of	   IFN	   genes	   is	   in	   most	   part	   mediated	   by	   multiple	  
transcription	  factors	  known	  as	  interferon	  regulatory	  factors	  (IRFs)	  post	  TLR/RLR	  signalling	  (see	  
section	  1.4.1	  and	  1.4.2).	  This	  leads	  to	  first	  phase	  of	  IFN	  production	  that	  in	  turn	  activates	  Janus	  
kinase	   (JAK)-­‐	   signal	   transducer	   and	   activator	   of	   transcription	   (STAT)	   and	   MAPK	   signalling	  
pathway	  resulting	  in	  further	  IFN	  production	  (Darnell	  et	  al.,	  1994).	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1.2.1.4	  Regulated	  on	  activation,	  normal	  T	  cell	  expressed	  and	  secreted	  
(RANTES)	  or	  CCL5	  
	  
RANTES,	   also	   known	   as	   CCL5,	   is	   a	   7.8	   kDa	  member	   of	   the	   CC	   chemokine	   family	  with	   a	   pro-­‐
inflammatory	   role	   in	   chronic	   inflammation.	   RANTES/CCL5	   is	   an	   IFN	   inducible	   gene	   secreted	  
upon	   viral	   infection	   by	   cell	   types	   including	   endothelial	   cells,	   smooth	  muscle	   cells,	   epithelial	  
cells,	  macrophages	  and	  platelet-­‐activated	  T	  cells.	  	  RANTES/CCL5	  causes	  the	  selective	  adhesion	  
and	  transmigration	  of	  human	  blood	  monocytes,	  CD4+,	  and	  CD45R0+	  positive	  T	  lymphocytes	  in	  
endothelial-­‐free	  system	  and	  CD4+	  and	  CD8+	  T	  lymphocytes	  in	  transendothelial	  assays	  (Roth	  et	  
al.,	  1995;	  Schall	  et	  al.,	  1990).	  RANTES/CCL5	  also	  induces	  NK	  cell	  migration	  and	  activation	  and	  
eosinophil	   activation	   (Rot	   et	   al.,	   1992;	   Taub	   et	   al.,	   1995).	   The	   effects	   of	   RANTES/CCL5	   are	  
mediated	  through	  the	  receptors	  CCR1,	  CCR3	  and	  CCR5	  (Combadiere	  et	  al.,	  1996;	  Daugherty	  et	  
al.,	  1996;	  Gao	  et	  al.,	  1993).	  
	  
1.3	  Exacerbations	  of	  COPD	  	  
	  
The	   clinical	   course	   of	   COPD	   is	   interspersed	   by	   acute	   exacerbations.	   Exacerbations	   of	   COPD	  
have	  been	  characterised	  as	  an	  acute	  increase	  in	  respiratory	  symptoms	  that	  are	  beyond	  normal	  
daily	  variations	  (Vestbo	  et	  al.,	  2013).	  Symptoms	  of	  exacerbations	  include	  dyspnoea,	  cough	  and	  
increase	   in	   sputum	   volume	   or	   purulence	   and	  may	   result	   in	   the	   administration	   of	   additional	  
treatments	   such	   as	   steroids	   or	   systemic	   antimicrobials	   (Kurai	   et	   al.,	   2013).	   There	   is	   a	   direct	  
correlation	  between	  the	  frequency	  of	  exacerbations	  and	  accelerated	  decline	   in	   lung	  function	  
(Patel	  et	  al.,	  2002;	  Seemungal	  et	  al.,	  1998).	   	  Acute	  exacerbations	  of	  COPD	  severely	  affect	  the	  
state	   of	   health	   of	   patients.	   A	   distinct	   subgroup	   of	   patients	   termed	   ‘frequent	   exacerbators’	  
have	  also	  been	  recognized	  as	  being	  particularly	  susceptible	  to	  exacerbations	  (Wedzicha	  et	  al.,	  
2013).	   The	   severity	   and	   rapidly	   escalating	   frequency	   of	   exacerbations	   leads	   to	   significant	  
increasing	   burdens	   on	   healthcare	   costs	   as	   well	   as	   patient	   quality	   of	   life	   (Seemungal	   et	   al.,	  
1998).	  	  
	  
Many	   triggers	   of	   acute	   exacerbations	   of	   COPD	   have	   been	   reported,	   with	   bacterial	   or	   viral	  
respiratory	  infections	  of	  the	  airway,	  or	  indeed	  co-­‐infection	  with	  both	  pathogens,	  identified	  as	  
the	  predominant	  cause	  of	  acute	  exacerbations	  (Caramori	  et	  al.,	  2006;	  Celli	  and	  Barnes,	  2007).	  
Bacteria	   such	   as	   Streptococcus	   pneumoniae,	   Haemophilus	   influenzae,	  Moraxella	   catarrhalis,	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and	  Pseudomonas	  aeruginosa	  and	  viruses	  such	  as	  human	  rhinovirus	  (RV),	  respiratory	  syncytial	  
virus	  (RSV),	  influenza	  virus,	  human	  metapneumovirus	  (HMPV)	  and	  coronavirus	  are	  commonly	  
detected	  during	  exacerbations	  (Sapey	  and	  Stockley,	  2006;	  Sethi	  and	  Murphy,	  2008).	  	  
	  
Interestingly,	   while	   respiratory	   virus-­‐induced	   exacerbations	   appear	   similar	   at	   the	   various	  
stages	  of	  disease	  progression,	  bacteria-­‐induced	  exacerbations	  increase	  with	  the	  severity	  of	  the	  
disease	  or	  decrease	  in	   lung	  function	  (Dimopoulos	  et	  al.,	  2012).	  Studies	  have	  determined	  that	  
up	  to	  50%	  of	  COPD	  patients	  harbour	  bacteria	  in	  their	  lower	  respiratory	  tracts	  (Zalacain	  et	  al.,	  
1999).	   Respiratory	   viruses	   have	   also	   been	   identified	   as	   the	   cause	   of	   up	   to	   57%	   of	   COPD	  
exacerbations,	  with	  RV	  accounting	  for	  up	  to	  26.6%,	  RSV	  up	  to	  40.5%	  and	  influenza	  virus	  up	  to	  
22.4%	   (Beckham	   et	   al.,	   2005;	   Dimopoulos	   et	   al.,	   2012;	   Hutchinson	   et	   al.,	   2007;	   Kherad	   and	  
Rutschmann,	  2010;	  Ko	  et	  al.,	  2007;	  Kurai	  et	  al.,	  2013;	  McManus	  et	  al.,	  2008;	  Papi	  et	  al.,	  2006;	  
Perotin	  et	  al.,	  2013;	  Seemungal	  et	  al.,	  2001;	  Tan	  et	  al.,	  2003).	  
	  
Co-­‐infection	  with	  RV	  and	  bacterial	  pathogens	  can	  lead	  to	  an	  even	  more	  pronounced	  functional	  
impairment	   of	   the	   airway	   resulting	   in	   a	   rise	   in	   severity	   and	   frequency	   of	   exacerbations	  
(Wilkinson	   et	   al.,	   2006).	   It	   has	   been	   suggested	   that	   respiratory	   virus-­‐induced	   exacerbations	  
result	   in	   a	   worse	   prognosis	   with	   larger	   lung	   function	   decline	   and	   recovery	   than	   non-­‐viral	  
exacerbations	  (Bafadhel	  et	  al.,	  2011;	  Seemungal	  et	  al.,	  2001).	  These	  exacerbations	  can	  in	  turn	  
result	  in	  secondary	  bacterial	  infections	  culminating	  in	  severe	  respiratory	  symptoms	  (Wilkinson	  
et	  al	  2006b;	  Harper	  et	  al.,	  2009;	  Mallia	  et	  al.,	  2012).	  	  
	  
1.3.1	  Cigarette	  smoke	  
	  
Cigarette	  smoking	  or	  active	  exposure	  to	  cigarette	  smoke	  is	  the	  predominant	  causative	  factor	  in	  
the	  development	  of	  COPD	  and	  contributes	  to	  increased	  incidence	  of	  pulmonary	  diseases	  such	  
as	  asthma,	  allergic	  rhinitis	  and	  cancer	  (Reviewed	  by	  (Thorley	  and	  Tetley,	  2007)).	  In	  the	  United	  
States	  cigarette	  smoking	  accounts	  for	  over	  80%	  of	  COPD	  cases	  (Sethi	  and	  Rochester,	  2000).	  In	  
2008,	  the	  WHO	  estimated	  that	  5.4	  million	  premature	  deaths	  worldwide	  could	  be	  attributed	  to	  
cigarette	  smoking.	  
	  
Cigarette	  smoke	  is	  a	  complex	  and	  reactive	  mixture	  composed	  of	  over	  5000	  chemicals	  some	  of	  
which	   are	   highly	   toxic	   and	   carcinogenic	   (Borgerding	   and	   Klus,	   2005).	   Cigarette	   smoke	  
components	   can	   be	   split	   into	   the	   gaseous	   phase	   and	   the	   particulate	   phase.	   The	   gaseous	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components	   of	   cigarette	   smoke	   include	   oxygen,	   nitrogen,	   carbon	   dioxide,	   acetaldehyde,	  
methane,	   hydrogen	   cyanide,	   nitric	   acid	   and	   ammonia	   to	   name	   a	   few	   of	   the	   most	   studied	  
components	  (Borgerding	  and	  Klus,	  2005).	  The	  particulate	  components	  include	  carboxylic	  acids,	  
phenols,	  nicotine,	  terpenoids,	  paraffin	  waxes	  and	  tobacco-­‐specific	  nitrosamines.	  	  
	  
Long	  term	  exposure	  to	  cigarette	  smoke	  can	  result	  in	  epithelial	  cell	  changes	  associated	  with	  the	  
development	  of	  bronchitis	  (Vestbo	  and	  Hogg,	  2006).	  It	  can	  lead	  to	  goblet	  cell	  and	  submucosal	  
gland	  hypertrophy	  linked	  with	  the	  loss	  of	  ciliated	  epithelial	  cell	  function	  resulting	  in	  decreased	  
mucociliary	  clearance	  and	  mucus	  plug	  formation	  in	  the	  large	  airways	  (Jeffery,	  1998).	  Increased	  




Human	  RVs	  are	  the	  predominant	  cause	  of	  the	  common	  cold	  and	  are	  a	  major	  cause	  of	  asthma	  
and	   COPD	   acute	   exacerbations	   (Johnston,	   2005).	   Human	   RVs	   are	   members	   of	   the	  
Picornaviridae	   viral	   family	  and	  are	  non-­‐enveloped	  viruses	  with	  an	   icosahedral	  protein	   capsid	  
encasing	   a	   single-­‐stranded,	   positive-­‐sense	   RNA	   genome	   (Rossmann	   and	   Palmenberg,	   1988).	  
RVs	  are	  small	  viruses	  around	  30nm	  in	  diameter	  containing	  a	  genome	  of	  approximately	  7.2	  kb	  
composed	  of	  a	  5’	  untranslated	  region	  (UTR),	  an	  open	  reading	  frame	  coding	  for	  caspid	  proteins	  
VP1-­‐4	   and	   several	   non-­‐structural	   proteins,	   and	   a	   3’UTR	   and	   poly	   A	   tail	   (Huang	   et	   al.,	   2009;	  
Johnston	  et	  al.,	  1993).	  RVs	  are	  an	  extremely	  effective	  pathogen	  due	  to	   their	  small	  genomes,	  
fast	   replication	   cycles	   and	   high	   RNA	   mutation	   frequency	   wherein	   up	   to	   10-­‐3	   errors	   per	  
nucleotide	  are	  inserted	  per	  replication	  cycle	  (Drake,	  1999).	  
	  
Over	  100	  serotypes	  of	  RV	  haven	  been	  discovered	   to	  date	  and	   these	  can	  be	   sub-­‐divided	   into	  
three	  distinct	  genetic	  clades,	  HRV-­‐A,	  HRV-­‐B	  and	  HRV-­‐C	  (Cox	  and	  Le	  Souef,	  2014;	  Ledford	  et	  al.,	  
2004).	  Human	  RVs	  can	  also	  be	  sub-­‐divided	  based	  on	  their	  receptor	  specificity;	  the	  majority	  of	  
RVs	   enter	   host	   cells	   through	   the	   use	   of	   either	   intercellular	   adhesion	   molecule-­‐1	   (ICAM-­‐1)	  
termed	   the	   ‘major	   group’	   (these	   include	   strains	   belonging	   to	   both	   HRV-­‐A	   and	   HRV-­‐B).	   A	  
smaller	  population	  of	  RV	  strains	  gain	  host	  entry	  through	  the	  low-­‐density	  lipoprotein	  receptor	  
(LDLR)	   termed	   the	   ‘minor	   group’	   	   (HRV-­‐A	   strains	   only)	   (Greve	   et	   al.,	   1989;	  Marlovits	   et	   al.,	  
1998).	  However	  a	  very	  small	  group	  of	  human	  RVs	  use	  heparin	  sulphate	  proteoglycans	  instead	  
of	   ICAM-­‐1	   and	   LDLR	   to	   adhere	   onto	   cell	   surfaces	   (Vlasak	   et	   al.,	   2005).	   Once	   RV	   bind	   their	  
respective	   receptors,	   they	   are	   taken	   up	   into	   endosomes	   wherein	   low	   pH	   results	   in	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conformational	  changes	  of	  the	  capsid	  leading	  to	  viral	  RNA	  release	  into	  the	  cytoplasm	  (Nurani	  
et	  al.,	  2003).	  	  The	  receptors	  used	  by	  the	  third	  group	  of	  more	  recently	  identified	  HRV-­‐C	  strains,	  
remains	  unknown	  (Cox	  and	  Le	  Souef,	  2014).	  	  
	  
RV	   can	   gain	   entry	   into	   the	   respiratory	   tract	   through	   the	   nose	   or	   lacrimal	   duct	   in	   the	   eyes	  
before	  commencing	  infection	  in	  the	  nasopharynx.	  Upon	  cell	  entry,	  RV	  inhibits	  host	  cell	  protein	  
synthesis	   through	   the	   cleavage	   of	   CAP-­‐binding	   complex	   by	   viral	   protease	   2a	   before	   it	  
undergoes	  RNA	   translation	   through	   the	  binding	  of	  host	   ribosomes	   (Belsham	  and	  Sonenberg,	  
1996).	  Within	  6	  hours	  a	  single	  infection	  can	  result	  in	  the	  release	  of	  100,000	  mature	  virions	  into	  
the	   surrounding	   airway	   epithelia	   following	   viral-­‐induced	   cell	   lysis	   (Belsham	   and	   Sonenberg,	  
1996).	  
	  
RVs	   are	   capable	   of	   infecting	   ciliated	   epithelial	   cells	   in	   the	   upper	   respiratory	   tract,	   however	  
increasing	  evidence	  suggests	  RVs	  can	  also	  replicate	  in	  the	  lower	  respiratory	  tract	  (Kirchberger	  
et	   al.,	   2007).	  Under	  normal	   respiratory	   conditions,	   human	  RVs	  only	   infect	   and	   replicate	   in	   a	  
small	  proportion	  of	  epithelial	  cells	  (approximately	  10%)	  with	  little	  cytopathic	  effect	  (Heikkinen	  
and	   Jarvinen,	   2003).	   However,	   RV	   infection	   is	   accompanied	   by	   a	   release	   of	   inflammatory	  
mediators	   including	   cytokines	   such	   as	   IL-­‐1β,	   IL-­‐8/CXCL8,	   TNFα,	   IL-­‐6	   and	   IL-­‐11,	   as	   well	   as	  
chemokines	   including	   RANTES/CCL5,	   MCP-­‐1	   and	   IP-­‐10	   (Kirchberger	   et	   al.,	   2007).	   Increasing	  
sputum	   levels	   of	   IL-­‐8/CXCL8	   and	   IL-­‐6	   directly	   correlates	   with	   the	   severity	   of	   symptoms	  
following	   RV	   infection	   (Turner	   et	   al.,	   1998;	   Zhu	   et	   al.,	   1996).	   COPD	   patients	   experimentally	  
infected	  with	  RV	  present	  with	  increased	  viral	  load,	  which	  is	  consistent	  with	  increased	  sputum	  
neutrophils	   and	   IL-­‐8/CXCL8	   levels	   (Mallia	   et	   al.,	   2011).	  As	   a	   result	  of	   inflammatory	  mediator	  
production,	   RV	   infection	   leads	   to	   the	   initiation	   and	   amplification	   of	   host	   inflammatory	  
response	  through	  the	  proliferation,	  chemotaxis	  and	  activation	  of	  innate	  immune	  cells.	  
	  
In	  healthy	  individuals	  RV	  infections	  are	  generally	  contained	  within	  the	  upper	  airways	  with	  little	  
evidence	  of	  lower	  respiratory	  tract	  involvement	  (Message	  et	  al.,	  2008).	  However	  people	  with	  
COPD,	   it	   has	   been	   reported	   that	   RV	   infection	   is	   more	   severe	   and	   shows	   prolonged	   lower	  
respiratory	   symptoms	   including	   airway	   obstruction	   and	   increased	   numbers	   of	   neutrophils	  
when	  compared	  to	  healthy	  controls	  (Mallia	  et	  al.,	  2011).	  RVs	  have	  also	  been	  associated	  with	  
the	   attenuation	   of	   anti-­‐bacterial	   innate	   immune	   responses	   in	   COPD.	   RV	   infection	   results	   in	  
increased	   neutrophil	   elastase	   production	   and	   the	   consequent	   reduction	   in	   antimicrobial	  
peptides,	   such	   as	   elafin	   and	   secretory	   leukoprotease	   inhibitor,	   lead	   to	   the	   predisposition	   to	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secondary	  bacterial	  infection	  often	  seen	  in	  COPD	  patient	  airways	  (Mallia	  et	  al.,	  2012).	  RV	  can	  
also	   interfere	  with	   epithelial	   cell	   barrier	   function	   allowing	   bacterial	   translocation	   across	   the	  
epithelium	  (Sajjan	  et	  al.,	  2008).	  	  
	  
Exacerbation	   prone	   COPD	   patients	   present	   with	   lower	   serum	   levels	   of	   rhinovirus-­‐specific	  
antibody,	   anti-­‐VP1	   IgG1,	   and	   IL-­‐21	   than	   stable	   COPD	  patients	   (Yerkovich	   et	   al.,	   2012).	   COPD	  
patients	  experimentally	  infected	  with	  RV	  also	  show	  reduced	  IFN	  induction	  (Mallia	  et	  al.,	  2011).	  
In	  addition,	  COPD	  patient	  airway	  epithelial	  cells	  have	  been	  shown	  to	  be	  more	  susceptible	  to	  RV	  
infection	   in	   vitro	   (Schneider	   et	   al.,	   2010).	   	   These	   data	   suggest	   COPD	   patients	   may	   have	  
impaired	  host	  responses	  to	  RV.	  
	  
1.4	  Pattern	  recognition	  receptors	  (PRRs)	  and	  Innate	  Immunity	  
	  
The	  innate	  immune	  system	  is	  the	  first	  form	  of	  host	  defence	  against	  the	  invasion	  of	  pathogenic	  
microorganisms.	   Innate	   immunity	   was	   once	   thought	   to	   be	   a	   non-­‐specific	   mechanism	   for	  
recognising	  microbial	  components,	  subsequently	  leading	  to	  a	  more	  specific	  adaptive	  immunity.	  
However	  the	  emergence	  of	  a	  wide	  variety	  of	  germline-­‐encoded	  pattern	  recognition	  receptors	  
(PRRs)	   has	   since	   bestowed	   specificity	   to	   innate	   immunity.	   Host-­‐pathogen	   interactions	   are	  
initiated	  by	  the	  recognition	  of	  either	  endogenous	  danger	  signals	  such	  as	   IL-­‐1,	  or	   through	  the	  
recognition	   of	   pathogen	   components	   termed	   pathogen-­‐associated	   molecular	   patterns	  
(PAMPs)	  (Janeway	  and	  Medzhitov,	  2002).	  	  In	  addition,	  PRRs	  can	  also	  detect	  molecules	  released	  
from	   damaged	   tissue	   or	   necrotic	   cells	   known	   as	   damage-­‐associated	   molecular	   patterns	  
(DAMPs)	   to	   promote	   an	   inflammatory	   response	   (Jiang	   et	   al.,	   2005).	   The	   innate	   immune	  
response	  comprises	  the	  effective	  sensing	  of	  PAMPs	  by	  PRRs	  followed	  by	  a	  rapid	   induction	  of	  
complex	   signalling	   pathways	   that	   culminate	   in	   the	   induction	   of	   inflammatory	   responses	  
regulated	   by	   a	   plethora	   of	   cytokines	   and	   chemokines	   to	   facilitate	   the	   elimination	   of	   the	  
invading	  pathogen.	  	  	  
	  
To	  date,	  several	  classes	  of	  PRR	  have	  been	   identified,	  of	  these	  receptors,	   the	  transmembrane	  
and	  endosomal	  bound	  toll-­‐like	  receptors	  (TLRs)	  are	  the	  most	  extensively	  studied	  (Reviewed	  by	  
(O'Neill	   et	   al.,	   2013)).	   The	   discovery	   of	   TLR3	   gene-­‐disrupted	   mice	   with	   preserved	   anti-­‐viral	  
signalling	  to	  specific	  viral	  agonists	  led	  to	  the	  surfacing	  identification	  of	  additional	  PRRs	  (Takeda	  
and	  Akira,	  2004).	  Since,	  PRR	  such	  as	  retinoic	  acid-­‐inducible	  gene-­‐I	  (RIG-­‐I)	  like	  receptors	  (RLRs)	  
(Reviewed	   by	   (Loo	   and	   Gale,	   2011)),	   nucleotide-­‐binding	   oligomerization	   domain	   (NOD)-­‐	   like	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receptors	   (NLRs)	   (Reviewed	  by	   (Chen	  et	  al.,	  2009))	  and	   the	   recently	   identified	  cytosolic	  DNA	  
receptors	   (CDRs)	   have	   been	   identified	   (Kato	   et	   al.,	   2011;	   Keating	   et	   al.,	   2011)	   (Reviewed	  by	  
(Paludan	  and	  Bowie,	  2013)).	  	  
	  
Each	  set	  of	  receptors	  has	  distinct	  expression	  patterns	  and	  activate	  specific	  signalling	  pathways,	  
which	   can	   lead	   to	   targeted	   anti-­‐pathogen	   responses.	   However,	   similarities	   in	   structure	   and	  
cross	   talk	   between	   these	   receptors,	   and	   overlap	   in	   signalling	   pathways	   have	   been	  
documented.	   The	   following	   sections	   will	   summarise	   TLR	   and	   RLR	   signalling	   due	   to	   their	  
relevance	  to	  this	  thesis.	  
	  
1.4.1	  Toll-­‐like	  Receptors	  (TLRs)	  	  
	  
Toll	  protein	  was	  originally	  discovered	  in	  Drosophila	  melanogaster	  involved	  in	  establishment	  of	  
dorsoventral	  polarity	  during	  embryogenesis	   (Hashimoto	  et	  al.,	  1988).	  Their	   important	   role	   in	  
innate	  defence	  was	  first	  observed	  when	  mutation	  of	  the	  Toll	  gene	  was	  found	  to	  render	  adult	  
flies	  susceptible	  to	  fungal	  infections	  (Lemaitre	  et	  al.,	  1996).	  The	  cloning	  and	  characterisation	  of	  
the	  human	  homologues	  of	  Toll	  led	  to	  widespread	  interest	  in	  this	  family	  of	  proteins	  (Medzhitov	  
et	  al.,	  1997).	  Subsequently,	   ten	  highly	  conserved	  homologues	  were	   identified	   in	  humans	  and	  
designated	  as	  toll-­‐like	  receptors,	  each	  recognising	  specific	  PAMPs	  (detailed	  in	  Table	  1.1).	  	  
	  
TLRs	   are	   type	   I	   transmembrane	   receptors	   characterised	   by	   an	   ectodomain	   consisting	   of	  
leucine-­‐rich	   repeats	   (LRR)	   containing	   the	   consensus	   sequence	   L(X2)LXL(X2)NXL(X2)L(X7)L(X2),	  
essential	   for	   the	   recognition	   of	   specific	   ligands	   (Bowie	   and	   O'Neill,	   2000;	   Kobe	   and	  
Deisenhofer,	  1994).	  The	  cytoplasmic	  domain	  of	  TLRs	  contains	  an	  IL-­‐1R	  homologue	  termed	  the	  
Toll/IL-­‐1R	  (TIR)	  domain	  because	  of	  the	  sequence	  similarity	  between	  IL-­‐1R1	  and	  the	  Drosophila	  
melanogaster	  protein	  Toll	   (Gay	  and	  Keith,	  1991),	  which	  consists	  of	  a	  200	  amino	  acid	  domain	  
arranged	  into	  three	  highly	  conserved	  regions,	  termed	  box1,	  box2	  and	  box3.	  Box1	  and	  box2	  are	  
involved	  in	  protein-­‐protein	  interactions	  whilst	  box3	  is	  mostly	  involved	  in	  the	  localisation	  of	  the	  
receptor	  through	  its	  interactions	  with	  the	  cytoskeleton	  (Slack	  et	  al.,	  2000).	  The	  TIR	  domain	  in	  
turn	   recruits	   various	   TIR-­‐containing	   adaptor	   proteins	   to	   activate	   the	   transmission	   of	  
downstream	  signalling	  (Akira	  et	  al.,	  2006;	  Bowie	  and	  O'Neill,	  2000).	  	  	  
	  
TLRs	  can	  be	  broadly	  categorized	  into	  two	  subgroups	  based	  on	  their	  cellular	  localisation.	  TLR1,	  
TLR2,	  TLR4,	  TLR5,	  TLR6	  and	  TLR10	  are	   located	  on	   the	  plasma	  membrane	  of	   cells	  and	  can	  be	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subdivided	   based	   on	   their	   related	   agonists;	   TLR1,	   TLR2	   and	   TLR6	   recognise	   lipids.	   TLR2	   can	  
form	   dimer	   complexes	   with	   TLR1	   and	   TLR6	   and	   respond	   to	   major	   components	   of	   Gram-­‐
positive	  bacteria	  cell	  wall	  such	  as	  lipopeptides	  and	  lipoteichoic	  acids	  (LTA)	  (Knapp	  et	  al.,	  2004).	  
This	   combinational	   pattern	   of	   TLR	   heterodimerisation	   enhances	   the	   diversity	   of	   PAMP	  
recognition	  by	  TLRs.	  	  
	  
Some	   TLRs	   can	   detect	   multiple	   structurally	   unrelated	   ligands.	   For	   example,	   TLR4,	   the	   first	  
human	   TLR	   to	   be	   reported,	   acts	   as	   a	   homodimer	   eliciting	   a	   response	   to	   a	   broad	   range	   of	  
agonists	   including	   the	   fusion	   protein	   of	   RSV,	   fibronectin	   and	   heat	   shock	   proteins	   amongst	  
others	  (Akira	  et	  al.,	  2006).	  TLR4	  is	  also	  critical	  in	  mediating	  responses	  to	  components	  of	  Gram-­‐
negative	  bacteria	  outer-­‐membrane	  known	  as	  lipopolysaccharide	  (LPS)	  (Hoshino	  et	  al.,	  1999).	  In	  
this	   particular	   instance,	   TLR4	   requires	   functional	   interacting	   partners	   such	   as	   myeloid	  
differentiation	  protein-­‐2	  (MD-­‐2)	  and	  CD14	  to	  elicit	  NF-­‐κB	  activation	  resulting	  in	  the	  production	  
of	  pro-­‐inflammatory	  cytokines	  (see	  section	  1.6.1).	  Flagellins,	  found	  in	  both	  Gram-­‐positive	  and	  
Gram-­‐negative	  bacteria,	  are	  identified	  exclusively	  by	  TLR5	  (Zhang	  et	  al.,	  2005).	  The	  agonist	  for	  
TLR10	  still	   remains	  to	  be	   identified,	  however	  studies	  suggest	   it	  may	  act	  by	  dimerisation	  with	  
TLR1	  and	  TLR2	  (Hasan	  et	  al.,	  2005).	  	  
	  
TLR3,	   TLR7,	   TLR8	   and	   TLR9	   are	   located	   intracellularly	   on	   endoplasmic	   reticulum	   (ER),	  
lysosomes	   and	   endosomes	   where	   they	   predominantly	   detect	   viral	   nucleic	   acids.	   TLR3	  
recognises	   viral	   genomic	   double-­‐stranded	   RNA	   (dsRNA)	   or	   viral	   replication	   intermediates	  
released	  in	  endolysosomal	  compartments	  (Akira	  et	  al.,	  2006;	  Alexopoulou	  et	  al.,	  2001).	  TLR3	  is	  
also	  activated	  by	  endogenous	  dsRNA	  released	  from	  dying	  cells	  (Kariko	  et	  al.,	  2004).	  In	  addition,	  
the	   stable	   synthetic	   dsRNA	   analogue	   Polyinosinic:polycytidylic	   acid	   [poly(I:C)],	   is	   also	  
frequently	  used	  as	  a	  TLR3	  agonist	  to	  mimic	  viral	  infection.	  	  
	  
TLR7	  and	  TLR8	  recognise	  viral	  ssRNA.	  Both	  TLR7	  and	  TLR8	  are	  structurally	  homologous	  but	  are	  
primarily	  presented	  in	  different	  cell	  types.	  TLR7	  is	  mainly	  expressed	  in	  plasmacytoid	  dendritic	  
cells	  (pDCs)	  and	  B	  cells	  whilst	  TLR8	  is	  located	  in	  myeloid	  dendritic	  cells	  (mDCs)	  and	  monocytes	  
(Lund	   et	   al.,	   2004;	   Triantafilou	   et	   al.,	   2005;	   Yoneyama	   and	   Fujita,	   2010).	   	   In	   contrast,	   TLR9	  
recognises	  nonmethylated	  CpG	  motifs	  found	  predominantly	  in	  pathogenic	  DNA	  (Chuang	  et	  al.,	  
2002).	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TLRs	   are	   expressed	   on	   various	   cell	   types	   including	   immune	   cells	   (monocytes,	  macrophages,	  
dendritic	   cells)	   and	   non-­‐immune	   cells	   (epithelial	   cells	   and	   fibroblasts).	   Their	   expression	   and	  
regulation	   is	   both	   cell	   type	   and	   stimulus	   dependent	   which	   adds	   to	   the	   complexity	   of	   their	  
characterisation	   and	   function.	   TLR	   signalling	   is	   a	   tightly	   regulated	   process	  wherein	   even	   the	  
slightest	  mutation	  or	  disruption	  can	  result	   in	   impaired	   immune	  responses	  and	  disease	  onset.	  
For	   instance,	   two	   naturally	   occurring	   intronic	   single	   nucleotide	   polymorphisms	   (SNP)	   TLR2	  
rs1898830	  and	  rs11938228	  were	  associated	  with	  a	  lower	  level	  of	  forced	  expiratory	  volume	  in	  1	  
second	   (FEV1)	   and	   higher	   numbers	   of	   inflammatory	   cells	   present	   in	   sputum	   from	   COPD	  
patients	  suggesting	  a	  role	  in	  the	  severity	  and	  progression	  of	  COPD	  (Budulac	  et	  al.,	  2012).	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TLR	   Localisation	   Ligand	   Adaptor	  Protein	  




TLR	  2	   Cell	  membrane	  
Zymosan	  (Fungi)	  
MyD88	  
TLR	  3	   Intracellular	   dsRNA	   TRIF/TRAM	  
LPS	   MyD88/TIRAP	  
F	  protein	  (RSV)	   TRIF/TRAM	  
TLR	  4	   Cell	  membrane	  
Env	  (MMTV)	   	  
TLR	  5	   Cell	  membrane	   Flagellin	   MyD88	  
TLR	  6	   Cell	  membrane	   Diacyl	  lipopeptide	   MyD88	  
ssRNA	  TLR	  7	   Intracellular	  
Imiquimod	  
MyD88	  
ssRNA	  TLR	  8	   Intracellular	  
Resiquimod	  
MyD88	  
TLR	  9	   Intracellular	   CpG	  DNA	   MyD88	  
TLR	  10	   Cell	  membrane	   Unknown	   Unknown	  
 
Table	  1.1	  TLRs,	  their	  ligands	  and	  adaptor	  proteins	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1.4.2	  RIG-­‐I-­‐like	  receptors	  (RLRs)	  	  
	  
The	  preserved	  immune	  response	  in	  TLR3	  knockout	  mice	  to	  poly(I:C)	  and	  viral	   infection	  led	  to	  
the	   discovery	   of	   two	   new	   receptors,	   retinoic	   acid	   inducible	   gene-­‐I	   (RIG-­‐I)	   and	   melonoma	  
differentiation-­‐associated	   gene	   5	   (MDA5),	   involved	   in	   cytoplasmic	   viral	   RNA	   detection	  
(Yoneyama	   et	   al.,	   2004)	   (see	   Figure	   1.1).	   These	   receptors	   are	   capable	   of	   recognising	   the	  
genomic	  content	  of	  dsRNA	  viruses	  as	  well	  as	  ssRNA	  viruses	  via	  their	  intermediate	  dsRNA-­‐state	  
seen	   during	   viral	   replication	   as	  well	   as	   host	   self	   RNA	   in	   the	   cytoplasm	   (Takeuchi	   and	   Akira,	  
2009;	  Yoneyama	  and	  Fujita,	  2008).	  Specifically,	  RIG-­‐I	  recognises	  blunt-­‐ended	  dsRNA	  with	  a	  5′-­‐
triphosphate	  cap	  while	  MDA5	  binds	  dsRNA	  greater	  than	  1kb	  in	  size	  (Berke	  et	  al.,	  2013).	  A	  third	  
RLR,	   laboratory	   of	   genetics	   and	   physiology	   2	   (LGP2),	   has	   been	   shown	   to	   have	   an	   inhibitory	  
affect	  on	  RIG-­‐I	  signalling,	  as	  it	  has	  greater	  affinity	  for	  dsRNA	  then	  RIG-­‐I.	  LGP2	  structurally	  lacks	  
caspase	   recruitment	   domain	   (CARD)	   copies	   (Akira	   et	   al.,	   2006;	   Tanner	   and	   Linder,	   2001;	  
Yoneyama	  and	  Fujita,	  2007).	   It	  has	  been	  postulated	   that	  LPG2	  cooperates	  with	  MDA5	   in	   the	  
recognition	   of	   dsRNA,	   however	   the	   precise	  mechanisms	   behind	   LPG2	   signalling	   are	   still	   not	  
completely	  understood	  (Komuro	  and	  Horvath,	  2006;	  Yoneyama	  and	  Fujita,	  2010).	  
	  
Structurally,	   both	   RIG-­‐I	   and	   MDA5	   contain	   two	   copies	   of	   CARD,	   required	   for	   downstream	  
signalling,	   and	   a	   DExD/H	   box	   RNA	   helicase	   domain,	   with	   the	   ability	   to	   intrinsically	   unwind	  
dsRNA	   (Tanner	   and	   Linder,	   2001).	   The	   CARD	   domains	   transduce	   signals	   that	   lead	   to	   the	  
activation	  of	  IRF-­‐3	  and	  NF-­‐κB	  whilst	  the	  RNA	  helicase	  domain	  can	  bind	  viral	  RNA	  directly	  in	  an	  
ATP-­‐dependent	  manner	  (Saito	  et	  al.,	  2007;	  Yoneyama	  et	  al.,	  2004).	  RIG-­‐I	  recognises	  members	  
of	  the	  Paramyxoviridae,	  Rhabdoviridae,	  and	  Orthomyxoviridae	  virus	  genera,	  whilst	  MDA5	  has	  
been	   linked	   to	   members	   of	   the	   Picornaviridae	   (Kato	   et	   al.,	   2006;	   Loo	   and	   Gale,	   2011).	   	   In	  
contrast,	   both	   RIG-­‐I	   and	  MDA5	   can	   detect	   a	   subset	   of	   viruses	   which	   include	   Dengue	   virus,	  
West	  Nile	  virus	  and	  reovirus	  (Fredericksen	  et	  al.,	  2008;	  Loo	  et	  al.,	  2008).	  	  
	  
RIG-­‐I	   and	  MDA-­‐5	   both	   interact	  with	   Interferon	   beta	   promoter	   stimulator-­‐1	   (IPS-­‐1),	   which	   is	  
also	   known	   as	   mitochondrial	   antiviral	   signalling	   protein	   (MAVS),	   virus-­‐induced	   signalling	  
adaptor	   (VISA)	   or	   CARD	   adaptor	   inducing	   interferon-­‐β	   (Cardif).	   IPS-­‐1	   is	   a	   CARD	   containing	  
mitochondrial	   adaptor	   molecule	   that	   links	   RIG-­‐I	   and	   MDA5	   with	   downstream	   signalling	  
molecules	  (Kawai	  et	  al.,	  2005;	  Meylan	  et	  al.,	  2005;	  Seth	  et	  al.,	  2005;	  Xu	  et	  al.,	  2005).	  	  The	  RIG-­‐I	  
or	   MDA5	   and	   IPS-­‐1	   complex	   recruits	   several	   signalling	   molecules,	   including	   TRAF3/6,	   TNF	  
receptor	   associated	   death	   domain	   (TRADD),	   RIP1,	   caspase-­‐8/10	   and	   Fas-­‐associated	   death	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domain	   (FADD).	   	   These	   signalling	   molecules	   set	   in	   motion	   the	   activation	   of	   IKKα/IKKβ	   and	  
TBK1/IKKi	  complexes	  resulting	  in	  NF-­‐κB,	  and	  IRF-­‐3	  and	  IRF-­‐7	  activation	  and	  translocation	  into	  
the	  nucleus	  that	  ultimately	  leads	  to	  the	  induction	  of	  proinflammatory	  cytokine	  and	  type	  I	  IFN	  
genes	  (Takeuchi	  and	  Akira,	  2010;	  Yoneyama	  and	  Fujita,	  2010).	  	  
	  
1.5	  TLR	  signalling	  
	  
TLR	   signalling	   can	   be	   divided	   into	   a	   further	   two	   categories	   based	   on	   the	   distinct	   signalling	  
pathways	  which	  lead	  to	  the	  production	  of	  a	  plethora	  of	  proinflammatory	  cytokines	  and	  type	  I	  
interferons	   (IFNs).	   The	   distinction	   is	   made	   based	   on	   the	   TIR-­‐domain-­‐containing	   adaptor	  
molecules	  that	  bind	  to	  the	  TLR-­‐cytoplasmic	  domain,	  Myeloid	  differentiation	  primary	  response	  
gene	  88	  (MyD88)	  and	  TIR-­‐domain	  containing	  adaptor	  protein	  inducing	  IFN	  (TRIF).	  
	  
1.5.1	  MyD88-­‐dependent	  signalling	  
	  
MyD88	  is	  a	  pivotal	  adaptor	  protein	  utilized	  by	  all	  TLRs	  with	  the	  exception	  of	  TLR3	  (Figure	  1.1	  
and	  1.2).	  It	  was	  identified	  because	  of	  shared	  homology	  to	  the	  TIR	  domain	  (Hultmark,	  1994).	  A	  
further	  TIR	  domain-­‐containing	  adaptor	  protein	  was	  identified	  as	  a	  bridging	  adaptor	  for	  MyD88-­‐
dependent	  signalling	  through	  TLR2	  and	  TLR4	  activation	  known	  as	  MyD88	  adaptor	  like	  (MAL)	  or	  
TIR	  domain	  containing	  adaptor	  protein	  (TIRAP)	  (Fitzgerald	  et	  al.,	  2001;	  Horng	  et	  al.,	  2002).	  	  
	  
MyD88	  is	  recruited	  to	  the	  cytoplasmic	  TIR	  domain	  of	  the	  TLR	  receptor	  after	  ligand	  stimulation	  
and	   interacts	   with	   IL-­‐1R-­‐associated	   kinase	   (IRAK)-­‐4	   through	   its	   cytosolic	   death	   domain	  
contained	   within	   the	   N-­‐terminus	   of	   MyD88.	   The	   death	   domain	   mediates	   protein-­‐protein	  
interactions	  giving	  MyD88	  its	  adaptor	  molecule	  properties.	  	  
	  
The	  MyD88/IRAK-­‐4	  complex	  then	  results	  in	  the	  recruitment	  and	  phosphorylation	  of	  IRAK-­‐1	  and	  
IRAK-­‐2,	  which	  sequentially	  activates	  TNF	  receptor-­‐associated	  factor	  (TRAF)-­‐6	  (Kawagoe	  et	  al.,	  
2008).	  TRAF6	  is	  an	  E3	  ubiquitin	  ligase	  that	  catalyzes	  the	  formation	  of	  lysine	  63-­‐linked	  ubiquitin	  
chain	  through	  the	  interaction	  with	  E2	  ubiquitin-­‐conjugating	  enzymes	  Ubc12	  and	  Uev1A	  (Xia	  et	  
al.,	   2009)	   (see	   section	   1.7.2).	   This	   results	   in	   the	   activation	  of	   the	   complex	   known	  as	   TGF-­‐β-­‐
activated	  kinase	  (TAK)-­‐1/TAK1	  binding	  protein	  (TAB)	  -­‐1,	  -­‐2	  and	  3.	  TAK-­‐1	  activates	  the	  IκB	  kinase	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(IKK)	   complex	   comprised	   of	   two	   catalytic	   subunits	   IKK-­‐α	   and	   IKK-­‐β	   and	   a	   non-­‐catalytic	  
regulatory	   subunit	   NF-­‐κB	   essential	   modulator	   (NEMO)	   resulting	   in	   IκBα	   ubiquitination	   and	  
degradation	   (Muzio	  et	  al.,	  2000).	  This	  classical	  pathway	  otherwise	  known	  as	  canonical	  NF-­‐κB	  
signalling	   results	   the	   freeing	   of	   the	   nuclear	   localisation	   domain	   of	   NF-­‐κB	   allowing	   its	  
translocation	  to	  the	  nucleus	  to	  act	  as	  a	  pro-­‐inflammatory	  gene	  transcription	  factor	  (see	  section	  
1.6.1)	  (Baeuerle	  and	  Baltimore,	  1996)	  (Karin	  and	  Ben-­‐Neriah,	  2000).	  
	  
	  The	   activation	   of	   TAK1	   also	   activates	   the	   parallel	  mitogen	   activated	   protein	   kinase	   (MAPK)	  
signalling	   pathway	   resulting	   in	   the	   activation	   or	   the	   transcription	   factor	   AP-­‐1	   (Ropert	   et	   al.,	  
2001)	   (see	   section	   1.6.3).	   These	   pathways	   lead	   to	   the	   transcription	   of	   numerous	  
proinflammatory	  genes,	  including	  IL-­‐1,	  TNFα,	   IL-­‐8/CXCL8	  and	  IL-­‐6.	  (Brown	  et	  al.,	  2010;	  Cao	  et	  
al.,	  1996;	  Kawai	  et	  al.,	  2001;	  Takeuchi	  and	  Akira,	  2001).	  	  
	  
1.5.2	  MyD88-­‐independent	  signalling	  
	  
As	  noted	  above,	  TLR3	  signals	  via	  TRIF	  (Figure	  1.2),	  an	  adapter	  protein	  that	  was	  first	  discovered	  
following	   the	   stimulation	   of	  MyD88-­‐deficient	   mice	   with	   LPS	   wherein	   the	   mice	   showed	   late	  
phase	  activation	  of	  NF-­‐κB	   (see	   section	   1.6.1)	  and	  MAPKs	   (see	   section	  1.6.3)	  associated	  with	  
the	  activation	  of	   type	   I	   IFNs	   (see	   section	   1.2.1.3)	   (Kawai	   et	   al.,	   1999;	  Kawai	   et	   al.,	   2001).	   In	  
contrast,	   the	  knockdown	  of	  TRIF	   resulted	   in	  early	  phase	  NF-­‐κB	   signalling	  but	  a	   reduced	  pro-­‐
inflammatory	  cytokine	  and	  type	  I	  IFN	  production	  in	  mice	  (Hoebe	  et	  al.,	  2003;	  Yamamoto	  et	  al.,	  
2003).	  	  
	  
TRIF	   is	   selectively	   recruited	   by	   TLR3	   and	   TLR4,	   however	   TLR4	   requires	   a	   further	   bridging	  
adaptor	   protein	   TRIF	   related	   adaptor	   molecule	   (TRAM)	   (Yamamoto	   et	   al.,	   2003).	   	   The	  
activation	  of	  TRIF	  post	  ligand	  stimulation	  leads	  to	  the	  recruitment	  of	  TRAF3.	  Activated	  TRAF3	  is	  
involved	   in	  the	  nuclear	   translocation	  of	   IFN	  regulatory	   factor	   (IRF)-­‐3	  and	   IRF7	  by	  activating	  a	  
complex	   known	   as	   TRAF-­‐family	   member	   associated	   NF-­‐κB	   activator	   (TANK)-­‐binding	   kinase	  
(TBK)-­‐1/IKKi.	  IRF3	  and	  IRF7	  form	  homo-­‐	  or	  heterodimers	  post	  phosphorylation	  and	  bind	  to	  the	  
IFN-­‐stimulated	  response	  element	  (ISRE)	  leading	  to	  the	  expression	  of	  IFN-­‐inducible	  genes.	  This	  
process	   results	   in	   the	   induction	   of	   type	   I	   (IFN	  α,	  β)	   and	   type	   III	   (IFNλ)	   genes.	   TRIF	   can	   also	  
recruit	   and	   activate	   TRAF6,	  which	   leads	   to	   the	   interaction	  with	   receptor	   interacting	   protein	  
(RIP)-­‐1,	   resulting	   in	   canonical	   NF-­‐κB	   activation	   and	   cytokine	   production	   (Akira	   et	   al.,	   2006;	  
Brown	  et	  al.,	  2010;	  Honda	  et	  al.,	  2005).	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TLR4	   activates	   both	   MyD88-­‐dependent	   pathway	   and	   TRIF-­‐dependent	   pathway.	   It	   has	   been	  
shown	   that	   TLR4	   activation	   occurs	   at	   the	   plasma	  membrane	   whereby	  MyD88	   and	   bridging	  
adaptor,	   TIRAP,	   activate	   NF-­‐κB	   gene	   transcription	   as	   described	   above,	   which	   leads	   to	   the	  
translocation	   of	   TLR4	   into	   the	   endosome	   or	   lysosome	   to	   recruit	   TRAM.	   The	   subcellular	  
localisation	   of	   TRAM	   is	   essential	   for	   efficient	   signal	   transduction	   and	   is	   controlled	   by	  
myristoylation	  and	  phosphorylation	  resulting	  in	  activation	  of	  IRF	  gene	  transcription	  (Kenny	  and	  
O'Neill,	  2008;	  Tanimura	  et	  al.,	  2008).	  	  




Figure	  1.1	  Mechanisms	  of	  Viral	  Detection	  
TLR3	   and	   RIG-­‐I/MDA5	   recognise	   cytoplasmic	   viral	   dsRNA	   and	   recruit	   TRIF,	   leading	   to	   the	  
activation	   of	   NF-­‐κB	   via	   TRAF6	   and	   RIP1	   and	   the	   phosphorylation	   of	   IRF3	   via	   the	   TBK/IKKi	  
complex.	   	   RIG-­‐I/MDA5	   requires	   the	  mitochondria-­‐bound	  adaptor	  molecule,	   IPS-­‐1,	   to	  achieve	  
this	  activation.	  This	  results	  in	  the	  induction	  of	  type	  I	  IFNs	  and	  proinflammatory	  cytokines.	  	  
TLR7/8	   and	   TLR9	   recognise	   cytoplasmic	   viral	   ssRNA	   and	   CpG	   DNA	   respectively.	   MyD88	   is	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with	   IRAK-­‐4,	   IRAK-­‐1,	   TRAF3	   and	   TRAF6.	   This	   interaction	   leads	   to	   the	   phosphorylation	   and	  
subsequent	  nuclear	  translocation	  of	  IRF-­‐7	  resulting	  in	  type	  I	  IFN	  production.	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Figure	  1.2	  Mechanisms	  of	  Bacterial	  Detection	  
TLRs	  and	  IL-­‐1R	  share	  common	  signaling	  pathways.	  TLR2,	  TLR4	  and	  TLR5	  recognise	  lipoproteins,	  
LPS	   and	   flagellins	   respectively	   whilst	   IL-­‐1R	   recognises	   IL-­‐1	   family	   members.	   Once	  
ligand/receptor	   interaction	   occurs,	   MyD88	   is	   recruited	   to	   the	   receptor.	   TLR4	   requires	   an	  
additional	  bridging	  molecule	  TIRAP	  to	  subsequently	   form	  a	  complex	  with	   IRAK-­‐4,	   IRAK-­‐1	  and	  
TRAF6.	   This	   results	   in	   the	   activation	   of	   TAK1/TAB,	   which	   is	   ultimately	   responsible	   for	   the	  
activation	   of	   NF-­‐κB	   signaling	   through	   the	   IKK	   complex	   and	   MAPK	   respectively	   leading	   to	  
induction	  of	  proinflammatory	  cytokine.	  
TLR4	  also	  triggers	  the	  TRIF-­‐dependent	  pathway	  via	  the	  adaptor	  molecule	  TRAM.	  This	  leads	  to	  
the	  activation	  of	  NF-­‐κB	  and	  IRF-­‐3	  and	  IRF-­‐7	  phosphorylation,	  resulting	  in	  the	  expression	  of	  IFN-­‐
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1.6	  PRR-­‐induced	  transcription	  factors	  
1.6.1	  NF-­‐κB	  
	  
The	  NF-­‐κB	  family	  regulates	  multiple	  biological	  processes	  including	  immunity,	  inflammation,	  cell	  
survival,	  growth	  and	  differentiation	  (Hayden	  and	  Ghosh,	  2008).	  In	  mammals,	  the	  NF-­‐κB	  family	  
of	   transcription	   factors	   is	   comprised	  of	   five	  members:	   RelA	   (p65),	   RelB,	   c-­‐Rel,	   p105	   (NFKB1)	  
and	  p100	  (NFKB2).	  These	  NF-­‐κB	  proteins	  can	  be	  characterised	  by	  their	  shared	  conserved	  300-­‐
amino	  acid	  Rel	  homology	  domain	  (RHD),	  which	  is	  responsible	  for	  homo-­‐	  or	  heterodimerisation,	  
IκB	  interaction	  and	  encompasses	  DNA-­‐binding	  motifs	  and	  a	  nuclear	  localisation	  sequence	  (NLS)	  
(Hayden	  and	  Ghosh,	  2004).	  
	  
1.6.1.1	  Canonical	  NF-­‐κB	  signalling	  
	  
NF-­‐κB	  activation	  is	  signal	  dependent	  and	  can	  be	  regulated	  by	  a	  number	  of	  extracellular	  stimuli	  
including	   viral	   or	   bacterial	   pathogens,	   cytokines,	   oxidative	   stress	   and	   injury	   (Sun,	   2011).	   In	  
unstimulated	   cells,	   NF-­‐κB	   is	   sequestered	   in	   the	   cytoplasm	   through	   its	   interaction	   with	   IκB	  
inhibitory	  proteins.	  Seven	  members	  of	  the	  mammalian	  IκB	  family	  have	  been	  identified	  and	  are	  
characterised	  by	  their	  inhibitory	  role	  through	  their	  binding	  of	  ankyrin-­‐like	  repeats	  to	  the	  RHD	  
resulting	  in	  the	  masking	  of	  the	  nuclear	  localisation	  signal	  (Hatada	  et	  al.,	  1992).	  IκBα,	  IκBβ	  and	  
IκBε	  have	  been	   associated	  with	  mammalian	  NF-­‐κB	  due	   to	   the	  N-­‐terminal	   regulatory	   regions	  
necessary	  for	  stimulus-­‐induced	  degradation	  (Arenzana-­‐Seisdedos	  et	  al.,	  1997).	  
	  
Following	   extracellular	   stimulation	   IκBs	   undergo	   degradation	   regulated	   by	   the	   IKK	   complex	  
(Karin	   and	   Ben-­‐Neriah,	   2000).	   The	   serine	   kinases	   IKKα	   and	   IKKβ	   contain	   N-­‐terminal	   kinase	  
domains,	  a	  C-­‐terminus	  helix-­‐loop-­‐helix	  motif	  and	  leucine-­‐zipper	  domain	  within	  their	  structure	  
(Mercurio	   et	   al.,	   1997).	   In	   canonical	   NF-­‐κB	   signaling,	   IKKβ	  mediates	   the	   phosphorylation	   of	  
IκBα	   and	   IκBβ	   at	   two	   N-­‐terminal	   serine	   residues	   (Ser-­‐32	   &	   Ser-­‐36	   and	   Ser-­‐19	   &	   Ser-­‐23	  
respectively)	   leading	   to	   Lys-­‐48	   linked	   polyubiquitination	   (see	   section	   1.7.2)	   and	   subsequent	  
protein	   degradation	   releasing	   NF-­‐κB	   dimers	   for	   nuclear	   translocation	   (Lee	   et	   al.,	   1997;	  
Mercurio	  et	  al.,	  1997;	  Napetschnig	  and	  Wu,	  2013)	  (Figure	  1.3).	   Interestingly,	  whilst	   IKKβ	  and	  
NEMO	   are	   indispensable	   for	   canonical-­‐NF-­‐κB	   gene	   transcription,	   the	   role	   of	   IKKα	   remains	  
poorly	  understood	  (Gray	  et	  al.,	  2014),	  although	  in	  macrophages,	  IKKα	  has	  been	  described	  as	  a	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negative	   regulator	   of	   activation	   and	   inflammation	   through	   the	   accelerated	   removal	   of	   RelA	  
and	  c-­‐Rel	  from	  the	  NF-­‐κB	  gene	  promoter	  (Lawrence	  et	  al.,	  2005).	  
	  
1.6.1.2	  Non-­‐canonical	  NF-­‐κB	  signalling	  
	  
Whilst	  canonical	  NF-­‐κB	  activation	  relies	  on	  the	  inducible	  degradation	  of	  IκBs	  to	  release	  NF-­‐κB	  
dimeric	  complexes,	  non-­‐canonical	  NF-­‐κB	  relies	  on	   the	   inducible	  proteolytic	  processing	  of	   the	  
precursors	  p105	  (NFKB1)	  or	  p100	  (NFKB2)	  by	  the	  proteasome	  to	  produce	  their	  active	  subunits	  
p50	  and	  p52	  respectively	  (Betts	  and	  Nabel,	  1996;	  Fan	  and	  Maniatis,	  1991).	  Structurally,	  p105	  
and	   p100	   contain	   C-­‐terminus	   ankyrin	   repeat-­‐containing	   domains	   (ARD)	   giving	   them	   similar	  
inhibitory	  characteristics	   to	   IκBs	  and	  constricting	  their	   inactive	  forms	  to	  the	  cytoplasm.	  Once	  
processed,	  the	  active	  p50	  and	  p52	  do	  not	  contain	  transactivation	  domains	  (TAD)	  essential	  for	  
targeting	  gene	  transcription.	  p50	  and	  p52	  therefore	  require	  dimerization	  with	  TAD-­‐containing	  
RelA,	   RelB	   or	   c-­‐Rel	   to	   activate	   NF-­‐κB	   gene	   transcription.	   The	   formation	   of	   p52	   and	   p50	  
homodimers	   are	   associated	  with	   negative	   regulation	   of	   NF-­‐κB	   through	   the	   association	  with	  
histone	   deacetylase-­‐1	   (HDAC-­‐1)	   resulting	   in	   inhibition	   of	   gene	   transcription	   (Zhong	   et	   al.,	  
2002).	  
	  
p105	  is	  constitutively	  processed	  into	  its	  active	  fragment	  p50	  through	  the	  partial	  proteolysis	  by	  
the	   26S	   proteasome.	   	   In	   addition	   to	   containing	   a	   RHD	   required	   for	   homo-­‐	   (p50/p50)	   and	  
heterodimerisation	  (p50/p65),	  p105	  also	  presents	  with	  a	  glycine-­‐rich	  region	  (GRR)	  responsible	  
for	  preventing	  its	  complete	  degradation	  by	  the	  26S	  proteasome	  and	  stabilising	  the	  active	  p50	  
protein	  (Lin	  et	  al.,	  1998).	  	  
	  
In	  addition	  to	  regulating	  NF-­‐κB	  signalling,	  p105	  has	  also	  been	  associated	  with	  other	  signalling	  
pathways	   involved	   in	  the	  regulation	  of	  cell	  signalling.	  For	   instance,	  p105	  can	  bind	  Caspase-­‐8-­‐
related	  protein	  (Casper)/	  Cellular	  FLICE-­‐like	  inhibitory	  protein	  (c-­‐flip),	  a	  protein	  involved	  in	  the	  
regulation	  of	  caspase-­‐8	  induced	  apoptosis.	  This	  interaction	  is	  mediated	  through	  IκBγ	  and	  halts	  
p105	   proteasomal	   processing	   resulting	   in	   the	   inhibition	   of	   NF-­‐κB	   activation	   and	   increase	   in	  
Casper/c-­‐flip	   induced	   apoptosis	   (Li	   et	   al.,	   2003).	   p105	   also	   plays	   a	   role	   in	   the	   regulation	   of	  
MAPK	   signalling	   by	   forming	   a	   complex	   with	   the	   otherwise	   unstable	   Tpl2	   (MEK	   kinase).	   The	  
p105/Tpl2	  complex	  inhibits	  MAPK	  signalling	  in	  unstimulated	  cells	  whilst	  maintaining	  a	  cellular	  
reservoir	   of	   Tpl2	   required	   for	   effective	   activation	   of	   MAPK	   signalling	   in	   response	   to	   LPS	  
(Pereira	  and	  Oakley,	  2008).	  
	   42	  
	  
Contrary	   to	   p105	   constitutive	   processing,	   p100	   is	   a	   tightly	   regulated	   process	   dependent	   on	  
inducible	  phosphorylation	  and	  ubiquitination	  (Xiao	  et	  al.,	  2001).	  The	  activation	  of	  specific	  TNF-­‐
family	   receptors	   has	   been	   identified	   as	   the	   trigger	   for	   the	   processing	   of	   p100,	   including	  
lymphotoxin-­‐b	  receptor	  (LTβR),	  B	  cell–activating	  factor	  receptor	  (BAFF-­‐R),	  CD40	  and	  receptor	  
activator	  for	  NF-­‐κB	  (RANK)	  (Coope	  et	  al.,	  2002;	  Dejardin	  et	  al.,	  2002;	  Kayagaki	  et	  al.,	  2002).	  In	  
addition,	  TNF-­‐induced	  cytokine	  TNF-­‐like	  weak	  inducer	  of	  apoptosis	  (TWEAK)	  and	  the	  bacterial	  
PAMP,	   LPS,	   have	   also	   been	   associated	   with	   instigating	   p100	   processing	   (Mordmuller	   et	   al.,	  
2003;	  Saitoh	  et	  al.,	  2003).	  	  
	  
The	   activation	   of	   p100	   signalling	   is	   dependent	   on	   the	   catalytic	   properties	   of	  NF-­‐κB-­‐inducing	  
kinase	  (NIK).	  In	  unstimulated	  cells,	  NIK	  undergoes	  constant	  rapid	  synthesising	  and	  degradation	  
through	   the	   interaction	   with	   a	   TRAF-­‐cIAP	   E3	   complex	   consisting	   of	   TRAF2,	   TRAF3,	   cellular	  
inhibitor	  of	  apoptosis	  1	  (cIAP1)	  and	  cIAP2	  complex	  (Sun,	  2010).	  Upon	  extracellular	  stimulation	  
NIK	   is	   released	   from	   this	   complex	   and	   in	   turn	   recruits	   and	   activates	   IKKα	   (but	   not	   IKKβ	   or	  
NEMO)	  resulting	  in	  the	  formation	  of	  a	  p100	  complex	  through	  the	  NIK-­‐induced	  phosphorylation	  
of	  two	  serine	  residues	  (ser-­‐866	  and	  ser-­‐870)	  in	  the	  C-­‐terminus	  NIK-­‐responsive	  domain	  of	  p100	  
(Fong	  and	  Sun,	   2002;	  Xiao	  et	   al.,	   2004).	   Consequently,	   specific	  p100	   serine	   residues	   (ser-­‐99,	  
ser-­‐108,	   ser-­‐115,	   ser-­‐123,	   and	   ser-­‐872)	   are	   phosphorylated	   by	   IKKα	   resulting	   in	   the	  
ubiquitination	   of	   p100	   and	   processing	   into	   p52	   (Xiao	   et	   al.,	   2004).	  Whilst	   p100	   serves	   as	   a	  
precursor	  to	  p52,	  p100	  also	  acts	  as	  a	  cytoplasmic	  inhibitor	  much	  like	  IκB	  proteins	  and	  inhibits	  
RelB	   nuclear	   translocation	   and	   NF-­‐κB	   gene	   transcription	   (Heusch	   et	   al.,	   1999;	   Solan	   et	   al.,	  
2002).	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Figure	  1.3:	  Canonical	  and	  Non-­‐canonical	  NF-­‐κB	  signalling	  pathway	  
Following	  receptor	  activation,	  the	  canonical	  NF-­‐κB	  pathway	  activates	  the	   IKKβ	  subunit	  of	  the	  
IKK	  complex.	   IKKβ	   then	  phosphorylates	  classical	   IκB	  proteins	  bound	   to	  NF-­‐κB	  dimers	   such	  as	  
p50-­‐p65	  resulting	   in	   IκB	  ubiquitination	  and	  proteasome-­‐induced	  degradation	  releasing	  NF-­‐κB	  
to	  translocate	  to	  the	  nucleus	  where	  it	  activates	  target	  genes.	  	  
Non-­‐canonical	  NF-­‐κB	   signalling	  pathway	   requires	  NIK	  activation	   followed	  by	  phosphorylation	  
of	   two	   IKKα	   subunits.	   The	   activated	   IKKα	   complex	   leads	   to	   the	   phosphorylation	   of	   the	   IκB	  
domain	  of	  p100	  subunit	   releasing	  the	  active	  p52	  component.	   	  The	  active	  p52	  dimerises	  with	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1.6.2	  Interferon	  Regulatory	  Factors	  (IRFs)	  	  
	  
The	   IRF	   family	   comprises	   of	   nine	   transcription	   factors	   known	   as	   IRF-­‐1,	   IRF-­‐2,	   IRF-­‐3,	   IRF-­‐4	  
(otherwise	  known	  as	  ICSAT	  or	  PIP),	  IRF-­‐5,	  IRF-­‐6,	  IRF-­‐7,	  IRF-­‐8	  (alternately	  known	  as	  ICSBP)	  and	  
IRF-­‐9.	   	  As	   the	  name	   suggests,	   IRFs	   are	   responsible	   for	   the	   transcriptional	   regulation	  of	   IFNs.	  
However,	   IRFs	   also	   play	   multiple	   roles	   in	   the	   regulation	   of	   innate	   and	   adaptive	   immune	  
responses,	  including	  roles	  in	  pathogen	  response,	  cytokine	  signalling	  and	  cell	  growth	  regulation.	  	  
	  
All	   IRFs	   share	   homology	   in	   their	   N-­‐terminal	   DNA	   binding	   domain	   that	   encompasses	   five	  
tryptophan	   residue	   repeats.	   The	  DNA	  binding	  domain	   forms	  a	  helix-­‐turn-­‐helix	  binding	  motif,	  
which	   allows	   the	   recognition	   of	   the	   IFN-­‐stimulated	   response	   element	   (ISRE),	   found	   in	  
promoters	  of	  most	  IFN-­‐inducible	  genes	  (Mamane	  et	  al.,	  1999).	  All	   IRFs,	  with	  the	  exception	  of	  
IRF-­‐1	  and	   IRF-­‐2	  contain	  an	   IRF	  association	  domain	   in	  their	  C-­‐terminal	   region,	  which	  accounts	  
for	   the	   regulation	   of	   homo-­‐	   and	   heterodimerisation	   with	   family	   members	   or	   other	  
transcription	  factors	  (Mamane	  et	  al.,	  1999;	  Taniguchi	  et	  al.,	  2001).	  IRF-­‐1,	  IRF-­‐3,	  IRF-­‐5	  and	  IRF-­‐7	  
have	  been	  implicated	  as	  positive	  regulators	  of	  type	  I	  IFN	  genes.	  	  	  
	  	  
IRF-­‐3	  and	  IRF-­‐7	  share	  the	  greatest	  homology	  with	  both	  playing	  a	  role	  in	  regulating	  type	  I	  and	  
type	   III	   IFN	  gene	  expression	   induced	  by	  viruses	  via	   the	  RIG-­‐I/MDA5	  signalling	  pathway.	   IRF-­‐3	  
can	  also	  be	  induced	  via	  TRIF	  in	  TLR3	  and	  TLR4	  signalling,	  whilst	  IRF-­‐7	  is	  induced	  via	  TLR7,	  TLR8	  
and	  TLR9	  signalling	  (Honda	  et	  al.,	  2005;	  Taniguchi	  et	  al.,	  2001).	  IRF-­‐3	  is	  constitutively	  expressed	  
in	   its	   inactive	   form	   the	   cytosol	   of	  most	   cells.	  Upon	   viral	   stimulation,	   IRF-­‐3	   undergoes	   serine	  
phosphorylation	  followed	  by	  homodimerisation	  or	  heterodimerisation	  with	   IRF-­‐7	  (Honda	  and	  
Taniguchi,	  2006).	  This	  dimer	  complex	  then	  undergoes	  nuclear	   translocation	  where	   it	   forms	  a	  
holocomplex	   with	   the	   transcriptional	   co-­‐activators,	   cyclic-­‐AMP	   responsive	   element	   binding	  
protein	   (CREB)-­‐binding	   protein	   (CBP)	   and	   p300,	   ultimately	   resulting	   in	   type	   I	   IFN	   gene	  
activation	   (Lin	   et	   al.,	   1998;	   Sato	   et	   al.,	   1998).	   The	  different	   combinations	  of	   IRF-­‐3	   and	   IRF-­‐7	  
dimer	  complexes	  result	  in	  altered	  gene	  transcription	  profiles,	  where	  IRF3	  specifically	  activates	  
IFN-­‐β	   genes	   and	   IFN-­‐α4	   whilst	   IRF7	   results	   in	   the	   activation	   of	   both	   IFN-­‐α	   and	   IFN-­‐β	   gene	  
transcription	   (Marie	   et	   al.,	   1998;	   Sato	   et	   al.,	   1998;	   Sato	   et	   al.,	   2001).	   Unlike	   IRF-­‐3,	   IRF-­‐7	   is	  
expressed	  in	  small	  quantities	  in	  most	  cell	  types	  unless	  induced	  by	  type	  I	  and	  III	  IFNs.	  Type	  I	  IFNs	  
elicit	   the	   induction	   of	   IRF-­‐7	   via	   activation	   of	   IFN-­‐stimulated	   gene	   factor	   3	   (ISGF3),	   a	  
heterotrimeric	  transcriptional	  activator	  consisting	  of	  IRF-­‐9,	  STAT1	  and	  STAT2.	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1.6.3	  MAPK	  Signalling	  
	  
TLR	   signalling	   results	   in	   the	   activation	   of	   transcription	   factors	   such	   as	   NF-­‐κB	   and	   mitogen-­‐
activated	  protein	  kinases	   (MAPKs).	  MAPKs	  are	  a	  highly	   conserved	   family	  of	   serine/threonine	  
protein	  kinases	  (Arthur	  and	  Ley,	  2013;	  Blenis,	  1993).	  MAPK	  signalling	  plays	  a	  key	  role	  in	  many	  
fundamental	   cellular	   processes	   including	   induction	   of	   cell	   proliferation,	   cell	   growth,	  
differentiation	  and	  the	  inflammatory	  response.	  The	  three	  best-­‐characterised	  members	  of	  the	  
MAPK	  family	  includes	  the	  extracellular	  signal	  regulated	  kinase	  (ERK),	  C-­‐Jun	  N-­‐terminal	  kinase/	  
stress-­‐activated	   protein	   kinase	   (JNK/SAPK)	   and	   p38	   MAPK.	   MAPKs	   form	   part	   of	   a	   protein	  
kinase	   cascade	   consisting	   of	   at	   least	   three	   sequentially	   activated	   enzymes.	   This	   three-­‐stage	  
protein	  kinase	  cascade	  begins	  with	  the	  phosphorylation	  of	  MAPKK	  by	  MAPKKK	  resulting	  in	  the	  
activation	  of	  p38s,	  ERK	  and	  JNK/SAPKs	  (Karin,	  1996)	  (Figure	  1.4).	  
	  
ERKs	  were	  the	  first	  mammalian	  members	  of	  the	  MAPK	  family	  to	  be	  cloned	  and	  characterised	  
(Boulton	  et	  al.,	  1991;	  Boulton	  et	  al.,	  1990).	   	  ERK1/2	  are	   regulated	  by	   their	  upstream	  MAPKK	  
ligands	   MAPK/ERK	   kinase	   1	   and	   2	   (MEK1	   and	   MEK2),	   which	   in	   turn	   are	   activated	   by	   their	  
upstream	   counterparts	  MAPKKK,	   A-­‐Raf,	   B-­‐Raf	   and	   Raf-­‐1.	   A	   further	   two	  MAPKKKs,	  Mos	   and	  
Tpl2	  (also	  known	  as	  Cot),	  have	  also	  been	  identified	  but	  function	  only	  in	  restricted	  cell	  type	  and	  
stimulus	  specific	  manner	  (Posada	  et	  al.,	  1993;	  Waterfield	  et	  al.,	  2003).	  	  
	  
The	  JNK	  family	  consists	  of	  three	  isoforms	  termed	  JNK1,	  JNK2	  and	  JNK3.	  Whilst	  JNK1	  and	  JNK2	  
are	  broadly	  distributed	  amongst	  tissue,	  JNK3	  is	  mostly	  localised	  to	  neuronal	  tissues,	  testis	  and	  
cardiac	  myocytes	  (Bode	  and	  Dong,	  2007).	  The	  MAPKKKs	  involved	  in	  the	  JNK	  signalling	  pathway	  
differ	   from	   those	   of	   ERK.	  MEK	   kinase	   1	   (MEKK1)	   functions	   as	  MAPKKK	   in	   the	   JNK	   pathway.	  
MEKK1	   then	  phosphorylates	  MKK4	  at	   serine	  and	   threonine	   residues	  consequently	   leading	   to	  
JNK	  phosphorylation	  and	  activation.	  	  
	  
The	  p38	  MAPKs	  were	  originally	  described	  as	  protein	  kinases	  activated	  by	  LPS	  following	  tyrosine	  
phosphorylation	  (Han	  et	  al.,	  1994).	  A	  total	  of	  four	  p38	  isoforms	  have	  been	  identified	  as	  p38α,	  
p38β,	  p38γ	  and	  p38δ.	  Similarly	  to	  JNK,	  a	  plethora	  of	  MAPKKKs	  are	   involved	  in	  p38	  activation	  
including	  MEKK1-­‐3,	  MLK2/3,	  TAK1,	  ASK1,	  TAO1/2	  and	  Tpl2	  (Cuadrado	  and	  Nebreda,	  2010).	  The	  
MAPKK	  MKK6	  acts	  on	  all	  p38	  isoforms	  whilst	  MMK3	  selectively	  phosphorylates	  p38α,	  p38γ	  and	  
p38δ.	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AP-­‐1	   is	   a	  heterodimer	   composed	  of	   sequence-­‐specific	   transcriptional	   activators	  belonging	   to	  
the	  basic	   leucine	   zipper	   (bZIP)	   superfamily	  of	  DNA	  binding	  proteins	   such	  as	   c-­‐Jun,	   c-­‐Fos	   and	  
ATF2	  (Karin,	  1996;	  Karin	  et	  al.,	  1997).	  MAPKs	  can	  regulate	  the	  activation	  of	  activator	  protein-­‐1	  
(AP-­‐1)	  by	  direct	  phosphorylation	  of	  AP-­‐1	  proteins	  and	  altering	  the	  abundance	  of	  individual	  AP-­‐
1	  components	  within	  a	  cell	  (Silvers	  et	  al.,	  2003).	  ERK,	  p38	  and	  JNK	  substrates	  such	  as	  Elk-­‐1	  or	  
serum	  response	  factor	  accessory	  protein	  (SAP)	  1a	  and	  2	  increase	  AP-­‐1	  complex	  component,	  c-­‐
Fos	  (Pearson	  et	  al.,	  2001).	  Both	  p38	  and	  JNK	  can	  phosphorylate	  the	  transactivating	  domain	  of	  
ATF2,	  while	  JNK	  can	  directly	  phosphorylate	  the	  c-­‐Jun	  activation	  domain.	  In	  addition,	  both	  ERK	  
and	  p38	  phosphorylate	  MEF2	   transcription	   factors	   that	   bind	   the	   c-­‐jun	  promoter	   (Han	   et	   al.,	  
1997).	  AP-­‐1	  activation	  results	  in	  transcription	  of	  multiple	  genes	  including	  IL-­‐1,	  TNF,	  c-­‐Jun	  itself	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Figure	  1.4:	  MAPK	  cascades	  in	  mammalian	  cells	  
MAPK	  signalling	  cascade	  involves	  the	  sequential	  phosphorylation	  of	  three	  kinases:	  MAP	  kinase	  
kinase	   kinase	   (MAPKKK),	   MAP	   kinase	   kinase	   (MAPKK)	   and	   MAP	   kinase	   (MAPK).	   This	   figure	  
provides	  a	  simple	  overview	  of	  three	  mammalian	  MAPK	  cascades	  that	  regulate	  the	  activity	  of	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1.7	  Pellino	  
	  
Pellino	  was	   first	   characterised	   in	  Drosophila	  melanogaster	  as	   a	   binding	  partner	   of	   Pelle,	   the	  
Drosophila	   counterpart	   of	   mammalian	   IRAK	   (Grosshans	   et	   al.,	   1999).	   In	   Drosophila	  
melanogaster,	   Pellino	   positively	   regulates	   the	   innate	   immunity	   in	   response	   to	   gram-­‐positive	  
bacteria	   (Haghayeghi	  et	  al.,	  2010).	  Since	   its	  discovery,	  a	   role	   for	  Pellino	   in	  TLR/IL-­‐1	  signalling	  
has	   been	   identified	   (Grosshans	   et	   al.,	   1999).	   In	   humans	   the	   Pellino	   family	   is	   composed	   of	  
Pellino-­‐1,	   Pellino-­‐2	   and	   splice	   variants	   Pellino-­‐3a	   and	   Pellino-­‐3b	   (Jensen	   and	   Whitehead,	  
2003a;	   Jiang	  et	   al.,	   2003;	  Resch	  et	   al.,	   2001;	  Rich	  et	   al.,	   2000;	   Yu	  et	   al.,	   2002).	   These	  highly	  
conserved	  Pellino	   isoforms	   share	  approximately	  85%	  homology	  with	  each	  other	   (Jensen	  and	  
Whitehead,	  2003b).	  Pellino-­‐1,	  Pellino-­‐2	  and	  Pellino-­‐3	  have	  all	  been	  shown	  to	  interact	  with	  TLR	  
signalling	  molecules	   such	  as	   IRAK1,	   IRAK	  4,	   TRAF6	  and	  TAK1	   (Butler	  et	  al.,	   2005;	   Jensen	  and	  
Whitehead,	   2003a,	   b;	   Jiang	   et	   al.,	   2003;	   Yu	   et	   al.,	   2002).	   Previous	  work	   from	  my	   group	   has	  
identified	  a	  role	  for	  Pellino-­‐1	  in	  the	  regulation	  of	  human	  pathogens	  indicating	  a	  potential	  novel	  




Pellino-­‐1	   is	   a	   ubiquitously	   expressed	   protein,	   however	   its	   levels	   of	   expression	   vary	   across	  
different	   organs;	   In	  murine	   tissue	   Pellino-­‐1	   was	   found	   to	   be	   highly	   expressed	   in	   peripheral	  
blood	  leukocytes,	  moderately	  in	  lung,	  liver,	  placenta,	  kidney,	  spleen	  and	  brain,	  with	  low	  levels	  
of	  expression	  in	  the	  small	  intestine,	  heart	  and	  colon	  (Jiang	  et	  al.,	  2003).	  	  
	  
Pellino-­‐1	   was	   first	   described	   in	   2003	   and	   associated	   with	   TLR/IL-­‐1R	   signalling.	   Jiang	   et	   at	  
identified	   a	   role	   for	   Pellino-­‐1	   in	   the	   IL-­‐1-­‐dependent	   activation	   of	   NF-­‐κB	   signalling	   and	   the	  
resulting	  CXCL-­‐8	  production;	  the	  group	  proposed	  Pellino-­‐1	  induces	  its	  effects	  through	  its	  IL-­‐1-­‐
dependent	   interaction	   with	   the	   IRAK4/IRAK1/TRAF6	   signalling	   complex	   (Jiang	   et	   al.,	   2003).	  
Initially	  Pellino-­‐1	  was	  believed	  to	  function	  solely	  as	  a	  scaffolding	  protein	  due	  to	  its	  perceptible	  
lack	   of	   enzymatic	   activity	   and	   functional	   domains.	   However,	   in	   2006	   Schauvliege	   et	   al	  
determined	  Pellino-­‐1’s	  biochemical	  function	  as	  an	  E3-­‐ubiquitin	   ligase	  (see	  section	  1.7.2).	  The	  
group	   identified	   a	   novel	   RING	   (really	   interesting	   new	   gene)-­‐like	  motif,	   CHC2CHC2,	   in	   the	   C-­‐
terminal	   containing	   a	   unique	   Cys-­‐Gly-­‐His	   triplet	   sandwiched	   between	   two	   Cys-­‐Pro-­‐X-­‐Cys	  
motifs,	  which	  closely	  resemble	  the	  structure	  of	  a	  traditional	  C3HC4	  RING,	  best	  known	  for	  their	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occurrence	   in	  RING	  E3-­‐ubiquitin	   ligases	   (Schauvliege	  et	  al.,	  2006).	  The	  group	   further	  showed	  
that	  Pellino-­‐1	  exerts	  its	  activation	  on	  NF-­‐κB	  signalling	  through	  polyubiquitination	  of	  IRAK-­‐1	  via	  
its	   RING-­‐like	   domain;	   whilst	   Pellino-­‐1	   mutants	   containing	   mutated	   cysteine	   and	   histidine	  
residues	  did	  not	  induce	  the	  polyubiquitination	  of	  IRAK1	  (Schauvliege	  et	  al.,	  2006,	  2007).	  	  	  
	  
Subsequent	   publications	   confirmed	   the	   role	   for	   Pellino-­‐1	   as	   an	   E3-­‐ubiquitin	   ligase	   and	  
identified	   its	   ability	   to	   catalyse	   a	   variety	   of	   polyubiquitin	   chains	   in	   vitro,	   depending	   on	   the	  
presence	   of	   the	   E2	   enzymes	   available	   (Butler	   et	   al.,	   2007).	   Pellino-­‐1	   can	   act	   with	   E2	  
conjugating	  complex	  UbcH3	  to	  form	  Lys48-­‐linked	  polyubiquitin	  chains,	  or	  interact	  with	  UbcH4,	  
UbcH5a	  or	  UbcH5b	  to	  catalyse	  the	  formation	  of	  Lys48-­‐	  and	  Lys11-­‐linked	  chains	  (Ordureau	  et	  
al.,	  2008).	  Pellino-­‐1	  can	  also	   interact	  with	  E2	  heterodimer	  Ubc13-­‐Uev1a	  to	  form	  Lys63-­‐linked	  
polyubiquitin	  chains	  associated	  with	  IRAK1	  ubiquitination	  (Butler	  et	  al.,	  2007;	  Ordureau	  et	  al.,	  
2008;	  Xiao	  et	  al.,	  2008).	  	  
	  
1.7.2	  Ubiquitination	  	  
	  
Ubiquitination	  plays	  a	  critical	  role	  in	  regulating	  a	  host	  of	  crucial	  cellular	  functions	  including	  the	  
initiation	  of	   inflammatory	   responses	   through	   the	   regulation	  of	   signalling	  molecules	   (Deng	  et	  
al.,	   2000;	   Pickart,	   2001)	   (Reviewed	   extensively	   by	   (Malynn	   and	   Ma,	   2010)).	   The	   highly	  
conserved	  process	  of	  ubiquitination	  involves	  the	  formation	  of	  an	  isopeptide	  bond	  between	  the	  
C-­‐terminus	  of	  the	  76-­‐amino	  acid	  peptide,	  ubiquitin,	  to	  the	  ε-­‐amino	  group	  of	  a	  lysine	  residue	  of	  
the	  target	  protein.	  This	  post-­‐translational	  modification	  occurs	  through	  the	  sequential	  action	  of	  
three	  enzymes:	  E1	  ubiquitin-­‐activating	  enzyme	  (E1),	  E2	  ubiquitin-­‐conjugating	  enzyme	  (E2)	  and	  
E3	  ubiquitin-­‐protein	  ligase	  (E3)	  (Figure	  1.5).	  Initially,	  ubiquitin	  is	  activated	  via	  the	  formation	  of	  
a	   thioester	  bond	  between	   the	  C-­‐terminus	  of	  ubiquitin	   and	   the	  active	   site	   cysteine	  of	   the	  E1	  
enzyme.	   The	   thioester-­‐ubiquitin	   is	   then	   transiently	   transferred	   by	   the	   E2	   enzyme	   to	   the	   E3	  
ligase	  where	  it	  is	  covalently	  attached	  to	  its	  target	  substrate	  (Pickart,	  2001)	  (d'Azzo	  et	  al.,	  2005).	  	  	  
	  
Although	  there	  are	  only	  two	  isoforms	  of	  E1	  enzymes	  encoded	  in	  the	  human	  genome,	  there	  are	  
37	   E2	   enzymes	   known,	   and	   over	   600	   E3	   ligases	   dictating	   the	   substrate	   specificity	   of	   the	  
ubiquitination	   process	   (Komander,	   2009).	   	   There	   are	   three	   primary	   types	   of	   E3	   ligases	  
distinguished	   by	   the	   presence	   of	   a	   HECT	   (homologous	   to	   E6-­‐AP	   carboxyl	   terminus)	   domain,	  
RING	  domain	  and	  U-­‐box	  domain	   (Hatakeyama	  and	  Nakayama,	  2003).	  E3	   ligases	  containing	  a	  
HECT	   domain	   catalyse	   ubiquitination	   by	   intermediately	   binding	   ubiquitin	   through	   the	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formation	   of	   a	   thioester	   bond	   before	   transferring	   to	   the	   target	   substrate.	   In	   contrast,	   E3	  
ligases	   containing	   a	  RING	  domain	   and	  U-­‐box	  domain	   serve	   as	   a	   scaffold	   that	   bridges	   the	   E2	  
enzyme’s	  active	  site	  directly	  to	  the	  substrate.	  
	  
Ubiquitin	   contains	   seven	  distinct	   lysine	   residues,	   Lys6,	   Lys11,	   Lys27,	   Lys29,	   Lys33,	   Lys48	  and	  
Lys63,	  which	   can	   result	   in	   further	   versatility	   of	   the	   reaction.	   The	  multiple	   lysine	   residues	   in	  
ubiquitin	  allow	   for	   the	  addition	  of	   further	  ubiquitin	  molecules	   to	   itself,	   resulting	   in	  ubiquitin	  
polymers.	  A	  substrate	  ubiquitinated	  with	  a	  single	  ubiquitin	  molecule	  on	  a	  single	  lysine	  residue	  
is	  termed	  monoubiquitination;	  whilst	  the	  ubiquitination	  of	  multiple	  ubiquitin	  chains	  can	  form	  
via	   a	  process	   termed	  polyubiquitination.	   The	  nature	  of	   the	   lysine	   linkages	  used	   in	   individual	  
polyubiquitin	   chains	   have	   great	   physiological	   implications.	   The	   conjugation	   of	   lysine-­‐specific	  
ubiquitin	   chains	   to	   a	   substrate	   protein	   can	   result	   in	   the	  modulation	   of	   a	  myriad	   of	   cellular	  
processes.	   For	   instance,	   the	   mediation	   of	   protein	   degradation	   by	   26S	   proteasome	   occurs	  
through	   the	   recognition	   of	   Lys48-­‐tagged	   polyubiquitin	   chains.	   Whereas	   Lys63	   polyubiquitin	  
chains	  are	  involved	  in	  the	  regulation	  of	  gene	  expression	  through	  its	  effects	  on	  protein-­‐protein	  
interactions	  and	  activation	  of	  kinases	  and	  phosphatases	   (d'Azzo	  et	  al.,	  2005;	  Liu	  et	  al.,	  2005;	  
Moynagh,	  2009).	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Figure	  1.5:	  Ubiquitination	  pathway	  
Ubiquitination	  is	  a	  post-­‐translational	  modification	  that	  occurs	  in	  a	  three	  step	  process.	  Firstly	  an	  
ATP-­‐dependent	  thioester	  bond	  is	  formed	  between	  the	  C-­‐terminus	  of	  ubiquitin	  and	  the	  active	  
site	  cysteine	  of	  the	  E1	  enzyme	  (Step	  1).	  The	  thioester-­‐ubiquitin	  is	  then	  transiently	  transferred	  
by	   the	   E2	   enzyme	   (Step	   2)	   to	   the	   E3	   ligase	   where	   it	   is	   covalently	   attached	   to	   its	   target	  
substrate	   (Step	  3).	   The	  multiple	   lysine	   residues	   in	  ubiquitin	  allow	   for	   the	  addition	  of	   further	  
ubiquitin	  molecules	  to	  itself,	  resulting	  in	  ubiquitin	  polymers	  (Step	  4).	  The	  conjugation	  of	  lysine-­‐
specific	   ubiquitin	   chains	   to	   a	   substrate	   protein	   can	   result	   in	   the	  modulation	   of	   a	  myriad	   of	  
cellular	   processes.	   For	   instance,	   Lys48-­‐tagged	   polyubiquitin	   result	   in	   protein	   degradation	   by	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1.7.3	  Pellino-­‐1	  phosphorylation	  
	  
In	   addition,	   IRAK1	   and	   IRAK4	   have	   the	   potential	   to	   phosphorylate	   Pellino-­‐1	   and	   in	   turn	  
enhance	  Pellino-­‐1’s	  E3-­‐ubiquitin	   ligase	  activity	  culminating	   in	  the	  polyubiquitination	  of	   IRAK1	  
(Ordureau	   et	   al.,	   2008;	   Schauvliege	   et	   al.,	   2006).	   Phosphorylation	   of	   any	   of	   the	   Pellino-­‐1	  
activating	   serine/threonine	   residues	   Ser-­‐76,	   Thr-­‐86,	   Thr-­‐288	  or	   Ser-­‐293,	  or	   a	   combination	  of	  
Ser-­‐78,	   Thr-­‐80	   and	   Ser-­‐82	   results	   in	   the	   complete	   activation	   of	   Pellino-­‐1	   E3	   ubiquitin	   ligase	  
activity	  (Smith	  et	  al.,	  2009).	  
Pellino-­‐1	   serves	   as	   a	   substrate	   for	   the	   IRAK1	   kinase	   domain	   which	   results	   in	   Pellino-­‐1	  
phosphorylation	   followed	   by	   IRAK1	   and	   IRAK4	   Lys63-­‐polyubiquitination	   (Butler	   et	   al.,	   2007;	  
Schauvliege	   et	   al.,	   2006;	   Xiao	   et	   al.,	   2008).	   This	   process	   however	   also	   promotes	   IRAK-­‐
dependent	  Pellino-­‐1	  degradation	  via	  a	  reciprocal	  polyubiquitination	  by	  a	  separate	  unidentified	  
E3	   ubiquitin	   (Butler	   et	   al.,	   2007).	   This	   bidirectional	   signalling	   between	   the	   IRAK	   and	   Pellino	  
family	  may	  act	  as	  a	  negative	  feedback	  loop	  to	  sequester	  TLR/IL-­‐1R	  signalling.	  	  
	  
1.7.4	  Pellino-­‐1	  sumoylation	  
	  
Pellino-­‐1	  also	  undergoes	  a	  post-­‐translational	  modification	  called	  sumoylation.	  The	  process	  of	  
sumoylation	  is	  similar	  with	  that	  of	  ubiquitination	  wherein	  a	  protein	  called	  small	  ubiquitin-­‐like	  
modifier	   (SUMO)	   covalently	   adheres	   to	   lysine	   residues	   of	   target	   substrates	   through	   an	  
analogous	   enzyme	   cascade	   of	   E1-­‐activating	   enzyme,	   E2-­‐conjugating	   enzymes	   and	   E3-­‐ligase	  
enzymes.	  Pellino	  1	  undergoes	  sumoylation	   to	   its	   Lys169,	  Lys202,	  Lys266,	  Lys295,	  Lys297	  and	  
Lys303	  regions,	  which	  coincide	  with	  its	  ubiquitination	  sites	  Lys169,	  Lys202,	  and	  Lys266	  (Kim	  et	  
al.,	   2011a).	   This	   not	   only	   suggests	   a	   competitive	   nature	   between	   ubiquitination	   and	  
sumoylation,	  but	  also	  infers	  a	  further	  distinct	  role	  for	  Pellino-­‐1	  that	  has	  yet	  to	  be	  identified.	  	  
	  
1.7.5	  Pellino-­‐1	  Physiological	  function	  
	  
The	   physiological	   function	   of	   Pellino-­‐1	   remains	   elusive	   with	   existing	   data	   providing	   both	  
varying	  and	  contradicting	  results.	  A	  role	  for	  Pellino-­‐1	  was	  first	  identified	  in	  MyD88-­‐dependent	  
signalling	   wherein	   Pellino-­‐1	   regulated	   IL-­‐1	   induced	   NF-­‐κB	   activation	   and	   IL-­‐8/CXCL8	   gene	  
expression	  in	  the	  HEK293	  cell	  line	  (Jiang	  et	  al.,	  2003).	  Interestingly,	  this	  regulation	  of	  TLR/IL-­‐1R	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signalling	  by	  Pellino-­‐1	  can	  be	  negatively	  regulated	  by	  the	  anti-­‐inflammatory	  cytokine,	  TGF-­‐β1,	  
through	   its	   induction	   of	   inhibitory	   Smads	   (I-­‐Smads),	   Smad6	   and	   Smad7.	   I-­‐Smads	   exert	   their	  
anti-­‐inflammatory	   activity	   by	  binding	  Pellino	   1	   and	   restricting	  NF-­‐κB	   activation	  by	  disrupting	  
the	   formation	   of	   Pellino-­‐1/IRAK4/IRAK1/TRAF6	   complex	   (Choi	   et	   al.,	   2006;	   Lee	   et	   al.,	   2010).	  	  
Similarly,	   microRNA-­‐21	   (miR-­‐21)	   has	   been	   shown	   to	   negatively	   regulate	   NF-­‐κB	   signalling	   by	  
directly	   inhibiting	   Pellino-­‐1	   expression	   during	   the	   proliferative	   phases	   of	   liver	   regeneration.	  
miR-­‐21	   exerts	   its	   effects	   on	   Pellino-­‐1	   by	   binding	   to	   the	   3’	   untranslated	   region	   (UTR)	   of	   its	  
mRNA	  resulting	  in	  reduction	  of	  Pellino-­‐1	  expression	  (Marquez	  et	  al.,	  2010).	  	  
	  
More	  recently	  with	  the	  generation	  of	  the	  Pellino1	  knockout	  mouse,	  it	  has	  been	  suggested	  that	  
it	   is	   involved	   in	  TLR3	  signalling	  (Chang	  et	  al.,	  2009).	  Pellino1	  deficient	  mice	  develop	  normally	  
but	   are	   resistant	   to	   LPS-­‐induced	   toxic	   shock	   and	   show	   impaired	   B-­‐cell	   proliferation	   and	  
induction	   of	   co-­‐stimulatory	   molecules	   CD86	   and	   MHC	   class	   II	   molecules.	   In	   contrast	   to	  
previous	   studies,	   Pellino1	  deficient	  MEFs	   showed	  preserved	   IL-­‐1	   signalling	   but	   had	   impaired	  
responses	   to	   the	   TLR3	   agonist	   and	   viral	  mimic	   poly(I:C)	   (Chang	   et	   al.,	   2009).	   This	   study	   also	  
showed	   that	   Pellino-­‐1	   was	   capable	   of	   binding	   to	   and	   ubiquitinating	   RIP1	   and	   this	   was	  
suggested	  as	  a	  potential	  Pellino-­‐1	  target	  in	  TLR3	  signalling	  (Chang	  et	  al.,	  2009).	  
	  
These	  data	  indicate	  Pellino-­‐1	  has	  an	  important	  role	  in	  mediating	  TLR/IL-­‐1R	  signalling.	  However,	  
with	   the	  generation	  of	  Pellino-­‐1	  knockout	  mice	   came	   the	  discovery	  of	  a	   role	   for	  Pellino-­‐1	   in	  
TLR3	  and	  TLR4	   signalling	   (Chang	  et	  al.,	   2009).	  Pellino-­‐1	  knockout	  mice	  develop	  normally	  but	  
show	   resistance	   to	   LPS-­‐	   and	  poly(I:C)-­‐induced	   sceptic	   shock	  and	   resulted	   in	  decreased	  B-­‐cell	  
proliferation.	  	  In	  addition	  a	  role	  for	  Pellino-­‐1	  in	  the	  TRIF-­‐dependent	  IKK-­‐signalling	  arm	  of	  TLR3	  
signalling	  via	  its	  interaction	  with	  RIP1	  and	  mediation	  of	  RIP1	  ubiquitination	  in	  MEFs	  taken	  from	  
the	  Pellino-­‐1	  knockout	  mouse	  was	  identified	  (Chang	  et	  al.,	  2009).	  Furthermore	  and	  in	  contrast	  
to	   previous	   data,	   Pellino-­‐1	   was	   found	   to	   be	   dispensable	   for	   MyD88-­‐dependent	   and	   IL-­‐1R	  
signalling	   in	   Pellino-­‐1	   deficient	   MEFs	   (Chang	   et	   al.,	   2009).	   Pellino-­‐1	   phosphorylation	   and	  
activation	  has	  been	  shown	  to	  be	  mediated	  by	  IKKε	  and	  TBK1	  axis	  of	  TLR3	  signalling	  in	  murine	  
bone	   marrow	   derived	   macrophages	   (BMDM)	   in	   an	   IRF-­‐3	   dependent	   manner	   (Smith	   et	   al.,	  
2011).	  In	  addition,	  Pellino-­‐1	  knockdown	  performed	  on	  HEK293	  cells	  did	  not	  affect	  IL-­‐1	  and	  LPS-­‐	  
induced	  IRAK1	  Lys63-­‐linked	  polyubiquitination	  (Kim	  et	  al.,	  2012).	  These	  studies	  contradict	  the	  
results	   obtained	   from	   previous	   studies	   and	   also	   highlight	   the	   increasingly	   complex	   field	   of	  
Pellino-­‐1	  physiology.	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1.8	  Hypothesis	  and	  Aims	  
	  
Viral	   and	   bacterial	   infections	   account	   for	   the	   majority	   of	   exacerbations	   of	   COPD	   and	   can	  
subsequently	   result	   in	   pronounced	   functional	   impairment	   of	   the	   airway	   increasing	   both	   the	  
severity	   of	   the	   disease	   and	   frequency	   of	   exacerbations.	   In	   addition,	   COPD	   patient	   airways	  
often	   chronically	  harbour	  bacterial	   and	   viral	   pathogens	  within	   their	   airways	  despite	  ongoing	  
inflammation	   aimed	   at	   their	   resolution	   (Hurst	   et	   al.,	   2006).	   Thus,	   understanding	   the	   key	  
regulatory	  pathways	  governing	  pathogen-­‐induced	  chronic	   inflammation	  could	  provide	  pivotal	  
information	  regarding	  COPD	  pathogenesis.	  
	  
Pellino-­‐1,	   originally	   identified	   as	   a	   regulator	   of	   IL-­‐1	   signalling	   (Jiang	   et	   al.,	   2003),	   and	  more	  
recently	  identified	  in	  TLR	  signalling	  in	  response	  to	  viral	  infection	  (Chang	  et	  al.,	  2009)	  may	  play	  a	  
central	   role	   in	   the	   regulation	   of	   innate	   immunity.	   This	   thesis	   investigates	   the	   regulation	   of	  
Pellino-­‐1	  and	  its	  role	  in	  viral	  infection	  in	  human	  bronchial	  airway	  epithelial	  cells.	  	  
	  
Therefore,	  it	  was	  hypothesized	  that:	  
1. Continuous	   activation	  of	   human	  bronchial	   epithelial	   cells	   by	  pathogenic	   agonists	  will	  
alter	  their	  ongoing	  inflammatory	  response.	  	  
2. Pellino-­‐1	  regulates	  inflammatory	  responses	  to	  viral	  pathogens.	  
	  
The	  aims	  of	  this	  thesis	  were:	  
1. To	  create	  an	  in	  vitro	  model	  of	  chronic	  airway	  inflammation	  using	  cell	  lines	  and	  primary	  
airway	  epithelial	  cells.	  	  
2. To	  understand	  whether	  chronic	   inflammation	  uses	  different	  molecular	  pathways	  and	  
presents	  different	  targets	  for	  treatment	  of	  disease.	  
3. To	  dissect	  of	  the	  roles	  of	  Pellino-­‐1	   in	  regulation	  of	  TLR3	  signaling	   in	  response	  to	  viral	  
stimuli.	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Reagents	  were	  purchased	   from	  Sigma-­‐Aldrich	   (Poole,	  UK)	   or	   Invitrogen	   (Paisley,	  UK),	   except	  
where	   specified.	   Recombinant	   human	   IL-­‐1β	   was	   purchased	   from	   Peprotech	   (London,	   UK).	  
Poly(I:C)	  was	  purchased	  from	  Invivogen	  (Toulouse,	  France)	  and	  purified	  LPS	  was	  from	  Axxora	  
(Nottingham,	  UK).	  IL-­‐1Ra	  was	  from	  the	  National	  Institute	  for	  Biological	  Standards	  and	  Control	  
(Potters	  Bar,	  UK).	  OptiPrepTM	  density	  gradient	  was	  purchased	  from	  Axis	  shield	  (Oslo,	  Norway).	  
MACS	   LS	   columns	  were	   purchased	   from	  Miltenyi	   Biotec	   (Bergisch	   Gladbach,	   Germany).	   Cell	  
culture	   flasks	  were	   purchased	   from	  Nunc	   (Thermo	   Fisher	   Scientific,	   Loughborough,	   UK)	   and	  
cell	  culture	  plates	  were	  purchased	  from	  Costar	  (Sigma-­‐Aldrich).	  All	  flow	  cytometry	  antibodies	  
and	  isotype	  controls	  were	  from	  eBioscience	  (San	  Diego,	  USA).	  The	  protease	  inhibitor	  cocktail	  III	  
was	   from	  Calbiochem	  (Nottingham,	  UK),	  30%	  polyacrylamide	   from	  Gene	  Flow	   (Staffordshire,	  
UK)	   RT-­‐PCR	   primers	   were	   ordered	   from	   Eurogentec	   (Southampton,	   UK)	   unless	   otherwise	  
stated.	  Matched	  ELISA	  antibody	  pairs	  were	  purchased	  from	  R&D	  Systems	  (Abingdon,	  UK).	  
 
2.2	  Mammalian	  Cell	  Culture	  
	  
2.2.1	  BEAS-­‐2B	  cell	  line	  maintenance	  
 
The	   immortalized	   bronchial	   epithelial	   cell	   line	   BEAS-­‐2B	  was	   purchased	   from	   American	   Type	  
Culture	  Collection	  (Manassas,	  VA,	  USA)	  and	  maintained	  in	  RPMI	  1640	  supplemented	  with	  10%	  
low-­‐endotoxin	   Foetal	  Bovine	   Serum	   (FBS)	  purchased	   from	  Promocell	   (Heidelberg,	  Germany),	  
100	  U/ml	  penicillin	  and	  100	  µg/ml	  streptomycin.	  
	  
Cells	  were	  seeded	  at	  a	  density	  of	  1x106	  cells	  per	  T75	  cm2	  flask	  and	  were	  passaged	  when	  80-­‐
90%	  confluence	  was	  reached	  (approximately	  every	  3	  days).	  	  Cell	  detachment	  was	  obtained	  by	  
gently	  washing	  the	  cell	  surface	  layer	  with	  10	  ml	  PBS	  followed	  by	  the	  addition	  of	  2	  ml	  of	  non-­‐
enzymatic	  cell-­‐dissociation	  solution	  and	  incubation	  at	  37°C	  for	  between	  5	  to	  10	  minutes.	  This	  
reaction	  was	   suspended	   by	   the	   addition	   of	   a	   further	   8	  ml	   of	   cell	   culture	  media.	   Cells	   were	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maintained	   at	   37°C	   and	   humidified	   5%	   CO2.	   Cell	   culture	  media	   was	   tested	  monthly	   for	   the	  
presence	   of	   mycoplasma	   using	   EZ-­‐PCR	   mycoplasma	   test	   kit	   (Geneflow,	   Staffordshire,	   UK)	  
according	  to	  manufacturer’s	  instructions.	  
 
2.2.2	  THP-­‐1	  cell	  line	  maintenance	  
 
The	   human	   acute	  monocytic	   leukemic	   cell	   line	   THP-­‐1	  was	   purchased	   from	  ATCC	   (Manassas,	  
VA,	  USA)	  and	  maintained	   in	  RPMI	  1640	  medium	  supplemented	  with	  10%	  low-­‐endotoxin	  FBS,	  
100	  U/ml	  penicillin	  and	  100	  µg/ml	  streptomycin	  2	  mM	  L-­‐glutamine.	  	  
	  
Cells	  were	  maintained	  at	  2x105	  cells/ml	  and	  were	  passaged	  when	  8x105	  cells/ml	  was	  reached	  
by	  the	  replacement	  or	  addition	  of	  fresh	  media.	  Cells	  were	  maintained	  at	  37°C	  and	  humidified	  
5%	  CO2.	  Cell	  culture	  media	  was	  tested	  monthly	  for	  the	  presence	  of	  mycoplasma	  using	  EZ-­‐PCR	  
mycoplasma	  test	  kit	  (Geneflow,	  Staffordshire,	  UK)	  according	  to	  manufacturer’s	  instructions	  
 
2.2.3	  Human	  bronchial	  epithelial	  primary	  cell	  (HBEpC)	  maintenance	  
	  
Primary	   human	   bronchial	   epithelial	   cells	   from	   healthy	   volunteers	   were	   purchased	   from	  
PromoCell	   (Heidelberg,	   Germany)	   and	   maintained	   in	   Airway	   Epithelial	   Cell	   Growth	   (AECG)	  
medium	   purchased	   from	   PromoCell	   (Heidelberg,	   Germany)	   supplemented	   with	   bovine	  
pituitary	   extract	   (0.05	   mg/ml),	   epidermal	   growth	   factor	   (10	   ng/ml),	   insulin	   (5	   µg/ml),	  
hydrocortisone	   (0.5	   µg/ml),	   epinephrine	   (0.5	   µg/ml),	   triiodo-­‐L-­‐thyronine	   (6.7	   ng/ml),	  
transferring	   (10	   µg/ml),	   retinoic	   acid	   (0.1	   ng/ml),	   100	   U/ml	   penicillin	   and	   100	   µg/ml	  
streptomycin.	  	  
	  
Cells	  were	  seeded	  at	  a	  density	  of	  7.5x105	  cells	  per	  T75	  cm2	  flask	  and	  were	  passaged	  when	  85-­‐
95%	   confluence	   was	   reached.	   Cell	   detachment	   was	   obtained	   using	   PromoCell	   DetachKit	  
according	  to	  manufacturer’s	  instruction.	  Cells	  were	  maintained	  at	  37°C	  and	  humidified	  5%	  CO2.	  
Cell	   culture	   media	   was	   tested	   monthly	   for	   the	   presence	   of	   mycoplasma	   using	   EZ-­‐PCR	  
mycoplasma	  test	  kit	  (Geneflow,	  Staffordshire,	  UK)	  according	  to	  manufacturer’s	  instructions.	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2.3	  Peripheral	  Blood	  Mononuclear	  Cell	  (PBMC)	  isolation	  
 
2.3.1	  Cell	  separation	  by	  OptiPrepTM	  gradient	  
 
Peripheral	  venous	  blood	  was	  taken	  from	  consenting	  healthy	  volunteers	   in	  accordance	  with	  a	  
protocol	   approved	   by	   the	   South	   Sheffield	   Local	   Research	   Ethics	   Committee.	   4.4	   ml	   of	   the	  
anticoagulant	  3.8	  %	  tri-­‐sodium	  citrate	  was	  added	  to	  35.6	  ml	  of	  blood	  and	  centrifuged	  at	  320	  g	  
for	   20	   minutes.	   The	   plasma	   upper	   phase	   was	   removed	   and	   centrifuged	   at	   1000	   g	   for	   20	  
minutes	  to	  produce	  platelet	  poor	  plasma	  (PPP).	  	  
	  
The	  cell	  rich	  lower	  phase	  from	  the	  first	  centrifugation	  step	  was	  mixed	  with	  6	  ml	  of	  6%	  Dextran	  
T500,	  then	  topped	  up	  to	  50	  ml	  with	  0.9%	  saline	  and	  gently	  inverted	  to	  mix.	  The	  erythrocytes	  
were	   then	   allowed	   to	   sediment	   for	   30	  minutes.	   The	   leukocyte-­‐rich	   layer	   was	   removed	   and	  
centrifuged	  at	  221	  g	  for	  6	  minutes.	  The	  remaining	  leukocyte	  pellet	  was	  gently	  resuspended	  in	  6	  
ml	  of	  Hank’s	  Buffered	  Salt	   Solution	   (HBSS)	   supplemented	  with	  20%	  PPP	   followed	  by	  4	  ml	  of	  
OptiPrepTM.	   After	   gentle	   inversion,	   the	   cell	   mixture	   was	   overlaid	   with	   10	   ml	   1.095	   g/ml	  
OptiPrepTM	  (8.036	  ml	  HBSS	  with	  20%	  PPP	  and	  3	  ml	  OptiPrepTM).	  A	  further	  10	  ml	  of	  1.080	  g/ml	  
OptiPrepTM	  (10.435	  ml	  HBSS	  with	  20%	  PPP	  and	  3	  ml	  OptiPrepTM)	  was	  overlaid	  followed	  by	  a	  10	  
ml	   layer	   of	   HBSS	  with	   20%	   PPP.	   These	   layers	   resulted	   in	   an	  OptiPrepTM	   gradient	  which	  was	  
centrifuged	  at	  700	  g	  for	  30	  minutes	  without	  a	  deceleration	  break.	  This	  led	  to	  the	  separation	  of	  
three	  distinct	  populations	  of	  cells	  (Figure	  2.1)	  including	  a	  red	  cell	  layer	  located	  below	  the	  1.095	  
g/ml	  OptiPrepTM,	  a	  polymorphonuclear	  (PMN)	  layer	  located	  between	  the	  1.095	  g/ml	  and	  1.080	  
g/ml	   OptiPrepTM	   layers,	   and	   a	   PBMC	   layer	   located	   between	   the	   1.080	   g/ml	   OptiPrepTM	   and	  
HBSS	  with	   20%	   PPP.	   The	   PBMCs	  were	   harvested	   using	   a	   Pasteur	   pipette,	   transferred	   into	   a	  
clean	  tube,	  resuspended	  in	  10	  ml	  HBSS	  with	  20%	  PPP	  and	  centrifuged	  at	  511	  g	  for	  6	  minutes.	  
The	  resulting	  pellet	  was	  resuspended	  in	  RPMI	  1640	  with	  10%	  low	  endotoxin	  FBS,	  1%	  penicillin	  
(100	  units/ml)	  and	  1%	  streptomycin	  (100ug/ml).	  
 
	   58	  
	  
Figure	  2.1	  The	  OptiPrepTM	  gradient	  demonstrating	  separation	  of	  cell	  populations	  
 
2.4	  Negative	  magnetic	  selection	  of	  monocytes	  
 
Monocytes	  were	  extracted	  from	  the	  PBMC	  mixture	  by	  negative	  magnetic	  selection	  using	  the	  
Monocyte	   Isolation	   Kit	   II	   (Miltenyi	   Biotec,	   Audurn,	   CA,	   USA)	   according	   to	   manufacturer’s	  
protocol.	  PBMCs	  prepared	  in	  section	  2.2.1	  were	  resuspended	  in	  monocyte	  column	  buffer	  at	  30	  
μl	  per	  10	  x	  106.	  The	  negative	  magnetic	  selection	  worked	  by	  depleting	  the	  non-­‐monocytic	  cells	  
within	   the	  mixture,	   including	   red	   cells,	   T	   cells,	   B	   cells,	   granulocytes	   and	   natural	   killer	   cells.	  
These	   non-­‐monocytic	   cells	   were	   labelled	   with	   a	   biotin-­‐conjugated	   monoclonal	   antibody	  
cocktail	  at	  10	  μl	  per	  10	  x	  106	  (CD3,	  CD7,	  CD16,	  CD19,	  CD56,	  CD123	  and	  Glycophorin	  A)	  and	  a	  
secondary	  labelling	  anti-­‐biotin	  monoclonal	  antibodies	  conjugated	  to	  MicroBeads™	  at	  20μl	  per	  
10	   x	   106.	   These	  magnetically	   labelled	   cells	   were	   then	   depleted	   due	   to	   their	   retention	   on	   a	  
MACS	  Column	  in	  the	  magnetic	  field	  of	  a	  MACS	  separator	  allowing	  the	  unlabelled	  monocytes	  to	  
pass	  through.	  	  	  
 
2.4.1	  Flow	  cytometry	  for	  monocyte	  purity	  
 
The	  purified	  cells	  obtained	  by	  negative	  selection	  were	  resuspended	  at	  a	  density	  of	  2-­‐3	  x	  105	  
cells	  in	  22.5	  µl	  of	  PBS,	  followed	  by	  the	  addition	  of	  2.5	  µl	  of	  PE-­‐conjugated	  mouse	  anti-­‐human	  
CD14	  antibody	  or	  mouse	  IgG1	  isotype	  control	  antibody	  and	  incubated	  for	  20	  minutes	  at	  4	  °C	  in	  
the	  dark.	  Cells	  were	   centrifuged	   for	  3	  minutes	  at	  1000	  g	   then	   fixed	  with	  10%	  CellFIX	  before	  
fluorescence	  analysis	  using	  FACSCalibur	  flow	  cytometer.	  All	  data	  analysis	  was	  performed	  using	  









	   59	  
 
2.5	  Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  
 
Supernatants	   from	   stimulated	   cells	   were	   collected	   into	   fresh	   microcentrifuge	   tubes	   then	  
centrifuged	   at	   1000	   g	   for	   3	   minutes	   to	   pellet	   any	   cells	   in	   suspension.	   The	   remaining	  
supernatant	  was	  transferred	  to	  a	  fresh	  microcentrifuge	  tube	  and	  stored	  at	  -­‐80	  °C	  until	  use.	  	  
	  
A	  Maxisorp	  plate	  was	  coated	  with	  CXCL8	  or	  RANTES/CCL5	  coating	  antibody	  at	  1.5	  µg/ml	  or	  2	  
µg/ml	  respectively	  diluted	  in	  coating	  buffer	  (see	  Appendix)	  and	  incubated	  overnight	  at	  room	  
temperature.	  The	  plate	  was	  washed	  with	  wash	  buffer	  (see	  Appendix)	  4	  times	  using	  an	  ELx50	  
auto	   strip	   washer	   followed	   by	   a	   1	   hour	   block	   with	   100	   µl/well	   of	   1%	   ovalbumin	   in	   coating	  
buffer.	   All	   incubations	   occurred	   on	   an	   orbital	   shaker	   at	   room	   temperature.	   The	   plate	   was	  
washed	  again	  as	  above,	  followed	  by	  the	  addition	  of	  100	  µl	  duplicates	  of	  each	  CXCL8	  standard	  
(ranging	   from	   5000	   pg/ml	   to	   15.625	   pg/ml)	   or	   RANTES/CCL5	   standard	   (ranging	   from	   10000	  
pg/ml-­‐	  39pg/ml	  or	  samples	   (diluted	   in	  basal	  media	  as	  required to	  ensure	  analysis	  within	  the	  
linear	  portions	  of	  a	  log	  (concentration)	  /	  linear	  (optical	  density)	  standard	  curve)	  then	  incubated	  
for	  2	  hours.	  The	  plate	  was	  washed	  and	  incubated	  with	  100	  µl	  biotinylated	  CXCL8	  antibody	  (at	  
40	  ng/ml)	  or	  biotinylated	  RANTES/CCL5	  antibody	  (20ng/ml)	  diluted	  in	  wash	  buffer	  for	  2	  hours.	  
After	   further	   washing,	   the	   plate	   was	   incubated	   in	   the	   dark	   with	   streptavidin	   HRP	   (Horse	  
Radish	  Peroxidise)	  (Dako,	  UK)	  diluted	  1	  in	  200	  in	  wash	  buffer	  and	  finally	  washed	  again	  before	  
a	   final	   incubation	   with	   substrate	   reagent	   (R&D	   Systems)	   prepared	   according	   to	   the	  
manufacturer’s	  instructions)	  for	  between	  15-­‐20	  minutes.	  The	  reaction	  was	  terminated	  by	  the	  
addition	   of	   50	   µl	   of	   1	   M	   H2SO4.	   Absorbance	   was	   measured	   on	   an	   Opsys	   MR™	   Microplate	  
Reader	  using	  Revelation	  software.	  The	  optical	  density	  (OD)	  of	  the	  plate	  was	  read	  at	  450nm	  and	  
further	   analysed	   using	   GraphPad	   Prism®	   software	   and	   plotted	   using	   a	   log/linear	   standard	  
curve.	   The	  detection	   limit	  of	   the	  CXCL8/	  RANTES/CCL5	  ELISA	  was	  31.25	  pg/ml	  and	  39	  pg/ml	  
respectively.	  
	  
2.6	  Reverse	  transcription	  PCR	  (RT-­‐PCR)	  
2.6.1	  RNA	  isolation	  from	  cells	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DNA	   and	   RNA	   were	   isolated	   from	   cells	   using	   TRI	   Reagent®	   (Sigma-­‐Aldrich)	   according	   to	  
manufacturer’s	  instruction.	  Briefly,	  cells	  were	  washed	  with	  PBS	  before	  the	  addition	  of	  1	  ml	  of	  
TRI	   Reagent®	   per	   5-­‐10	  million.	   Cells	  were	   incubated	   for	   5	  minutes	   at	   room	   temperature	   to	  
allow	  for	  complete	  lysis.	  200	  µl	  of	  chloroform	  was	  added	  per	  1	  ml	  of	  TRI	  Reagent®	  and	  mixed	  
vigorously	   for	   15	   seconds	   before	   incubation	   at	   room	   temperature	   for	   10	  minutes.	   Samples	  
were	  centrifuged	  at	  12,000	  g	  for	  15	  minutes	  at	  4°C	  resulting	  in	  three	  distinct	  phases,	  an	  RNA-­‐
containing	  aqueous	  phase,	  DNA-­‐containing	   interphase	  and	  protein-­‐containing	  organic	  phase.	  	  
The	   aqueous	   phase	   was	   transferred	   into	   a	   fresh	   microcentrifuge	   tube	   and	   precipitated	   by	  
mixing	  with	   500	   µl	   of	   isopropanol	   and	   incubated	   for	   10	  minutes	   at	   room	   temperature.	   The	  
resulting	  RNA	  was	  then	  pelleted	  by	  centrifugation	  at	  12,000	  g	  for	  10	  minutes	  at	  4°C.	  The	  RNA	  
pellet	  was	  then	  washed	  with	  1	  ml	  of	  75	  %	  ethanol	  and	  centrifuged	  at	  7500	  g	  for	  5	  minutes	  at	  
4°C.	   The	   supernatant	   was	   discarded	   whilst	   the	   RNA	   pellet	   was	   air-­‐dried	   for	   5-­‐10	   minutes	  
before	  being	  resuspended	  in	  20	  µl	  of	  sterile	  water.	  	  
	  
2.6.2	  DNase	  treatment	  of	  purified	  RNA	  
 
Isolated	   RNA	   underwent	   a	   DNase	   treatment	   step	   using	   the	   DNA-­‐free	   kit	   from	   Applied	  
Biosciences	  according	  to	  manufacturer’s	  protocol.	  Briefly,	  0.1	  volume	  of	  DNase	  I	  Buffer	  and	  1	  
µl	   rDNase	   I	   were	   added	   to	   the	   RNA	   and	  mixed	   gently	   before	   a	   20-­‐30	  minute	   incubation	   at	  
37°C.	  	  0.1	  volume	  of	  DNase	  Inactivation	  Reagent	  was	  then	  added	  and	  incubated	  for	  2	  minutes	  
at	  room	  temperature	  with	  occasional	  mixing.	  	  The	  RNA	  sample	  was	  centrifuged	  at	  10,000	  g	  for	  
1.5	  minutes.	   The	   remaining	   RNA	   in	   suspension	  was	   transferred	   into	   a	   fresh	  microcentrifuge	  
tube	  and	  quantified	  using	  a	  NanoDrop™	  1000	  spectrometer	  (NanoDrop	  Tech.	  Inc.	  Wilmington,	  
USA).	  	  RNA	  integrity	  and	  purity	  was	  measured	  by	  optical	  density	  ratios	  at	  260/280	  nm	  (with	  a	  
ratio	  of	  1.8-­‐2)	  and	  260/230	  (with	  a	  ratio	  greater	  than	  1.8).	  	  
	  
2.6.3	  cDNA	  synthesis	  
 
RNA	   was	   reverse	   transcribed	   to	   produce	   cDNA	   using	   the	   High-­‐Capacity	   cDNA	   Reverse	  
Transcription	  Kit	  (Applied	  Biosystems)	  according	  to	  manufacturer’s	  protocol.	  Briefly,	  RNA	  was	  
resuspended	  in	  sterile	  water	  to	  make	  a	  1	  µg/	  20	  µl	  stock,	  which	  was	  mixed	  with	  the	  2x	  Reverse	  
Transcription	  Master	  Mix	  to	  form	  the	  components	  of	  the	  cDNA	  synthesis	  reaction	  as	  shown	  in	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Table	  2.1.	  	  This	  mix	  was	  then	  added	  to	  RNA	  reaction	  vials	  and	  the	  samples	  run	  on	  a	  Hybaid	  PCR	  
Express	  Thermal	  Cycler	  (Hybaid	  Ltd,	  UK)	  at	  25°C	  for	  10	  min	  followed	  by	  a	  37°C	  for	  120	  minutes	  
and	  85°C	  for	  5	  minutes.	  The	  samples	  were	  stored	  at	  -­‐	  80°C	  until	  required.	  
 
Component	   Volume/	  Reaction	  
10x	  RT	  Buffer	   4	  µl	  
25x	  dNTP	  Mix	  (100mM)	   1.6	  µl	  
10x	  RT	  Random	  primers	   4	  µl	  
MultiScribe™	  Reverse	  Transcriptase	   2	  µl	  
RNase	  Inhibitor	   2	  µl	  
Nuclease-­‐free	  water	   6.4	  µl	  
Template	  RNA	   20	  µl	  
Total	  Volume	   40	  µl	  
Table	  2.1	  Components	  of	  cDNA	  synthesis	  reaction	  
 
2.6.4	  Reverse	  transcription	  polymerase	  chain	  reaction	  (RT-­‐PCR)	  
	  
Template	  cDNA	  was	  incubated	  with	  reagents	  as	  described	  in	  Table	  2.2.	  The	  resulting	  mix	  was	  
then	  denatured	  at	  94°C	  for	  2	  minutes	  followed	  by	  a	  30	  cycle	  reaction	  step	  consisting	  of	  94°C	  
denaturing	  step	  for	  30	  seconds,	  an	  annealing	  step	  specific	  to	  the	  primer	  pairs	  (55	  °C-­‐	  68°C;	  see	  
Table	  2.3)	  for	  1	  minute	  and	  a	  72°C	  extension	  step	  for	  30	  seconds.	  A	  final	  extension	  step	  at	  72	  
°C	  for	  2	  minutes	  completed	  the	  process.	  The	  samples	  were	  run	  on	  Hybaid	  PCR	  Express	  Thermal	  
Cycler	  then	  stored	  at	  -­‐	  20°C	  until	  required.	  Primers	  sequences	  are	  detailed	  in	  Table	  2.3.	  
 
Component	   Volume	  /	  Reaction	  
5	  x	  Green	  GoTaq®	  Flexi	  Buffer	   5	  µl	  
MgCl2	  (25mM)	   1.5	  µl	  
dNTP	  Mix	  (10mM)	   1	  µl	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Forward	  primer	  (100uM)	   0.7	  µl	  
Reverse	  primer	  (100uM)	   0.7	  µl	  
GoTaq®	  DNA	  Polymerase	  (5U/	  µl)	   0.25	  µl	  
Nuclease-­‐free	  water	   13.85	  µl	  
Template	  cDNA	   2	  µl	  
Total	  Volume	   25	  µl	  
Table	  2.2	  Components	  of	  PCR	  synthesis	  reaction	  
	  
2.6.5	  Primers	  for	  PCR	  
 
All	   PCR	   primers	   (Table	   2.3)	   used	   in	   this	   project	   were	   designed	   using	   MacVector	   software	  
(MacVector	  Inc.,	  Cary,	  USA)	  and	  specificity	  checked	  using	  NCBI	  BLAST	  software.	  Genomic	  and	  
mRNA	  sequences	  used	  in	  the	  primer	  design	  were	  obtained	  from	  NCBI	  nucleotide	  database.	  	  All	  
primers	  were	  resuspended	  in	  nuclease-­‐free	  water	  and	  stored	  at	  -­‐20°C.	  
 
Primer	   Sequence	  (5’-­‐3’)	   Annealing	  Temperature	  
IRF	  1	  forward	   TGGCTGGGACATCAACAAGG	  
IRF	  1	  reverse	   TTCCTGCTCTGGTCTTTCACCTCC	  
63.3°C	  
IRF	  2	  forward	   GTCATCTCTGGGGCTTAGTAATGG	  
IRF	  2	  reverse	   CTCAGTGGTCACCTCTACAACTTGG	  
56.3°C	  
IRF	  3	  forward	   CAAGAGGCTCGTGATGGTCAAG	  
IRF	  3	  reverse	   TGGGTGGCTGTTGGAAATGTG	  
67.6°C	  
IRF	  4	  forward	   ACACACAGCAGTTCTTGTCAGAGC	  
IRF	  4	  reverse	   CTTGAATAGAGGAATGGCGGATAG	  
55.5°C	  
IRF	  5	  forward	   TTATGCCATCCGCCTGTGTC	  
IRF	  5	  reverse	   GCCATTCTTCCCCAAAGCAG	  
63.3°C	  
IRF	  6	  forward	   AGCGGTCAAGGGAAAGACAAGC	   64.2°C	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IRF	  6	  reverse	   TGGTGCCATCATACATCAGGTTG	   	  
IRF	  7	  forward	   TCGTGATGCTGCGGGATAAC	  
IRF	  7	  reverse	   ATGTGTGTGTGCCAGGAATGG	  
67.6°C	  
IRF	  8	  forward	   TTGGAAACACGCTGGCAAGC	  
IRF	  8	  reverse	   TCTGGGCTCTTATTCAAAGCACAG	  
59.4°C	  
IRF	  9	  forward	   GGATGTTGCTGAGCCCTACAAG	  
IRF	  9	  reverse	   AGAACTGTGCTGTCGCTTTGATG	  
63.3°C	  
GAPDH	  forward	   ACTTTGGTATCGTGGAAGGAC	  
GAPDH	  reverse	   TGGTCGTTGAGGGCAATG	  
50°C	  
Pellino1	  forward	   CCAAATGGCGATAGAGGAAGG	  
Pellino1	  reverse	   CATAAATCCGTGCTGTAAAGGGAG	  
55°C	  
Table	  2.3	  Primer	  Sequences	  
	  
2.6.6	  Gel	  electrophoresis	  
 
5	  µl	  of	  each	  PCR	  sample	  was	  resolved	  at	  100	  V	  for	  45	  minutes	  on	  a	  1	  %	  agarose	  electrophoresis	  
gel	   (1	   g	   in	  100	  ml	   TAE	  made	  up	   from	  a	  50x	  TAE	   stock	   (see	  Appendix))	  with	  3.5	  µl	   ethidium	  
bromide	   alongside	   the	   marker	   HyperLadder	   I	   (Bioline)	   and	   visualized	   under	   UV	   light	   using	  
Chemi	  Genius2	  Bio	  Imaging	  System	  (Syngene,	  Cambridge,	  UK).	  
 
2.7	  Quantitative	  PCR	  (qPCR)	  
	  
Quantitative	  PCR	  experiments	  were	  performed	  in	  a	  total	  volume	  of	  20μl	  consisting	  of	  1	  μl	  of	  
cDNA	   sample	   (section	   2.6.3)	   or	   standard	   (section	   2.7.1),	   10	   μl	   of	   2x	   qPCR	   Mastermix	  
(Eurogentec,	  Southampton,	  UK),	  1	  μl	  of	  pre-­‐mixed	  primer	  probes	  and	  8	  μl	  of	  sterile	  water.	  Pre-­‐
mixed	   primer	   probe	   sets	   were	   purchased	   from	   either	   Applied	   Biosystems	   (Pellino1,	  
Hs00221035_m1;	   IRF3,	   Hs01547283;	   IL-­‐1α,	   Hs00174092;	   IL-­‐1β,	   Hs01555410	   and	   GAPDH,	  
Hs00182082_m1)	  or	  as	  separate	  components	  from	  Sigma-­‐Aldrich	  (IFNβ	  and	  RV1B	  –	  sequences	  
are	  listed	  in	  Appendix).	  Primers	  purchased	  from	  Sigma-­‐Aldrich	  were	  diluted	  in	  sterile	  water	  to	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a	  concentration	  of	  300	  nM	  for	  forward	  primers,	  900	  nM	  for	  reverse	  primers	  and	  175	  nM	  for	  
probes.	  The	  384-­‐well	  qPCR	  plate	  was	  sealed	  with	  an	  optical	  lid	  and	  centrifuged	  at	  300	  g	  for	  2	  
min.	   The	  qPCR	   reactions	  were	   carried	  out	  using	   an	  ABI	   7900	  Automated	  TaqManTM	  (Applied	  
Biosystems),	  with	  an	  amplification	  cycle	  consisting	  of	  50°C	  for	  2	  min,	  94°C	  for	  10	  min,	  and	  45	  
cycles	   of	   94°C	   for	   15	   sec,	   60°C	   for	   15	   sec.	   The	   fluorescence	   is	   detected	   analysed	   using	   SDS	  
software	   version	   2.2.1	   (Applied	   Biosystems)	   and	   presented	   as	   ratio	   of	   target	   copy	   number	  
compared	  to	  a	  non-­‐regulated	  reference	  gene	  copy	  number	  or	  as	  arbitrary	  units.	  
	  
2.7.1	  qPCR	  standards	  and	  plasmid	  calculations	  
	  
Initially	  the	  plasmid	  yield	  was	  quantified	  and	  its	  integrity	  determined	  using	  a	  NanoDrop™	  1000	  
spectrometer	  (NanoDrop	  Tech.	  Inc.	  Wilmington,	  USA).	  	  The	  molecular	  weight	  of	  each	  plasmid	  
was	   determined	   based	   on	   the	   average	   molecular	   weight	   of	   a	   base	   pair,	   650	   Daltons.	   	   The	  
number	   of	   moles	   was	   then	   established	   by	   dividing	   the	   plasmid	   DNA	   yield	   by	   its	   molecular	  
weight.	   The	   number	   of	  molecules	   per	   sample	  were	   then	   determined	   by	   the	  multiplying	   the	  
number	  of	  moles	  (determined	  by	  equation	  1)	  by	  Avogadro’s	  constant	  (6.02x1023),	  then	  divided	  
by	  the	  volume	  of	  the	  plasmid	  (summarised	  by	  equation	  2).	  
	  
plasmid	  DNA	  yield(g)	  
(1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Moles	  =	   plasmid	  molecular	  weight	  (Daltons)	  
	   	  
(Moles	  x	  6.02x1023)	  
(2)	  	  	  	  	  Molecules	  (copies)/	  μl	  =	   plasmid	  volume	  (ul)	  
	   	  
	  
The	  optimum	  standard	  curve	  was	  then	  set	  up	  by	  running	  a	  range	  of	  serial	  dilutions	  of	  the	  stock	  
cDNA	  or	  plasmid	  standards	  (e.g.	  1:2,	  1:5	  and	  1:10)	  to	  determine	  the	  best	  range	  and	  intervals	  of	  
Ct	  values	  starting	  from	  around	  108	  copies	  per	  µl.	  
	  
2.8	  Western	  blot	  	  
	  
Following	  stimulation,	  BEAS-­‐2B	  cells	  or	  HBEpCs	  were	  collected	  and	  lysed	  for	  protein	  analysis	  by	  
western	   blot.	   Supernatants	   were	   discarded	   and	   the	   remaining	   adhered	   cellular	   monolayers	  
were	   lysed	   in	   phosphatase	   lysis	   buffer	   (see	  Appendix)	   containing	   1	  mM	  PMSF	   and	   1	   in	   100	  
diluted	  protease-­‐inhibitor	  cocktail	  (Calbiochem,	  Merck,	  Germany)	  added	  immediately	  prior	  to	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use.	  Following	  a	  2	  minute	   incubation	  on	   ice,	   samples	  were	   transferred	   into	  Eppendorf	   tubes	  
and	  spun	  by	  centrifugation	  at	  2000	  g	  for	  10	  minutes	  at	  4°C	  to	  remove	  insoluble	  material.	  The	  
resulting	   soluble	  material	  was	   then	   transferred	   and	   suspended	   in	   hot	   SDS-­‐PAGE	   lysis	   buffer	  
(see	  Appendix)	   and	   heated	   to	   95°C	   for	   5	   minutes.	   Lysates	   were	   then	   stored	   at	   -­‐80°C	   until	  
analysis.	  
	  
The	   Bio-­‐Rad	   mini	   PROTEIN	   II	   electrophoresis	   apparatus	   (Bio-­‐Rad	   Laboratories	   Ltd,	   UK)	   was	  
assembled	  according	   to	  manufacturer’s	   instructions	  prior	   to	  each	  use.	  The	   resolving	  gel	   (see	  
Appendix)	  containing	  freshly	  added	  TEMED	  was	  poured	  in	  between	  two	  glass	  plates	  separated	  
by	  0.75	  or	  1.25	  mm	  spacers.	  An	  approximate	  gap	  of	  2	  cm	  was	  left	  at	  the	  top	  of	  the	  resolving	  
gel	   and	  overlaid	  with	   a	   thin	   layer	   of	   isopropanol	   to	   avoid	   evaporation	  of	   the	   gel	   during	   the	  
setting	  at	  room	  temperature.	  Once	  set,	  the	  isopropanol	  was	  poured	  out	  and	  the	  remaining	  gel	  
rinsed	  with	  distilled	  water.	  The	  stacking	  gel	  (see	  Appendix)	  was	  then	  carefully	  overlaid	  and	  a	  
10	  or	  15-­‐well	  comb	  was	  carefully	  inserted	  to	  avoid	  the	  addition	  of	  bubbles.	  The	  set	  gels	  were	  
then	   transferred	   and	   assembled	   in	   the	   electrophoresis	   tank	   according	   to	   manufacturer’s	  
instructions	  and	  covered	  with	  SDS-­‐PAGE	  running	  buffer	  (see	  Appendix).	  The	  combs	  were	  then	  
carefully	   removed	   and	   15-­‐25	   μl	   of	   protein	   lysate	   were	   loaded	   into	   each	   well	   or	   5	   μl	   of	  
ColorPlus	   Prestained	   Protein	   Ladder	   (New	   England	   BioLabs,	   Massachusetts,	   USA)	   and	  
electrophoresed	  at	   60	  V	   for	   15	  minutes	   through	   the	   stacking	   gel	   and	  200	  V	   (PowerPac	  300,	  
Bio-­‐Rad	  Laboratories	  Ltd,	  UK)	  through	  the	  resolving	  gel.	  	  
	  
The	  proteins	  from	  the	  gel	  were	  transferred	  to	  a	  Hyband-­‐c-­‐extra	  nitrocellulose	  membrane	  (0.45	  
μm	  pore	  size;	  GE	  HealthcareLife	  Sciences,	  UK)	  by	  sandwiching	  the	  gel	  and	  membrane	  between	  
two	   pre-­‐soaked	   pieces	   of	   3	   mm	   filter	   paper	   and	   two	   fiber	   sponges	   encased	   in	   a	   transfer	  
cassette.	   The	   transfer	   cassettes	   were	   then	   assembled	   into	   the	   Trans-­‐Blot	   electrophoretic	  
transfer	   cell	   (Bio-­‐Rad	  Laboratories	   Ltd,	  UK)	  with	   the	  gel	   facing	   the	  black	   side	  of	   the	  cassette	  
(negative	  charge)	  and	   the	  membrane	   facing	   towards	   the	  white	   side	  of	   the	  cassette	   (positive	  
charge)	  to	  allow	  the	  effective	  transfer	  of	  proteins	  from	  the	  gel	  to	  the	  membrane.	  The	  tank	  was	  
then	   filled	   with	   transfer	   buffer	   (see	  Appendix)	   and	   the	   addition	   of	   an	   ice	   pack	   to	   prevent	  
overheating	  during	   the	  70	  minute	   transfer	   at	   100	  V.	   Protein	   transfer	   and	  equal	   loading	  was	  
visualized	  by	  Ponceau	  S	   staining	   for	  30-­‐60	   seconds	   then	   rinsed	  with	  0.2%	  PBS-­‐tween	  before	  
the	   addition	   of	   5%	   milk	   in	   0.2%	   PBS-­‐tween	   for	   1	   hour	   at	   room	   temperature	   on	   an	   orbital	  
shaker	  to	  block	  non-­‐specific	  binding	  sites.	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The	   nitrocellulose	   membrane	   was	   washed	   for	   5	   minutes	   in	   PBS	   before	   the	   incubation	   in	  
primary	  antibody	  (see	  Table	  2.4)	  in	  5%	  milk	  in	  0.2%	  PBS-­‐tween	  and	  incubated	  at	  4°C	  overnight	  
on	  an	  orbital	  shaker.	  The	  membrane	  was	  then	  washed	  4	  times	  for	   five	  minutes	   in	  0.2%	  PBS-­‐
tween	   to	   remove	   any	   unbound	   antibody	   before	   the	   addition	   of	   the	   corresponding	   HRP-­‐
conjugated	  secondary	  antibody	  (see	  Table	  2.4)	  diluted	  in	  5%	  milk	  in	  0.2%	  PBS-­‐tween	  for	  1	  hour	  
at	  room	  temperature	  on	  an	  orbital	  shaker.	  The	  membrane	  was	  washed	  4	  times	  for	  5	  minutes	  
in	   0.2%	   PBS-­‐tween	   to	   remove	   any	   unbound	   antibody	   before	   protein	   detection.	   Labelled	  
proteins	  were	  visualised	  by	  using	  EZ-­‐ECL	  mixture	   (EZ-­‐ECLTM	  Chemiluminescence	  Detection	  kit	  
for	   HRP,	   Geneflow)	   for	   2	   minutes	   before	   developing	   and	   analysing	   the	   membrane	   using	  
ChemiDoc	  XRS+	  System	  with	  Image	  Lab	  Software	  (BioRad	  Laboratories	  Ltd,	  UK).	  
	  
Membranes	  were	  occasionally	  stripped	  and	  re-­‐probed	  by	  the	  removal	  of	  bound	  primary	  and	  
secondary	  antibodies.	  Membranes	  were	  soaked	  in	  0.2	  M	  solution	  of	  sodium	  hydroxide	  for	  8-­‐10	  
minutes	  before	  rinsing	  the	  blot	  4	  times	  in	  0.2%	  PBS-­‐tween.	  The	  blots	  were	  then	  blocked	  in	  5%	  
milk	  in	  0.2%	  PBS-­‐tween	  before	  the	  addition	  of	  new	  antibodies	  as	  described	  above.	  
	  
Target	   Manufacturer	   Species	   Dilution	  
Pellino-­‐1	   Santa	  Cruz	  Biotechnology	   Mouse	   1:250	  
NFKB2	  (p100/p52)	   Cell	  Signaling	  Technology	  	   Rabbit	   1:500	  
NFKB1	  (p105/p50)	   Cell	  Signaling	  Technology	  	   Rabbit	   1:1000	  
Phospho	  p38	   Cell	  Signaling	  Technology	  	   Rabbit	   1:1000	  
Phospho	  IKKa/b	   Cell	  Signaling	  Technology	  	   Rabbit	   1:500	  
Phospho	  p44/p42	   Cell	  Signaling	  Technology	  	   Rabbit	   1:500	  
IkBa	   Cell	  Signaling	  Technology	  	   Rabbit	   1:500	  
RIP-­‐1	   BD	  Biosciences	  	   Mouse	   1:1000	  
Actin	   Sigma-­‐Aldrich	  	   Rabbit	   1:10000	  
Table	  2.4	  Working	  dilutions	  of	  western	  blotting	  antibodies	  	  
	  
2.9	  Transient	  siRNA	  knockdown	  
	  
Transfections	   were	   carried	   out	   on	   BEAS-­‐2B	   cells	   or	   HBEpCs	   cultured	   to	   approximately	   85%	  
confluence	   on	   12-­‐well	   plates.	   Target	   genes	   (Pellino-­‐1	   (L-­‐013814-­‐01-­‐0005),	  NFKB2	   (L-­‐003918-­‐
00-­‐0005),	   IRF3	   (L-­‐006875-­‐00-­‐0005)	  and	  RIP1	   (L-­‐004445-­‐00-­‐0005),	  Dharmacon,	  Thermo	  Fisher	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Scientific)	   were	   knocked	   down	   using	   ON-­‐TARGET	   plus	   SMARTpoolTM	   (Dharmacon,	   Thermo	  
Fisher	   Scientific)	   and	   Lipofectamin	   2000TM	   (Invitrogen)	   as	   the	   delivery	   tool.	   Non-­‐targeting	  
siRNA	  was	  used	  as	  a	  control.	  A	  200	  μl	  solution	  of	  1	  µM	  siRNA	  was	  prepared	  from	  20	  µM	  stocks	  
by	  diluting	  in	  Opti-­‐MEM,	  while	  in	  a	  separate	  Eppendorf	  tube	  containing	  2.5	  μl	  of	  Lipofectamine	  
2000	  was	  diluted	  with	  97.5	  μl	  of	  OptiMEM.	  Both	   tubes	  were	  gently	   inverted	  and	  allowed	   to	  
equilibrate	   for	   5	  minutes	   in	   dark	   at	   room	   temperature.	   Both	   tubes	  were	   then	   combined	   to	  
allow	  the	  siRNA	  to	  complex	  with	  the	  transfection	  reagent	  at	  room	  temperature	  for	  20	  minutes.	  
In	   the	  meantime,	   cells	  were	  washed	   twice	  with	   PBS	   before	   the	   addition	   of	   800	   μl	   of	   either	  
RPMI	  with	  10%	  FCS	  containing	  no	  antibiotics	  (for	  BEAS-­‐2B	  cells)	  or	  serum-­‐free	  Airway	  Epithelial	  
Cell	  Growth	  (AECG)	  medium	  containing	  no	  antibiotics	   (for	  HBEpCs).	  200	  μl	  of	   the	  complexed	  
siRNA	  was	  then	  combined	  with	  the	  800	  μl	  of	  media	  in	  each	  well	  to	  reach	  a	  total	  plating	  volume	  
of	  1,000	  μl	  per	  well.	  This	  was	  followed	  by	  cell	  incubation	  for	  4	  hours	  at	  37°C	  in	  5	  %	  CO2.	  Cells	  
were	  washed	  once	  with	  PBS	  followed	  by	  the	  addition	  of	  1	  ml	  complete	  growth	  media	  for	  BEAS-­‐
2B	  cells	  or	  complete	  AECG	  medium	  minus	  the	  bovine	  pituitary	  extract	  for	  HBEpCs	  for	  18	  hours	  
at	  37°C	  in	  5%	  CO2	  to	  allow	  for	  recovery	  before	  stimulation	  with	  pro-­‐inflammatory	  cytokines	  or	  
protein	  extraction.	  Additional	  mock	  transfected	  controls	  treated	  only	  with	  transfection	  reagent	  
in	  OptiMEM	  were	  also	  included.	  Knockdown	  efficiency	  was	  determined	  by	  measuring	  protein	  
expression	  of	  the	  target	  genes	  by	  western	  blotting.	  
	  
2.10	  Preparation	  of	  cigarette	  smoke	  extract	  (CSE)	  
	  
Research	   grade	   cigarettes	   3R4F	   (Tobacco	   and	   Health	   Research	   Institute,	   University	   of	  
Kentucky,	   Lexington,	   KY)	  were	   used	   in	   this	   thesis.	   Cigarette	   smoke	   extract	  was	   prepared	   as	  
previously	  described	  with	  some	  minor	  modifications	  (Proud	  et	  al.,	  2012).	  Mainstream	  smoke	  
of	   two	   unfiltered	   cigarettes	   was	   drawn	   through	   25	   ml	   of	   basal	   media	   with	   the	   use	   of	   a	  
peristaltic	  pump	  for	  5	  minutes	  each	  and	  regarded	  as	  100%.	  Particulate	  matter	  was	  extracted	  
through	   the	   use	   of	   a	   0.22	  mm	   filter	   syringe.	   CSE	  was	   freshly	   prepared	   before	   each	   use.	   All	  
exposures	  in	  this	  thesis	  were	  done	  using	  10%	  CSE.	  	  
	  
2.11	  Rhinoviral	  infection	  in	  vitro	  
 
Human	  rhinovirus	  (RV)	  stocks	  were	  prepared	  by	  other	  members	  of	  the	  research	  group.	  Prior	  to	  
rhinoviral	   infection	  of	  BEAS-­‐2Bs	  or	  HBEpCs	  with	  RV-­‐1B	  or	  RV-­‐16,	  cells	  were	  grown	   in	  12-­‐well	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plates	   until	   confluency	   was	   reached.	   Cells	   were	   rendered	   quiescent	   in	   RPMI	   1640	  
supplemented	   with	   2%	   FCS	   and	   1%	   penicillin	   and	   1%	   streptomycin	   (for	   BEAS-­‐2B	   cells)	   or	  
unsupplemented	  AECG	   (for	  HBEpCs)	   for	  18	  hours	  at	  37°C	  +	  5	  %	  CO2.	  Cells	  were	   rinsed	  once	  
with	  PBS	  before	  the	  addition	  of	  250	  μl	  of	  the	  desired	  concentration	  (determined	  by	  TCID50)	  of	  
RV	   was	   administered.	   An	   inactivated	   RV	   control	   was	   also	   administered	   to	   highlight	   viral	  
replication	  induced	  phenotype.	  The	  250	  μl	  control	  was	  inactivated	  under	  a	  UV	  cross	  linker	  at	  
1000	  mJ/cm2	  for	  10	  minutes.	  An	  additional	  filtrate	  control	  was	  obtained	  by	  centrifuging	  viral	  
inocula	  in	  0.2	  micron	  filter	  tubes	  (Millipore,	  Cork,	  Ireland)	  at	  12000	  x	  g	  for	  5	  min.	  The	  virus	  and	  
respective	  controls	  were	  then	  incubated	  at	  room	  temperature	  for	  1	  hour	  on	  an	  orbital	  shaker.	  
Virus	   was	   then	   removed	   and	   replaced	   with	   1	   ml	   of	   fresh	   basal	   media	   (RPMI	   1640	  
supplemented	   with	   2%	   FCS	   and	   1%	   penicillin	   and	   1%	   streptomycin	   (for	   BEAS-­‐2B	   cells)	   or	  
unsupplemented	  AECG	  (for	  HBEpCs)	  for	  24	  hours	  at	  37°C	  +	  5	  %	  CO2.	  
	  
2.12	  Caspase-­‐8	  activity	  
	  
The	   caspase-­‐8	   activity	   levels	   were	   determined	   using	   Promega’s	   Caspase-­‐Glo®	   8	   assay	  
(Wisconsin,	   USA).	   HBEpCs	   were	   grown	   in	   24-­‐well	   plates	   and	   allowed	   to	   reach	   confluence	  
before	  undergoing	  stimulation	  of	  interest	  for	  24	  hours.	  	  
	  
Prior	  to	  starting,	  the	  Caspase-­‐Glo®	  8	  reagent	  was	  thawed	  to	  room	  temperature.	  250	  μl	  of	  the	  
existing	  500	  μl	  of	  supernatant	  was	  removed	  and	  discarded	  per	  well.	  250	  μl	  of	  the	  Caspase-­‐Glo®	  
8	   reagent	  was	   then	   added	   to	   each	   sample,	   including	   a	   cell-­‐free	   control.	   The	   contents	  were	  
then	  gently	  mixed	  on	  an	  orbital	  shaker	  for	  30	  seconds	  followed	  by	  a	  1	  hour	  incubation	  at	  room	  
temperature.	   This	   enables	   the	   reagent	   to	   lyse	   the	   cells	   allowing	   caspase	   cleavage	   of	   the	  
substrate	   and	   generating	   a	   luminescent	   signal	   produced	   by	   the	   luciferase	   reaction.	   The	  
luminescence	   for	   each	   sample	   was	   then	   determined	   using	   Opsys	   MR™	   Microplate	   Reader	  
(Dynex	  technologies)	  using	  Revelation	  software	  (Dynex	  technologies)	  for	  analysis.	  
	  
2.13	  Statistical	  Analysis	  	  
 
Statistical	  analysis	  were	  performed	  using	  GraphPad	  Prism®	  v6.0.	  (GraphPad	  Inc,	  San	  Diego,	  CA,	  
USA).	  Data	  are	  presented	  as	  means	  ±	  SEM.	  Data	  were	  analysed	  using	  the	  appropriate	  statistical	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test	   and	   post-­‐test	   as	   stated	   in	   the	   figure	   legends.	   A	   p	   value	   of	   ≤	   0.05	   was	   considered	  
statistically	  significant.	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CHAPTER	  3	  -­‐	  RESULTS.	  ESTABLISHING	  AN	  IN	  VITRO	  CHRONIC	  MODEL	  OF	  
INFLAMMATION	  	  
	  
COPD	   is	   a	   chronic	   inflammatory	   disease	   that	   is	   driven	   by	   a	   multitude	   of	   inflammatory	  
mediators	  derived	  from	  activated	  inflammatory	  cells,	   including	  monocytes	  and	  macrophages,	  
as	  well	   as	   structural	   cells	   such	   as	   epithelial	   and	   endothelial	   cells	   (See	   section	   1.2).	   Patients	  
suffering	   from	  COPD	  display	  abnormal	   infiltration	  of	   inflammatory	  cells	   in	   their	  airways,	  and	  
the	   relationship	   between	   these	   cells	   and	   their	   effect	   on	   chronic	   inflammation	   within	   the	  
airways	  is	  not	  fully	  understood.	  	  
	  
The	  epithelial	   lining	   in	   the	  airway	   is	   the	   first	   form	  of	  defence	  against	   invading	  pathogens	  or	  
environmental	  insults.	  In	  addition	  to	  the	  formation	  of	  tight	  junctions	  and	  mucociliary	  clearance	  
to	   form	   a	   physical	   barrier	   to	   pathogens	   and	   other	   foreign	   substances,	   epithelial	   cells	   also	  
produce	  a	  plethora	  of	  immune	  cell-­‐recruiting	  cytokines	  as	  part	  of	  the	  innate	  immune	  response	  
against	  invading	  pathogens	  (Kulkarni	  et	  al.,	  2010).	  However,	  bacterial,	  viral	  and	  environmental	  
agents	  such	  as	  cigarette	  smoke	  (the	  predominant	  cause	  of	  COPD)	  can	  alter	  the	  epithelial	  cells’	  
ability	  to	  generate	  an	  effective	  innate	  immune	  response.	  As	  chronic	  inflammation	  of	  COPD	  is	  
underpinned	  by	  airway	  colonisation	  and	  infection,	  I	  hypothesised	  that	  persistent	  inflammation	  
would	  alter	  epithelial	  cell	  innate	  responses	  with	  consequences	  on	  the	  responses	  to	  infection.	  	  
	  
Cooperative	   signalling	   between	   inflammatory	   cells	   and	   resident	   tissue	   cells	   has	   been	   well	  
documented,	  and	  the	  importance	  of	  monocytes	  in	  mounting	  an	  effective	  immune	  response	  to	  
both	  bacteria	  and	  viruses	  highlighted	  (Chaudhuri	  et	  al.,	  2010;	  Morris	  et	  al.,	  2006;	  Parker	  et	  al.,	  
2008;	  Parker	  et	  al.,	  2007;	  Stokes	  et	  al.,	  2011;	  Ward	  et	  al.,	  2009).	  While	  these	  studies	  provide	  
valuable	  insight	  into	  crucial	  airway	  responses	  to	  pathogens,	  they	  only	  focus	  on	  the	  immediate	  
acute	   responses	   in	   these	   systems	   during	   the	   first	   24	   hours.	   Therefore	   the	   following	   study	  
sought	   to	   create	   an	   in	   vitro	   chronic	   model	   of	   inflammation	   to	   enable	   the	   exploration	   of	  
epithelial	  cell	  immunity	  and	  cellular	  communication	  during	  prolonged	  pathogen	  handling.	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3.1	  Comparison	  of	  LPS-­‐induced	  CXCL8	  release	  in	  monocytes	  and	  VitD3-­‐
differentiated	  THP-­‐1	  cells	  	  
	  
The	   effective	   inflammatory	   response	   to	   bacterial	   stimuli	   is	  mediated	   in	   part	   by	   cooperative	  
signalling	  between	  monocytes	  and	  airway	  tissue	  cells	   (Chaudhuri	  et	  al.,	  2010).	  The	  proposed	  
model	  for	  chronic	  inflammation	  therefore	  involved	  prolonged	  low-­‐grade	  bacterial	  stimulation	  
of	  epithelial	  cells	  in	  the	  presence	  of	  inflammation-­‐driving	  monocytes.	  However,	  the	  duration	  of	  
the	  proposed	  model	  and	  the	  large	  number	  of	  cells	  required	  presented	  a	  barrier	  to	  the	  use	  of	  
primary	  cells.	  The	  scale	  of	  the	  model	  would	  require	  the	  use	  of	  large	  volumes	  of	  donor	  blood	  to	  
obtain	  enough	  cell	  numbers,	  while	   the	   recurrent	  nature	  of	   the	  chronic	  model	  would	   require	  
multiple	   donors,	   each	   presenting	   with	   donor	   variability	   and	   adding	   an	   added	   layer	   of	  
complexity	   to	   the	   interpretation	   of	   results.	   Thus	   the	   use	   of	   a	   differentiated	   leukemic	  
monocytic	  cell	  line,	  THP-­‐1,	  was	  proposed	  and	  further	  explored	  in	  this	  thesis.	  
	  
Monocytic	   cells	   lines	   are	   often	   used	   in	   place	   of	   primary	   cells	   due	   to	   the	   ease	   of	   their	  
acquisition.	  THP-­‐1	  cells	  are	  an	  immortal	  human	  acute	  monocytic	  leukemic	  cell	  line	  (Tsuchiya	  et	  
al.,	  1980)	  and	  ideal	  for	  use	  in	  the	  chronic	  model	  due	  to	  their	  non-­‐adherent	  properties	  allowing	  
for	  ease	  of	  removal	  and	  replacement	  in	  vitro.	  	  Furthermore,	  THP-­‐1	  cells	  can	  be	  manipulated	  in	  
vitro	  into	  varying	  states	  of	  differentiation	  including	  a	  more	  monocytic	  phenotype	  (Parker	  et	  al.,	  
2004).	  The	  initial	  aims	  of	  this	  project	  were	  two-­‐fold;	  firstly	  it	  was	  necessary	  to	  determine	  the	  
efficacy	  of	  the	  chosen	  THP-­‐1	  differentiation	  protocol.	  Secondly,	  it	  was	  crucial	  to	  determine	  the	  
THP-­‐1	  cell	  density	  required	  to	  mimic	  primary	  monocyte	  responses	  in	  vitro.	  	  
	  
THP-­‐1	  cells	  were	  differentiated	  in	  accordance	  with	  established	  protocols	  of	  100nM	  of	  vitamin	  
D3	  (VitD3)	   (also	  known	  as	  calcitriol,	  a	  hormonally	  active	  metabolite	  of	  vitamin	  D3)	  stimulation	  
for	  72	  hours	  before	  use	  (Daigneault	  et	  al.,	  2010).	  The	  monocytic	  marker	  CD14	  expression	  was	  
measured	  by	  flow	  cytometry	  to	  establish	  differentiation	  efficacy.	  	  Undifferentiated	  THP-­‐1	  cells	  
showed	   no	   difference	   in	   CD14	   detected	   fluorescence	   intensity	   in	   comparison	   to	   the	   IgG1	  
isotype	   control	   (Figure	   3.1a	   and	   Figure	   3.1c).	   Conversely,	   VitD3-­‐differentiated	   THP-­‐1	   cells	  
showed	   an	   increased	   CD14	   expression	   confirming	   acquisition	   of	   a	  marker	   associated	  with	   a	  
monocytic	  phenotype	  (Figure	  3.1b	  and	  Figure	  3.1d).	  	  
	  
	   72	  
VitD3-­‐differentiated	   THP-­‐1	   CXCL8	   cytokine	   production	   in	   response	   to	   the	   bacterial	   cell	   wall	  
component	   LPS	   was	   then	   determined	   by	   ELISA	   (Figure	   3.2a)	   and	   compared	   with	   primary	  
monocyte	   responses	   (Figure	   3.2b).	  Varying	  numbers	  of	  both	  cell	   types	  were	  stimulated	  with	  
LPS	  (1	  ng/ml-­‐	  100	  ng/ml)	  for	  24	  hours	  respectively.	  Responses	  were	  quantified	  by	  the	  measure	  
of	   pro-­‐inflammatory	   cytokine	   CXCL8.	   The	  CXCL8	   release	   in	   THP-­‐1	   cells	  was	   less	   than	   that	   of	  
monocytes.	  Specifically,	  10,000	  and	  30,000	  THP-­‐1	  cells	  stimulated	  with	  LPS	  produced	  10	  fold	  
less	  CXCL8	  than	  10,000	  and	  30,000	  LPS-­‐stimulated	  monocytes	  respectively	  (Figure	  3.2).	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Figure	   3.1	   Representative	   flow	   analysis	   histograms	   demonstrating	   THP-­‐1	   CD14	   expression	  
following	  Vitamin	  D3	  differentiation	  
THP-­‐1	   differentiation	   was	   determined	   by	   staining	   with	   a	   PE-­‐conjugated	   mouse	   anti-­‐human	  
CD14	  antibody	  or	  mouse	  IgG1	  isotype	  control	  antibody.	  Fluorescence	  was	  measured	  in	  the	  FL-­‐2	  
channel	  of	  a	  FACSCalibur	  flow	  cytometer.	  Data	  analysis	  was	  performed	  using	  FlowJo	  software.	  	  
(A)	  Histogram	  of	  undifferentiated	  THP-­‐1	  cells,	  (B)	  Histogram	  of	  vitamin	  D3	  differentiated	  THP-­‐1	  
cells,	   (C)	   Fluorescence	   intensity	  of	  undifferentiated	  THP-­‐1	  cells,	   (D)	   Fluorescence	   intensity	  of	  
vitamin	  D3	  differentiated	  THP-­‐1	  cells.	  n=1	  
	  
20112102 Workspace.jo Layout-7
14/7/11 15:06 Page 1 of 1 (FlowJo v9.3)
































(FL2-H): Geom. Mean = 9.73
(FL2-H): Geom. Mean = 8.95
(FL2-H): Geom. Mean = 7.25
(FL2-H): Geom. Mean = 377
	   74	  
A	   Monocytes
	  
B	  	   THP-­‐1	  cells	  
	  
Figure	  3.2	  Comparison	  of	  THP-­‐1	  and	  monocyte	  responses	  to	  LPS	  	  
Increasing	  numbers	  of	  (A)	  highly	  purified	  human	  monocytes	  derived	  from	  volunteer	  donors	  or	  
(B)	  VD3	  differentiated	  THP-­‐1	  cells	  were	  stimulated	  with	  LPS	  (1	  ng/ml-­‐	  100	  ng/ml)	  for	  24	  hours.	  
Supernatants	  were	  collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  
mean	  ±	  SEM	  of	  n=3.	  Statistical	  analysis	  was	  carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  
post-­‐test	  (*p<0.05,	  **p<0.01	  and	  ***p<0.001).	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3.2	  Comparison	  of	  direct	  interaction	  between	  monocytic	  cells	  and	  BEAS-­‐
2B	  in	  an	  acute	  model	  of	  inflammation	  	  
 
An	   acute	   model	   of	   inflammation	   was	   then	   created	   to	   investigate	   the	   ability	   of	   VitD3-­‐
differentiated	  THP-­‐1	  cells	  to	  replace	  monocytes	  in	  the	  effective	  cooperative	  signalling	  between	  
monocytes	   and	   airway	   epithelial	   cells.	   Increasing	   numbers	   of	   monocytes	   (1,000-­‐30,000	  
cells/well)	   or	   VitD3-­‐differentiated	   THP-­‐1	   cells	   (3,000-­‐100,000	   cells/well)	   were	   added	   to	   a	  
confluent	  BEAS-­‐2B	  monolayer	  in	  the	  presence	  or	  absence	  of	  LPS	  (1	  ng/ml).	  LPS-­‐induced	  CXCL8	  
release	   was	   synergistically	   enhanced	   in	   the	   presence	   of	   monocytes	   (Figure	   3.3a),	   VitD3-­‐
differentiated	   THP-­‐1	   cells	   recapitulated	   a	   comparably	  muted	   increase	   in	   LPS-­‐induced	   CXCL8	  
(Figure	   3.3b).	   	  While	   the	   addition	   of	   5,000	  monocytes	   results	   in	   levels	   of	   CXCL8	   of	   over	   30	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A	   Monocytes	  
	  	  
B	   THP-­‐1	  cells	  
	  
Figure	  3.3	  Comparison	  of	  direct	  interaction	  between	  monocytic	  cells	  and	  BEAS-­‐2B	  in	  an	  acute	  
model	  of	  inflammation	  
BEAS-­‐2B	  were	  seeded	  at	  3	  x	  106	  cells/24-­‐well	  plate	  (125,000	  cells/well)	  for	  24	  hours	  followed	  
by	   the	  addition	  of	   increasing	  numbers	  of	   (A)	  highly	  purified	  human	  monocytes	  derived	   from	  
volunteer	   donors	   or	   (B)	   VD3	   differentiated	   THP-­‐1	   cells.	   These	   were	   stimulated	   with	   LPS	   (1	  
ng/ml)	   for	   24	   hours.	   Supernatants	  were	   collected	   and	   analysed	   for	   CXCL8	   release	   by	   ELISA.	  
Data	   are	   expressed	   as	  mean	   ±	   SEM	   of	   n=3.	   Statistical	   analysis	   was	   carried	   out	   by	   two-­‐way	  
ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05	  and	  ***p<0.001).	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3.3	  The	  effect	  of	  cell	  culture	  inserts	  on	  the	  interaction	  between	  
monocytic	  cells	  and	  BEAS-­‐2B	  in	  an	  acute	  model	  of	  inflammation	  	  
 
The	   importance	   of	   cellular	   communication	   between	   immune	   cells	   and	   tissue	   cells	   for	   an	  
effective	   inflammatory	   response	   is	   well	   known	   (Morris	   et	   al.,	   2006;	   Parker	   et	   al.,	   2008;	  
Standiford	   et	   al.,	   1990).	   However,	   examining	   this	   communication	   in	   vitro	   over	   an	   extended	  
period	  of	  time	  required	  the	  control	  of	  several	  variables	  including	  the	  change	  of	  cell	  phenotype	  
over	  time,	  effects	  of	  apoptosis	  and	  the	  ability	   to	  maintain	  a	  constant	  cell	  number	  across	  the	  
range	  of	  stimulated	  and	  unstimulated	  samples.	  Therefore	  to	  enable	  the	  repeated	  addition	  of	  
newly	  differentiated	  cells	  to	  cultures	  over	  several	  days,	  the	  use	  of	  cell	  culture	  inserts	  with	  a	  0.4	  
μm	  pore	   size	  was	  explored.	   This	   alteration	   in	  protocol	   allowed	   for	   the	   complete	   removal	   of	  
ageing	  monocytic	  cells	  while	  maintaining	   the	  essential	   released	  soluble	   factors	  necessary	   for	  
cellular	  communication.	  	  	  
	  
Increasing	  numbers	  of	  monocytes	  or	  VitD3-­‐differentiated	  THP-­‐1	  cells	  in	  cell	  culture	  inserts	  were	  
added	  to	  a	  confluent	  BEAS-­‐2B	  monolayer	   in	  the	  presence	  or	  absence	  of	  LPS	  (1	  ng/ml)	   for	  24	  
hours.	   The	   use	   of	   cell	   culture	   inserts	   resulted	   in	   an	   approximately	   6-­‐fold	   decrease	   in	   CXCL8	  
release	   from	   monocytes	   (Figure	   3.4a)	   when	   compared	   to	   monocytes	   in	   direct	   cell-­‐to-­‐cell	  
contact	   (Figure	  3.3a).	  Similarly,	  LPS-­‐induced	  CXCL8	  release	  was	  dampened	  by	  4-­‐fold	   in	  VitD3-­‐
differentiated	  THP-­‐1	  cells	  in	  cell	  culture	  inserts	  (Figure	  3.4b)	  in	  comparison	  to	  the	  direct	  cell-­‐to-­‐
cell	   contact	  model	   (Figure	   3.3b).	  Additionally,	   in	   line	  with	  previous	  data,	  VitD3-­‐differentiated	  
THP-­‐1	  cells	  released	  less	  CXCL8	  than	  monocytes.	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A	   Monocytes
	  	  
B	   THP-­‐1	  cells	  
	  
Figure	   3.4	   Comparison	   of	   indirect	   interaction	   between	  monocytic	   cells	   and	   BEAS-­‐2B	   in	   an	  
acute	  model	  of	  inflammation	  
BEAS-­‐2B	   cells	   were	   seeded	   at	   3	   x	   106	   cells/24-­‐well	   plate	   (125,000	   cells/well)	   for	   24	   hours	  
followed	   by	   the	   addition	   of	   increasing	   numbers	   of	   (A)	   highly	   purified	   human	   monocytes	  
derived	   from	  volunteer	  donors	  or	   (B)	  VitD3-­‐differentiated	  THP-­‐1	  cells	  separated	  by	  a	  0.4	  μm	  
cell	   culture	   insert.	   This	   was	   followed	   by	   stimulation	   with	   LPS	   (1	   ng/ml)	   for	   24	   hours.	  
Supernatants	  were	  collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	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mean	  ±	  SEM	  of	  n=3.	  Statistical	  analysis	  was	  carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  
post-­‐test	  (**p<0.01	  and	  ***p<0.001).	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3.4	  Establishing	  a	  chronic	  model	  of	  inflammation	  
3.4.1	  Utilising	  a	  model	  system	  with	  cell	  separation	  via	  cell	  culture	  inserts	  
  
A	   more	   chronic	   model	   of	   inflammation	   was	   developed	   to	   further	   explore	   how	   continued	  
exposure	  of	  BEAS-­‐2B	  cells	  to	  a	  proinflammatory	  environment	  would	  affect	  their	  responses	  to	  
stimuli	  such	  as	  pathogens.	  During	  the	  design	  of	  the	  chronic	  model	  of	   inflammation	  a	  modest	  
but	  detectable	   response	   to	   LPS	  was	  deemed	  appropriate	   to	  provide	  a	   continuous	   low-­‐grade	  
inflammation.	   Therefore,	   based	   on	   previous	   data	   (Figure	   3.4b)	   100,000	   VitD3-­‐differentiated	  
THP-­‐1	  cells	  per	  sample	  were	  determined	  sufficient	  to	  elicit	  cellular	  response.	  
	  
The	  proposed	  chronic	  model	  of	  inflammation	  allowed	  24	  hours	  for	  BEAS-­‐2B	  cell	  adherence	  to	  
culture	  wells.	  On	  day	  1	  BEAS-­‐2B	  monolayers	  were	  washed	  with	  media	  before	  the	  addition	  of	  
cell	   culture	   inserts	   containing	   VitD3-­‐differentiated	   THP-­‐1	   cells.	   These	   inserts	   were	   replaced	  
with	   freshly	  differentiated	  THP-­‐1	  cells	  on	  days	  1,	  3	  and	  5	  of	   the	  experiment.	   In	  addition,	   the	  
BEAS-­‐2B	  monolayers	  and	  inserts	  were	  also	  stimulated	  with	  fresh	  LPS	  (1ng/ml)	  on	  these	  days.	  
Finally,	   on	   day	   7,	   cell	   culture	   inserts	   were	   removed	   and	   primary	   monocytes	   were	   added	  
directly	  onto	  the	  BEAS-­‐2B	  monolayer	  in	  combination	  with	  a	  fresh	  dose	  of	  LPS	  (1ng/ml).	  On	  day	  
8	   supernatants	   were	   collected	   and	   measured	   for	   CXCL8	   release	   by	   ELISA	   (chronic	   model	  
method	  depicted	  in	  Figure	  3.5d).	  	  
	  
The	  baseline	  CXCL8	   release	   (0.5-­‐0.6	  ng/ml)	   from	  unchallenged	  BEAS-­‐2Bs	   served	   as	   a	   control	  
(method	  depicted	   in	  Figure	  3.5a).	  The	  multiple	  challenges	  with	  LPS	  on	  days	  1,	  3,	  5	  and	  7	  did	  
not	  alter	  the	  baseline	  CXCL8	  release	  in	  these	  cells	  (Figure	  3.6a).	  The	  introduction	  of	  cell	  culture	  
inserts	  containing	  VitD3-­‐differentiated	  THP-­‐1	  cells	  (method	  depicted	  in	  Figure	  3.5b)	  served	  as	  a	  
second	  control	  group	  and	  revealed	  no	  further	  effect	  of	  THP-­‐1	  cells	  on	  baseline	  CXCL8	  release	  
following	  continuous	  LPS	  stimulation	  (0.5-­‐0.6	  ng/ml)	  (Figure	  3.6b).	  	  
	  
In	  the	  final	  control	  group	  BEAS-­‐2B	  cells	  underwent	  the	  same	  continuous	  stimulation	  with	  LPS	  
on	  days	  1,	  3,	  5	  and	  7	  followed	  by	  the	  direct	  addition	  of	  monocytes	  with	  a	  final	  LPS	  stimulation	  
on	   day	   7	   for	   a	   further	   24	   hours	   (method	   depicted	   in	   Figure	   3.5c).	   The	   direct	   addition	   of	  
monocytes	  to	  the	  primed	  BEAS-­‐2B	  monolayer	  resulted	  in	  a	  marked	  CXCL8	  production	  (over	  50	  
ng/ml)	   (Figure	   3.6c).	   Interestingly,	   no	   difference	   in	   CXCL8	   release	   was	   observed	   when	  
compared	  with	  the	  proposed	  chronic	  model	  when	  BEAS-­‐2B	  cells	  were	  challenged	  with	  LPS	  on	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days	  1,	  3,	  5	  and	  7	  in	  the	  presence	  of	  VitD3-­‐differentiated	  THP-­‐1	  cells	  in	  culture	  inserts	  followed	  
by	   the	   direct	   addition	   of	   monocytes	   to	   the	   primed	   BEAS-­‐2B	   monolayer	   on	   day	   7	   (method	  
depicted	   in	  Figure	   3.5d	  and	   results	   in	   Figure	   3.6d).	   In	   further	  experiments	   to	  determine	   the	  
relevance	   of	   IL-­‐1	   to	   chronic	   inflammation,	   BEAS-­‐2B	   were	   also	   stimulated	   with	   LPS	   in	   the	  
presence	   of	   IL-­‐1ra	   on	   day	   7	   and	   resulted	   in	   a	   significant	   inhibition	   of	   LPS	   and	   monocyte-­‐
induced	  CXCL8	  release	  (Figure	  3.6c	  and	  Figure	  3.6d).	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A	  BEAS-­‐2B	  alone	  
	  
B	  BEAS-­‐2B	  and	  THP-­‐1	  cells	  
	  
C	  BEAS-­‐2B	  and	  Monocytes	  
	  
D	  BEAS-­‐2B,	  THP-­‐1	  cells	  and	  Monocytes	  
	  
Figure	   3.5	   Depiction	   of	   the	   chronic	   model	   system	   utilising	   cell	   culture	   inserts	   and	   its	  
respective	  controls	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BEAS-­‐2B	  were	   seeded	   at	   3	   x	   106	   cells/24-­‐well	   plate	   (125,000	   cells/well)	   for	   24	   hours.	   These	  
were	  then	  split	  into	  4	  groups	  titled:	  A)	  BEAS-­‐2B	  alone,	  B)	  BEAS-­‐2B	  and	  THP-­‐1	  cells,	  C)	  BEAS-­‐2B	  
and	  Monocytes	   and	   D)	   BEAS-­‐2B,	   THP-­‐1	   cells	   and	  Monocytes.	   In	   each	   group,	   samples	   were	  
stimulated	  with	  LPS	  at	  1	  ng/ml	  on	  days	  1,	  3,	  5	  and	  7.	  Groups	  B	  and	  D	  also	  had	  the	  addition	  of	  
cell	   culture	   inserts	   containing	   100,000	   VitD3-­‐differentiated	   THP-­‐1	   cells	   on	   days	   1,	   3,	   and	   5.	  
Finally	   on	   day	   7,	   all	   cell	   culture	   inserts	   were	   discarded	   and	   all	   wells	   washed	   with	   media	  
carefully.	   Group	   C	   and	  D	   then	   underwent	   the	   addition	   of	   human	   CD14	   positive	  monocytes.	  
These	  were	   isolated	   from	  healthy	  donors	  and	  directly	  added	  onto	   the	  epithelial	   cell	   layer	   to	  
generate	  co-­‐cultures.	  All	  groups	  also	  underwent	  one	  final	  treatment	  with	  LPS	  (1	  ng/ml)	  with	  or	  
without	   IL-­‐1ra	   (10	   μg/ml)	   for	   24	   hours	   before	   the	   collection	   of	   supernatants	   for	   further	  
analysis.  	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Figure	  3.6	  Establishing	  a	  chronic	  model	  system	  with	  cell	  separation	  via	  cell	  culture	  inserts	  
BEAS-­‐2B	  were	  seeded	  at	  3	  x	  106	  cells/24-­‐well	  plate	  (125,000	  cells/well)	  for	  24	  hours	  and	  were	  
either	   unstimulated	   for	   7	   days	   (unchallenged)	   or	   underwent	   chronic	   stimulation	   (chronic	  
challenge)	  as	  described	  in	  Figure	  3.5.	  A)	  BEAS-­‐2B	  alone,	  B)	  BEAS-­‐2B	  and	  THP-­‐1,	  C)	  BEAS-­‐2B	  and	  
monocytes	  and	  D)	  BEAS-­‐2B,	  THP-­‐1	  and	  monocytes	  were	  stimulated	  with	  LPS	  (1ng/ml)	  and	  IL-­‐
1ra	  (10μg/ml)	  in	  the	  indicated	  wells.	  
After	  24	  hours,	  Cell	  free	  supernatants	  were	  generated	  and	  CXCL8	  release	  measured	  by	  ELISA.	  
Data	   shown	  are	  mean	  ±	   SEM	  of	   n=3	   experiments.	   Significant	   differences	   are	   denoted	  by	   **	  
(p<0.01)	  and	  ***	  (p<	  0.001)	  as	  measured	  by	  2-­‐way	  ANOVA	  and	  Bonferroni’s	  post	  test.	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3.4.2	  Utilising	  a	  model	  system	  with	  direct	  cell-­‐to-­‐cell	  contact	  
The	   model	   of	   chronic	   inflammation	   with	   cell	   separation	   via	   cell	   culture	   inserts	   showed	   no	  
detectable	   differences	   between	   the	   BEAS-­‐2B	   cells	   that	   underwent	   the	   complete	   treatment	  
with	   LPS,	   THP-­‐1	   and	   monocytes	   (Figure	   3.6d)	   and	   the	   control	   of	   just	   LPS	   and	   monocytes	  
(Figure	   3.6c).	   It	   was	   hypothesised	   that	   the	   use	   of	   cell	   culture	   inserts	  may	   have	   resulted	   in	  
ineffective	   cytokine	   production	   required	   for	   effective	   inflammatory	   responses	   due	   to	   cell	  
separation.	   	   A	   model	   of	   cell-­‐to-­‐cell	   contact	   wherein	   vitD3-­‐differentiated	   THP-­‐1	   cells	   are	   no	  
longer	  contained	  in	  cell	  culture	  inserts	  for	  the	  duration	  of	  the	  experiment	  was	  proposed.	  
	  
Similarly	  to	  section	  3.4.1,	  BEAS-­‐2B	  cells	  alone	  challenged	  with	  LPS	  on	  days	  1,	  3,	  5	  and	  7	  were	  
served	  as	  a	  negative	  control	  with	  baseline	  CXCL8	  levels	  of	  0.5-­‐0.6	  ng/ml	  (method	  depicted	  in	  
Figure	   3.7a	   and	   results	   in	   Figure	   3.8a).	   The	   second	   control	   group	   aimed	   to	   determine	   the	  
effect	  of	  THP-­‐1	  cell	  contact	  on	  BEAS-­‐2B	  cells	  following	  multiple	  treatments	  with	  LPS	  (depicted	  
in	   Figure	   3.7b)	   and	   revealed	   a	   negligible	   effect	   on	   baseline	   CXCL8	   release	   (0.6-­‐0.7	   ng/ml)	  
(Figure	   3.8b).	   In	   the	   third	   control	   group	   (method	   depicted	   in	   Figure	   3.7c),	   BEAS-­‐2B	   cells	  
underwent	  multiple	   LPS	   treatments	   on	   days	   1,	   3	   and	   5	   followed	  by	   the	   addition	   of	   purified	  
human	  monocytes	   in	   combination	   with	   a	   final	   LPS	   stimulation	   on	   day	   7	   resulting	   in	   CXCL8	  
release	  of	  20-­‐30	  ng/ml	  (Figure	  3.8c).	  	  
	  
Finally,	   BEAS-­‐2B	   cells	  were	   stimulated	  with	   LPS	   and	   fresh	   vitD3-­‐differentiated	   THP-­‐1	   cells	   on	  
days	  1,	  3	  and	  5	  before	  a	  final	  challenge	  with	  LPS	  in	  the	  presence	  of	  monocytes	  on	  day	  7.	  The	  
resulting	  CXCL8	  generation	  with	  levels	  of	  12	  ng/ml	  was	  marginally	  lower	  (Figure	  3.8d)	  than	  the	  
BEAS-­‐2B	  and	  monocyte	  control	  group	  with	  levels	  of	  20	  ng/ml	  (Figure	  3.8c).	  However	  it	  is	  also	  
important	  to	  note	  that	  the	  despite	  the	  decrease	  in	  CXCL8	  levels	  between	  the	  two	  models,	  the	  
unchallenged	   control	   in	   BEAS-­‐2B,	   THP-­‐1	   and	   monocyte	   model	   (Figure	   3.8d)	   also	   showed	  
decreased	   levels	   of	   CXCL8	   generation	   (levels	   of	   18	   ng/ml)	   compared	  with	   the	   unchallenged	  
control	  on	  the	  BEAS-­‐2B	  and	  monocytes	  control	  group	  (levels	  of	  32	  ng/ml)	  (Figure	  3.8c).	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A	  BEAS-­‐2B	  alone	  
	  
B	  BEAS-­‐2B	  and	  THP-­‐1	  cells	  
	  
C	  BEAS-­‐2B	  and	  Monocytes	  
	  
D	  BEAS-­‐2B,	  THP-­‐1	  cells	  and	  Monocytes
	  
Figure	  3.7	  Depiction	  of	  the	  direct	  cell-­‐to-­‐cell	  chronic	  model	  system	  and	  its	  respective	  controls	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BEAS-­‐2B	  were	   seeded	  at	   3	   x	   106	   cells/24-­‐well	   plate	   (125,000	   cells/well)	   for	   24	  hours.	   These	  
were	  then	  split	  into	  4	  groups	  titled:	  A)	  BEAS-­‐2B	  alone,	  B)	  BEAS-­‐2B	  and	  THP-­‐1	  cells,	  C)	  BEAS-­‐2B	  
and	  Monocytes	   and	  D)	   BEAS-­‐2B,	   THP-­‐1	   cells	   and	  Monocytes.	   In	   each	   group,	   samples	   were	  
stimulated	  with	  LPS	  at	  1	  ng/ml	  on	  days	  1,	  3,	  5	  and	  7.	  Groups	  B	  and	  D	  also	  had	  the	  addition	  of	  
100,000	  vitamin	  D3	  differentiated	  THP-­‐1	  cells	  on	  days	  1,	  3,	  and	  5	  where	  all	  wells	  were	  washed	  
with	  media	  carefully	  in	  between	  each	  addition.	  Group	  C	  and	  D	  then	  underwent	  the	  addition	  of	  
human	   CD14	   positive	   monocytes	   on	   day	   7.	   These	   were	   isolated	   from	   healthy	   donors	   and	  
directly	  added	  onto	  the	  epithelial	  cell	  layer	  to	  generate	  co-­‐cultures.	  All	  groups	  also	  underwent	  
one	  final	  treatment	  with	  LPS	  (1	  ng/ml)	  with	  or	  without	   IL-­‐1ra	  (10	  μg/ml)	  for	  24	  hours	  before	  
the	  collection	  of	  supernatants	  for	  further	  analysis.  	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Figure	  3.8	  Establishing	  a	  chronic	  model	  system	  with	  direct	  cell	  contact	  
BEAS-­‐2B	  were	  seeded	  at	  3	  x	  106	  cells/24-­‐well	  plate	  (125,000	  cells/well)	  for	  24	  hours	  and	  were	  
either	   unstimulated	   for	   7	   days	   (unchallenged)	   or	   underwent	   chronic	   stimulation	   (chronic	  
challenge)	  as	  described	  in	  Figure	  3.7.	  A)	  BEAS-­‐2B	  alone,	  B)	  BEAS-­‐2B	  and	  THP-­‐1,	  C)	  BEAS-­‐2B	  and	  
monocytes	  and	  D)	  BEAS-­‐2B,	  THP-­‐1	  and	  monocytes	  were	  stimulated	  with	  LPS	  (1ng/ml)	  and	  IL-­‐
1ra	   (10μg/ml)	   in	   the	   indicated	   wells.	   Supernatants	   were	   collected	   and	   analysed	   for	   CXCL8	  
release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=3.	  Statistical	  analysis	  was	  carried	  out	  
by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05	  and	  **p<0.01).	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3.5	  IRFs	  1,2,3,6,7	  and	  9	  are	  expressed	  in	  BEAS-­‐2B	  cells	  
 
In	  parallel	  with	  the	  establishment	  of	  the	  chronic	  model	  to	  study	  prolonged	  pathogen	  handling,	  
techniques	  for	  the	  exploration	  of	  cellular	  signalling	  and	  thus	  downstream	  cytokine	  production	  
and	  cellular	  communication	  were	  also	  developed.	  
	  
IRFs	  are	  key	  transcription	  factors	  that	  are	  involved	  in	  cytokine	  production	  in	  the	  regulation	  of	  
innate	   immune	   responses	   and	   are	   involved	   predominantly	   in	   viral	   but	   also	   in	   bacterial	  
detection	  systems	  (Section	  1.2.3.1).	  Basal	  expression	  levels	  of	  IRFs	  1-­‐9	  were	  measured	  by	  RT-­‐
PCR	  as	  described	   in	  Section	  2.5.	  The	  results	   in	  Figure	  3.5	   reveal	  that	   IRFs	  1,2,3,6,7	  and	  9	  are	  
expressed	  in	  BEAS-­‐2B	  whilst	  IRFs	  1,2,3,4,5,7,	  8	  and	  9	  are	  expressed	  in	  PBMCs,	  which	  were	  used	  
as	   a	   positive	   control	   for	   the	   primers.	   The	   housekeeping	   gene	   Glyceraldehyde-­‐3-­‐phosphate	  
dehydrogenase	  (GAPDH)	  was	  a	  used	  as	  a	  control	  for	  loading.	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Figure	  3.9	  IRF	  expression	  levels	  within	  BEAS-­‐2B	  cells	  
IRF	  expressions	  levels	  within	  BEAS-­‐2B	  cells	  and	  PBMC	  were	  measured	  by	  RT-­‐PCR	  as	  described	  
in	  section	  2.6.	  IRF	  1,2,3,6,7	  and	  9	  were	  expressed	  in	  BEAS-­‐2B	  cells	  whilst	  IRF	  1,2,3,4,5,7,8	  and	  9	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3.6	  Establishing	  a	  model	  of	  inflammation	  using	  cigarette	  smoke	  
	  
Cigarette	  smoking	  is	  a	  major	  risk	  factor	  in	  the	  development	  of	  COPD.	  	  The	  numerous	  adverse	  
effects	  of	  cigarette	  smoke	  exposure	  include	  increased	  susceptibility	  to	  infections	  as	  well	  as	  the	  
increased	   severity	   and	   prevalence	   of	   respiratory	   infections	   (Eddleston	   et	   al.,	   2011;	   Stampfli	  
and	  Anderson,	  2009).	  	  
	  
Cigarette	  smoke	  exposure	  alters	  the	  first	   line	  of	  defence	  within	  the	  airway	  resulting	   in	  tissue	  
damage.	   These	   damages	   include	   disrupted	   epithelial	   cell	   junctions,	   decreased	   extracellular	  
matrix	   remodelling	  and	  proliferation	  of	  mesenchymal	  cells	   leading	   to	  fibrogenesis	  and	   tissue	  
destruction	   (Ojo	   et	   al.,	   2014).	   Indeed	   enhanced	   airway	   epithelial	   cell	   permeability	   and	  
impaired	  mucociliary	  clearance	  increase	  the	  burden	  on	  immunologic	  host	  defences	  (Eddleston	  
et	   al.,	   2011;	   van	   der	   Vaart	   et	   al.,	   2004).	   This	   is	   supported	   by	   the	   elevation	   in	   both	  
proinflammatory	   cell	   types	   such	   as	   neutrophils,	   monocytes	   and	   macrophages	   and	  
consequently	  proinflammatory	  cytokines	  such	  as	  CXCL8	  (Tanino	  et	  al.,	  2002),	  TNF-­‐α	  (Churg	  et	  
al.,	  2004)	  and	  IL-­‐1β	  (Hellermann	  et	  al.,	  2002;	  Ryder	  et	  al.,	  2002).	  
	  
In	  section	  3.4	  I	  demonstrated	  that	  an	  obvious	  chronic	  perturbation	  of	  cellular	  phenotype	  was	  
not	   achieved	   with	   repeated	   stimulation	   using	   endotoxin/monocytes	   in	   combination.	   I	  
therefore	   proposed	   an	   alternative	   model	   using	   the	   predominant	   risk	   factor	   for	   the	  
development	   of	   COPD	   as	   the	   main	   chronic	   stimulus.	   It	   is	   well	   documented	   that	   cigarette	  
smoking	  can	  alter	  airway	  epithelial	  cell	  responses	  to	  both	  bacterial	  (Pace	  et	  al.,	  2008)	  and	  viral	  
infections	   (Eddleston	   et	   al.,	   2011),	   and	  while	   these	   studies	   provide	   valuable	   insight	   into	   the	  
crucial	   airway	   responses	   to	  pathogens,	   the	  effect	  of	   long-­‐term	  cigarette	   smoke	  exposure	  on	  
inflammation	  and	  on	  the	  innate	  immunity	  of	  the	  airway	  remains	  poorly	  understood.	  Therefore	  
this	   study	   aimed	   to	   create	   an	   in	   vitro	   chronic	   model	   of	   inflammation	   to	   enable	   the	  
understanding	   of	   whether	   chronic	   inflammation	   uses	   different	   molecular	   pathways	   and	  
presents	  different	  targets	  for	  treatment	  of	  disease.	  
	  
BEAS-­‐2B	   cells	  were	   cultured	   for	   24	   hours	  with	   increasing	   concentrations	   of	   cigarette	   smoke	  
extract	  (CSE)	  (ranging	  from	  0-­‐55%	  CSE)	  and	  measured	  for	  CXCL8	  production	  (Figure	  3.10).	  Cell	  
death	  was	  visibly	  detected	  under	   light	  microscopy	  from	  concentrations	  above	  25%	  CSE	  (data	  
not	  shown).	  Therefore	  taken	   in	  combination	  with	  existing	   literature	  and	  keeping	   in	  mind	  the	  
nature	  of	  the	  model	  to	  be	  explored,	  wherein	  continuous	  low-­‐grade	  exposure	  to	  CSE	  attempts	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to	   mimic	   frequent	   cigarette	   smoke	   exposure,	   10%	   was	   deemed	   sufficient	   to	   elicit	   cellular	  
response	  without	  inducing	  overwhelming	  toxic	  effects.	  	  
	  
Subsequently	  BEAS-­‐2B	  cells	  were	  acutely	  stimulated	  with	  10%	  CSE	  alone	  or	  in	  the	  presence	  of	  
proinflammatory	  stimuli	  for	  24	  hours	  then	  measured	  for	  CXCL8	  production.	  10%	  CSE	  alone	  was	  
sufficient	  to	  significantly	  increase	  the	  CXCL8	  baseline	  levels	  by	  a	  third	  (Figure	  3.11a).	  The	  same	  
levels	  of	  CXCL8	  production	  were	  measured	   in	   the	  LPS	  stimulated	  sample	  suggesting	   that	   the	  
measured	   increase	   is	   independent	   of	   LPS	   stimulation	   (Figure	   3.11b).	   In	   addition,	   CXCL8	  
production	  in	  response	  to	  poly(I:C)	  was	  inhibited	  by	  the	  presence	  of	  CSE	  (Figure	  3.11c).	  While	  	  
an	  increase	  in	  CXCL8	  production	  in	  response	  to	  IL-­‐1β	  was	  measured	  (Figure	  3.11d).	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Figure	  3.10	  Increasing	  concentrations	  of	  CSE	  results	  in	  enhanced	  CXCL8	  production	  in	  BEAS-­‐
2Bs	  
BEAS-­‐2B	  were	  seeded	  at	  3	  x	  106	  cells/24-­‐well	  plate	  (125,000	  cells/well)	  for	  24	  hours	  followed	  
by	   a	   24	   hour	   stimulation	  with	   increasing	   concentrations	   of	   CSE	   (5-­‐55%).	   Supernatants	  were	  
collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=3.	  
Statistical	  analysis	  was	  carried	  out	  by	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	   (**p<0.01	  
and	  ***p<0.001).	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Figure	   3.11	   BEAS-­‐2B	   cells	   exhibit	   differential	   regulation	   to	   proinflammatory	   stimuli	   in	   the	  
presence	  of	  CSE	  
BEAS-­‐2B	   cells	   were	   seeded	   at	   3	   x	   106	   cells/24-­‐well	   plate	   (125,000	   cells/well)	   for	   24	   hours	  
followed	  by	  stimulation	  with	  (A)	  CSE	  (10%)	  alone,	  or	  the	  combination	  of	  CSE	  (10%)	  and	  (B)	  LPS	  
(1ug/ml),	   (C)	   Poly(I:C)	   (10ug/ml)	   or	   	   (D)	   IL-­‐1β	   (10ng/ml)	   for	   24	   hours.	   Supernatants	   were	  
collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=7.	  
Statistical	  analysis	  was	  carried	  out	  by	   two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	   (**p<0.01	  
and	  ***p<0.001).	  	  
	   95	  
3.7	  CSE	  potentiates	  proinflammatory	  responses	  to	  TLR	  agonists	  in	  a	  
chronic	  model	  of	  inflammation	  
	  
To	   begin	   to	   assess	   whether	   chronic	   exposure	   to	   CSE	   interferes	   with	   airway	   epithelial	   cells’	  
ability	   to	   mount	   an	   effective	   inflammatory	   response	   in	   an	   ongoing	   proinflammatory	  
environment,	  the	  BEAS-­‐2B	  cell	  line	  was	  pre-­‐treated	  with	  CSE	  for	  6	  days	  wherein	  fresh	  CSE	  (at	  
2%	   or	   10%)	   was	   replaced	   every	   24	   hours	   before	   the	   final	   stimulation	   with	   TLR	   agonists,	  
poly(I:C)	  and	  IL-­‐1β,	  in	  combination	  with	  a	  fresh	  dose	  of	  CSE	  (method	  depicted	  in	  Figure	  3.12a).	  	  
	  
As	  per	  previous	  findings	  in	  the	  acute	  model	  (Figure	  3.11a),	  repeated	  stimulation	  with	  10%	  CSE	  
results	  in	  an	  elevated	  baseline	  of	  CXCL8	  production	  (Figure	  3.12b).	  Similarly,	  the	  stimulation	  of	  
BEAS-­‐2B	  cells	  with	   IL-­‐1β	   (10	  ng/ml)	   following	   six	  days	  of	   repeated	   stimulation	  with	  10%	  CSE	  
also	  resulted	  in	  a	  significant	  increase	  in	  the	  production	  of	  CXCL8	  (Figure	  3.12d).	  In	  contrast	  to	  
previous	   findings	   in	   the	   acute	   stimulation	   model	   however	   (Figure	   3.11c),	   the	   repeated	  
stimulation	   of	   BEAS-­‐2B	   cells	   with	   2%	   and	   10%	   CSE	   followed	   by	   a	   single	   stimulation	   with	  
poly(I:C)	   (10	   ug/ml)	   resulted	   in	   an	   increase	   in	   CXCL8	   production	   (Figure	   3.12c).	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A.	  Chronic	  Model	  of	  inflammation	  using	  CSE	  
	  
Figure	   3.12	   Repeated	   exposure	   to	   CSE	   potentiates	   the	   CXCL8	   response	   to	   TLR	   agonists	   in	  
BEAS-­‐2B	  cells	  
(A)	  BEAS-­‐2B	  cells	  were	  seeded	  at	  3	  x	  106	  cells/24-­‐well	  plate	  (125,000	  cells/well)	   for	  24	  hours	  
followed	  by	   stimulation	  with	  CSE	   (2%	  or	  10%)	  every	  24	  hours	   for	   6	  days	   followed	  by	  a	   final	  
stimulation	  of	  CSE	  with	  or	  without	  a	  TLR	  agonist	   for	  a	  further	  24	  hours.	  Supernatants	  for	   (B)	  
CSE	  (2%	  and	  10%)	  alone,	  or	  the	  combination	  of	  CSE	  (2%	  and	  10%)	  and	  (C)	  poly(I:C)	  (10ug/ml)	  
or	   (D)	   IL-­‐1β	   (10ng/ml)	   were	   collected	   and	   analysed	   for	   CXCL8	   release	   by	   ELISA.	   Data	   are	  
expressed	  as	  mean	  ±	  SEM	  of	  n=5.	  Statistical	  analysis	  was	  carried	  out	  by	  one-­‐way	  ANOVA	  with	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3.8	  MyD88	  and	  IRF3	  stable	  knockdown	  differentially	  regulate	  CXCL8	  
secretion	  to	  multiple	  proinflammatory	  stimuli	  in	  BEAS-­‐2B	  cells	  	  
	  
LPS	   triggers	   the	   TLR4	   dependent	   activation	   of	   NF-­‐κB,	   IRF-­‐3	   and	  MAPK	   pathways,	   which	   are	  
mediated	  by	  the	  adaptors	  MyD88	  and	  Mal.	  This	  early	  activation	  results	  in	  the	  expression	  of	  a	  
plethora	   of	   pro-­‐inflammatory	   cytokines	   following	   the	   phosphorylation	   and	   activation	   of	   the	  
IRAK1/IRAK4/TRAF6	   activation	   complex.	   At	   late	   stage	   activation	   however,	   LPS	   results	   in	   the	  
internalisation	   of	   TLR4	   into	   endosomes	   allowing	   it	   to	   associate	   with	   TRIF	   and	   activate	   the	  
MyD88-­‐independent	   pathway	   (O'Neill	   et	   al.,	   2013).	   Therefore	   in	   order	   to	   dissect	   the	   effects	  
and	  roles	  of	  IL-­‐1β	  and	  IFN	  signalling	  on	  bacterial	  infection	  and	  viral	  infection	  in	  more	  detail	  two	  
stable	   knockdowns	   were	   used:	   MyD88	   knockdown	   (IL-­‐1R1	   signalling	   adaptor)	   and	   IRF3	  
knockdown	  (IFN	  signalling	  transcription	  factor).	  	  
	  
Both	  stable	  knockdown	  cell	  lines	  were	  previously	  created	  by	  a	  post-­‐doctoral	  researcher	  within	  
the	  group,	  Dr	  Clare	  Stokes,	  using	  a	   lentiviral	  delivery	  system	  containing	  a	  shRNA	  that	   inserts	  
into	   the	   chromosome	   and	   results	   in	   RNA	   interference	   by	   the	   long-­‐term	   degradation	   of	   the	  
target	  mRNA	  (Stokes	  et	  al.,	  2011).	  	  
	  
Both	  MyD88KD	  and	  IRF3KD	  showed	  decreasing	  trends	  in	  CXCL8	  production	  when	  compared	  with	  
WT	   even	   in	   the	   absence	   of	   any	   stimulus	   (Figure	   3.13a).	   The	   exposure	   to	   CSE	   for	   24	   hours	  
resulted	   in	  a	   significant	   increase	   in	  CXCL8	   release	   in	  WT	  cells	   and	  an	   increasing	   trend	   in	   the	  
MyD88KD	  or	  IRF3KD	  cell	  lines	  (Figure	  3.13a).	  This	  phenotype	  was	  replicated	  with	  the	  addition	  of	  
LPS,	   wherein	   CXCL8	   baseline	   levels	   were	   significantly	   increased	   in	  WT	   cell	   line	   only	   (Figure	  
3.13b).	  	  
	  
However,	   when	   stimulated	   with	   poly(I:C)	   alone,	   the	   CXCL8	   levels	   in	   the	   WT	   cell	   line	   were	  
significantly	   higher	   than	   the	  decreasing	   trend	  measured	   in	   both	  MyD88KD	   and	   IRF3KD	  (Figure	  
3.13c).	  Interestingly,	  the	  addition	  of	  CSE	  to	  poly(I:C)	  resulted	  in	  a	  decrease	  in	  WT	  CXCL8	  release	  
with	  minimal	  change	  measured	   in	  MyD88	  and	   IRF3KD	  CXCL8	   levels	   (Figure	  3.13c).	  Finally,	   the	  
stimulation	   of	   WT	   and	   IRF3KD	   cells	   with	   the	   combination	   of	   CSE	   and	   IL-­‐1β	   resulted	   in	   an	  
increase	   in	   levels	   of	   CXCL8	   while	   MyD88KD	   cells	   remained	   unchanged	   (Figure	   3.13d).	   It	   is	  
important	   to	   note	   that	  MyD88KD	   and	   IRF3KD	   CXCL8	   levels	   produced	  were	   consistently	   lower	  
than	  WT,	  even	  when	  unstimulated.	  	  
	   98	  
	  
	  
Figure	  3.13	  MyD88KD	  and	  IRF3KD	  epithelial	  cell	  lines	  exhibit	  selective	  defects	  in	  responses	  to	  
proinflammatory	  stimuli	  
BEAS-­‐2B,	   MyD88KD	   and	   IRF3KD	   cells	   were	   seeded	   at	   3	   x	   106	   cells/24-­‐well	   plate	   (125,000	  
cells/well)	  for	  24	  hours	  followed	  by	  stimulation	  with	  (A)	  CSE	  (10%)	  alone,	  or	  the	  combination	  
of	  CSE	  (10%)	  and	  (B)	  LPS	  (1ug/ml),	  (C)	  Poly(I:C)	  (10ug/ml)	  or	  	  (D)	  IL-­‐1β	  (10ng/ml)	  for	  24	  hours.	  
Supernatants	  were	  collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  
mean	  ±	  SEM	  of	  n=7.	  Statistical	  analysis	  was	  carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  
post-­‐test	  (**p<0.01	  and	  ***p<0.001).	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3.9	  Altered	  acute	  model	  results	  in	  increased	  CXCL8	  production	  to	  
poly(I:C)	  stimulation	  in	  the	  presence	  of	  CSE	  	  
	  
My	   previous	   data	   indicated	   an	   altered	   BEAS-­‐2B	   CXCL8	   response	   to	   poly(I:C)	   stimulation	  
following	  repeated	  exposure	  to	  CSE	  over	  7	  days	  when	  compared	  to	  an	  acute	  24	  hour	  exposure.	  
While	  poly(I:C)	  alone	  in	  both	  models	  resulted	  in	  the	  increase	  of	  CXCL8	  production,	  the	  addition	  
of	  poly(I:C)	  in	  the	  presence	  of	  CSE	  for	  24	  hours	  lead	  to	  a	  reduction	  in	  CXCL8	  production	  acutely	  
(Figure	  3.11c).	  Interestingly,	  the	  repeated	  pretreatment	  of	  BEAS-­‐2B	  cells	  with	  CSE	  prior	  to	  a	  24	  
hours	  poly(I:C)	  stimulation	  resulted	  in	  a	  potentiated	  CXCL8	  response	  (Figure	  3.12c).	  In	  order	  to	  
determine	  whether	  this	  differential	  was	  indeed	  caused	  by	  the	  repetitive	  CSE	  pretreatment	  and	  
not	   the	  method	   itself,	  a	  new	  more	  comparable	  control	  experiment	  was	  developed.	  The	  new	  
control	  acute	  model	   is	  maintained	  for	  7	  days,	  the	  same	  period	  of	  time	  as	  the	  chronic	  model,	  
and	  in	  the	  same	  environment	  however	  remains	  unstimulated	  until	  the	  final	  24	  hours.	  	  
	  
BEAS-­‐2Bs	   were	   grown	   to	   confluence	   and	   split	   into	   the	   acute	   model	   or	   the	   repeated	  
exposure/chronic	  model.	  Cells	  from	  the	  acute	  model	  were	  maintained	  in	  RPMI	  1640	  with	  5%	  
FCS	  fresh	  media	  changed	  every	  24	  hours	  for	  6	  days	  (method	  depicted	  in	  Figure	  3.14).	  Whilst	  
cells	  from	  the	  chronic	  model	  were	  exposed	  to	  fresh	  CSE	  (10%)	  in	  RPMI	  1640	  with	  5%	  FCS	  every	  
24	  hours	  for	  6	  days	  (method	  depicted	  in	  Figure	  3.14).	  On	  day	  7	  both	  groups	  were	  washed	  with	  
PBS	   and	   stimulated	   with	   poly(I:C)	   (10	   ug/ml)	   in	   basal	   RPMI	   1640	   for	   24	   hours	   before	  
supernatant	   collection	   and	   analysis.	   As	   per	   previous	   results	   (Figure	   3.12c),	   the	   repeated	  
exposure	  model	  resulted	  in	  an	  increase	  in	  CXCL8	  production	  in	  response	  to	  poly(I:C)	  and	  CSE	  in	  
BEAS-­‐2B	  cells	  (Figure	  3.14b).	   Interestingly,	   in	  contrast	  to	  previous	  findings	  (Figure	  3.11c),	  the	  
acute	   model	   also	   resulted	   in	   an	   increase	   in	   CXCL8	   production	   to	   poly(I:C)	   (Figure	   3.14a)	  
suggesting	  the	   increase	   in	  CXCL8	  previously	  observed	   in	   the	  chronic	  model	  alone	  was	   in	   fact	  
not	   due	   to	   repeated	   CSE	   stimulation,	   but	   instead	   due	   to	   the	   changes	   in	   cells	   over	   time	   in	  
culture.	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Figure	   3.14	   Both	   acute	   and	   repeated	   exposure	   to	   CSE	   potentiates	   CXCL8	   production	   in	  
response	  to	  poly(I:C)	  
BEAS-­‐2B	  cells	  were	  pretreated	  with	  (A)	  fresh	  media	  or	  (B)	  10%	  CSE	  every	  24	  hours	  for	  6	  days	  
before	  undergoing	  a	   final	   stimulation	  with	  poly(I:C)	   (10	  μg/ml).	   Supernatants	  were	   collected	  
and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4.	  Statistical	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3.10	  Pretreatment	  with	  CSE	  decreased	  BEAS-­‐2B	  cells	  antiviral	  response	  
to	  RV-­‐16	  
	  
Cigarette	  smoke	  exposure	  is	  linked	  with	  increased	  occurrence	  of	  respiratory	  viral	  infections	  in	  
addition	  to	  increased	  periods	  of	  infection	  and	  worse	  prognosis.	  Epithelial	  cells	  are	  the	  primary	  
target	  of	  human	  rhinoviral	   infections	  and	  therefore,	  their	  response	  essential	  to	  the	  launch	  of	  
an	  effective	  innate	  immune	  response.	  Evidence	  supports	  a	  role	  for	  acute	  CSE	  exposure	  in	  the	  
inhibition	  of	  anti-­‐viral	   responses	   (Eddleston	  et	  al.,	  2011).	  Therefore	   it	  was	  hypothesised	   that	  
the	   repeated	   exposure	   of	   BEAS-­‐2B	   cells	   to	   CSE	   would	   result	   in	   an	   altered	   response	   to	   RV	  
infection.	  
	  
CCL5	   is	   among	   the	  most	   highly	   induced	   chemokines	   following	   rhinoviral	   infection	   of	   airway	  
epithelial	   cells.	   To	   determine	   whether	   repeated	   exposure	   to	   CSE	   alters	   antiviral	   responses,	  
BEAS-­‐2B	   cells	   were	   pre-­‐treated	   with	   fresh	   10%	   CSE	   every	   24	   hours	   for	   6	   days	   and	   then	  
stimulated	  with	  RV-­‐16	  at	  an	  MOI	  of	  1.3	  or	  control	  media	  for	  a	  final	  24	  hours.	  CCL5	  production	  
was	  then	  measured	  by	  ELISA.	  Pretreatment	  with	  CSE	  alone	  did	  not	  increase	  CCL5	  production,	  
however,	   CSE	   pretreatment	   did	   decrease	   the	   BEAS-­‐2B	   cell	   response	   to	   RV-­‐16	   in	   both	   the	  
control	  acute	  model	  (Figure	  3.15a)	  and	  repeated	  chronic	  model	  (Figure	  3.15b).	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Figure	  3.15	  CSE	  inhibits	  BEAS-­‐2B	  antiviral	  response	  following	  CSE	  pretreatment	  
BEAS-­‐2B	  cells	  were	  pretreated	  with	  (A)	  fresh	  media	  or	  (B)	  10%	  CSE	  every	  24	  hours	  for	  6	  days	  
before	   undergoing	   a	   final	   stimulation	   with	   R	   V-­‐16	   at	   an	   MOI	   of	   1.3.	   Supernatants	   were	  
collected	  and	  analysed	  for	  CCL5	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4.	  
Statistical	   analysis	  was	   carried	   out	   by	   two-­‐way	   ANOVA	  with	   Bonferroni’s	   post-­‐test	   (*p<0.05	  
and	  **p<0.01).	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3.11	  CSE	  enhances	  BEAS-­‐2B	  proinflammatory	  responses	  to	  RV-­‐16	  	  
	  
Infection	  of	  human	  airway	  epithelial	  cells	  with	  rhinovirus	  generates	  the	  release	  of	  a	  multitude	  
of	  pro-­‐inflammatory	  cytokines	  and	  host-­‐defence	  genes	  resulting	  in	  an	  enhanced	  inflammatory	  
environment	   (Hudy	  and	  Proud,	  2013;	  Proud	  et	  al.,	   2008).	  While	   there	   is	   increasing	  evidence	  
supporting	  CSE’s	  ability	  to	  alter	  anti-­‐viral	  defences	  in	  epithelial	  cells,	  these	  are	  in	  most	  cases	  a	  
down	  regulation	  of	  RV-­‐induced	  epithelial	  gene	  expression	  (Eddleston	  et	  al.,	  2011;	  Proud	  et	  al.,	  
2012;	   Wang	   et	   al.,	   2009).	   Interestingly,	   the	   opposite	   is	   true	   for	   the	   production	   of	   CXCL8	  
wherein	  CSE	  induces	  CXCL8	  mRNA	  and	  protein	  levels	  (Hudy	  et	  al.,	  2010;	  Wang	  et	  al.,	  2009).	  In	  
fact,	   the	  combination	  of	  CSE	  and	  RV	  results	   in	  at	   least	  an	  additive	  CXCL8	  secretion	   in	  airway	  
epithelial	  cells	  (Hudy	  and	  Proud,	  2013).	  The	  study	  however	  focuses	  on	  the	  immediate	  effects	  
of	  CSE	  in	  an	  acute	  environment.	  Therefore	  it	  was	  hypothesised	  that	  repeated	  exposure	  to	  CSE	  
may	  indeed	  result	  in	  an	  enhanced	  CXCL8	  response	  to	  RV.	  	  
	  
BEAS-­‐2B	  cells	  were	  either	  grown	   in	   fresh	  media	  or	  pre-­‐treated	  with	   fresh	  10%	  CSE	  every	  24	  
hours	  for	  6	  days	  and	  then	  stimulated	  with	  RV-­‐16	  at	  an	  MOI	  of	  1.3	  or	  control	  media	  for	  a	  final	  
24	  hours.	  CXCL8	  production	  was	  then	  measured	  by	  ELISA.	  Pretreatment	  with	  CSE	  resulted	  in	  an	  
additive	  CXCL8	  production	  in	  both	  the	  acute	  and	  the	  chronic	  repeated	  exposure	  model	  (Figure	  
3.16a	  and	  3.16b).	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Figure	  3.16	  CSE	  increases	  BEAS-­‐2B	  proinflammatory	  response	  following	  CSE	  pretreatment	  
BEAS-­‐2B	  cells	  were	  pretreated	  with	  (A)	  fresh	  media	  or	  (B)	  10%	  CSE	  every	  24	  hours	  for	  6	  days	  
before	   undergoing	   a	   final	   stimulation	   with	   RV-­‐16	   at	   an	   MOI	   of	   1.3.	   Supernatants	   were	  
collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4.	  
Statistical	   analysis	  was	   carried	   out	   by	   two-­‐way	   ANOVA	  with	   Bonferroni’s	   post-­‐test	   (*p<0.05	  
and	  **p<0.01).	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3.12	  CSE	  differentially	  regulates	  proinflammatory	  responses	  to	  TLR	  
agonists	  in	  a	  chronic	  model	  of	  inflammation	  in	  human	  bronchial	  
epithelial	  primary	  cells	  	  
	  
BEAS-­‐2B	   cells	   are	   an	   immortalised	   cell	   line	   which	   serve	   only	   as	   a	   representation	   of	   airway	  
epithelial	  cells.	  Cell	  signalling	  pathways	  in	  these	  cell	  types	  can	  be	  altered	  or	  switched	  on	  by	  the	  
immortalisation	  process	  making	   them	  convenient	  and	   reproducible	   cell	   type,	  but	  not	  always	  
truly	  reflective	  of	  the	  physiological	  functions	  in	  the	  airway.	  Therefore,	  it	  is	  vital	  to	  validate	  cell	  
line	  results	  with	  primary	  cells	  wherever	  possible.	  	  
	  
Human	  bronchial	  epithelial	  primary	  cells	  	  (HBEpCs)	  were	  thus	  also	  investigated	  using	  the	  acute	  
CSE	  exposure	  model	  and	  the	  chronic	  repeated	  CSE	  exposure	  model	  (method	  depicted	  in	  Figure	  
3.17).	   HBEpCs	   were	   grown	   to	   confluence	   and	   split	   into	   the	   acute	   model	   or	   the	   repeated	  
exposure/chronic	  model.	   Cells	   from	   the	   acute	  model	  were	   treated	  with	   50%	   supplemented	  
Airway	  Epithelial	  Cell	  Growth	   (AECG)	  media	  minus	  hydrocortisone	  every	  24	  hours	   for	  6	  days	  
whilst	   cells	   from	   the	   chronic	  model	  were	   exposed	   to	   fresh	  CSE	   (10%)	   in	   50%	   supplemented	  
AECG	  minus	   hydrocortisone	   every	   24	   hours	   for	   6	   days.	  On	  day	   7	   both	   groups	  were	  washed	  
with	  PBS	  and	  stimulated	  with	  LPS	   (1ng/ml),	  poly(I:C)	   (10ug/ml)	   	  and	   IL-­‐1β	   (10ng/ml)	   in	  basal	  
AECG	  media	  for	  24	  hours	  before	  supernatant	  collection	  and	  analysis.	  There	  was	  no	  difference	  
in	  CXCL8	  measured	   in	  the	  presence	  of	  CSE	   in	  both	  the	  acute	  model	  and	  the	  repeated	  model	  
(Figure	   3.17a).	  The	  presence	  of	  CSE	  also	  did	  not	   significantly	  alter	  CXCL8	  production	   in	  both	  
LPS	   stimulated	   (Figure	   3.17b)	   and	   poly(I:C)	   stimulated	  models	   (Figure	   3.17c).	   However,	   the	  
addition	  of	  CSE	  resulted	  in	  a	  significant	  increase	  in	  CXCL8	  in	  response	  to	  IL-­‐1β	  stimulation	  seen	  
only	  in	  the	  acute	  model	  (Figure	  3.17d).	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Figure	   3.17	   HBEpCs	   cells	   exhibit	   differential	   regulation	   to	   proinflammatory	   stimuli	   in	   the	  
presence	  of	  CSE	  	  
HBEpCs	   cells	   were	   stimulated	   with	   fresh	   media	   (labelled:	   acute)	   or	   10%	   CSE	   (labelled:	  
repeated)	  every	  24	  hours	  for	  6	  days	  before	  undergoing	  a	  final	  stimulation	  with	  TLR	  agonists	  for	  
a	  further	  24	  hours.	  The	  final	  stimuli	  were:	  (A)	  Unstimulated	  control	  group,	  (B)	  LPS	  (1ug/ml),	  (C)	  
Poly(I:C)	  (10ug/ml)	  or	  (D)	  IL-­‐1β	  (10ng/ml).	  Supernatants	  were	  collected	  and	  analysed	  for	  CXCL8	  
release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4.	  Statistical	  analysis	  was	  carried	  out	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3.13	  Summary	  	  
	  
The	   aim	   of	   this	   chapter	   was	   to	   generate	   an	   in	   vitro	   chronic	   model	   of	   inflammation	   to	  
understand	   the	   effects	   of	   prolonged	   inflammation	   on	   epithelial	   cell	   immunity	   and	   cellular	  
communication.	   A	   homogenous	   differentiated	   leukemic	   monocytic	   cell	   line,	   THP-­‐1,	   was	  
differentiated	  with	  vitamin	  D3	   to	  model	  monocyte	   function	   since	  primary	  monocytes	   cannot	  
be	   readily	   acquired	   or	   maintained	   for	   the	   duration	   of	   the	   proposed	  model.	   The	  monocytic	  
phenotype	   of	   these	   cells	  was	   determined	   by	   the	  measure	   of	   the	  monocytic	   surface	  marker	  
CD14.	  In	  addition,	  VitD3-­‐differentiated	  THP-­‐1	  cells	  are	  responsive	  to	  LPS	  challenge	  as	  measured	  
by	  CXCL8	  production,	  albeit	  releasing	  lower	  levels	  of	  CXCL8	  than	  primary	  monocytes.	  
	  
VitD3-­‐differentiated	  THP-­‐1	  cells	  also	  effectively	  replicated	  the	  cooperative	  signalling	  between	  
monocytes	   and	   BEAS-­‐2B	   cells	   in	   response	   to	   LPS,	   however	   the	   levels	   of	   the	   inflammatory	  
marker	   CXCL8	   produced	   in	   this	   model	   were	   substantially	   inferior	   when	   VitD3-­‐differentiated	  
THP-­‐1	  cells	  were	  used.	  When	  monocytic	  cells	  were	  separated	  from	  the	  BEAS-­‐2B	  monolayer	  by	  
the	  use	  of	  a	  cell-­‐culture	  insert,	  VitD3-­‐differentiated	  THP-­‐1	  cells	  were	  similarly	  less	  sensitive	  to	  
LPS	   challenge	   when	   compared	   to	   monocytes.	   To	   compensate,	   100,000	   VitD3-­‐differentiated	  
THP-­‐1	   cells	   were	   used	   in	   the	   proposed	   chronic	  model	   of	   inflammation.	   The	   reason	   for	   this	  
decreased	  sensitivity	  in	  THP-­‐1	  is	  most	  likely	  due	  to	  decreased	  levels	  of	  CD14	  expression	  in	  THP-­‐
1	  cells	  required	  for	  effective	  LPS	  response.	  
 
The	  chronic	  model	  of	  inflammation	  involved	  a	  continuous	  low	  grade	  LPS	  challenge	  of	  BEAS-­‐2B	  
cells	  for	  the	  duration	  of	  8	  days.	  VitD3-­‐differentiated	  THP-­‐1	  cells	  were	  separated	  from	  the	  BEAS-­‐
2B	  monolayer	  by	  cell	  culture	  inserts	  and	  replaced	  regularly	  (on	  days	  1,	  3,	  and	  5).	  This	  method	  
of	  cell	  separation	  aimed	  to	  replicate	  cellular	  communication	  through	  released	  soluble	  factors.	  
On	  day	  7,	  cell	  culture	  inserts	  were	  removed,	  and	  the	  BEAS-­‐2B	  cells	  directly	  challenged	  with	  a	  
fresh	   dose	   of	   LPS	   in	   the	   presence	   of	   primary	   monocytes.	   Interestingly,	   the	   continuous	   LPS	  
challenge	  did	  not	  alter	  BEAS-­‐2B	  inflammatory	  responses	  as	  measured	  by	  CXCL8.	  The	  addition	  
of	  VitD3-­‐differentiated	  THP-­‐1	  cells	  also	  had	  no	  impact	  on	  the	  BEAS-­‐2B	  cells’	  ability	  to	  mount	  an	  
effective	  inflammatory	  response	  to	  the	  final	  challenge	  with	  LPS	  and	  monocytes.	  	  
	  
This	   led	  to	  the	  hypothesis	  that	   the	   lack	  of	  direct	  cell-­‐to	  cell	  contact	  between	  THP-­‐1	  cells	  and	  
BEAS-­‐2B	   monolayer	   may	   have	   led	   to	   ineffective	   cytokine	   production	   required	   for	   effective	  
	   108	  
inflammatory	  response.	  Therefore,	  the	  same	  protocol	  was	  repeated,	  only	  vitD3-­‐differentiated	  
THP-­‐1	   cells	   were	   then	   in	   direct	   contact	   with	   BEAS-­‐2Bs	   from	   day	   1-­‐7	   of	   the	   experiment.	  
Interestingly,	   while	   the	   levels	   of	   CXCL8	   produced	   in	   the	   direct	   cell	   contact	   model	   were	  
marginally	   lower	   than	   that	   of	   the	   control	   model	   that	   did	   not	   have	   THP-­‐1	   cells	   throughout,	  
there	  were	   still	   no	  measurable	  differences	   in	  CXCL8	  production	  between	   the	   LPS	   challenged	  
model	  and	  the	  unchallenged	  control.	  
	  
The	   resistant	   nature	   of	   BEAS-­‐2B	   cells	   to	  multiple	   low-­‐grade	   stimulation	  with	   LPS	   led	   to	   the	  
development	   of	   an	   alternative	   model	   which	   proposed	   the	   use	   of	   CSE	   as	   a	   BEAS-­‐2B	   cell	  
antagonist.	  Cigarette	  smoke	   is	  one	  of	   the	  predominant	  causes	   for	   the	  development	  of	  COPD	  
and	  was	  therefore	  considered	  an	  appropriate	  stimulus	  for	  this	  study.	  Acute	  exposure	  of	  BEAS-­‐
2B	  cells	  to	  10%	  CSE	  alone	  significantly	  increased	  CXCL8	  baseline	  levels.	  The	  addition	  of	  LPS	  did	  
not	   alter	   the	   CSE-­‐induced	   CXCL8	   levels,	   however	   stimulation	   with	   IL-­‐1β	   significantly	  
upregulated	   CSE-­‐induced	   CXCL8	   release.	   In	   contrast,	   CXCL8	   production	  was	   inhibited	   by	   the	  
presence	  of	  CSE	  in	  response	  to	  poly(I:C).	  	  
	  
It	  was	  then	  hypothesised	  that	  repeated	  exposure	  to	  CSE	  would	  result	  in	  an	  altered	  and	  primed	  
epithelium	  to	  further	  pathogenic	  stimulation.	  The	  repeated	  exposure	  of	  BEAS-­‐2B	  cells	  to	  CSE	  
followed	  by	  a	  single	   IL-­‐1β	  challenge	  resulted	   in	  a	  significant	   increase	   in	  CXCL8	  release	  as	  per	  
the	   acute	  model.	  Of	   interest	   however,	   chronic	   stimulation	  with	   CSE	   resulted	   in	   a	   significant	  
increase	   in	   CXCL8	   release	   in	   response	   to	   poly(I:C)	   in	   contrast	   to	   the	   acute	  model.	  However,	  
when	  determining	  whether	   this	  differential	  was	   caused	  by	   the	  multiple	  exposures	   to	  CSE	  or	  
the	   method	   itself,	   we	   found	   that	   BEAS-­‐2B	   cells	   maintained	   for	   7	   days	   with	   no	   CSE	   pre-­‐
treatment	   prior	   to	   a	   single	   CSE	   challenge	   with	   poly(I:C)	   resulted	   in	   the	   increased	   CXCL8	  
phenotype	  as	  per	  the	  chronic	  model.	  
	  
CXCL8	   and	   CCL5	   release	   was	   also	   quantified	   in	   BEAS-­‐2B	   cells	   infected	  with	   RV-­‐16	   following	  
acute	  and	   repeated	  CSE	  exposure.	  While	  CCL5	   release	  was	  downregulated	  by	  CSE	  exposure,	  
CXCL8	  was	  upregulated	  in	  both	  acute	  and	  CSE	  pre-­‐treated	  models.	  
	  
In	  contrast	  to	  BEAS-­‐2B	  cells,	  CSE	  did	  not	  result	  in	  an	  elevated	  CXCL8	  release	  in	  HBEpCs.	  In	  fact,	  
acutely	  or	  repeatedly	  pre-­‐treated	  HBEpCs	  with	  CSE	  did	  not	  significantly	  alter	  LPS-­‐	  or	  poly(I:C)-­‐
induced	  CXCL8	  release.	  While	  HBEpCs	  acutely	  stimulated	  with	  the	  combination	  of	  CSE	  and	  IL-­‐
1β	  produced	  significant	   levels	  of	  CXCL8,	   the	  repeated	  pre-­‐treatment	  with	  CSE	  prevented	  the	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IL-­‐1β	   induced	   CXCL8	   release.	   It	   is	   however	   important	   to	   note	   that	   some	   of	   the	   changes	   to	  
chemokine	  production	  could	  have	  been	  in	  part	  as	  a	  result	  of	  cell	  death	  which	  was	  unmeasured	  
in	   these	   experiments	   and	   would	   need	   to	   be	   further	   explored	   in	   future	   experiments.
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CHAPTER	  4	  -­‐	  RESULTS.	  THE	  ROLE	  OF	  PELLINO-­‐1	  IN	  INFLAMMATORY	  
SIGNALLING	  
	  
Viral	   infections,	   such	  as	   rhinoviruses	   (RVs),	   account	   for	   a	  majority	  of	   exacerbations	  of	  COPD	  
(Johnston,	   2005)	   and	   can	   subsequently	   result	   in	   pronounced	   functional	   impairment	   of	   the	  
airway	  increasing	  both	  the	  severity	  of	  the	  disease	  and	  frequency	  of	  exacerbations.	  Therefore	  
the	  reduction	  of	  RV-­‐induced	  airway	  inflammation	  would	  be	  of	  immense	  clinical	  value	  with	  the	  
reduction	  in	  severity	  and	  duration	  of	  the	  disease	  improving	  patient	  quality	  of	  life	  and	  reducing	  
morbidity	   and	   mortality.	   Thus,	   targeting	   signalling	   pathways	   involved	   in	   RV-­‐induced	  
inflammation	  is	  an	  important	  goal.	  An	  optimal	  anti-­‐inflammatory	  treatment	  would	  reduce	  RV-­‐
induced	  airway	  inflammation	  without	  impairing	  host	  defence.	  	  
	  
Pellino-­‐1	  was	  originally	  identified	  as	  a	  regulator	  of	  IL-­‐1	  signalling	  (Jiang	  et	  al.,	  2003),	  however	  
while	   knockdown	   of	   Pellino-­‐1	   in	   immortalised	   epithelial	   cell	   line	   BEAS-­‐2B	   reduces	   IL-­‐1β-­‐
induced	  expression	  of	  pro-­‐inflammatory	  cytokines,	  the	  knockdown	  of	  Pellino-­‐1	   in	  HBEpC	  had	  
no	   such	   effect	   overall	   suggesting	   that	   regulation	   of	   IL-­‐1	   responses	  may	   have	   solely	   been	   a	  
feature	   of	   transformed	   cell	   lines	   (Bennett	   et	   al.,	   2012).	   Strikingly,	  more	   recent	   observations	  
have	   highlighted	   a	   role	   for	   Pellino-­‐1	   in	   viral	   signalling	   wherein	   Pellino-­‐1	   regulates	   pro-­‐
inflammatory	  responses	  to	  RV	  infection	  but	  does	  not	  appear	  to	  control	  production	  of	  antiviral	  
IFNs	   (Bennett	   et	   al.,	   2012;	   Chang	   et	   al.,	   2009).	   These	   data	   strongly	   support	   Pellino-­‐1	   as	   a	  
potential	   therapeutic	   drug	   target.	   This	   thesis	   investigates	   the	   regulation	   of	   Pellino-­‐1	   and	   its	  
role	  in	  viral	  infection	  in	  human	  bronchial	  airway	  epithelial	  cells.	  	  
	  
4.1	  Poly(I:C)	  induced	  Pellino-­‐1	  mRNA	  expression	  is	  inhibited	  by	  CSE	  in	  
primary	  human	  bronchial	  epithelial	  cells	  
	  
Since	  its	  discovery,	  increasing	  evidence	  suggests	  a	  role	  for	  Pellino-­‐1	  in	  viral	  signalling	  wherein	  
Pellino-­‐1	  modulates	  innate	  cellular	  responses	  to	  viral	  infection	  (Bennett	  et	  al.,	  2012;	  Chang	  et	  
al.,	   2009).	   To	   begin	   investigating	   the	   regulation	   of	   Pellino-­‐1	   in	   airway	   epithelial	   cells	   in	  
response	   to	   viral	   stimuli,	   HBEpCs	   were	   stimulated	   with	   the	   TLR-­‐3	   agonist	   and	   viral	   mimic,	  
poly(I:C)	  (50	  μg/ml).	  Quantitative	  RT-­‐PCR	  (qPCR)	  was	  used	  to	  determine	  the	  changes	  to	  Pellino-­‐
1	  mRNA	  transcripts	  following	  a	  24	  hour	  stimulation	  with	  poly(I:C)	  and	  resulted	  in	  a	  significant	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increase	  in	  Pellino-­‐1	  mRNA	  expression	  (Figure	  4.1).	  
	  
Cigarette	  smokers	  are	  reported	  to	  experience	  more	  frequent	  and	  severe	  airway	  infections	  than	  
non-­‐smokers	  (Cohen	  et	  al.,	  1993).	  Several	  studies	  have	  shown	  that	  cigarette	  smoke	  exposure	  
can	  impair	  innate	  immune	  responses	  in	  the	  airway	  (Bauer	  et	  al.,	  2008;	  Eddleston	  et	  al.,	  2011;	  
Hudy	   et	   al.,	   2014;	   Modestou	   et	   al.,	   2010).	   Whilst	   the	   underlying	   mechanisms	   are	   not	  
completely	   understood,	   cigarette	   smoke	   can	   result	   in	   suppressed	   anti-­‐viral	   responses,	  
enhanced	  pro-­‐inflammatory	  defences,	  remodelling	  of	  the	  airway	  and	  cellular	  apoptosis.	  	  
	  
To	  determine	  the	   impact	  of	  cigarette	  smoking	  on	  Pellino-­‐1	  expression	  during	  viral	   infections,	  
HBEpCs	  were	  also	  exposed	  to	  CSE	  (10%)	  both	  singularly	  and	  in	  combination	  with	  poly(I:C)	  (50	  
μg/ml).	   	   Stimulation	   with	   CSE	   alone	   did	   not	   alter	   Pellino-­‐1	   mRNA	   expression.	   However	   of	  
interest,	  the	  combined	  stimulation	  with	  poly(I:C)	  and	  CSE	  resulted	  in	  a	  suppression	  of	  poly(I:C)-­‐
induced	  Pellino-­‐1	  expression	  (Figure	  4.1).	  
	  
Similarly,	   Pellino-­‐1	   protein	   expression,	   measured	   by	   western	   blotting,	   was	   significantly	  
enhanced	  following	  a	  24	  hour	  poly(I:C)	  stimulation,	  and	  this	  increase	  was	  significantly	  inhibited	  
when	  HBEpCs	  were	  co-­‐stimulated	  with	  poly(I:C)	  and	  CSE	  (Figure	  4.2).	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Figure	  4.1:	  Poly(I:C)	  induced	  Pellino-­‐1	  mRNA	  expression	  is	  inhibited	  by	  CSE	  in	  primary	  human	  
bronchial	  epithelial	  cells	  
HBEpCs	  were	  stimulated	  with	  poly(I:C)	  (50	  μg/ml),	  CSE	  (10%)	  or	  the	  combination	  of	  both	  for	  24	  
hours.	  mRNA	  expression	  was	  determined	  by	  quantitative	  RT-­‐PCR	  (qPCR).	  Pellino-­‐1	  expression	  
was	  normalized	   to	  GAPDH	  copy	  numbers	   (loading	  control)	  and	  expressed	  as	  mean	  ±	  SEM	  of	  
n=3,	  with	  each	  replicate	  performed	  on	  separate	  donors.	  	  Statistical	  analysis	  was	  carried	  out	  by	  
one-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05	  and	  **p<0.01).	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A	  	  




Figure	   4.2:	   Poly(I:C)	   induced	   Pellino-­‐1	   protein	   expression	   is	   inhibited	   by	   CSE	   in	   primary	  
human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  stimulated	  with	  poly(I:C)	  (50	  μg/ml),	  CSE	  (10%)	  or	  the	  combination	  of	  both	  for	  24	  
hours.	   Cell	   lysates	   were	   analysed	   for	   Pellino-­‐1	   or	   actin	   expression	   by	   western	   blot.	  	  
Representative	   blot	   is	   shown	   in	   figure	   (A).	   Quantitative	   signals	   were	   determined	   by	  
densitometry	  and	  expressed	  as	  mean	  ±	  SEM	  of	  n=3,	  with	  each	  replicate	  performed	  on	  separate	  
donors	  (B).	  	  Statistical	  analysis	  was	  carried	  out	  by	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  
(**p<0.01	  and	  ***p<0.001).	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4.2	  Pellino-­‐1	  transient	  knockdown	  reduces	  poly(I:C)	  induced	  CXCL8	  
expression	  and	  secretion	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
	  
Previous	  work	  has	  established	  a	  role	   for	  Pellino-­‐1	   in	  MyD88-­‐independent	  NF-­‐κB	  activation	   in	  
primary	   airway	   epithelial	   cells	   in	   response	   to	   poly(I:C)	   (Chang	   et	   al.,	   2009)	   (Bennett	   et	   al.,	  
2012).	  Bennett	  et	  al.	  demonstrated	  that	  CXCL8	  release	  in	  response	  to	  poly(I:C)	  stimulation	  was	  
inhibited	   in	   Pellino-­‐1	   knockdown	   cells	   obtained	   from	   a	   single	   donor.	   It	   was	   therefore	  
hypothesized	   that	   Pellino-­‐1	   selectively	   regulates	   the	   NF-­‐κB	   arm	   of	   virally	   induced	   TLR3	  
signalling,	   wherein	   targeting	   of	   Pellino-­‐1	   could	   ultimately	   reduces	   inflammation	   whilst	  
preserving	  antiviral	  immunity.	  	  
	  
Initial	   experiments	   assessed	   efficiency	   of	   transient	   knockdown	   showing	   Pellino-­‐1	   transcripts	  
were	   significantly	   knocked	   down	   by	   Pellino-­‐1	   siRNA	   transfection	   for	   24	   hours	   (Figure	   4.3).	  
HBEpCs	   obtained	   from	   5	   different	   donors	   were	   subsequently	   transfected	   with	   Pellino-­‐1	  
targeted	  siRNA	  and	  non-­‐targeted	  scrambled	  siRNA	  control	  before	  undergoing	  treatment	  with	  
poly(I:C)	  for	  4,	  8,	  16	  and	  24	  hours.	  The	  generation	  of	  CXCL8,	  a	  NF-­‐κB	  stimulated	  gene,	  at	  levels	  
of	  mRNA	  expression	  (Figure	  4.4a)	  and	  protein	  release	  (Figure	  4.4b)	  were	  measured	  using	  qPCR	  
and	   ELISA	   respectively.	   CXCL8	   levels	   were	   most	   pronounced	   at	   16	   and	   24	   hours.	   Pellino-­‐1	  
knockdown	   significantly	   inhibited	   both	   CXCL8	   mRNA	   expression	   and	   the	   resulting	   CXCL8	  









Figure	   4.3:	   Pellino-­‐1	   transient	   knockdown	   reduces	   Pellino-­‐1	   expression	   in	   primary	   human	  
bronchial	  epithelial	  cells	  	  
HBEpCs	  were	   transiently	   transfected	  with	  Pellino-­‐1	   siRNA,	  non-­‐targeting	   scrambled	   siRNA	  or	  
mock	  infected	  (described	  in	  Section	  2.9).	  Cell	  lysates	  were	  collected	  24	  hours	  post-­‐transfection	  
and	  analysed	  for	  Pellino-­‐1	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  
figure	   (A).	   Quantitative	   signals	  were	   determined	   by	   densitometry	   and	   expressed	   as	  mean	   ±	  
SEM	  of	  n=4,	  with	  each	   replicate	  performed	  on	  separate	  donors	   (B).	   	   	   Statistical	  analysis	  was	  
carried	  out	  by	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  Post-­‐test	  (*p<0.05).	  
	  





Figure	   4.4:	   Pellino-­‐1	   transient	   knockdown	   reduces	   poly(I:C)	   induced	   CXCL8	   expression	   and	  
secretion	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	   (50	  μg/ml)	   for	  4,	  8,	  16	  and	  24	  hours.	  RNA	  was	  
extracted	  and	  CXCL8	  expression	  levels	  were	  analysed	  by	  quantitative	  RT-­‐PCR	  (A).	  Supernatants	  
were	  collected	  and	  analysed	  for	  CXCL8	  release	  by	  ELISA	  (B).	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  
of	  n=5,	  with	  each	  replicate	  performed	  on	  separate	  donors.	  	  Statistical	  analysis	  was	  carried	  out	  
by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05	  and	  ***p<0.001).	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4.3	  Pellino-­‐1	  transient	  knockdown	  does	  not	  alter	  poly(I:C)	  induced	  IFNβ	  
expression	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
	  
The	  pattern	  recognition	  receptor	  TLR3	  recognises	  dsRNA	  from	  replicating	  viruses	  and	  triggers	  
signalling	   pathways	   resulting	   in	   the	   production	   of	   pro-­‐inflammatory	   cytokines,	   chemokines	  
and	   type	   I	   IFNs.	   The	   production	   of	   type	   I	   IFNs	   is	   dependent	   on	   the	   activation	   of	   IKKε/TBK1	  
complex	  and	  the	  resulting	  activation	  of	  IRF3.	  	  
 
The	  only	  other	  study	  on	  the	  roles	  of	  Pellino-­‐1	  in	  viral	  infection	  has	  shown	  that	  Pellino-­‐1	  does	  
not	  alter	  anti-­‐viral	  IFN	  generation	  and	  IFN-­‐stimulated	  gene	  transcription	  responses	  in	  primary	  
bronchial	   epithelial	   cells	   (Bennett	   et	   al.,	   2012).	   	   These	   data	  were	   the	   result	   of	   experiments	  
performed	  on	  bronchial	  epithelial	  cells	  from	  a	  single	  donor	  stimulated	  with	  poly(I:C)	  or	  RV-­‐1B	  
for	  24	  hours.	   In	  an	  attempt	  to	  support	  the	  hypothesis	  that	  Pellino-­‐1	  selectively	  regulates	  the	  
NF-­‐κB	   arm	   of	   virally	   induced	   TLR3	   signalling	   by	   regulating	   inflammation	   whilst	   preserving	  
antiviral	   immunity,	   a	   Pellino-­‐1	   transient	   knockdown	   was	   created.	   The	   experiments	   were	  
performed	  on	  5	  unique	  donors	  to	  increase	  robustness	  and	  over	  a	  time-­‐course	  of	  4-­‐24	  hours.	  
	  
Pellino-­‐1	  gene	  expression	  in	  HBEpCs	  induced	  with	  poly(I:C)	  (50	  μg/ml)	  was	  transiently	  inhibited	  
by	  transfection	  with	  Pellino-­‐1	  siRNA	  for	  24	  hours.	  The	  induction	  of	  IFNβ	  transcripts	  by	  poly(I:C)	  
peaked	   at	   4	   hours	   and	   returned	   to	   baseline	   levels	   by	   8	   hours	   (Figure	   4.5).	   	   In	   addition,	   the	  
absence	  of	  Pellino-­‐1	  did	  not	  result	   in	  any	  changes	  to	  poly(I:C)	   induced	  IFNβ	  expression	  when	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Figure	  4.5:	  Pellino-­‐1	  transient	  knockdown	  does	  not	  alter	  poly(I:C)	  induced	  IFNβ	  expression	  in	  
primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	   (50	  μg/ml)	   for	  4,	  8,	  16	  and	  24	  hours.	  RNA	  was	  
extracted	   and	   IFNβ	   expression	   levels	   were	   analysed	   by	   quantitative	   RT-­‐PCR.	   Data	   are	  
expressed	   as	   mean	   ±	   SEM	   of	   n=5,	   with	   each	   replicate	   performed	   on	   separate	   donors.	  
Statistical	  analysis	  was	  carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test.	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4.4	  Pellino-­‐1	  transient	  knockdown	  differentially	  regulates	  poly(I:C)	  
induced	  IL-­‐1	  expression	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
	  
Pellino-­‐1	   has	   been	   implicated	   in	   IL-­‐1	   signalling	   through	   its	   involvement	   with	   the	  
IRAK1/IRAK4/TRAF6	   complex.	   In	   the	   human	   embryonic	   kidney	   293	   (HEK293)	   cell	   line,	   the	  
transient	   knockdown	   of	   Pellino-­‐1	   by	   siRNA	   resulted	   in	   the	   impairment	   of	   IL-­‐1-­‐dependent	  
activation	  of	  NF-­‐κB	   (Choi	  et	  al.,	  2006;	   Jiang	  et	  al.,	  2003).	  However,	   in	  primary	  human	  airway	  
epithelial	   cells,	   Pellino-­‐1	   appears	   to	   exert	   its	   effects	   in	   an	   IRAK1-­‐independent	   manner,	   as	  
Bennett	  et	  al.	  clearly	  showed	  a	  role	  for	  Pellino-­‐1	  in	  TLR3	  activation	  in	  response	  to	  poly(I:C)	  and	  
RV-­‐1B	  (Bennett	  et	  al.,	  2012).	  
	  
COPD	  patients	  have	  increased	  baseline	  levels	  of	  IL-­‐1β	  within	  their	  airways,	  which	  are	  increased	  
further	  in	  instances	  of	  acute	  exacerbations	  (Chung,	  2001).	  There	  is	  also	  accumulating	  evidence	  
suggesting	  a	  role	  for	  IL-­‐1β	  in	  response	  to	  RV	  infections	  whereby	  IL-­‐1	  is	  released	  and	  acts	  as	  an	  
autocrine	   stimulus	   to	   further	   enhance	   inflammatory	   signalling	   (Grunstein	   et	   al.,	   2000;	  
Hakonarson	  et	  al.,	  1999;	  Piper	  et	  al.,	  2013;	  Stokes	  et	  al.,	  2011).	  	  
	  
Whilst	   a	   role	   for	   Pellino-­‐1	   in	   IL-­‐1	   signalling	   has	   only	   been	   established	   in	  MyD88-­‐dependent	  
activation,	   it	   was	   hypothesized	   that	   Pellino-­‐1	  may	   in	   fact	   play	   a	   role	   in	   virally	   induced	   IL-­‐1	  
production.	  To	  investigate	  this,	  Pellino-­‐1	  was	  transiently	  knocked	  down	  by	  siRNA	  transfection	  
for	  24	  hours	  prior	  to	  poly(I:C)	  (50	  μg/ml)	  stimulation	  for	  4,	  8,	  16	  and	  24	  hours	  respectively.	  IL-­‐1	  
is	  often	  described	  as	  an	  early	  phase	  cytokine,	  however	  the	  levels	  of	  both	  IL-­‐1α	  and	  IL-­‐1β	  were	  
only	   increased	   from	   16	   hours	   in	   response	   to	   poly(I:C)	   (Figure	   4.6a	   and	   Figure	   4.6b).	  
Interestingly,	  the	  knockdown	  of	  Pellino-­‐1	  also	  resulted	  in	  a	  significant	  reduction	  in	  IL-­‐1β	  gene	  
expression	   to	   poly(I:C)	   at	   16	   and	   24	   hours	   (Figure	   4.6b),	   whilst	   IL-­‐1α	   showed	   a	   similar	  
decreasing	  trend	  at	  16	  and	  24	  hours	  post-­‐stimulation	  (Figure	  4.6a).	  	  





Figure	   4.6:	   Pellino-­‐1	   transient	   knockdown	   differentially	   regulates	   poly(I:C)	   induced	   IL-­‐1	  
expression	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	   (50	  μg/ml)	   for	  4,	  8,	  16	  and	  24	  hours.	  RNA	  was	  
extracted	  and	  IL-­‐1α	  (A)	  and	  IL-­‐1β	  (B)	  expression	  levels	  were	  analysed	  by	  quantitative	  RT-­‐PCR.	  
Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4,	  with	  each	  replicate	  performed	  on	  separate	  donors.	  
Statistical	   analysis	   was	   carried	   out	   by	   two-­‐way	   ANOVA	   with	   Bonferroni’s	   post-­‐test	  
(***p<0.001).	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4.5	  Pellino-­‐1	  transient	  knockdown	  reduces	  poly(I:C)	  induced	  IKKα/β	  but	  
not	  IκBα	  phosphorylation	  in	  primary	  human	  bronchial	  epithelial	  cells	  
	  
The	  TLR3	  signalling	  pathway	  culminates	  in	  the	  activation	  of	  IRF-­‐3,	  NF-­‐κB	  and	  activating	  protein-­‐
1	   (AP-­‐1).	   Normally,	   NF-­‐κB	   resides	   within	   the	   cytoplasm	   in	   its	   inactive	   form	   through	   the	  
association	   with	   inhibitors	   of	   NF-­‐κB	   (IκB).	   However,	   following	   TLR3	   activation,	   TRAF6	   is	  
recruited	   and	   elicits	   RIP1	   activation	   followed	   by	   the	   degradation	   of	   IκBs.	   IκB	   degradation	   is	  
regulated	   through	   the	   activation	   of	   the	   IKK	   complex	   consisting	   of	   IKKα	   and	   IKKβ	   protein	  
kinases	   and	   IKKγ	   regulatory	  molecule.	   This	   results	   in	   the	   release	   and	   translocation	   of	  NF-­‐κB	  
into	   the	  nucleus	   for	   gene	   transcription	   (Han	  et	   al.,	   2004;	  Muzio	  et	   al.,	   2000).	   Therefore	   it	   is	  
possible	  to	  establish	  NF-­‐κB	  activation	  by	  determining	  the	  level	  of	  both	  IKK	  phosphorylation	  and	  
the	  resulting	  IκBα	  phosphorylation	  and	  degradation.	  
	  
Previous	  data	  has	  shown	  the	  ability	  of	  transient	  Pellino-­‐1	  knockdown	  to	  dampen	  epithelial	  cell	  
inflammatory	  signalling	  in	  the	  form	  of	  CXCL8	  expression	  and	  secretion	  in	  response	  to	  poly(I:C)	  
(Figure	   4.4).	   It	   was	   therefore	   hypothesised	   that	   this	   effect	  was	   due	   to	   diminishished	  NF-­‐κB	  
activation	  via	  negative	   regulation	  of	   the	  pathway	   in	   the	  absence	  of	  Pellino-­‐1.	  To	  assess	   this,	  
Pellino-­‐1	  was	  transiently	  transfected	  with	  siRNA	  before	  undergoing	  stimulation	  with	  poly(I:C)	  
for	   4	   and	   24	   hours.	   	   The	   stimulation	   of	   HBEpCs	   with	   poly(I:C)	   resulted	   in	   a	   decrease	   in	  
phosphorylation	  of	  IKKα/β	  (Figure	  4.7).	  This	  decreasing	  effect	  appears	  to	  be	  more	  prominent	  
in	  the	  phosphorylation	  of	   IKKβ	  as	   indicated	  by	  the	  top	  band	  seen	  in	  the	  western	  blot	  (Figure	  
4.7a).	   Interestingly,	   despite	   the	   decreased	   phosphorylation	   of	   IKKα/β,	   the	   levels	   of	   IκBα	   in	  
Pellino-­‐1	  knockdown	  cells	  remained	  unchanged	  over	  time	  (Figure	  4.8).	  Due	  to	  time	  constraints	  
and	   the	   continued	   interest	   in	   Pellino-­‐1,	   these	   experiments	   were	   performed	   jointly	   with	   a	  
colleague	  in	  our	  group,	  Elizabeth	  Prestwich.	  
	  





Figure	  4.7:	  Pellino-­‐1	  transient	  knockdown	  reduces	  poly(I:C)	  induced	  IKKα/β	  phosphorylation	  
in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  4	  and	  24	  hour.	  Cell	   lysates	  were	  
analysed	  for	  IKKα/β	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  figure	  
(A).	  Quantitative	  signals	  were	  determined	  by	  densitometry	  and	  expressed	  as	  mean	  ±	  SEM	  of	  
n=9,	  with	  replicates	  performed	  on	  5	  separate	  donors	  (B).	  Statistical	  analysis	  was	  carried	  out	  by	  
two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (***p<0.001).	  
Mock      -       +     -      -     +     -      -     +     -     -      
 Scr      -        -     +      -     -     +     -     -     +     -      
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Figure	  4.8:	  Pellino-­‐1	  transient	  knockdown	  does	  not	  alter	  poly(I:C)	  induced	  IκBα	  degradation	  
in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  4	  and	  24	  hour.	  Cell	   lysates	  were	  
analysed	  for	  IκBα	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  figure	  
(A).	  Quantitative	  signals	  were	  determined	  by	  densitometry	  and	  expressed	  as	  mean	  ±	  SEM	  of	  
n=8,	  with	  each	  replicate	  performed	  on	  5	  separate	  donors	   (B).	  Statistical	  analysis	  was	  carried	  
out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test.	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4.6	  Pellino-­‐1	  transient	  knockdown	  reduces	  poly(I:C)	  induced	  p38	  MAPK	  
phosphorylation	  in	  primary	  human	  bronchial	  epithelial	  cells	  
	  
Pro-­‐inflammatory	  stimuli	   such	  as	  viral	  dsRNA	  are	  capable	  of	   inducing	  CXCL8	  gene	  expression	  
through	  the	  activation	  of	  a	  number	  of	  protein	  kinases	  with	  the	  capability	  to	  modulate	  NF-­‐κB	  or	  
AP-­‐1	  activity.	  Although	  both	  of	  these	  transcription	  factors	  contribute	  to	  CXCL8	  transcriptional	  
regulation,	  they	  do	  so	  to	  varying	  degrees	  of	  importance.	  NF-­‐κB	  is	  essential	  for	  CXCL8	  induction	  
whilst	  AP-­‐1	  is	  crucial	  for	  maximal	  gene	  expression	  (Hoffmann	  et	  al.,	  2002).	  Both	  the	  activation	  
of	   NF-­‐κB	   and	   AP-­‐1	   occurs	   downstream	   of	   TRAF6	   and	   the	   TAB/TAK1	   complex	   wherein	   a	  
bifurcation	  of	  the	  signalling	  pathway	  occurs.	  AP-­‐1	  is	  regulated	  by	  a	  three-­‐stage	  protein	  kinase	  
cascade	  that	  begins	  with	  the	  phosphorylation	  of	  MAPKK	  by	  MAPKKK	  resulting	  in	  the	  activation	  
of	  p38s,	  ERK	  and	  JNK/SAPKs	  (Karin,	  1996).	  
	  
As	   Pellino-­‐1	   does	   not	   appear	   to	   elicit	   its	   effects	   through	   the	   degradation	   of	   IκBα,	   the	   rate-­‐
limiting	  step	  of	  NF-­‐κB	  signalling,	  it	  was	  hypothesised	  that	  instead	  Pellino-­‐1	  plays	  a	  role	  in	  the	  
regulation	  and	  activation	  of	  p38	  MAPK	  as	  an	  alternative	  route	  to	  CXCL8	  transcription.	  
	  
Pellino-­‐1	   was	   transiently	   knocked	   down	   with	   siRNA	   before	   undergoing	   stimulation	   with	  
poly(I:C)	   for	   4	   and	   24	   hours	   before	   protein	   lysates	   underwent	   immunoblotting	   for	  
phosphorylated	   p38	  MAPK.	   Stimulation	   with	   poly(I:C)	   for	   24	   hours	   resulted	   in	   a	   significant	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Figure	   4.9:	   Pellino-­‐1	   transient	   knockdown	   reduces	   poly(I:C)	   induced	   p38	   MAPK	  
phosphorylation	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  4	  and	  24	  hour.	  Cell	   lysates	  were	  
analysed	  for	  phosphorylated	  p38	  or	  actin	  expression	  by	  western	  blot.	   	  Representative	  blot	   is	  
shown	  in	  figure	  (A).	  Quantitative	  signals	  were	  determined	  by	  densitometry	  and	  expressed	  as	  
mean	  ±	   SEM	  of	  n=9,	  with	   replicates	  performed	  on	  5	   separate	  donors	   (B).	   Statistical	   analysis	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4.7	  Poly(I:C)	  and	  CSE	  stimulation	  differentially	  regulate	  RIP1	  expression	  
and	  cytokine	  release	  in	  primary	  human	  bronchial	  	  epithelial	  cells	  	  
	  
The	  TRIF-­‐dependent	  activation	  of	  the	  transcription	  factor	  NF-­‐κB	  occurs	  via	  the	  recruitment	  of	  
receptor	   interacting	   protein	   RIP-­‐1	   followed	   by	   IKK	   complex	   activation	   and	   IκB	   degradation	  
(Meylan	   et	   al.,	   2004).	   Chang	  et	   al.	   identified	   a	   role	   for	   Pellino-­‐1	   in	   regulating	   IKK	   activation	  
through	  interaction	  and	  Lys-­‐63	  polyubiquitination	  of	  RIP-­‐1	  in	  the	  TRIF-­‐dependent	  TLR	  pathway	  
(Chang	   et	   al.,	   2009).	   	   Interestingly,	   Bennett	   et	   al.	   challenged	   these	   findings	   through	   the	  
transient	   knockdown	   of	   RIP1,	  where	   instead	   of	  mimicking	   the	   Pellino-­‐1	   knockdown-­‐induced	  
decrease	   in	   pro-­‐inflammatory	   cytokine	   CXCL8,	   they	   instead	   showed	   a	   potentiation	   of	   CXCL8	  
release	  to	  poly(I:C)	  (Bennett	  et	  al.,	  2012).	  These	  findings	  indicated	  that	  whilst	  RIP1	  is	  involved	  
in	   the	   regulation	  of	  poly(I:C)-­‐activated	  TLR3	  pathway,	   it	   does	  not	   appear	   to	  be	   regulated	  by	  
Pellino-­‐1.	  	  
	  
In	   an	   attempt	   to	   determine	  whether	   poly(I:C)	   regulates	   RIP1	   expression,	   immunoblotting	   of	  
RIP1	  protein	  was	  performed	  and	  compared	  with	  the	  control	  housekeeping	  gene,	  actin.	  RIP1	  is	  
constitutively	  expressed	  in	  human	  bronchial	  epithelial	  cells	  (Figure	  4.10).	  The	  stimulation	  with	  
poly(I:C)	   (50	   μg/ml),	   CSE	   (10%)	   and	   the	   combination	   of	   both	   did	   not	   regulate	   RIP1	   protein	  
expression	  (Figure	  4.10).	  	  
	  
The	   targeted	   knockdown	   of	   Pellino-­‐1	   by	   siRNA	   transfection	   resulted	   in	   a	   modest	   and	   non-­‐
significant	   decrease	   (~35%)	   in	   RIP1	   protein	   expression	   in	   response	   to	   a	   24	   hour	   stimulation	  
with	  poly(I:C)	  (Figure	  4.11).	  	  
	  
The	   transient	   knockdown	   of	   RIP1	   by	   siRNA	   transfection	   in	   multiple	   donors	   stimulated	   with	  
poly(I:C)	  for	  24	  hours	  resulted	  in	  an	  increasing	  trend	  in	  CXCL8	  gene	  transcripts	  consistent	  with	  
Bennett	  et	  al.’s	  findings	  (Figure	  4.12a).	   IFNβ	  mRNA	  expression	  levels	  remained	  unchanged	  at	  
24	  hours	  post	  stimulation	  with	  poly(I:C)	  (Figure	  4.13a),	  whilst	  CXCL8	  (Figure	  4.12b)	  and	  CCL5	  
(Figure	   4.13b)	   release	   were	   also	   unaffected	   in	   RIP1	   knockdown	   samples	   stimulated	   with	  
poly(I:C),	  as	  measured	  by	  ELISA.	  In	  addition,	  CSE	  alone	  did	  not	  induce	  CXCL8	  (Figure	  4.12b)	  or	  
CCL5	  (Figure	  4.13b)	  release	  from	  HBEpCs	  but	  ablated	  their	  induction	  by	  poly(I:C).	  






Figure	  4.10:	  Poly(I:C)	  and	  CSE	  stimulation	  does	  not	  alter	  RIP1	  protein	  expression	  in	  primary	  
human	  bronchial	  	  epithelial	  cells	  
HBEpCs	  were	  stimulated	  with	  poly(I:C)	  (50	  μg/ml),	  CSE	  (10%)	  or	  the	  combination	  of	  both	  for	  24	  
hours.	  Cell	  lysates	  were	  analysed	  for	  RIP1	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  
blot	   is	   shown	   in	   figure	   (A).	   Quantitative	   signals	   were	   determined	   by	   densitometry	   and	  
expressed	   as	   mean	   ±	   SEM	   of	   n=3,	   with	   each	   replicate	   performed	   on	   separate	   donors	   (B).	  	  	  
Statistical	  analysis	  was	  carried	  out	  by	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test.	  
	  
	  



















Figure	   4.11:	   Pellino-­‐1	   transient	   knockdown	   does	   not	   regulate	   RIP1	   protein	   expression	   in	  
primary	  human	  bronchial	  epithelial	  cells	  stimulated	  with	  poly(I:C)	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  4	  and	  24	  hour.	  Cell	   lysates	  were	  
analysed	  for	  RIP1	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  figure	  
(A).	  Quantitative	  signals	  were	  determined	  by	  densitometry	  and	  expressed	  as	  mean	  ±	  SEM	  of	  
n=3,	  with	  each	   replicate	  performed	  on	  a	  separate	  donors	   (B).	  Statistical	  analysis	  was	  carried	  
out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (***p<0.001).	  






Figure	  4.12:	  RIP1	  transient	  knockdown	   increases	  poly(I:C)	   induced	  CXCL8	  mRNA	  expression	  
and	   does	   not	   alter	   CSE	   induced	   inhibition	   of	   CXCL8	   release	   in	   primary	   human	   bronchial	  
epithelial	  cells	  	  
HBEpCs	  were	  transiently	   transfected	  with	  RIP1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	   hours	   prior	   to	   treatment	  with	   poly(I:C)	   (50	   μg/ml)	   for	   24	   hours.	   RNA	  was	   extracted	   and	  
CXCL8	  expression	  levels	  were	  analysed	  by	  qPCR	  (A).	  Supernatants	  were	  collected	  and	  analysed	  
for	  CXCL8	  release	  by	  ELISA	  (B).	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4,	  with	  each	  replicate	  
performed	  on	   separate	   donors.	   Statistical	   analysis	  was	   carried	   out	   by	   two-­‐way	  ANOVA	  with	  
Bonferroni’s	  post-­‐test	  (*p<0.05,	  **p<0.01	  and	  ***p<0.001).	  
	  





Figure	   4.13:	   RIP1	   transient	   knockdown	   does	   not	   alter	   CCL5	   release	   in	   primary	   human	  
bronchial	  epithelial	  cells	  stimulated	  with	  poly(I:C)	  or	  CSE	  
HBEpCs	  were	  transiently	   transfected	  with	  RIP1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  24	  hours.	  RNA	  was	  extracted	  and	  IFNβ	  
expression	   levels	  were	   analysed	   by	   qPCR	   (A).	   Supernatants	  were	   collected	   and	   analysed	   for	  
CCL5	   release	   by	   ELISA	   (B).	   Data	   are	   expressed	   as	   mean	   ±	   SEM	   of	   n=3,	   with	   each	   replicate	  
performed	  on	   separate	   donors.	   Statistical	   analysis	  was	   carried	   out	   by	   two-­‐way	  ANOVA	  with	  
Bonferroni’s	  post-­‐test.	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4.8	  RIP1	  transient	  knockdown	  does	  not	  alter	  poly(I:C)	  and	  CSE	  induced	  
Pellino-­‐1	  expression	  in	  primary	  human	  bronchial	  epithelial	  cells	  
	  
Chang	  et	  al.	  identified	  Pellino-­‐1	  as	  a	  binding	  partner	  and	  mediator	  of	  RIP1	  ubiquitination	  that	  
results	   in	  both	   the	   recruitment	  and	  activation	  of	   IKK	  and	   subsequent	  activation	  of	   canonical	  
NF-­‐κB	  signalling	  (Chang	  et	  al.,	  2009).	  However,	  the	  transient	  silencing	  of	  RIP1	  gene	  expression	  
by	   siRNA	   did	   not	   recapitulate	   the	   phenotype	   of	   Pellino-­‐1	   knockdown	   cells,	   as	   CXCL8	   was	  
significantly	   increased	   in	  RIP1	  knockdown	  and	  decreased	   in	  Pellino-­‐1	  knockdown	  in	  response	  
to	  poly(I:C)	  stimulation	  (Figure	  4.12	  and	  Figure	  4.4).	  	  
	  
In	  order	  to	  determine	  the	  involvement	  of	  RIP1	  with	  Pellino-­‐1	  and	  their	  ability	  to	  regulate	  each	  
other,	  a	   transient	  RIP1	  knockdown	  was	  performed	  followed	  by	  stimulation	  with	  poly(I:C)	   (50	  
μg/ml)	  for	  24	  hours.	  The	  resulting	  Pellino-­‐1	  mRNA	  expression	  levels	  were	  measured	  by	  qPCR.	  
RIP1	   knockdown	   does	   not	   alter	   Pellino-­‐1	   expression	   in	   response	   to	   poly(I:C),	   CSE	   nor	   the	  
combination	  of	  both	  (Figure	  4.14).	  
	   132	  
	  
Figure	  4.14:	  RIP1	  transient	  knockdown	  does	  not	  alter	  poly(I:C)	  induced	  Pellino-­‐1	  expression	  
in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	   transfected	  with	  RIP1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml),	  CSE	  (10%)	  or	  a	  combination	  of	  both	  for	  
24	  hours.	  RNA	  was	  extracted	  and	  Pellino-­‐1	  expression	  levels	  were	  analysed	  by	  quantitative	  RT-­‐
PCR.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=3,	  with	  each	   replicate	  performed	  on	   separate	  
donors.	  	  Statistical	  analysis	  was	  carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test.	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4.9	  Pellino-­‐1	  transient	  knockdown	  reduces	  poly(I:C)	  induced	  NFKB1	  and	  
NFKB2	  protein	  expression	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
	  
The	  transcription	  factor	  NF-­‐κB	  consists	  of	  five	  members:	  RelA	  (p65),	  RelB,	  c-­‐Rel,	  NFKB1	  (p105)	  
and	  NFKB2	  (p100).	  During	  the	  classical	  activation	  of	  NF-­‐κB,	  also	  termed	  canonical-­‐NF-­‐κB,	  RelA,	  
RelB	  and	  c-­‐Rel	  are	  sequestered	  by	   IκB	  proteins	  until	   IKK-­‐induced	  degradation	  of	   IκB	   releases	  
them	  for	  translocation	  to	  the	  nucleus.	  However	  during	  the	  alternative	  activation	  of	  NF-­‐κB,	  also	  
known	  as	  non-­‐canonical	  NF-­‐κB,	  precursor	  proteins	  NFKB1	  and	  NFKB2	  are	  phosphorylated	  and	  
processed	  to	  release	  their	  active	  components	  p50	  and	  p52	  respectively.	  The	  freed	  p50	  and	  p52	  
active	  fragments	  form	  dimers	  with	  other	  members	  of	  the	  NF-­‐κB	  family	  before	  translocating	  to	  
the	  nucleus	  and	  initiating	  gene	  transcription	  (Hayden	  and	  Ghosh,	  2004).	  
	  
The	  transient	  knockdown	  of	  Pellino-­‐1	  resulted	  in	  an	  anti-­‐inflammatory	  phenotype	  in	  response	  
to	  poly(I:C)	  stimulation	  (Figure	  4.4)	  whilst	  maintaining	  an	   intact	  anti-­‐viral	   response	  mediated	  
by	  IFNβ	  (Figure	  4.5).	  These	  data	  suggest	  that	  Pellino-­‐1	  is	  eliciting	  its	  effects	  through	  the	  NF-­‐κB	  
pathway.	   However	   the	   lack	   of	   effective	   suppression	   of	   IκBα	   degradation	   by	   Pellino-­‐1	  
knockdown	  (Figure	  4.8)	  led	  to	  the	  investigation	  of	  possible	  roles	  for	  Pellino-­‐1	  on	  non-­‐canonical	  
NF-­‐κB	   signalling.	   Cell	   lysates	   of	   Pellino-­‐1	   and	   scrambled	   siRNA	   transfected	   HBEpCs	   were	  
collected	   4	   and	   24	   hours	   post-­‐stimulation	  with	   poly(I:C)	   and	   immunoblotted	   for	  NFKB1	   and	  
NFKB2	  and	  p52.	  Pellino-­‐1	  knockdown	  does	  not	  alter	  NFKB1	  expression	  in	  HBEpC	  in	  response	  to	  
poly(I:C)	   (Figure	   4.15).	   However,	   NFKB2	   protein	   expression	   was	   increased	   by	   poly(I:C)	  
stimulation.	  In	  turn,	  Pellino-­‐1	  knockdown	  prevented	  the	  poly(I:C)	  induced	  expression	  of	  NFKB2	  
(Figure	  4.16),	  suggesting	  a	  role	  for	  Pellino-­‐1	  regulation	  of	  the	  non-­‐canonical	  NF-­‐κB	  signalling.	  
Due	   to	   time	   constraints	   and	   the	   continued	   interest	   in	   Pellino1,	   these	   experiments	   were	  
performed	  jointly	  with	  a	  colleague	  in	  our	  group,	  Elizabeth	  Prestwich.	  
	  
	  





Figure	  4.15:	   Pellino-­‐1	   transient	   knockdown	  does	  not	   regulate	  NFKB1	  protein	   expression	   in	  
primary	  human	  bronchial	  epithelial	  cells	  stimulated	  with	  poly(I:C)	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
24	   hours	   prior	   to	   treatment	   with	   poly(I:C)	   (50	   μg/ml)	   for	   4	   and	   24	   hour.	   Cell	   lysates	   were	  
analysed	  for	  NFKB1	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  figure	  
(A).	  Quantitative	  signals	  were	  determined	  by	  densitometry	  and	  expressed	  as	  mean	  ±	  SEM	  of	  
n=8,	  with	  replicates	  performed	  on	  5	  separate	  donors	  (B).	  Statistical	  analysis	  was	  carried	  out	  by	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Figure	   4.16:	   Pellino-­‐1	   transient	   knockdown	   significantly	   inhibits	   NFKB2	   expression	   in	  
response	  to	  poly(I:C)	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	  24	  hours	  prior	  to	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  4	  and	  24	  hour.	  Cell	   lysates	  were	  
analysed	  for	  NFKB2	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  figure	  
(A).	  Quantitative	  signals	  were	  determined	  by	  densitometry	  and	  expressed	  as	  mean	  ±	  SEM	  of	  
n=9,	  with	  replicates	  performed	  on	  5	  separate	  donors	  (B).	  Statistical	  analysis	  was	  carried	  out	  by	  
two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (***p<0.001).	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4.10	  NFKB2	  transient	  knockdown	  increases	  poly(I:C)	  induced	  CXCL8	  
expression	  and	  CCL5	  release	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
	  
Previous	  data	  showed	  NFKB2	  induction	  as	  a	  result	  of	  poly(I:C)	  stimulation	  of	  HBEpCs.	  Targeted	  
knockdown	  of	   Pellino-­‐1	  by	   siRNA	   in	   these	   cells	   however	   results	   in	  decreased	  NFKB2	  protein	  
expression	   in	   response	   to	   poly(I:C)	   (Figure	   4.16).	   In	   addition,	   the	   knockdown	   of	   Pellino-­‐1	  
results	  in	  a	  decrease	  in	  CXCL8	  gene	  transcription	  and	  cytokine	  release	  (Figure	  4.4a	  and	  Figure	  
4.4b),	   whilst	   IFNβ	  mRNA	   expression	   remains	   unchanged	   (Figure	   4.5).	   These	   data	   combined	  
suggest	  a	  specific	  function	  for	  Pellino-­‐1	  in	  non-­‐canonical	  NF-­‐κB	  signalling	  and	  warrant	  further	  
investigation.	  	  
	  
While	  the	  knockdown	  of	  Pellino-­‐1	  downregulated	  poly(I:C)	   induced	  NFKB2	  expression	  (Figure	  
4.16),	  the	  knockdown	  of	  NFKB2	  in	  turn	  did	  not	  alter	  Pellino-­‐1	  expression	  (Figure	  4.17).	  Taken	  
in	  combination	  these	  data	  led	  to	  the	  hypothesis	  that	  Pellino-­‐1	  may	  target	  NFKB2	  activation	  to	  
viral	  stimuli	  by	  acting	  as	  a	  negative	  regulator;	  thus	  the	  transient	  knockdown	  of	  NFKB2	  should	  
recapitulate	   the	   phenotype	   of	   Pellino-­‐1	   knockdown.	   NFKB2	   transcripts	   were	   significantly	  
knocked	   down	   following	   a	   transient	   transfection	   with	   NFKB2	   siRNA	   for	   24	   hours	   prior	   to	  
poly(I:C)	  stimulation	  for	  a	  further	  24	  hours	  to	  determine	  efficiency	  of	  knockdown	  (Figure	  4.18).	  
NFKB2	   expression	   was	   then	   transiently	   inhibited	   by	   siRNA	   transfection	   prior	   to	   stimulation	  
with	  poly(I:C)	  (50	  μg/ml)	  for	  24	  hours	  to	  determine	  the	  hypothesis.	  Interestingly,	  the	  resulting	  
CXCL8	  mRNA	  expression	  was	  significantly	  increased	  in	  the	  NFKB2	  knockdown	  when	  compared	  
to	   the	   scrambled	   control	   in	   response	   to	   poly(I:C)	   (Figure	   4.19).	   Furthermore,	   the	   poly(I:C)-­‐
induced	   CCL5	   cytokine	   release	  was	   significantly	   increased	   in	   the	   NFKB2	   knockdown	  HBEpCs	  
(Figure	  4.20).	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Figure	   4.17:	   NFKB2	   transient	   knockdown	   does	   not	   regulate	   poly(I:C)	   induced	   Pellino-­‐1	  
expression	  
HBEpCs	  were	  transiently	  transfected	  with	  NFKB2	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	   hours	   prior	   to	   treatment	  with	   poly(I:C)	   (50	   μg/ml)	   for	   24	   hours.	   RNA	  was	   extracted	   and	  
Pellino-­‐1	  expression	  levels	  were	  analysed	  by	  quantitative	  RT-­‐PCR.	  Data	  are	  expressed	  as	  mean	  
±	   SEM	   of	   n=3,	   with	   each	   replicate	   performed	   on	   separate	   donors.	   Statistical	   analysis	   was	  
carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test.	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Figure	  4.18:	  NFKB2	  transient	  knockdown	  inhibits	  poly(I:C)	  induced	  NFKB2	  mRNA	  expression	  
in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  NFKB2	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	   hours	   prior	   to	   treatment	  with	   poly(I:C)	   (50	   μg/ml)	   for	   24	   hours.	   RNA	  was	   extracted	   and	  
NFKB2	  expression	  levels	  were	  analysed	  by	  quantitative	  RT-­‐PCR.	  Data	  are	  expressed	  as	  mean	  ±	  
SEM	  of	  n=3,	  with	  each	  replicate	  performed	  on	  separate	  donors.	  Statistical	  analysis	  was	  carried	  
out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (**p<0.01).	  
	  




Figure	  4.19:	  NFKB2	  transient	  knockdown	  increases	  poly(I:C)	  induced	  CXCL8	  mRNA	  expression	  
in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	   were	   transiently	   transfected	   with	   NFKB2	   siRNA	   and	   non-­‐targeting	   scrambled	   siRNA	  
followed	  by	   treatment	  with	  poly(I:C)	   (50	  μg/ml)	   for	  24	  hours.	  RNA	  was	  extracted	  and	  CXCL8	  
expression	  levels	  were	  analysed	  by	  quantitative	  RT-­‐PCR.	  Statistical	  analysis	  was	  carried	  out	  by	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Figure	  4.20:	  NFKB2	  transient	  knockdown	  increases	  poly(I:C)	  induced	  CCL5	  release	  in	  primary	  
human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  NFKB2	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	   hours	   prior	   to	   treatment	   with	   poly(I:C)	   (50	   μg/ml)	   for	   24	   hours.	   Supernatants	   were	  
collected	  and	  analysed	  for	  CCL5	  release	  by	  ELISA.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=4,	  
with	  each	  replicate	  performed	  on	  separate	  donors.	  Statistical	  analysis	  was	  carried	  out	  by	  two-­‐
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4.11	  Rhinoviral	  infection	  increases	  Pellino-­‐1	  mRNA	  expression	  in	  primary	  
human	  bronchial	  epithelial	  cells	  from	  COPD	  patient	  airways	  	  
	  
Chronic	  obstructive	  pulmonary	  disease	  (COPD)	  is	  a	  complex	  airway	  inflammatory	  disease	  with	  
poor	  prognosis	  and	  inadequate	  reversibility.	  By	  2020,	  COPD	  is	  predicted	  to	  be	  the	  world’s	  third	  
leading	   cause	   of	   death	   and	   fifth	   cause	   of	   disability	   (Lopez	   and	   Murray,	   1998).	   Acute	  
exacerbations	  are	  a	  hallmark	  of	  COPD	  and	  are	  often	  associated	  with	  exposure	  to	  respiratory	  
viruses	  such	  as	  the	  commonly	  detected	  rhinovirus	  (Mallia	  et	  al.,	  2006).	  	  
	  
In	  order	  to	  determine	  the	  viability	  of	  Pellino-­‐1	  as	  a	  potential	  therapeutic	  drug	  target	  for	  COPD	  
it	   is	  essential	  to	  investigate	  the	  regulation	  of	  Pellino-­‐1	  and	  its	  role	  in	  viral	   infection	  in	  human	  
bronchial	  airway	  epithelial	  cells	  in	  patients	  suffering	  from	  COPD.	  Previous	  data	  supports	  a	  role	  
for	   Pellino-­‐1	   in	   the	   TLR3	   signalling	   pathway	   in	   primary	   airway	   epithelial	   cells,	   as	   Pellino-­‐1	  
knockdown	   resulted	   in	   a	   significant	   reduction	   in	   CXCL8	   production	   in	   response	   to	   poly(I:C).	  
However	   to	   determine	   whether	   the	   role	   of	   Pellino-­‐1	   is	   altered	   in	   COPD	   patient	   airways,	  
Pellino-­‐1	   expression	   was	   quantified	   in	   epithelial	   cells	   isolated	   from	   COPD	   patients	   then	  
infected	  with	  the	  natural	  human	  viral	  pathogen,	  rhinovirus.	  
	  
Irene	  H	  Heijink	  from	  the	  University	  Medical	  Centre	  in	  Groningen	  supplied	  the	  primary	  airway	  
epithelial	   cells	   isolated	   from	   brushings	   of	   COPD	   patient	   airways.	   	   Dr.	   Heijink	   and	   her	   group	  
cultured	  the	  harvested	  airway	  epithelial	  cells	  in	  vitro	  and	  infected	  them	  with	  rhinovirus-­‐16	  (RV-­‐
16)	  and	  rhinovirus-­‐1B	  (RV-­‐1B),	  supplied	  by	  the	  Ian	  Sabroe	  group	  at	  the	  University	  of	  Sheffield,	  
at	  an	  approximate	  MOI	  of	  3	   for	  24	  and	  48	  hours	  before	  RNA	  extraction.	  The	   resulting	  cDNA	  
was	   then	  analysed	  and	  quantified	  by	  qPCR	  at	   the	  University	  of	  Sheffield	  by	   the	  group	  and	   I.	  
Pellino-­‐1	   mRNA	   transcripts	   in	   COPD	   epithelial	   cells	   marginally	   increase	   at	   24	   hours	   post-­‐
infection	  with	  RV-­‐16.	  However,	  at	  48	  hours,	  Pellino-­‐1	  is	  significantly	   increased	  in	  response	  to	  
RV-­‐16	  when	  compared	  to	  baseline	  (Figure	  4.21a).	  Similarly,	  Pellino-­‐1	  appears	  to	  be	  regulated	  
by	  RV-­‐1B	  at	  48	  hours	  post-­‐infection	  (Figure	  4.21b).	  	  
	  
	  





Figure	   4.21:	   Rhinoviral	   infection	   increases	   Pellino-­‐1	   mRNA	   expression	   in	   primary	   human	  
bronchial	  epithelial	  cells	  from	  COPD	  patient	  airways	  
HBEpC	  isolated	  from	  COPD	  patient	  airways	  were	  stimulated	  with	  RV-­‐16	  (A)	  and	  RV-­‐1B	  (B)	  for	  
24	  and	  48	  hours.	  Pellino-­‐1	  mRNA	  expression	  was	  determined	  by	  quantitative	  RT-­‐PCR	  (qPCR).	  
Pellino-­‐1	  expression	  was	  normalized	  to	  GAPDH	  copy	  numbers	  (loading	  control)	  and	  expressed	  
as	  mean	  ±	  SEM	  of	  n=4,	  with	  each	  replicate	  performed	  on	  separate	  donors.	  	  Statistical	  analysis	  
was	  carried	  out	  by	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05).	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4.12	  Rhinoviral	  infection	  increases	  NFKB2	  mRNA	  expression	  in	  primary	  
human	  bronchial	  epithelial	  cells	  from	  COPD	  patient	  airways	  	  
	  
Previous	   data	   show	   a	   role	   for	   Pellino-­‐1	   in	   regulating	   NFKB2	   expression	   in	   response	   to	   viral	  
stimulation	   wherein	   transient	   Pellino-­‐1	   knockdown	   decreases	   NFKB2	   protein	   expression	  	  
(Figure	  4.16).	  In	  epithelial	  cells	  obtained	  from	  COPD	  patient	  airways,	  Pellino-­‐1	  expression	  was	  
significantly	   increased	   in	   response	   to	   viral	   stimulation	   (Figure	   4.21).	   It	   was	   therefore	  
hypothesised	  that	  NFKB2	  expression	  is	  regulated	  by	  Pellino-­‐1,	  and	  is	  in	  turn	  increased	  in	  COPD	  
patient	  airways.	  
	  
As	  described	  in	  Section	  4.11,	  Irene	  H	  Heijink	  from	  the	  University	  Medical	  Centre	  in	  Groningen	  
supplied	  the	  primary	  airway	  epithelial	  cells	   isolated	  from	  brushings	  of	  COPD	  patient	  airways.	  	  
Dr.	  Heijink	  and	  her	  group	  cultured	   the	  harvested	  airway	  epithelial	   cells	   in	   vitro	   and	   infected	  
them	  with	  rhinovirus-­‐16	  (RV-­‐16)	  and	  rhinovirus-­‐1B	  (RV-­‐1B),	  supplied	  by	  the	  Ian	  Sabroe	  group	  
at	   the	  University	   of	   Sheffield,	   at	   an	   approximate	  MOI	   of	   3	   for	   24	   and	   48	   hours	   before	   RNA	  
extraction.	  The	  resulting	  cDNA	  was	  then	  analysed	  and	  quantified	  by	  qPCR	  at	  the	  University	  of	  
Sheffield	  by	  the	  group	  and	  I.	  The	  resulting	  NFKB2	  mRNA	  transcripts	  were	  quantified	  by	  qPCR.	  
In	  accordance	  with	  Pellino-­‐1	  expression	  (Figure	  4.21a),	  NFKB2	  expression	  was	  unchanged	  at	  24	  
hours	  but	  significantly	  increased	  in	  COPD	  epithelial	  cells	  at	  48	  hours	  post-­‐infection	  with	  RV-­‐16	  
(Figure	   4.22a).	   Infection	   of	   COPD	   epithelial	   cells	   with	   RV-­‐1B	   also	   resulted	   in	   a	   significant	  
induction	  of	  NFKB2	  gene	  expression	  at	  48	  hours	  (Figure	  4.22b).	  
	  





Figure	   4.22:	   Rhinoviral	   infection	   increases	   NFKB2	   mRNA	   expression	   in	   primary	   human	  
bronchial	  epithelial	  cells	  from	  COPD	  patient	  airways	  
HBEpC	  isolated	  from	  COPD	  patient	  airways	  were	  stimulated	  with	  RV-­‐16	  (A)	  and	  RV-­‐1B	  (B)	  for	  
24	   and	   48	   hours.	   NFKB2	  mRNA	   expression	   was	   determined	   by	   quantitative	   RT-­‐PCR	   (qPCR).	  
Pellino-­‐1	  expression	  was	  normalized	  to	  GAPDH	  copy	  numbers	  (loading	  control)	  and	  expressed	  
as	  mean	  ±	  SEM	  of	  n=4,	  with	  each	  replicate	  performed	  on	  separate	  donors.	  	  Statistical	  analysis	  
was	  carried	  out	  by	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05,	  **p<0.01).	  
	  
	   145	  
4.13	  MEK1	  inhibitors	  regulate	  Pellino-­‐1	  expression	  in	  response	  to	  
poly(I:C)	  stimulation	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  	  
	  
dsRNA	   recognition	  by	   TLR3	   results	   in	   the	   initiation	  of	   inflammatory	   signalling	   culminating	   in	  
the	  activation	  of	  NF-­‐κB,	  IRF-­‐3	  and	  AP-­‐1.	  Whilst	  NF-­‐κB	  activation	  is	  regulated	  by	  IκB	  degradation	  
through	   IKK	  complex,	  AP-­‐1	  activation	   is	  mediated	  by	  MAP	  kinases	   such	  as	   JNK,	  ERK	  and	  p38	  
(Kawai	  and	  Akira,	  2007).	  Preliminary	  data	  suggested	  a	  role	  for	  Pellino-­‐1	  in	  the	  regulation	  of	  AP-­‐
1	   through	   p38	   MAPK	   wherein	   transient	   knockdown	   of	   Pellino-­‐1	   decreased	   phospho	   p38	  
activity	  (Figure	  4.9).	  	  
	  
A	  pilot	  experiment	  aimed	  to	  assess	  the	  impact	  of	  the	  inhibition	  of	  the	  MAPKs	  JNK,	  ERK	  and	  p38	  
on	   Pellino-­‐1	   expression.	   JNK,	   ERK	   and	   p38	   activity	   was	   suppressed	   by	   their	   respective	  
inhibitors:	  SP600125,	  PD98059	  and	  SB203580.	  Pellino-­‐1	  mRNA	  expression	  was	  then	  quantified	  
using	   qPCR.	   While	   JNK	   and	   p38	   inhibition	   did	   not	   alter	   Pellino-­‐1	   expression,	   the	   MEK1	  
inhibitor,	   PD98059	   resulted	   in	   a	   decrease	   in	   Pellino-­‐1	   expression	   (Figure	   4.23).	   These	   initial	  
results	  led	  to	  the	  hypothesis	  that	  ERK	  signalling	  may	  regulate	  Pellino-­‐1	  expression.	  	  
	  
HBEpCs	  were	  pre-­‐incubated	  with	  MEK1	  inhibitors	  PD98059	  and	  U0126	  respectively	  for	  1	  hour	  
prior	  to	  stimulation	  with	  poly(I:C)	   for	  24	  hours.	  PD98059	  and	  U0126	  effectively	   inhibited	  the	  
phoshporylation	   of	   p44/p42	   or	   ERK1/2	   as	   demonstrated	   by	  western	   blotting	   (Figure	   4.24a).	  
Both	   inhibitors,	   PD98059	   and	   U0126,	   also	   effectively	   reduced	   poly(I:C)	   induced	   Pellino-­‐1	  
protein	   expression	   (Figure	   4.24b).	   In	   keeping	   with	   changes	   to	   protein	   expression,	   poly(I:C)	  
induced	   Pellino-­‐1	   mRNA	   expression	   was	   also	   significantly	   inhibited	   by	   both	   PD98059	   and	  
U0126	  suggesting	  a	  role	  in	  the	  regulation	  of	  Pellino-­‐1	  by	  ERK	  (Figure	  4.25).	  
	  
Pellino-­‐1	  expression	  was	  transiently	  inhibited	  by	  siRNA	  transfection	  followed	  by	  a	  stimulation	  
with	  poly(I:C)	  for	  4	  and	  24	  hours.	  ERK1/2	  protein	  activity	  was	  measured	  by	  western	  blot	  and	  
showed	  high	  levels	  at	  baseline	  at	  0	  hours	  (unstimulated	  samples)	  across	  mock,	  scrambled	  and	  
Pellino-­‐1	   knockdown	   samples	   (Figure	   4.26a	   and	   Figure	   4.26b).	   A	   slight	   decrease	   in	   ERK1/2	  
levels	  compared	  with	  baseline	  can	  be	  detected	  at	  4	  hours	  post-­‐stimulation	  with	  poly(I:C).	  At	  24	  
hours	   post-­‐stimulation,	   both	   scrambled	   control	   and	   Pellino-­‐1	   knockdown	   show	   modestly	  
increased	  levels	  of	  ERK1/2	  when	  compared	  with	  baseline	  (Figure	  4.26b).	  
	  




Figure	   4.23:	   MAPK	   inhibitors	   alter	   Pellino-­‐1	   protein	   expression	   in	   response	   to	   poly(I:C)	  
stimulation	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  pre-­‐treated	  with	  PD98059	  (20μM),	  SP600125	  (20μM)	  and	  SB203580	  (20μM)	  for	  
1	  hour	   followed	  by	  treatment	  with	  poly(I:C)	   (50	  μg/ml)	   for	  24	  hours.	  Quantitative	  signals	   for	  
Pellino-­‐1	  expression	  were	  determined	  by	  densitometry	  from	  a	  single	  experiment.	  





Figure	   4.24:	   MEK1	   inhibitors	   reduce	   Pellino-­‐1	   protein	   expression	   in	   response	   to	   poly(I:C)	  
stimulation	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  pre-­‐treated	  with	  PD98059	   (20	  μM)	  and	  U0126	   (10	  μM)	   for	  1	  hour	   followed	  by	  
treatment	   with	   poly(I:C)	   (50	   μg/ml)	   for	   24	   hours.	   Cell	   lysates	   were	   analysed	   for	   phospho	  
p44/p42,	  Pellino-­‐1	  or	  actin	  expression	  by	  western	  blot.	  	  Representative	  blot	  is	  shown	  in	  figure	  
(A).	   Quantitative	   signals	   for	   Pellino-­‐1	   expression	   were	   determined	   by	   densitometry	   and	  
expressed	  as	  mean	  ±	  SEM	  of	  n=3,	  with	  replicates	  performed	  on	  separate	  donors	  (B).	  Statistical	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Figure	   4.25:	   MEK1	   inhibitors	   reduce	   Pellino-­‐1	   mRNA	   expression	   in	   response	   to	   poly(I:C)	  
stimulation	  in	  primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  pre-­‐treated	  with	  (20	  μM)	  and	  U0126	  (10	  μM)	  for	  1	  hour	  followed	  by	  treatment	  
with	   poly(I:C)	   (50	   μg/ml)	   for	   24	   hours.	   Pellino-­‐1	   mRNA	   expression	   was	   determined	   by	  
quantitative	   RT-­‐PCR	   (qPCR).	   Pellino-­‐1	   expression	   was	   normalized	   to	   GAPDH	   copy	   numbers	  
(loading	   control)	   and	   expressed	   as	   mean	   ±	   SEM	   of	   n=4,	   with	   each	   replicate	   performed	   on	  
separate	   donors.	   Statistical	   analysis	   was	   carried	   out	   by	   two-­‐way	   ANOVA	   with	   Bonferroni’s	  
post-­‐test	  (***p<0.001).	  





Figure	   4.26:	   Pellino-­‐1	   transient	   knockdown	   does	   not	   regulate	   poly(I:C)	   induced	   p44/p42	  
phosphorylation	  in	  primary	  human	  bronchial	  epithelial	  cells	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
followed	  by	  treatment	  with	  poly(I:C)	  (50	  μg/ml)	  for	  4	  and	  24	  hours.	  Cell	  lysates	  were	  analysed	  
for	   phospho	   p44/p42	   or	   actin	   expression	   by	  western	   blot.	   	   Representative	   blot	   is	   shown	   in	  
figure	   (A).	   Quantitative	   signals	  were	   determined	   by	   densitometry	   and	   expressed	   as	  mean	   ±	  
SEM	  of	  n=3,	  with	  replicates	  performed	  on	  separate	  donors	  (B).	  Statistical	  analysis	  was	  carried	  
out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05).	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4.14	  IRF-­‐3	  transient	  knockdown	  decreases	  Pellino-­‐1	  mRNA	  expression	  in	  
response	  to	  poly(I:C)	  in	  primary	  human	  bronchial	  epithelial	  cells	  
	  
The	  pattern	  recognition	  receptor	  TLR3	  recognises	  dsRNA	  from	  replicating	  viruses	  and	  triggers	  
signalling	   pathways	   resulting	   in	   the	   production	   of	   pro-­‐inflammatory	   cytokines,	   chemokines	  
and	   type	   I	   IFNs.	   The	   production	   of	   type	   I	   IFNs	   is	   dependent	   on	   the	   activation	   of	   IKKε/TBK1	  
complex	  and	  the	  resulting	  activation	  of	  IRF3.	  Indeed,	  TBK1/IKKε	  complex	  have	  been	  identified	  
as	  mediators	  of	  Pellino-­‐1’s	  E3	  ligase	  activity	  in	  addition	  to	  the	  induction	  of	  the	  transcription	  of	  
its	  gene	  in	  a	  TLR3	  dependent	  manner	  (Smith	  et	  al.,	  2011).	  	  
	  
Previous	   data	   indicates	   that	   Pellino-­‐1	   selectively	   regulates	   NF-­‐κB	   signalling	   while	   retaining	  
antiviral	   immunity	   in	   the	   form	   of	   IFN	   signalling.	   IFNβ	   mRNA	   expression	   was	   unaffected	   by	  
poly(I:C)	   stimulation	   following	   transient	   Pellino-­‐1	   knockdown	   (Figure	   4.5).	   However,	   data	  
generated	  through	  the	  creation	  of	  a	  Pellino-­‐1	  knock-­‐in	  mouse	  with	  a	  point	  mutation	  inhibiting	  
its	  E3	  ligase	  activity	  identified	  a	  role	  for	  Pellino-­‐1	  in	  IFNβ	  signalling	  through	  the	  interaction	  with	  
IRF3	  (Enesa	  et	  al.,	  2012).	  While	  the	  observations	  from	  previous	  data	  do	  not	  indicate	  Pellino-­‐1	  is	  
essential	   for	   IFN	   signalling,	   it	   was	   hypothesised	   that	   Pellino-­‐1	   activation	   may	   be	   partially	  
regulated	  by	  IRF3	  activation.	  
	  
IRF3	  transcripts	  were	  significantly	  knocked	  down	  following	  a	   transient	   transfection	  with	   IRF3	  
siRNA	  for	  24	  hours	  prior	  to	  poly(I:C)	  stimulation	  for	  a	  further	  24	  hours	  to	  determine	  efficiency	  
of	   knockdown	   (Figure	   4.27a).	   Similarly	   IFNβ	   (Figure	   4.27b)	   showed	   a	   decreasing	   trend	   of	  
expression	   following	   IRF3	   knockdown.	   IRF3	   expression	   was	   then	   inhibited	   by	   siRNA	  
transfection	  prior	  to	  stimulation	  with	  poly(I:C)	  (50	  μg/ml)	  for	  24	  hours	  to	  investigate	  whether	  
IRF-­‐3	  regulates	  Pellino-­‐1	  expression.	  The	  resulting	  upregulation	  of	  Pellino-­‐1	  mRNA	  expression	  
was	   inhibited	   in	   the	   IRF3	   knockdown	   HBEpCs	   when	   compared	   to	   the	   scrambled	   control	   in	  
response	  to	  poly(I:C)	  (Figure	  4.27c).	   In	  addition,	  while	  the	  stimulation	  with	  CSE	  alone	  did	  not	  
induce	  Pellino-­‐1	  expression	   in	  both	   IRF3	  knockdown	  HBEpCs	  and	   scrambled	  control	  HBEpCs,	  
the	  combination	  of	  CSE	  and	  poly(I:C)	  resulted	  in	  a	  decrease	  in	  Pellino-­‐1	  expression	  which	  was	  
further	  decreased	  in	  the	  IRF3	  knockdown	  cells	  (Figure	  4.27c)	  
	  






Figure	  4.27:	  IRF-­‐3	  transient	  knockdown	  decreases	  Pellino-­‐1	  mRNA	  expression	  in	  response	  to	  
poly(I:C)	  in	  primary	  human	  bronchial	  epithelial	  cells	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HBEpCs	  were	  transiently	  transfected	  with	  IRF-­‐3	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  for	  
24	   hours	   prior	   to	   treatment	   with	   poly(I:C)	   (50	   μg/ml)	   for	   4,	   8,	   16	   and	   24	   hours.	   RNA	   was	  
extracted	   and	   (A)	   IRF-­‐3,	   (B)	   IFNβ	   and	   (C)	   Pellino-­‐1	   expression	   levels	   were	   analysed	   by	  
quantitative	  RT-­‐PCR.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  of	  n=3,	  with	  each	  replicate	  performed	  
on	  separate	  donors.	  Statistical	  analysis	  was	  carried	  out	  by	  two-­‐way	  ANOVA	  with	  Bonferroni’s	  
post-­‐test.	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4.15	  Pellino-­‐1	  transient	  knockdown	  increases	  poly(I:C)	  induced	  caspase-­‐8	  
activity	  in	  primary	  human	  bronchial	  epithelial	  cells	  
	  
The	  pattern	  recognition	  receptor	  TLR3	  recognises	  dsRNA	  released	  during	  viral	   infections	  that	  
triggers	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  and	  type	  I	  IFNs.	  However	  in	  addition	  to	  
the	  activation	  of	  innate	  immune	  responses,	  TLR3	  can	  induce	  host	  cell	  apoptosis	  as	  a	  means	  to	  
prevent	   viral	   replication,	   viral	   dissemination	   or	   persistent	   viral	   infection	   (Barber,	   2001)	  
(Estornes	  et	  al.,	  2012).	  Apoptosis	  is	  a	  form	  of	  programmed	  cell	  death	  regulated	  by	  a	  family	  of	  
effector	   caspases.	   dsRNA	   or	   TLR3-­‐induced	   apoptosis	   occurs	   independently	   of	   both	   IRF3	   and	  
NF-­‐κB	   but	   is	   dependent	   on	   the	   c-­‐terminal	   region	   of	   TRIF	   containing	   a	   RIP	   homotypic	  
interaction	   motif	   (RHIM)	   (Kaiser	   and	   Offermann,	   2005).	   In	   the	   presence	   of	   dsRNA,	   TRIF	  
complexes	  with	   RHIM-­‐containing	   protein	   RIP1	   resulting	   in	   the	   recruitment	   and	   activation	   of	  
FADD/caspase8	  complex.	  	  
	  
Poly(I:C)	   has	   been	   shown	   to	   induce	   apoptosis	   in	   HBEpCs	   via	   a	   TLR3-­‐mediated	   caspase-­‐8	  
dependent	  pathway	   (Numata	  et	  al.,	  2011)	   (Kalai	  et	  al.,	  2002).	  Therefore	   it	  was	  hypothesised	  
that	  Pellino-­‐1	  may	   regulate	   caspase-­‐8	  activity	   through	   its	  potential	   interaction	  with	  RIP1.	   To	  
determine	   this,	   targeted	   knockdown	   of	   Pellino-­‐1	   by	   siRNA	   transfection	   was	   performed	   on	  
HBEpCs	  followed	  by	  stimulation	  with	  poly(I:C)	  for	  24	  hours.	  Caspase-­‐8	  activity	  was	  determined	  
by	   luminescence	   with	   the	   use	   of	   a	   proluminogenic	   caspase-­‐8	   substrate	   (Caspase-­‐Glo;	  
Promega)	  (see	  Section	  2.12).	   	  The	  generated	   luminescence	  signal	  corresponds	  proportionally	  
to	   the	   amount	   of	   caspase-­‐8	   activity	   present.	   Pellino-­‐1	   knockdown	   cells	   showed	   significantly	  
increased	   levels	   of	   caspase-­‐8	   activity	   to	   poly(I:C)	   stimulation	   when	   compared	   to	   scrambled	  
control	  (Figure	  4.28).	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Figure	  4.28:	  Pellino-­‐1	  transient	  knockdown	   increases	  poly(I:C)	   induced	  caspase-­‐8	  activity	   in	  
primary	  human	  bronchial	  epithelial	  cells	  	  
HBEpCs	  were	  transiently	  transfected	  with	  Pellino-­‐1	  siRNA	  and	  non-­‐targeting	  scrambled	  siRNA	  
for	   24	   hours	   prior	   to	   treatment	   with	   Poly(I:C)	   (50	   μg/ml)	   for	   24	   hour.	   Cell	   lysates	   were	  
analysed	  for	  caspase-­‐8	  activity	  using	  Caspase-­‐Glo	  8	  Assay	  system	  (described	  in	  Section	  2.12).	  
Quantitative	  signals	  were	  determined	  by	  luminescence	  and	  expressed	  as	  mean	  ±	  SEM	  of	  n=4,	  
with	   replicates	  performed	  on	  4	   separate	  donors.	   Statistical	   analysis	  was	   carried	  out	  by	   two-­‐
way	  ANOVA	  with	  Bonferroni’s	  post-­‐test	  (*p<0.05).	  
	   155	  
4.16	  Identifying	  Pellino-­‐1	  interacting	  proteins	  by	  proteomics	  &	  mass	  
spectrometry	  
	  
With	  the	  generation	  of	  the	  Pellino-­‐1	  knockout	  mouse	  came	  the	  discovery	  of	  its	  involvement	  in	  
the	   binding	   and	   ubiquitination	   of	   RIP1,	   from	   which	   RIP1	   was	   suggested	   to	   be	   a	   potential	  
Pellino-­‐1	   intermediary	   in	   TLR3	   signalling	   (Chang	   et	   al.,	   2009).	   While	   a	   role	   for	   Pellino-­‐1	   in	  
regulating	   IKK	  activation	  through	  the	   interaction	  and	  Lys-­‐63	  polyubiquitination	  of	  RIP1	   in	  the	  
TRIF-­‐dependent	  pathway	  has	  been	  identified	  (Chang	  et	  al.,	  2009),	  data	  generated	  in	  this	  thesis	  
do	   not	   support	   this	   interaction	   between	   Pellino-­‐1	   and	   RIP1.	   In	   order	   to	   determine	  whether	  
Pellino-­‐1	  does	  in	  fact	  interact	  with	  RIP1	  during	  anti-­‐viral	  signalling,	  a	  proteomics	  analysis	  was	  
commissioned.	  
	  
Additionally,	   while	   a	   role	   for	   ERK	   and	   to	   a	   lesser	   extent	   IRF-­‐3,	   has	   been	   proposed	   for	   the	  
regulation	   of	   Pellino-­‐1,	   the	   targets	   of	   Pellino-­‐1	   itself	   remain	   to	   be	   elucidated.	   To	   determine	  
potential	   Pellino-­‐1	   targets	   proteomics	   analysis	   was	   performed	   and	   may	   therefore	   provide	  
supporting	  evidence	  and	  additional	  insight	  to	  existing	  data.	  	  
	  
HBEpCs	  were	   stimulated	  with	  poly(I:C)	   for	  4	  and	  24	  hours	   respectively.	  Cells	  were	  collected,	  
washed	  and	  lysed	  by	  freeze	  thawing.	  The	  collected	  samples	  were	  then	  sent	  to	  the	  University	  of	  
Leeds	   and	   analysed	   by	   Alexandre	   Zoughman	   using	   the	   Strap	   method	   for	   bottom-­‐up	  
proteomics,	   followed	   by	   liquid	   chromatography	   tandem	   mass	   spectrometry,	   and	   data	  
processing	  (Reviewed	  in	  (Zougman	  et	  al.,	  2014)).	  The	  advantage	  of	  bottom-­‐up	  proteomics	  is	  its	  
ability	   to	   process	   membrane	   proteins	   which	   are	   otherwise	   not	   easily	   digested	   in	   aqueous	  
environments	  due	  to	  their	  hydrophobic	  properties.	  
	  
A	   total	   334	   proteins	   were	   identified	   (See	   Appendix)	   providing	   an	   extensive	   list	   of	   viable	  
candidates	  for	  Pellino-­‐1	  binding.	  However	  many	  of	  these	  proteins	  show	  equally	  high	  affinity	  to	  
Pellino-­‐1	  as	  the	  control	  mouse	  IgG2A	  suggesting	  the	  possibility	  of	  non-­‐specific	  binding	  although	  
Pellino-­‐1	  was	  itself	  was	  identified	  suggesting	  some	  viability	  of	  the	  data.	  Table	  4.1	   lists	  all	  the	  
protein	  targets	  and	  their	  resulting	  peptide	  hits	  that	  did	  show	  high	  affinity	  to	  Pellino-­‐1.	  Among	  
these	  targets,	  A20	  and	  two	  of	  its	  adaptor	  proteins	  TNIP1	  and	  TAX1BP1,	  have	  been	  linked	  with	  
the	  negative	  regulation	  of	  NF-­‐κB	  signalling.	  	  
	  
	  














Voltage-­‐dependent	  L-­‐type	  calcium	  channel	  subunit	  
alpha-­‐1D	  
0	   2	   0	   0	  




0	   2	   0	   1	  
CKAP4	   Cytoskeleton-­‐associated	  protein	  4	   0	   0	   0	   6	  
COL1A2	   Collagen	  alpha-­‐2(I)	  chain	   0	   3	   0	   4	  
COL3A1	   Collagen	  alpha-­‐1(III)	  chain	   0	   1	   0	   1	  
COPS2	   	   0	   1	   0	   0	  
CSNK1A1;CS
NK1A1L	  
Casein	  kinase	  I	  isoform	  alpha;Casein	  kinase	  I	  isoform	  
alpha-­‐like	  
0	   1	   0	   0	  
CTNNA1	   Catenin	  alpha-­‐1	   0	   2	   0	   1	  
CTSB	  
Cathepsin	  B;Cathepsin	  B	  light	  chain;Cathepsin	  B	  heavy	  
chain	  
0	   0	   0	   2	  
DBN1	   Drebrin	   0	   1	   0	   0	  
ETHE1	   Protein	  ETHE1,	  mitochondrial	   0	   0	   0	   2	  
FADS2	   Fatty	  acid	  desaturase	  2	   0	   0	   0	   1	  
FTH1	   Ferritin	  heavy	  chain;Ferritin	   0	   3	   0	   0	  
HIST1H1B	   Histone	  H1.5	   0	   2	   0	   1	  
HNRNPA1	   Heterogeneous	  nuclear	  ribonucleoprotein	  A1	   0	   0	   0	   1	  
HNRNPAB	   	   0	   0	   0	   1	  
HNRNPH1;H
NRNPF	  
Heterogeneous	  nuclear	  ribonucleoprotein	  
H;Heterogeneous	  nuclear	  ribonucleoprotein	  H,	  N-­‐
terminally	  processed;Heterogeneous	  nuclear	  
ribonucleoprotein	  F;Heterogeneous	  nuclear	  
ribonucleoprotein	  F,	  N-­‐terminally	  processed	  
0	   1	   0	   0	  
HNRNPL	   Heterogeneous	  nuclear	  ribonucleoprotein	  L	   0	   1	   0	   0	  
HSPE1	   10	  kDa	  heat	  shock	  protein,	  mitochondrial	   0	   0	   0	   2	  
HYOU1	   Hypoxia	  up-­‐regulated	  protein	  1	   0	   0	   0	   4	  
IARS	   Isoleucine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   0	   0	   0	   1	  
KAT5	   Histone	  acetyltransferase	  KAT5	   0	   0	   0	   1	  
LGALS3BP	   Galectin-­‐3-­‐binding	  protein	   0	   0	   0	   2	  
LRPPRC	  
Leucine-­‐rich	  PPR	  motif-­‐containing	  protein,	  
mitochondrial	  
0	   0	   0	   4	  
LYZ	   Lysozyme	  C	   0	   1	   0	   0	  
MTMR4	   Myotubularin-­‐related	  protein	  4	   0	   0	   0	   1	  
NARS2	   Probable	  asparagine-­‐-­‐tRNA	  ligase,	  mitochondrial	   0	   0	   0	   1	  
NOP56;NOL
5A	  
Nucleolar	  protein	  56	   0	   0	   0	   2	  
OSBPL10	  
Oxysterol-­‐binding	  protein-­‐related	  protein	  10;Oxysterol-­‐
binding	  protein	  
0	   1	   0	   0	  
PDHB	  
Pyruvate	  dehydrogenase	  E1	  component	  subunit	  beta,	  
mitochondrial	  
0	   1	   0	   3	  
PELI1	   E3	  ubiquitin-­‐protein	  ligase	  pellino	  homolog	  1	   0	   1	   0	   1	  
PKP3	   Plakophilin-­‐3	   0	   1	   0	   0	  
PLEC	   Plectin	   0	   19	   0	   0	  
PLOD2	   Procollagen-­‐lysine,2-­‐oxoglutarate	  5-­‐dioxygenase	  2	   0	   0	   0	   1	  
PPA2	   Inorganic	  pyrophosphatase	  2,	  mitochondrial	   0	   0	   0	   1	  
PTBP3;PTBP
1	  
Polypyrimidine	  tract-­‐binding	  protein	  3;Polypyrimidine	  
tract-­‐binding	  protein	  1	  
0	   0	   0	   1	  
RPRD2	  
Regulation	  of	  nuclear	  pre-­‐mRNA	  domain-­‐containing	  
protein	  2	  
0	   0	   0	   1	  
RPS19	   40S	  ribosomal	  protein	  S19	   0	   1	   0	   0	  
RPS8	   40S	  ribosomal	  protein	  S8	   0	   1	   0	   0	  
SCP2	   Non-­‐specific	  lipid-­‐transfer	  protein	   0	   0	   0	   2	  
SLC16A1	   Monocarboxylate	  transporter	  1	   0	   0	   0	   1	  
SLC35E1	   Solute	  carrier	  family	  35	  member	  E1	   0	   0	   0	   1	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SQSTM1	   Sequestosome-­‐1	   0	   5	   0	   0	  
SRSF4;SRSF
6;SRSF5	  
Serine/arginine-­‐rich	  splicing	  factor	  4;Serine/arginine-­‐
rich	  splicing	  factor	  6;Serine/arginine-­‐rich	  splicing	  factor	  
5	  
0	   1	   0	   0	  
TAX1BP1	   Tax1-­‐binding	  protein	  1	   0	   1	   0	   0	  
TBRG4	   Protein	  TBRG4	   0	   0	   0	   1	  
TENC1	   Tensin-­‐like	  C1	  domain-­‐containing	  phosphatase	   0	   1	   0	   1	  
TICAM1	   TIR	  domain-­‐containing	  adapter	  molecule	  1	   0	   1	   0	   0	  
TM9SF3	   Transmembrane	  9	  superfamily	  member	  3	   0	   0	   0	   1	  
TMED10	   Transmembrane	  emp24	  domain-­‐containing	  protein	  10	   0	   1	   0	   0	  
TNFAIP3	   Tumor	  necrosis	  factor	  alpha-­‐induced	  protein	  3	   0	   17	   0	   1	  
TNIP1	   TNFAIP3-­‐interacting	  protein	  1	   0	   10	   0	   8	  
VANGL1	   Vang-­‐like	  protein	  1	   0	   1	   0	   0	  
YIF1A	   Protein	  YIF1A	   0	   0	   0	   1	  
Table	  4.1:	  Potential	  Pellino-­‐1	  interacting	  partners	  generated	  by	  mass	  spectometry	  	  
HBEpCs	  were	  stimulated	  with	  poly(I:C)	   (50	  μg/ml)	   for	  4	  and	  24	  hours.	  Protein	  was	  extracted	  
and	   analysed	   by	   bottom-­‐up	   proteomics	   with	   consequent	   characterization	   of	   the	   generated	  
peptides	  by	  mass	  spectrometry	  based	  on	  peptide	  hits.	  Complete	  table	  listed	  in	  Appendix.	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4.17	  Summary	  
	  
The	   aim	   of	   this	   chapter	   was	   to	   understand	   the	   roles	   of	   Pellino-­‐1	   in	   TLR3	   signalling	   and	   to	  
identify	  proteins	  or	  complexes	  regulated	  by	  Pellino-­‐1	   in	   response	  to	  viral	   stimuli.	  The	  results	  
demonstrate	   that	   the	   stimulation	   of	  HBEpCs	  with	   poly(I:C)	   resulted	   in	   a	  marked	   increase	   of	  
Pellino-­‐1	  at	  both	  mRNA	  and	  protein	  levels;	  however	  experiments	  exposing	  these	  cells	  	  to	  CSE	  
had	  no	  effects	  on	  Pellino-­‐1	  expression.	  Although,	  the	  combination	  of	  poly(I:C)	  and	  CSE	  led	  to	  a	  
significant	  reduction	  in	  poly(I:C)-­‐induced	  Pellino-­‐1	  expression.	  	  
	  
Transient	  knockdown	  of	  Pellino-­‐1	  by	  targeted	  siRNA	  transfection	  showed	  a	  profound	  reduction	  
in	  Pellino-­‐1	  mRNA	  expression.	  This	  Pellino-­‐1	  knockdown	   in	  HBEpCs	   led	  to	  a	  decrease	   in	  both	  
CXCL8	   mRNA	   expression	   and	   CXCL8	   cytokine	   release.	   However	   in	   contrast,	   Pellino-­‐1	  
knockdown	   in	   HBEpCs	   did	   not	   alter	   IFNβ	   mRNA	   expression	   in	   response	   to	   poly(I:C).	  
Interestingly,	  the	  transient	  knockdown	  of	  IRF-­‐3	  in	  HBEpCs	  modestly	  decreases	  Pellino-­‐1	  mRNA	  
expression	  in	  response	  to	  poly(I:C)	  suggesting	  a	  possible	  role	  for	  IRF3	  in	  Pellino-­‐1	  regulation.	  	  
	  
Viral	  dsRNA	  is	  capable	  of	  inducing	  CXCL8	  gene	  expression	  through	  the	  activation	  of	  a	  number	  
of	   protein	   kinases	   with	   the	   capability	   of	   modulating	   NF-­‐κB.	   As	   Pellino-­‐1	   knockdown	  
significantly	  reduced	  CXCL8	  expression	  and	  release,	  it	  was	  hypothesized	  that	  Pellino-­‐1	  elicits	  its	  
effects	   through	   the	  NF-­‐κB	  arm	  of	  TLR3	  signalling.	  These	   results	   show	  that	   the	  stimulation	  of	  
Pellino-­‐1	   knockdown	   HBEpCs	   with	   poly(I:C)	   resulted	   in	   a	   decrease	   in	   phosphorylation	   of	  
IKKα/β.	   However,	   despite	   this	   decreased	   phosphorylation	   of	   IKKα/β,	   the	   levels	   of	   IκBα	  
degradation	   in	   Pellino-­‐1	   knockdown	   cells	   remained	   unchanged	   suggesting	   Pellino-­‐1	   is	   not	  
regulating	   NF-­‐κB	   activation.	   These	   interesting	   findings	   led	   to	   the	   investigation	   of	   a	   role	   for	  
Pellino-­‐1	   in	   non-­‐canonical	   NF-­‐κB	   signalling.	   While	   Pellino-­‐1	   knockdown	   does	   not	   alter	   the	  
expression	   of	   the	   non-­‐canonical	   NF-­‐κB	   precursor	   protein,	   NFKB1,	   following	   poly(I:C)	  
stimulation,	   Pellino-­‐1	   knockdown	   suppressed	   NFKB2	   protein	   expression	   in	   response	   to	  
poly(I:C)	  stimulation.	  	  
	  
As	  preliminary	  data	  suggested	  Pellino-­‐1	  negatively	  regulates	  the	  non-­‐canonical	  NF-­‐κB	  signalling	  
through	   NFKB2,	   it	   was	   hypothesised	   that	   transient	   knockdown	   of	   NFKB2	   in	   HBEpCs	   would	  
recreate	   the	   phenotype	   of	   Pellino-­‐1	   knockdown.	   However	   interestingly,	   NFKB2	   knockdown	  
resulted	   in	   significant	   CXCL8	  mRNA	   and	   protein	   expression	   increase	   in	   contrast	   to	   Pellino-­‐1	  
knockdown.	   Additionally,	   NFKB2	   knockdown	   does	   not	   in	   turn	   regulate	   Pellino-­‐1	   mRNA	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expression	  when	  cells	  are	  stimulated	  with	  poly(I:C).	  However,	  the	  interferon	  stimulated	  gene	  
CCL5	  cytokine	  release	  was	  significantly	  increased	  in	  NFKB2	  knockdown	  HBEpCs	  stimulated	  with	  
poly(I:C).	  Pellino-­‐1	  and	  NFKB2	  expression	  was	  also	  quantified	   in	  epithelial	   cells	   isolated	   from	  
diseased	   lung	  airway	  epithelium	  of	  COPD	  patients	  then	   infected	  with	  RV-­‐1B	  and	  RV-­‐16.	  Both	  
Pellino-­‐1	   and	  NFKB2	  were	   significantly	   expressed	   in	   these	   cells	   at	   48	  hours	   post	   stimulation	  
compared	  with	  unstimulated	  control.	  	  
	  
As	  Pellino-­‐1	  seems	  to	  have	  a	  role	  in	  distinct	  inflammatory	  pathways,	  we	  wanted	  to	  investigate	  
whether	  Pellino-­‐1	  regulated	  other	  major	  signalling	  pathways	  mediators	  –	  the	  MAPKs.	  The	  data	  
in	  this	  thesis	  suggests	  Pellino-­‐1	  may	  play	  a	  role	  in	  the	  regulation	  and	  activation	  of	  p38	  MAPK	  as	  
an	   alternative	   route	   to	   CXCL8	   transcription.	   Pellino-­‐1	   knockdown	   dampened	   the	   poly(I:C)	  
induced	   p38	   protein	   expression.	   p38	   regulates	   the	   transcription	   factor	   AP-­‐1	  which	   is	   crucial	  
but	  not	  essential	  for	  maximal	  CXCL8	  gene	  expression.	  	  
	  
Pilot	  data	  aiming	  to	  assess	  the	  impact	  of	  the	  inhibition	  of	  the	  MAPKs	  on	  Pellino-­‐1	  expression	  
led	   to	   the	   discovery	   of	   ERK	   as	   a	   potential	   Pellino-­‐1	   regulator.	   An	   ERK-­‐specific	   MAP	   kinase,	  
MEK1	  inhibitors	  PD98059	  and	  U0126	  effectively	  reduced	  poly(I:C)	  induced	  Pellino-­‐1	  mRNA	  and	  
protein	  levels.	  Moreover,	  Pellino-­‐1	  knockdown	  does	  not	  alter	  ERK	  expression.	  
	  
Pellino-­‐1	  was	   originally	   implicated	   in	   IL-­‐1	   signalling	   however	   previously	   published	  work	   and	  
data	   in	  this	  thesis	  suggest	  Pellino-­‐1	  may	  exert	   its	  effects	   in	  an	  IRAK1-­‐independent	  manner.	   It	  
was	   hypothesized	   that	   Pellino-­‐1	   may	   in	   fact	   play	   a	   role	   in	   virally	   induced	   IL-­‐1	   production.	  
Poly(I:C)	  induced	  late	  phase	  IL-­‐1α	  and	  IL-­‐1β	  mRNA	  expression,	  which	  in	  turn	  was	  dampened	  by	  
the	  knockdown	  of	  Pellino-­‐1.	  Specifically,	   IL-­‐1β	  gene	  expression	  was	  significantly	  decreased	   in	  
Pellino-­‐1	  knockdown	  HBEpCs.	  
	  
A	   role	   for	   Pellino-­‐1	   in	   regulating	   TLR3	   signalling	   through	   the	   interaction	   with	   RIP1	   has	  
previously	   been	   identified	   (Chang	   et	   al.,	   2009).	   However	   this	   role	   for	   RIP1	   as	   a	   target	   of	  
Pellino-­‐1	   remains	   controversial.	   It	   was	   hypothesised	   that	   if	   RIP1	   were	   indeed	   a	   target	   of	  
Pellino-­‐1	   then	   RIP1	   knockdown	   should	   recapitulate	   the	   Pellino-­‐1	   knockdown	   phenotype.	   In	  
contrast,	   RIP1	   knockdown	   significantly	   increased	   CXCL8	   generation	   in	   response	   to	   poly(I:C).	  
Proteomics	  analysis	  of	  Pellino-­‐1	  interacting	  proteins	  did	  not	  identify	  RIP1	  as	  a	  Pellino-­‐1	  binding	  
partner	  at	  4	  or	  24	  hours	  post	  stimulation	  with	  poly(I:C).	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RIP1	   is	   also	   associated	  with	   the	   recruitment	   and	   activation	   of	   the	   FADD/caspase-­‐8	   complex	  
resulting	  in	  cellular	  apoptosis.	  Viral	  infection	  can	  result	  in	  host	  cell	  death	  as	  a	  form	  of	  anti-­‐viral	  
defence	  to	  prevent	  further	  viral	  replication	  and	  dissemination.	  Therefore	  it	  was	  hypothesised	  
that	   Pellino-­‐1	   may	   have	   a	   regulatory	   role	   in	   caspase-­‐8	   apoptosis	   through	   the	   possible	  
interaction	  with	  RIP1.	  Pellino-­‐1	  knockdown	  HBEpCs	  stimulated	  with	  poly(I:C)	  showed	  increased	  
levels	  of	  caspase-­‐8	  activity	  when	  compared	  to	  scrambled	  control.	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CHAPTER	  5-­‐	  DISCUSSION	  
	  
Viral	   infections,	   such	  as	   rhinoviruses	   (RVs),	   account	   for	   a	  majority	  of	   exacerbations	  of	  COPD	  
(Johnston,	   2005)	   and	   can	   subsequently	   result	   in	   pronounced	   functional	   impairment	   of	   the	  
airway	  increasing	  both	  the	  severity	  of	  the	  disease	  and	  frequency	  of	  exacerbations.	  Therefore	  
the	  reduction	  of	  RV-­‐induced	  airway	  inflammation	  would	  be	  of	  immense	  clinical	  value	  with	  the	  
reduction	  in	  severity	  and	  duration	  of	  the	  disease	  improving	  patient	  quality	  of	  life	  and	  reducing	  
morbidity	   and	   mortality.	   Thus,	   targeting	   signalling	   pathways	   involved	   in	   RV-­‐induced	  
inflammation	  is	  an	  important	  goal.	  An	  optimal	  anti-­‐inflammatory	  treatment	  would	  reduce	  RV-­‐
induced	  airway	  inflammation	  without	  impairing	  host	  defence.	  	  
	  
Pellino-­‐1	  was	  originally	  identified	  as	  a	  regulator	  of	  IL-­‐1	  signalling	  (Jiang	  et	  al.,	  2003),	  however	  
while	   knockdown	   of	   Pellino-­‐1	   in	   immortalised	   epithelial	   cell	   line	   BEAS-­‐2B	   reduces	   IL-­‐1β-­‐
induced	  expression	  of	  pro-­‐inflammatory	  cytokines,	  the	  knockdown	  of	  Pellino-­‐1	   in	  HBEpC	  had	  
no	   such	   effect	   overall	   suggesting	   that	   regulation	   of	   IL-­‐1	   responses	  may	   have	   solely	   been	   a	  
feature	   of	   transformed	   cell	   lines	   (Bennett	   et	   al.,	   2012).	   Strikingly,	  more	   recent	   observations	  
have	   highlighted	   a	   role	   for	   Pellino-­‐1	   in	   viral	   signalling	   wherein	   Pellino-­‐1	   regulates	   pro-­‐
inflammatory	  responses	  to	  RV	  infection	  but	  does	  not	  appear	  to	  control	  production	  of	  antiviral	  
IFNs	   (Bennett	   et	   al.,	   2012;	   Chang	   et	   al.,	   2009).	   These	   data	   strongly	   support	   Pellino-­‐1	   as	   a	  
potential	   therapeutic	   drug	   target.	   This	   thesis	   investigates	   the	   regulation	   of	   Pellino-­‐1	   and	   its	  
role	  in	  viral	  infection	  in	  human	  bronchial	  airway	  epithelial	  cells.	  	  
	  
5.1	  Chronic	  Inflammation	  
 
COPD	   is	   a	   chronic	   inflammatory	   disease	   that	   is	   driven	   by	   a	   multitude	   of	   inflammatory	  
mediators	  derived	  from	  activated	  inflammatory	  cells,	   including	  monocytes	  and	  macrophages,	  
as	   well	   as	   structural	   cells	   such	   as	   epithelial	   and	   endothelial	   cells	   (See	   section	   1.2).	   COPD	  
patients	   often	   exhibit	   chronic	   or	   sustained	   infiltration	   of	   inflammatory	   cells,	   including	  
monocytes,	  macrophages,	   neutrophils	   and	   T	   lymphocytes,	   into	   their	   airway.	   The	   continuous	  
recruitment	   of	   monocytes	   into	   COPD	   patient	   airways	   (described	   in	   Section	   1.2)	   causes	   an	  
initial	   release	   of	   chemotactic	   factors	   such	   as	   CXCL8	   from	   epithelial	   cells	   through	   their	   IL-­‐1	  
driven	  communication	  and	  eventually	  other	  subsequent	   factors	   leading	  to	   further	  neutrophil	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infiltration	   (Di	   Stefano	   et	   al.,	   1994;	   Tanino	   et	   al.,	   2002).	   Alveolar	  macrophages,	  monocytes,	  
neutrophils	   and	   epithelial	   cells	   themselves	   are	   sources	   of	   CXCL8	   which	   is	   present	   in	   high	  
quantities	   in	  COPD	  patient	  sputum	  (Beeh	  et	  al.,	  2003).	  This	  reinforces	  the	   importance	  of	  cell	  
communication	   in	   COPD	   pathophysiology	   (Marsh	   et	   al.,	   1995),	   and	   can	   also	   explain	   the	  
excessive	  inflammatory	  responses	  witnessed	  in	  patients.	  
	  
Exposure	  to	  inhaled	  pollutants	  such	  as	  cigarette	  smoke	  is	  thought	  to	  be	  a	  leading	  cause	  of	  the	  
chronic	   airway	   inflammation	   seen	   in	   COPD	   through	   the	   activation	   of	   structural	   and	  
inflammatory	   cells	  within	   the	   lung	   resulting	   in	   a	   perpetuating	   state	   of	   chronic	   inflammation	  
through	  the	  release	  of	  chemotactic	  factors	  (Rovina	  et	  al.,	  2013).	  It	  was	  hypothesised	  that	  this	  
perpetual	   state	   of	   chronic	   inflammation	   leads	   to	   a	   ‘hypersensitive	   state’	   leaving	   the	   airway	  
susceptible	  to	  further	  common	  viral	  and	  bacterial	  respiratory	  infections	  often	  associated	  with	  
exacerbations	   of	   COPD.	   Therefore	   the	   work	   in	   this	   thesis	   was	   designed	   to	   investigate	   the	  
mechanisms	  that	  underpin	  the	  pathogenesis	  of	  the	  disease	  by	  elucidating	  dysregulation	  of	  the	  
immune	  signalling	  in	  these	  patients.	  
	  
With	   particular	   interest	   in	   patients	   presenting	   with	   chronic	   bacterial	   and/or	   viral	   infections	  
within	   their	   airways	   and	   the	   resulting	   effects	   on	   their	   responses	   to	   further	   stimuli,	   it	   was	  
hypothesised	   that	   this	   persistent	   infection	   leaves	   airways	   primed	   to	   further	   pathogenic	  
invasion	   presented	   in	   the	   form	   of	   acute	   exacerbations.	   Chronic	   inflammation	   of	   COPD	   is	  
underpinned	   by	   airway	   colonization	   and	   infection,	   and	   activation	   of	   both	   IL-­‐1	   and	   IFN	  
pathways.	   The	   model	   of	   chronic	   inflammation	   proposed	   in	   this	   thesis	   therefore	   aimed	   to	  
better	  understand	  the	  intrinsic	  changes	  to	  patient	  epithelium	  caused	  by	  prolonged	  infection	  in	  
healthy	  epithelial	  cells.	  The	  chronic	  model	  aimed	  to	  mimic	  this	  prolonged	  infection	  through	  the	  
exposure	   of	   epithelial	   cells	   to	   long-­‐term	   low-­‐grade	   bacterial	   stimulation	   in	   the	   presence	   of	  
monocytic	  cells	  (THP-­‐1	  cells	  and	  purified	  monocytes)	  to	  simulate	  inflammatory	  cell	  infiltration.	  	  
	  
Interactions	   between	   different	   cell	   types	   are	   paramount	   when	   mounting	   an	   effective	  
inflammatory	   response	   to	   varied	   stimuli.	   Evidence	   from	   in	   vitro	   studies	   supports	   the	   role	  of	  
cell-­‐cell	   communication	   in	   driving	   the	   inflammation	   observed	   in	   COPD,	   with	   co-­‐culturing	   of	  
inflammatory	  cells	  and	  structural	  cells	  (such	  as	  epithelial	  cells,	  endothelial	  cells	  and	  vascular	  or	  
airway	   smooth	   muscle	   cells)	   causing	   synergistic	   production	   of	   cytokines	   (Chaudhuri	   et	   al.,	  
2010;	  Morris	  et	  al.,	  2006;	  Morris	  et	  al.,	  2005;	  Ward	  et	  al.,	  2009).	  For	   instance,	  the	  combined	  
culturing	  of	  airway	  smooth	  muscle	  cells	  with	  low	  numbers	  of	  PBMCs	  resulted	  in	  a	  cooperative	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response	   to	   TLR	   stimuli,	   and	   synergistic	   production	   of	   cytokines	   CXCL8	   and	   IL-­‐6.	   This	  
stimulation	  was	  dependent	  on	   IL-­‐1	  production	   from	  monocytes	   that	  activated	   tissue	  cells	   to	  
produce	   proinflammatory	   cytokines	   in	   response	   to	   LPS	   (Morris	   et	   al.,	   2005).	   The	   collective	  
research	  into	  co-­‐cultures	  reinforce	  the	  importance	  of	  cell	  networks	  and	  cooperative	  signalling	  
between	  cells	  of	  the	  immune	  system	  and	  tissue	  cells	  in	  mounting	  a	  response	  to	  bacterial	  and	  
viral	   pathogens.	   The	   chronic	  model	   of	   inflammation	   described	   in	   this	   thesis	   uses	  monocytic	  
cells	  due	  to	  their	  predominant	  role	  in	  COPD.	  	  
	  
The	   chronic	   model	   of	   inflammation	   was	   set	   up	   with	   the	   use	   of	   BEAS-­‐2B	   cells,	   which	   are	  
themselves	   a	  model	   of	   primary	   epithelial	   cells.	   BEAS-­‐2B	   cells	   are	  well	   described	   and	   closely	  
resemble	  bronchial	  epithelial	  cells	  as	  demonstrated	  by	  electron	  microscopy,	  mucin	  production,	  
formation	  of	  tight	  junctions,	  and	  presence	  of	  keratin	  (Noah	  et	  al.,	  1995;	  Reddel	  et	  al.,	  1988).	  As	  
BEAS-­‐2Bs	   are	   derived	   from	   airway	   epithelium	   and	   retain	   these	   physiological	   features,	   the	  
results	   of	   altered	   signalling	   to	   the	   stimulus	   tested	   could	   potentially	   signpost	   to	   their	  
involvement	  in	  disease	  tissue.	  These	  cells	  also	  provide	  initial	  reproducibility,	  which	  is	  essential	  
in	  the	  early	  stages	  of	  establishing	  the	  model.	  	  
	  
The	   chronic	  model	   of	   inflammation	   also	   uses	   the	  monocytic	   cell	   line	   THP-­‐1	  due	   to	   its	  many	  
obvious	  advantages	  in	  terms	  of	  availability,	  immortality	  and	  standardisation	  of	  responses	  due	  
to	   lack	   of	   donor	   variability	   as	   compared	   to	   primary	   monocytes.	   The	   THP-­‐1	   state	   of	  
differentiation	   has	   also	   been	   previously	   optimised	   to	   best	   mimic	   monocytes	   (Colsky	   et	   al.,	  
1991;	   Daigneault	   et	   al.,	   2010;	   Murao	   et	   al.,	   1983;	   Tsuchiya	   et	   al.,	   1980).	   However,	   it	   was	  
observed	  that	  THP-­‐1	  cells	  are	  much	  less	  responsive	  to	  LPS	  in	  both	  mono-­‐	  and	  co-­‐cultures	  when	  
compared	  to	  primary	  monocytes.	  In	  an	  attempt	  to	  address	  this	  difference	  between	  monocytes	  
and	   THP-­‐1	   cells,	   the	   THP-­‐1	   cell	   numbers	   were	   normalised	   against	   the	   LPS-­‐induced	   CXCL8	  
output	  of	  10ng/ml	  per	  5,000	  monocytes	  as	  described	  in	  previously	  established	  acute	  models	  of	  
inflammation	   (Chaudhuri	   et	   al.,	   2010).	   It	   was	   therefore	   determined	   that	   100,000	   VitD3-­‐
differentiated	  THP-­‐1	  were	  required	  to	  reproduce	  this	  amount	  and	  to	  be	  used	  in	  the	  model	  and	  
for	  future	  work.	  
	  
Initial	  experiments	  aimed	  to	  determine	  the	  effect	  of	  repeated	  LPS	  stimulation	  on	  BEAS-­‐2B	  cells	  
in	   the	  presence	   and	   absence	  of	  monocytic	   cells	   in	   cell	   culture	   inserts	   showed	   that	  while	   an	  
increase	  in	  CXCL8	  in	  response	  to	  LPS	  was	  measured,	  this	  was	  not	  altered	  in	  challenged	  versus	  
unchallenged	   models.	   These	   data	   suggest	   that	   BEAS-­‐2B	   cells	   remained	   unaffected	   by	   the	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chronic	   low-­‐grade	   bacterial	   stimulation	   despite	   the	   inflammatory	  mediators	   released	   by	   the	  
THP-­‐1	   cells	   required	   for	   effective	   LPS	   response.	  While	  BEAS-­‐2B	   cells	   and	  bronchial	   epithelial	  
cells	  express	  TLR4	  constitutively,	  they	  lack	  CD14	  expression	  required	  for	  LPS	  recognition	  and	  in	  
turn	  do	  not	  release	  CXCL8	  when	  chronically	  stimulated	  with	  LPS	  (Frey	  et	  al.,	  1992;	  Landmann	  
et	  al.,	   1996).	   Instead,	  BEAS-­‐2B	  cells	   respond	   to	   LPS	   indirectly	   through	   the	  presence	  of	  other	  
inflammatory	  mediators	   such	  as	   IL-­‐1,	  as	   secreted	  by	  monocytes	  and	  THP-­‐1	  cells,	  and	   in	   turn	  
enhance	   their	   own	   inflammatory	   response	   resulting	   in	   a	   synergistic	   response	   to	   LPS	  
(Chaudhuri	  et	  al.,	  2010;	  Daigneault	  et	  al.,	  2010;	  Morris	  et	  al.,	  2006;	  Yang	  et	  al.,	  2001).	  	  
	  
A	  previously	  established	  acute	  model	  of	  inflammation	  highlighted	  IL-­‐1	  as	  a	  key	  communicator	  
leading	   to	   the	   synergistic	   CXCL8	   release	   by	   the	   co-­‐culture	   (Chaudhuri	   et	   al.,	   2010).	   To	  
determine	   the	   role	   of	   IL-­‐1	   cytokine	   release	   in	   the	   response	   of	   BEAS-­‐2B	   cells	   to	   LPS	   in	   the	  
chronic	   model,	   IL-­‐1	   receptor	   antagonist	   (IL-­‐1Ra)	   was	   used	   to	   prevent	   IL-­‐1	   signalling.	   A	  
significant	  inhibition	  of	  LPS-­‐induced	  CXCL8	  release	  was	  observed	  in	  the	  presence	  of	  IL-­‐1Ra.	  The	  
results	   show	   a	   role	   for	   IL-­‐1	   in	   eliciting	   CXCL8	   release	   during	   chronic	   inflammation.	   This	   is	  
particularly	   important	   as	   IL-­‐1	   has	   been	   described	   in	   COPD	   for	   its	   important	   roles	   in	  
leukocytosis	  and	  the	  release	  of	  other	  cytokines,	  including	  IL-­‐6,	  CXCL8	  and	  CCL5,	  from	  a	  variety	  
of	  cells.	  Patients	  with	  COPD	  show	  increased	  levels	  of	  IL-­‐1	  in	  both	  induced	  sputum	  and	  BAL	  as	  
well	   as	   increase	   in	   secretion	   from	   alveolar	  macrophages	   (Chung,	   2001).	   Of	   note,	   direct	   IL-­‐1	  
release	  from	  these	  chronically	  challenged	  BEAS-­‐2B	  cells	  could	  not	  be	  measured	  using	  standard	  
ELISA	  (data	  not	  shown)	  due	  to	  the	  low	  levels	  of	  the	  cytokine.	  Future	  work	  could	  include	  high-­‐
sensitivity	  ELISAs.	  Real-­‐time	  PCR	  could	  also	  be	  carried	  out	   to	  measure	  mRNA	  changes	  within	  
the	  epithelial	  cells,	  although	  IL-­‐1	  can	  be	  generated	  post	  translationally	  through	  inflammasome	  
activation	  (Martinon	  et	  al.,	  2002),	  therefore	  initial	  changes	  may	  not	  be	  detected.	  
	  
The	  lack	  of	  detectable	  IL-­‐1	  cytokine	  release	  by	  ELISA	  but	  significant	  reduction	  in	  CXCL8	  release	  
when	   co-­‐stimulated	   with	   IL-­‐1Ra	   may	   be	   explained	   by	   a	   more	   focussed	   release	   of	   high	  
concentrations	   of	   IL-­‐1	   directly	   on	   membrane	   receptors	   on	   BEAS-­‐2B,	   which	   would	   induce	   a	  
more	   pronounced	   effect.	   Lack	   of	   cell	   contact	   or	   proximity	   has	   been	   shown	   to	   lead	   to	   a	  
reduction	   in	   chemokine	   expression	   (Smith	   et	   al.,	   1997;	   Zujovic	   and	   Taupin,	   2003),	   which	   is	  
indeed	  supported	  by	  the	  direct	  cell-­‐to-­‐cell	  contact	  model.	  Data	  in	  this	  thesis	  showed	  that	  the	  
long-­‐term	  stimulation	  of	  BEAS-­‐2B	  cells	  with	  LPS	  in	  direct	  contact	  with	  THP-­‐1	  cells	  led	  to	  slightly	  
lower	  CXCL8	   release	  during	   the	   final	   24	  hour	   LPS	   stimulation	   in	   the	  presence	  of	  monocytes,	  
compared	   to	   the	   control	   group	   of	   BEAS-­‐2B	   and	   monocytes	   which	   did	   not	   have	   prior	   LPS	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stimulation.	  More	  importantly	  however,	  BEAS-­‐2B	  cells	  chronically	  stimulated	  with	  LPS	  show	  a	  
decrease	  in	  CXCL8	  release	  when	  monocytes	  and	  LPS	  are	  added	  on	  day	  8,	  whether	  or	  not	  THP-­‐1	  
cells	  were	  also	  present	  during	  the	  induction	  of	  chronic	  inflammation.	  Again,	  while	  these	  data	  
are	   not	   significant	   and	   require	   further	   exploration	   and	   reproduction,	   this	   lowering	  of	   CXCL8	  
release	  after	  induction	  of	  chronic	  inflammation	  by	  LPS	  may	  suggest	  tolerance	  of	  BEAS-­‐2B	  cells	  
to	   further	  pathogenic	  stimulation.	  The	  measure	  of	  other	  pro-­‐inflammatory	  cytokines	  such	  as	  
TNF-­‐α	  and	  IL-­‐6	  and	  anti-­‐inflammatory	  cytokine	  IL-­‐10	  would	  help	  provide	  a	  more	  complete	  and	  
informative	  picture.	  The	  DNA	  binding	  activity	  of	  NF-­‐κB	  in	  response	  to	  repeated	  LPS	  stimulaion	  
would	  also	  provide	  an	  alternative	  measure	  of	  the	  intensity	  of	  TLR4	  signalling.	  
	  
After	  induction	  of	  inflammation,	  BEAS-­‐2B	  cells	  were	  stimulated	  with	  monocytes	  and	  LPS.	  This	  
final	  stimulus	  of	  monocytes	  and	  LPS	  depends	  on	  IL-­‐1	  production	  by	  the	  monocytes	  to	  activate	  
epithelial	   cells,	   but	   could	   theoretically	   be	   tolerised	   by	   pretreatment	   of	   the	   BEAS-­‐2B	   cells	   by	  
LPS.	  LPS	  tolerance	  is	  a	  protective	  mechanism	  to	  prevent	  endotoxin	  shock,	  where	  cells	  exposed	  
to	   low	   levels	  of	  endotoxins	  are	  unaffected	  by	   further	  exposure.	   	  Therefore	   it	  was	  postulated	  
that	  the	  chronic	  LPS	  treatment	  could	  induce	  tolerance	  of	  IL-­‐1	  signalling.	  	  
	  
Tolerance	  in	  this	  context	  represents	  a	  complex	  diminished	  pro-­‐inflammatory	  response	  due	  to	  
exposure	   to	   low	   concentrations	   of	   endotoxins	   resulting	   in	   the	   reprogramming	   of	   innate	  
immune	  cells.	  This	  state	  of	  tolerance	  is	  not	  represented	  by	  ‘immunoparalysis’	  but	  instead	  the	  
activation	   of	   alternative	   pathways.	   The	   mechanisms	   of	   endotoxin	   tolerance	   are	   vague,	  
however	   roles	   for	   negative	   regulators	   such	   as	   suppressor	   of	   cytokine	   signalling	   1	   (SOCS1),	  
IRAK-­‐M	   and	   SHIP	   have	   been	   identified,	   in	   addition	   to	   the	   down	   regulation	   of	   TLR-­‐4	   on	   cell	  
surface	  and	  gene	  re-­‐programming.	  	  
	  
Induction	   of	   tolerance	   in	   cells	   has	   been	   shown	   to	   affect	   protein-­‐protein	   interactions	  
downstream	  of	  TLR-­‐receptors	  such	  as	  diminished	  IRAK-­‐1	  activity,	  MyD88-­‐TLR4	  association	  and	  
interaction	   of	   MyD88	   with	   IRAK-­‐1	   ultimately	   resulting	   in	   decreased	   pro-­‐inflammatory	  
cytokines	  (Medvedev	  et	  al.,	  2006).	  For	  example,	  repeated	  exposure	  to	  bioactive	  LPS	  present	  in	  
cigarette	  smoke	  impairs	  the	  function	  of	  alveolar	  macrophages	  (AM).	  This	  leads	  to	  a	  restriction	  
of	  LPS-­‐induced	  expression	  of	  TLR-­‐2	  and	  -­‐4	  induced	  pro-­‐inflammatory	  cytokine	  and	  chemokine	  
release	  including	  IL-­‐1β,	  IL-­‐6	  and	  TNFα.	  The	  activation	  of	  IRAK-­‐1,	  p38	  and	  NF-­‐κB	  was	  also	  found	  
to	   be	   impeded	   leading	   to	   a	   subdued	   expression	   of	   proinflammatory	  mediators	   (Chen	   et	   al.,	  
2007;	  Hasday	  et	  al.,	  1994).	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It	   is	   therefore	   possible	   that	   airways	   of	   COPD	   patients	   have	   a	   poorly	   explored	   underlying	  
epithelial	  microbial	   tolerance	   that	   limits	   the	   initial	  production	  of	  pro-­‐inflammatory	  cytokines	  
that	  results	  in	  hypersensitivity	  to	  secondary	  bacterial	  infections.	  	  
	  
	  
5.2	  CSE	  exposure	  results	  in	  an	  additive	  CXCL8	  release	  in	  response	  to	  
Poly(I:C)	  or	  RV-­‐16	  
	  
Cigarette	   smoking	   is	   a	   dangerous	   and	   addictive	   habit	   increasingly	   spreading	   throughout	   the	  
developing	  world.	  Smoking	  has	  profound	  consequences	  on	  human	  health	  and	  has	  been	  linked	  
to	  the	  progression	  of	  many	  diseases	  including	  respiratory	  conditions	  such	  as	  asthma	  and	  COPD	  
(Arnson	  et	  al.,	  2010).	  Human	  RVs	  are	  one	  of	  the	  predominant	  viral	  pathogens	  involved	  in	  the	  
onset	  of	   the	   common	  cold	  and	  are	  a	  major	   cause	  of	   asthma	  and	  COPD	  acute	  exacerbations	  
(Johnston,	  2005).	  Human	  rhinoviral	  infections	  have	  been	  linked	  to	  up	  to	  60%	  of	  exacerbations	  
of	   COPD	   (Del	   Vecchio	   et	   al.,	   2015).	   Although	   many	   studies	   have	   investigated	   airway	  
epithelial	   cell	   responses	   to	   RV	   infection	   and	   CSE	   contact,	   how	   repeated	   or	   chronic	  
exposure	   to	   CSE	   alters	   RV-­‐induced	   responses	   in	   airway	   epithelial	   cells	   remains	   to	   be	  
comprehensively	   explored.	   Therefore,	   this	   thesis	   sought	   to	   determine	   whether	   host	  
inflammatory	   responses	   to	   viral	   infections	   are	   affected	   following	   repeated	   exposure	   to	  
CSE.	  	  
	  
In	  accordance	  with	  previously	  published	  studies	  (Hudy	  and	  Proud,	  2013;	  Pace	  et	  al.,	  2008;	  
Wang	  et	  al.,	  2009),	  acute	  exposure	  to	  CSE	  alone	  resulted	  in	  a	  significant	  increase	  in	  CXCL8	  
production	  in	  airway	  epithelial	  cells.	  Surprisingly,	  the	  addition	  of	  the	  viral	  mimic	  poly(I:C)	  
in	   combination	   with	   CSE	   for	   24	   hours	   resulted	   in	   an	   inhibition	   of	   CXCL8	   production	   in	  
BEAS-­‐2B	  cells.	  In	  contrast,	  pre-­‐treatment	  with	  CSE	  for	  6	  days	  prior	  to	  poly(I:C)	  stimulation	  
resulted	  in	  a	  potentiation	  in	  CXCL8	  response.	  At	  first	  glance,	  these	  data	  appear	  to	  indicate	  
an	   effect	   of	   prolonged	   treatment	   of	   CSE	   on	   subsequent	   responses	   to	   viral	   infection,	  
supporting	   the	   hypothesis	   of	   altered	   cellular	   responses	   to	   invading	   pathogens	   by	   CSE.	  
However,	   following	   the	  modification	  of	   the	  protocol,	  wherein	  both	   the	  acute	  model	  and	  
chronic	  repeated	  model	  are	  maintained	  in	  the	  same	  environment	  for	  the	  duration	  of	  the	  
experiment,	   these	   differences	   in	   CXCL8	   production	   were	   lost.	   In	   fact,	   both	   acute	   pre-­‐
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treatment	  with	  CSE	  and	  repeated	  pre-­‐treatment	  with	  CSE	  followed	  by	  a	  single	  stimulation	  
with	  poly(I:C)	  resulted	  in	  a	  similarly	  exaggerated	  CXCL8	  production	  in	  both.	  These	  results	  
highlight	   the	   importance	   of	   the	   choice	   of	   experimental	   protocol	   and	   the	   detrimental	  
effects	   the	   inappropriate	   model	   can	   have	   in	   the	   interpretation	   of	   data.	   In	   vitro	  
experiments	   are	   inadvertently	   limited	   by	   the	   very	   nature	   of	   their	   simplicity,	   as	   it	   is	  
impossible	   to	   accurately	   replicate	   in	   vivo	   conditions	   in	   a	   cell-­‐culture	   plate.	   When	  
comparing	  the	  results	  obtained	  from	  the	  2	  day	  acute	  model	  with	  the	  8	  day	  acute	  model,	  it	  
is	  important	  to	  consider	  which	  model	  may	  be	  a	  better	  representative	  of	  airway	  epithelium.	  
While	  both	  models	  were	  treated	  using	  the	  same	  quantities	  of	  CSE	  and	  viral	  stimulus,	  the	  
biggest	  differentiating	  factor	  is	  the	  density	  of	  the	  BEAS-­‐2B	  cell	  monolayer.	  The	  8	  day	  acute	  
model	  allowed	   for	   the	  epithelial	  cell	   layer	   to	  grow	   into	  a	  compact	  and	  stable	  monolayer	  
more	  closely	  resembling	  airway	  epithelium	  than	  that	  of	  the	  2	  day	  acute	  model.	  	  
	  
With	  the	  use	  of	  the	  prolonged	  acute	  and	  repeated	  model,	  BEAS-­‐2B	  cells	  were	  also	  infected	  
with	   RV-­‐16	   and	   CSE.	   While	   CSE	   and	   RV-­‐16	   alone	   induced	   CXCL8	   production,	   the	  
combination	  of	  both	  resulted	  in	  an	  additive	  CXCL8	  response.	  Data	  published	  by	  Wang	  et	  al	  
did	   not	   demonstrate	   augmented	   CXCL8	   beyond	   that	   induced	   by	   RV	   alone	   in	   A549	   cells,	  
while	  Hudy	  et	  al	  showed	  enhanced	  CXCL8	  production	  to	  the	  combination	  of	  RV-­‐16	  and	  CSE	  
in	  primary	  bronchial	  epithelial	  cells	  (Hudy	  and	  Proud,	  2013;	  Wang	  et	  al.,	  2009).	  	  
	  
Under	  normal	  conditions,	  the	  infection	  of	  epithelial	  cells	  with	  RV	  induces	  a	  wide	  range	  of	  
cytokines,	   primarily	   CCL5	   and	   CXCL10	   at	   the	   highest	   concentrations	   (Proud,	   2008).	  
Therefore	   the	   CCL5	   induction	   by	   RV-­‐16	   was	   also	   assessed	   as	   an	   indirect	   measure	   of	  
effective	  early	  innate	  immune	  response.	  Indeed	  RV-­‐16	  infection	  of	  BEAS-­‐2B	  cells	  resulted	  
in	   increased	  CCL5	  production.	   The	   acute	   and	   repeated	  pre-­‐treatment	  with	  CSE	  however	  
attenuated	  the	  CCL5	  production	  to	  RV-­‐16.	  In	  fact,	  these	  results	  are	  in	  keeping	  with	  existing	  
studies	   wherein	   CSE	   decreases	   the	   activation	   of	   the	   IFN-­‐STAT-­‐1	   and	   SAP/JNK	   pathways	  
resulting	  in	  the	  suppression	  of	  CXCL10	  and	  CCL5	  production	  and	  lead	  to	  an	  increase	  in	  viral	  
RNA	  (Eddleston	  et	  al.,	  2011).	  CSE	  has	  also	  been	  shown	  to	  decrease	  the	  expression	  of	  IFN-­‐
stimulated	  gene	  15	  (ISG15)	  and	  IRF-­‐7	  transcripts	   in	  response	  to	  poly(I:C)	   in	  BEAS-­‐2B	  cells	  
and	  the	  translocation	  of	  NF-­‐κB	  and	  IRF3	  transcription	  factors	  (Bauer	  et	  al.,	  2008).	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5.3	  CSE	  differentially	  regulates	  epithelial	  cell	  response	  to	  LPS	  and	  IL-­‐1	  
	  
A	   chronic	   experimental	  model	   was	   created	   to	   understand	   the	   effects	   of	   repeated	   cigarette	  
smoking	   on	   epithelial	   cells’	   ability	   to	   respond	   to	   infections.	   In	   accordance	   with	   previous	  
published	   works,	   acute	   pre-­‐treatment	   with	   CSE	   increased	   the	   BEAS-­‐2B	   cell	   inflammatory	  
response,	  measured	   in	   the	   form	  of	  CXCL8	  production.	  However	  when	  pre-­‐treated	  cells	  were	  
stimulated	  with	  LPS,	  no	  additional	  CXCL8	  was	  measured.	  In	  fact	  these	  data	  are	  in	  contrast	  to	  
that	  of	  Pace	  et	  al,	  where	  they	  demonstrated	  that	  CSE	  exerts	  its	  effects	  through	  the	  increased	  
externalisation	  and	  expression	  of	  TLR4,	  and	  the	  ability	  to	  bind	  LPS	  with	  favoured	  ERK	  activation	  
instead	  of	  the	  NF-­‐κB	  signalling	  (Pace	  et	  al.,	  2008).	  Indeed	  CSE	  alone	  does	  not	  activate	  the	  ERK	  
pathway	   (Luppi	   et	   al.,	   2005)	   unless	   in	   combination	   with	   LPS	   wherein	   CSE	   differentially	  
regulates	  LPS-­‐induced	  signalling	   (Pace	  et	  al.,	  2008).	  Perhaps	  these	  results	  could	  be	  explained	  
by	   the	   different	   cell	   lines	   used.	   As	   previously	   discussed,	   BEAS-­‐2B	   cells	   express	   TLR4	  
constitutively	  but	  lack	  CD14	  expression	  required	  for	  LPS	  recognition	  and	  in	  turn	  do	  not	  release	  
CXCL8	  when	  chronically	  stimulated	  with	  LPS	  (Frey	  et	  al.,	  1992;	  Landmann	  et	  al.,	  1996)	  unless	  in	  
the	  presence	  of	  inflammatory	  mediators	  such	  as	  IL-­‐1.	  By	  stimulating	  CSE	  treated	  BEAS-­‐2B	  cells	  
with	  IL-­‐1,	  a	  potentiation	  in	  CXCL8	  production	  was	  measured.	  While	  this	  amplification	  of	  CXCL8	  
is	  MyD88	  dependent,	  additional	  experiments	  would	  need	  to	  be	  carried	  out	  to	  determine	  if	  this	  
effect	  is	  uniquely	  due	  to	  ERK.	  The	  measure	  of	  ERK	  by	  western	  blot	  analysis	  and	  ELISA	  would	  be	  
the	   first	   step	   experimentally	   to	   support	   the	   presence	   of	   ERK	   expression.	   This	   would	   be	  
followed	   by	   the	   inhibition	   of	   ERK	   using	   MEK1	   inhibitors	   to	   confirm	   effects	   measured	   are	  
uniquely	  due	   to	  ERK.	   Interestingly,	   in	  alveolar	  macrophages	  while	  CSE	  also	  modulates	  CXCL8	  
mRNA	  and	  protein	  expression	  (Sarir	  et	  al.,	  2009)	  CSE	  has	  been	  shown	  to	  amplify	  LPS-­‐induced	  
secretion	  of	  IL-­‐1βb	  and	  TNF-­‐α	  through	  NF-­‐κB	  activation	  (Xu	  et	  al.,	  2011).	  	  
	  
Repeated	  stimulation	  with	  CSE	  did	  not	  alter	  the	  CXCL8	  production	  of	  BEAS-­‐2B	  cells.	  Again,	  this	  
could	  be	  due	  to	  the	   insufficient	  pre-­‐treatment	  with	  CSE	  wherein	  the	  chronic	  model	   is	   in	   fact	  
not	   ‘chronic’	   enough,	   or	   simply	   the	   epithelial	   cells	   have	   a	   superior	   resistance	   to	   low	   grade	  
infection	  or	  stimulation	  than	  initially	  predicted.	  	  
	  
5.4	  Pellino-­‐1	  in	  NF-­‐κB	  signalling	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Pellino-­‐1	   is	   a	   ubiquitously	   expressed	   protein,	   however	   its	   relative	   levels	   of	   expression	   are	  
tissue	   specific.	   In	   the	   mouse,	   Pellino-­‐1	   is	   highly	   expressed	   in	   peripheral	   blood	   leukocytes,	  
moderately	  expressed	  in	  the	  placenta,	  lung,	  liver,	  kidney,	  spleen,	  thymus,	  skeletal	  muscle	  and	  
brain,	  and	  is	  expressed	  at	  low	  levels	  in	  the	  small	  intestine,	  colon	  and	  heart	  (Jiang	  et	  al.,	  2003).	  
The	  data	  in	  this	  thesis	  demonstrates	  Pellino-­‐1’s	  expression	  in	  primary	  human	  airway	  epithelial	  
cells	   in	  accordance	  with	  previous	  published	  data	   in	  the	  same	  cell	   type	  (Bennett	  et	  al.,	  2012).	  
Furthermore,	   Pellino-­‐1	   expression	   is	   upregulated	   in	   response	   to	   the	   TLR3	   agonist	   poly(I:C)	  
following	  24	  hours	  of	  stimulation	  in	  human	  airway	  epithelial	  cells.	  These	  data	  suggest	  Pellino-­‐1	  
is	   being	   upregulated	   in	   response	   to	   poly(I:C)	   activation	   of	   the	   TRIF-­‐dependent	   pathway	   it	  
regulates.	  These	  data	  also	  reflect	  findings	  from	  the	  Pellino-­‐1-­‐deficient	  mouse	  wherein	  Pellino-­‐1	  
has	  a	  functional	  role	  in	  TRIF-­‐dependent	  signalling	  (Chang	  et	  al.,	  2009).	  Data	  from	  murine	  bone	  
marrow	  derived	  macrophages	  stimulated	  with	  poly(I:C)	  also	  shows	  a	  striking	  enhancement	  of	  
Pellino-­‐1	   transcription	   and	   protein	   expression	   in	   a	   TRIF-­‐dependent	   induction	   (Smith	   et	   al.,	  
2011).	  
	  
The	  functionality	  of	  Pellino-­‐1	  in	  human	  airway	  epithelial	  cells	  was	  further	  investigated	  by	  the	  
transient	  knockdown	  of	  Pellino-­‐1	  by	  targeted	  siRNA	  transfection.	  The	  targeted	  knockdown	  of	  
Pellino-­‐1	   stimulated	  with	   poly(I:C)	   at	   4,	   8,	   16	   and	   24	   hours	   resulted	   in	   a	   decrease	   in	   CXCL8	  
mRNA	   expression	   and	   cytokine	   secretion	   in	   HBEpCs	   at	   the	   24	   hour	   time	   point.	   IFNβ	  mRNA	  
expression	   was	   also	   determined	   following	   transient	   Pellino-­‐1	   knockdown	   and	   poly(I:C)	  
stimulation,	   and	   resulted	   in	   no	  measurable	   effect	   on	   IFNβ	   production.	   These	   results	   reflect	  
previously	   published	   work	   wherein	   pro-­‐inflammatory	   cytokines	   CXCL8	   and	   IL-­‐6	   were	  
significantly	  inhibited	  in	  response	  to	  poly(I:C)	  in	  HBEpCs	  following	  Pellino-­‐1	  knockdown,	  whilst	  
the	   interferon-­‐stimulated	   gene	   CCL5	   remained	   unaffected	   (Bennett	   et	   al.,	   2012).	   Taken	  
together,	  these	  data	   indicate	  a	  role	  for	  Pellino-­‐1	   in	  selectively	  mediating	  the	  TRIF-­‐dependent	  
NF-­‐κB/MAPK	   pathway	   and	   not	   TLR3-­‐mediated	   IRF3	   and	   IFNβ	   activation.	   In	   support,	   the	  
Pellino-­‐1-­‐deficient	   mouse	   showed	   a	   decrease	   in	   circulating	   pro-­‐inflammatory	   cytokines	   in	  
serum	  1	  and	  4	  hours	  post	  systemic	  poly(I:C)	  challenge	  (Chang	  et	  al.,	  2009).	  In	  the	  mouse,	  the	  
group	  demonstrated	  that	  Pellino-­‐1	  both	   interacts	  with,	  and	  ubiquitinates	  RIP1	   leading	  to	   IKK	  
phosphorylation	   and	   the	   downstream	   activation	   of	   canonical	   NF-­‐κB	   in	   a	   TRIF-­‐dependent	  
manner.	  In	  addition,	  IKKε	  and	  IFNβ	  induction	  in	  embryonic	  fibroblasts	  from	  Pellino-­‐1-­‐deficient	  
mice	  remain	  intact	  (Chang	  et	  al.,	  2009).	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It	   is	   well	   documented	   that	   TLR3	   signalling	   pathway	   culminates	   in	   the	   activation	   of	   NF-­‐κB	  
among	  other	  transcription	  factors.	  Normally,	  NF-­‐κB	  resides	  within	  the	  cytoplasm	  in	  its	  inactive	  
form	  through	  the	  association	  with	  IκB	  inhibitors.	  Following	  TLR3	  activation,	  the	  canonical	  NF-­‐
κB	   proteins	   p65,	   RelB	   and	   c-­‐Rel	   are	   activated	   through	   the	   degradation	   of	   IκBs	   by	   the	   IKK	  
complex	  consisting	  of	  IKKα	  and	  IKKβ	  protein	  kinases	  and	  IKKγ	  regulatory	  molecule.	  This	  results	  
in	  the	  release	  and	  translocation	  of	  NF-­‐κB	   into	  the	  nucleus	   for	  gene	  transcription	  (Figure	  1.3)	  
(Han	   et	   al.,	   2004;	   Muzio	   et	   al.,	   2000).	   Therefore	   it	   is	   possible	   to	   establish	   the	   extent	   of	  
canonical	   NF-­‐κB	   activation	   by	   determining	   the	   level	   of	   both	   IKK	   phosphorylation	   and	   the	  
resulting	  IκBα	  phosphorylation	  and	  degradation.	  The	  transient	  knockdown	  of	  Pellino-­‐1	  in	  cells	  
stimulated	  with	  poly(I:C)	  for	  4	  and	  24	  hours	  resulted	  in	  the	  decrease	  in	  IKKα/β	  phosphorylation	  
at	   24	   hours	   post-­‐stimulation.	   Surprisingly,	   total	   IκBα	   degradation	   was	   not	   compromised	   in	  
Pellino-­‐1	  knockdown	  samples	  at	  4	  or	  24	  hours	  post-­‐stimulation,	  as	  would	  have	  been	  expected	  
following	  IKKα/β	  phosphorylation.	  It	  is	  possible	  that	  a	  lack	  of	  IκBα	  assay	  sensitivity	  is	  to	  blame	  
and	   the	   measure	   of	   NF-­‐κB	   phosphorylation	   status	   would	   be	   of	   great	   additional	   value	   to	  
determine	  if	  in	  fact	  poly(I:C)	  is	  acting	  via	  the	  canonical	  pathway.	  The	  measure	  of	  NF-­‐κB	  nuclear	  
translocation	   by	   microscopy	   could	   be	   an	   alternative	   experiment	   to	   further	   explore	   this.	  
Alternatively	  however,	  when	  taking	  this	  data	  in	  combination	  with	  that	  of	  Bennett	  et	  al.	  where	  
no	  evidence	  of	  IκBα	  degradation	  can	  be	  measured	  following	  poly(I:C)	  stimulation	  over	  15-­‐240	  
minutes	   in	   primary	   bronchial	   epithelial	   cells	   (Bennett	   et	   al.,	   2012),	   it	   is	   thus	   possible	   to	  
postulate	   that	   poly(I:C)	   itself	   does	   not	   utilize	   the	   canonical	   NF-­‐κB	   signaling	   pathway	   and	  
therefore	   the	   site	   at	   which	   Pellino-­‐1	   regulates	   NF-­‐κB	   signaling	   may	   also	   lay	   outside	   this	  
pathway.	  Since	  NF-­‐κB	  is	  essential	  for	  CXCL8	  induction	  and	  Pellino-­‐1	  regulates	  CXCL8	  expression	  
in	  response	  to	  poly(I:C),	  it	  is	  possible	  that	  Pellino-­‐1	  is	  operating	  through	  the	  non-­‐canonical	  NF-­‐
κB	  	  pathway	  (See	  Section	  1.6.1.2).	  	  
	  
COPD	  patients	  have	  increased	  baseline	  levels	  of	  IL-­‐1β	  within	  their	  airways,	  which	  are	  increased	  
further	  in	  instances	  of	  acute	  exacerbations	  (Chung,	  2001).	  There	  is	  also	  accumulating	  evidence	  
suggesting	  a	  role	  for	  IL-­‐1β	  in	  response	  to	  RV	  infections	  whereby	  IL-­‐1	  is	  released	  and	  acts	  as	  an	  
autocrine	   stimulus	   to	   further	   enhance	   inflammatory	   signalling	   (Grunstein	   et	   al.,	   2000;	  
Hakonarson	  et	  al.,	   1999;	  Piper	  et	  al.,	   2013;	   Stokes	  et	  al.,	   2011).	   In	  primary	  human	  epithelial	  
cells,	   both	   IL-­‐1α	   and	   IL-­‐1β	   are	   secreted	   following	   viral	   infection	   resulting	   in	   increased	   pro-­‐
inflammatory	   signalling	   and	   recruitment	   and	   activation	   of	   immune	   cells	   (Piper	   et	   al.,	   2013).	  
Through	   the	   knockdown	   of	   Pellino-­‐1,	   a	   significant	   reduction	   in	   IL-­‐1β	   gene	   expression	   to	  
poly(I:C)	  was	  measured	  at	  16	  and	  24	  hours,	  and	  a	  similar	  trend	  was	  noted	  in	  IL-­‐1α	  expression.	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In	  keeping	  with	  previous	  data,	   these	   findings	   support	   the	   role	   for	  Pellino-­‐1	   in	   IL-­‐1	   signalling,	  
providing	  further	  evidence	  of	  its	  involvement	  in	  NF-­‐κB	  regulation.	  	  
	  
5.5	  Pellino-­‐1	  in	  non-­‐canonical	  NF-­‐κB	  signalling 
	   
Originally,	   the	   non-­‐canonical	   NF-­‐κB	   pathway	   was	   mainly	   associated	   with	   the	   regulation	   of	  
specific	  adaptive	   immune	  functions	  such	  as	   lymphoid	  organogenesis,	  dendritic	  cell	  activation	  
and	  B-­‐cell	  survival	  and	  maturation	  (Dejardin,	  2006).	  Emerging	  evidence	  suggests	  that	  the	  non-­‐
canonical	   NF-­‐κB	   signalling	   pathway	   is	   also	   involved	   in	   the	   regulation	   of	   innate	   antiviral	  
immunity.	   A549	   cells	   showed	   inhibited	   RIG-­‐I-­‐mediated	   non-­‐canonical	   NF-­‐κB	   activation	   and	  
expression	  of	  the	  non-­‐canonical	  target	  CCL19	  following	  infection	  with	  influenza	  virus	  A	  (Ruckle	  
et	  al.,	  2012).	  More	  recently,	  non-­‐canonical	  NF-­‐κB	  signalling	  was	   found	  to	  negatively	   regulate	  
type	   I	   IFN	   induction	   in	   murine	   BMDM	   stimulated	   with	   Sendai	   virus	   and	   vascular	   stomatitis	  
virus	   (Jin	   et	   al.,	   2014).	   This	   increasing	   evidence	   for	   a	   non-­‐canonical	   NF-­‐κB	   role	   in	   antiviral	  
innate	   immunity	   coupled	   with	   lack	   of	   IκBα	   degradation	   in	   Pellino-­‐1	   KD	   following	   poly(I:C)	  
stimulation	   further	  support	  a	   role	   for	  Pellino-­‐1	   involvement	   in	   the	  non-­‐canonical	  arm	  of	   this	  
pathway.	  	  
	  
During	  non-­‐canonical	  NF-­‐κB	  signalling,	  the	  precursor	  proteins	  NFKB1	  (p105)	  and	  NFKB2	  (p100)	  
undergo	  proteolytic	  processing	  to	  release	  their	  active	  components,	  p50	  and	  p52	  respectively,	  
followed	   by	   dimerisation	   with	   RelB,	   c-­‐Rel	   or	   p65	   resulting	   in	   the	   nuclear	   translocation	   and	  
activation	  of	  gene	  transcription	  (Figure	  1.3)	  (Bonizzi	  and	  Karin,	  2004;	  Senftleben	  et	  al.,	  2001).	  
Preliminary	  data	   suggests	   that	  Pellino-­‐1	  plays	   a	   role	   in	   the	  processing	  of	  NFKB2	  as	  both	   the	  
measure	   of	   NFKB2	   protein	   and	   its	   p52	   active	   component	   in	   Pellino-­‐1	   knockdown	   HBEpCs	  
showed	   a	   reduced	   upregulation	   induced	   by	  NF-­‐κB	   in	   response	   to	   poly(I:C)	   at	   24	   hours	   post	  
stimulation.	  The	  data	   in	   this	   thesis	   specifically	  place	  Pellino-­‐1	   in	  NFKB2-­‐dependent	   signalling	  
arm	  rather	  than	  NFKB1	  as	  NFKB1	  protein	  levels	  remain	  unchanged	  in	  response	  to	  poly(I:C)	   in	  
Pellino-­‐1	   knockdown	   HBEpCs	   at	   both	   4	   and	   24	   hours	   while	   Pellino-­‐1	   knockdown	   prevents	  
upregulation	  of	  poly(I:C)	  induced	  NFKB2	  protein	  expression	  in	  HBEpCs.	  	  
	  
In	  an	  attempt	  to	  determine	  a	  role	  for	  Pellino-­‐1	  in	  NFKB2	  signalling	  and	  support	  the	  hypothesis	  
of	   NFKB2	   as	   a	   Pellino-­‐1	   target,	   NFKB2	   was	   transiently	   inhibited	   by	   siRNA	   transfection.	  
Interestingly,	  NFKB2	  knockdown	  resulted	  in	  an	  increase	  in	  both	  CXCL8	  expression	  and	  release	  
at	  24	  hours	  post	  stimulation,	  contrasting	  the	  Pellino-­‐1	  knockdown	  phenotype	  wherein	  CXCL8	  is	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suppressed	   in	   response	   to	   poly(I:C).	   Additionally,	   the	   transient	   knockdown	   of	   NFKB2	   also	  
increased	  CCL5	  secretion	  from	  HBEpCs	  at	  24	  hours	  post	  stimulation.	  This	  finding	  is	  perhaps	  not	  
surprising	  as	  NFKB2	  has	  recently	  been	  shown	  to	  negatively	  regulate	  type-­‐1	  IFN	  induction	  (Jin	  et	  
al.,	  2014).	  A	  preliminary	   interpretation	  of	  these	  data	  could	   indicate	  that	  the	  up-­‐regulation	  of	  
NFKB2	   could	   act	   as	   a	   compensatory	   negative	   feedback	   loop,	   potentially	   exerting	   its	   actions	  
through	  its	  ability	  to	  act	  as	  an	  IκB-­‐like	  molecule.	  The	  mechanism	  for	  this	  could	  be	  the	  result	  of	  
the	  formation	  of	  p52	  homodimers	  that	   function	  much	   like	   IκBs,	  however	   lack	  transactivation	  
domain	   (TADs)	   required	   to	   activate	   gene	   transcription	   (Zhong	   et	   al.,	   2002).	   NFKB2	   has	   also	  
been	   previously	   described	   as	   a	   negative	   regulator	   of	   NF-­‐κB	   through	   the	   supression	   of	  
preformed	  RelA:p50	  dimer	  activity	  following	  RSV-­‐infection	  or	  during	  prolonged	  TLR-­‐mediated	  
IKK	   signalling	   (Savinova	   et	   al.,	   2009).	   It	   is	   possible	   that	   following	   viral	   infection	   in	   airway	  
epithelial	   cells,	   TLR3	   activation	   culminates	   in	   the	   up-­‐regulation	   of	   Pellino-­‐1	   leading	   to	   an	  
increase	  in	  NFKB2	  expression,	  resulting	  in	  the	  suppression	  of	  NF-­‐κB	  specific	  gene	  transcription	  
(demonstrated	  in	  Figure	  5.1).	  Whilst	  regulation	  of	  TLR4	  signalling	  by	  induction	  of	  tolerance	  is	  
well-­‐described,	  this	  is	  the	  first	  clear	  negative	  regulatory	  pathway	  that	  may	  limit	  ongoing	  TLR3	  
signalling	  in	  a	  pathway-­‐specific	  manner,	  and	  suggests	  that	  future	  exploration	  of	  non-­‐canonical	  
NF-­‐κB	   signalling	   in	   airways	   epithelial	   cells	   will	   be	   important	   in	   understanding	   how	   chronic	  
inflammation	  may	  be	  regulated	  in	  these	  cells.	  
	  
The	   identification	   of	   a	   poxviral	   homolog	   of	   the	   Pellino	   family	   with	   immunoevasive	  
characteristics	   through	   the	   inhibition	  of	  TLR	   signalling	  highlights	  an	   interesting	   insight	   for	   its	  
role	   in	   disease	   (Griffin	   et	   al.,	   2011).	   	   Viral	   pellino	   showed	   functional	   consequences	   for	   pro-­‐
inflammatory	  gene	  expression	  wherein	   transduction	  of	  THP-­‐1	  cells	  with	   lentivirus	  expressing	  
Pellino	  caused	  the	   inhibition	  of	  CXCL8	  production	   in	   response	   to	  LPS.	   It	   is	  possible	   therefore	  
that	  viral	  homologues	  can	  deplete	  pellino	  functionality	  in	  a	  disease	  state	  like	  that	  of	  COPD.	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Figure	   5.1	   Possible	   mechanism	   for	   the	   negative	   regulation	   of	   NF-­‐κB	   by	   Pellino-­‐1	   through	  
NFKB2	  
This	   figure	   highlights	   a	   possible	   mechanism	   for	   the	   negative	   regulation	   of	   p100/NFKB2	   by	  
Pellino-­‐1	   in	   HBEpCs.	   Upon	   TLR3	   activation,	   Pellino-­‐1	   is	   up-­‐regulated	   by	   a	   currently	  
uncharacterised	   mediator	   leading	   to	   an	   increase	   in	   NFKB2	   expression	   which	   in	   turn	   has	   a	  
negative	   regulator	   role,	   possibly	   through	   suppression	   of	   RelA:p50	   dimer	   activity	   resulting	   in	  
the	  suppression	  of	  NF-­‐κB	  specific	  gene	  transcription	  
	  
5.6	  Pellino-­‐1	  and	  RIP1	  	  
	  
With	  the	  generation	  of	  the	  Pellino-­‐1	  knockout	  mouse	  came	  the	  discovery	  of	  its	  involvement	  in	  
the	   binding	   and	   ubiquitination	   of	   RIP1,	   from	   which	   RIP1	   was	   suggested	   to	   be	   a	   potential	  
Pellino-­‐1	  intermediary	  in	  TLR3	  signalling	  (Chang	  et	  al.,	  2009).	  RIP1	  has	  been	  implicated	  in	  TLR3-­‐
mediated	  NF-­‐κB	  response	  to	  dsRNA	  (Meylan	  et	  al.,	  2004)	  and	  shown	  to	  directly	  bind	  TRIF	  via	  
the	   RIP	   homotypic	   interaction	   motif	   (RHIM)	   where	   it	   then	   undergoes	   phosphorylation	   and	  
polyubiquitination,	  resulting	  in	  IKK	  activation	  (Cusson-­‐Hermance	  et	  al.,	  2005).	  The	  E3	  ubiquitin	  
ligase	  responsible	   for	   the	  ubiquitination	  of	  RIP1	   in	  the	  TRIF-­‐dependent	  TLR	  pathway	  remains	  
elusive.	  While	  a	  role	  for	  Pellino-­‐1	  in	  regulating	  IKK	  activation	  through	  the	  interaction	  and	  Lys-­‐
63	  polyubiquitination	  of	  RIP1	  in	  the	  TRIF-­‐dependent	  pathway	  has	  been	  identified	  (Chang	  et	  al.,	  
2009),	   contrasting	  data	  generated	   from	   the	  Pellino-­‐1	  knock-­‐in	  mouse,	   expressing	  a	  deficient	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polyubiquitination	   of	   RIP1,	   the	   downstream	  activation	   of	   canonical	   IKKs	   or	   the	   activation	   of	  
MAP	  kinases	  in	  BMDM,	  altogether	  eliminating	  Pellino-­‐1	  involvement	  (Enesa	  et	  al.,	  2012).	  The	  
differences	  are	  likely	  attributed	  to	  the	  model	  used	  for	  each	  study.	  Knock-­‐out	  mice	  are	  created	  
by	  the	  insertion	  of	  a	  selection	  marker	  or	  reporter	  into	  a	  target	  gene	  locus	  to	  either	  completely	  
remove	  one	  or	  more	  exons	   from	  a	  gene	   resulting	   in	  a	  mutated	  or	   truncated	  protein,	  or	   the	  
deletion	  of	  the	  protein	  altogether	  (Aida	  et	  al.,	  2014).	  While	  a	  knock-­‐in	  mouse	  is	  created	  by	  the	  
insertion	  of	  a	  transgene	  at	  a	  specific	  pre-­‐selected	  locus	  resulting	  in	  the	  exogenous	  expression	  
of	  the	  protein	  of	  choice	  (Aida	  et	  al.,	  2014).	  It	  is	  therefore	  possible	  that	  despite	  the	  lack	  of	  ligase	  
activity	  in	  the	  Pellino-­‐1	  knock-­‐in	  mouse,	  it	  may	  in	  fact	  still	  maintain	  a	  scaffolding	  role,	  bringing	  
in	  other	  signalling	  molecules	  that	  would	  otherwise	  not	  be	  recruited	  in	  the	  knock-­‐out	  mouse.	  It	  
is	  also	  plausible	  that	  these	  two	  different	  models	  result	  in	  different	  expression	  of	  compensatory	  
pathways,	   such	   as	   other	   Pellinos.	   However,	   it	   is	   critical	   to	   note	   that	   the	   differences	   in	   the	  
execution	  of	  both	  these	  models	  may	  have	  measurable	  effects	  on	  their	   results.	  Chang	  et	  al.’s	  
knockout	   mice	   were	   generated	   using	   conventional	   gene	   targeting	   strategy	   in	   which	   lacZ-­‐
neomycin	  cassette	  replaces	  the	  coding	  exons	  1	  and	  2.	  DNA	  from	  both	  WT	  mice	  and	  knockout	  
mice	  were	  genotyped	   to	  acertain	  effective	  knockout	  of	  Pelino-­‐1.	  Additionally	   knockout	  mice	  
showed	  no	  signs	  of	  birth	  or	  growth	  abnormalities	  compared	  to	  WT.	  
	  
However	   for	   the	   creation	  of	   knock-­‐in	  mice,	  Enesa	  et	  al.	  demonstrated	   low	  sequence	  affinity	  
following	   homology	   modelling	   between	   Pellino-­‐1	   RING	   domain	   and	   known	   RING	   figure	  
structures	  (Enesa	  et	  al.,	  2012).	  They	  generated	  their	  knock-­‐in	  mouse	  using	  partial	  matches	  to	  
Pellino-­‐1	   RING	   domain	   in	   the	   zinc-­‐coordinating	   residues	   of	   the	   E3	   ubiquitin	   ligase	   c-­‐Cbl.	  
Further	  structural	  studies	  resulted	  in	  the	  identification	  of	  contact	  points	  between	  c-­‐Cbl	  and	  E2-­‐
conjugating	   enzyme	   UbcH7	   leading	   to	   the	   putative	   identification	   of	   equivalent	   residues	   in	  
Pellino-­‐1.	   Furthermore	   the	   success	   of	   the	   knock-­‐in	   was	   determined	   by	   an	   artificial	   in	   vitro	  
assay	  wherein	  bacterial	  Pellino-­‐1’s	  E3	  ligase	  activity	  was	  abolished	  in	  a	  Ub	  assay.	  	  The	  greatest	  
flaw	   in	   the	   model	   is	   the	   lack	   of	   evidence	   of	   the	   loss	   of	   Pellino-­‐1	   E3	   ligase	   activity	   in	   vivo.	  
Additionally,	  the	  knock-­‐in	  mice	  demonstrated	  slightly	   lower	  than	  expected	  frequency	  in	  birth	  
rates.	  Most	  notably	  however,	  the	  expression	  of	  Pellino-­‐1	  protein	  in	  the	  knock-­‐in	  is	  lower	  than	  
WT	   protein	   in	   all	   studied	   tissues.	   	   Similarly,	   protein	   levels	   measured	   from	   BMDM	   were	  
consistently	  lower	  in	  knock-­‐in	  samples	  either	  before	  or	  after	  LPS	  and	  poly(I:C)	  stimulation.	  	  
	  
In	   order	   to	   determine	   whether	   RIP1	   is	   indeed	   a	   Pellino-­‐1	   target	   in	   primary	   cells,	   poly(I:C)	  
regulation	  of	  RIP1	  was	  first	  determined,	  and	  while	  RIP1	  is	  constitutively	  expressed	  in	  HBEpCs,	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the	   stimulation	   of	   these	   with	   poly(I:C)	   does	   not	   regulate	   RIP1	   protein	   expression.	  	  
Furthermore,	   the	   transient	   knockdown	   of	   RIP1	   by	   siRNA	   transfection	   resulted	   in	   both	   a	  
significant	   increase	   in	  CXCL8	  gene	  expression	   release	   in	   response	   to	  poly(I:C).	   These	   findings	  
do	   not	   reflect	   those	   of	   Pellino-­‐1	   knockdown	   wherein	   CXCL8	   was	   significantly	   reduced	   in	  
response	   to	   poly(I:C)	   which	   would	   indicate	   that	   whilst	   RIP1	   is	   involved	   in	   the	   regulation	   of	  
poly(I:C)-­‐activated	  TLR3	  pathway,	  it	  does	  not	  appear	  to	  be	  regulated	  by	  Pellino-­‐1.	  These	  data	  
are	  in	  keeping	  with	  previous	  work	  by	  Bennett	  et	  al.	  where	  the	  group	  challenged	  Pellino-­‐1	  as	  a	  
RIP1	   target	   through	   the	   transient	   knockdown	   of	   RIP1,	   similarly	   showing	   a	   potentiation	   of	  
CXCL8	  to	  poly(I:C)	  (Bennett	  et	  al.,	  2012).	  The	  study	  of	  Bennett	  et	  al	  showed	  a	  greater	  increase	  
in	   CXCL8	   release	   after	   RIP1	   knockdown	   in	   comparison	   to	   data	   presented	   in	   this	  
thesis.	  	  However,	  Bennett	  et	  al	  were	  only	  able	  to	  look	  at	  consequences	  of	  RIP1	  knockdown	  in	  a	  
single	   primary	   cell	   donor.	   The	   data	   presented	   in	   this	   thesis	   was	   obtained	   from	   up	   to	   5	  
individual	  donor	  cells	  and	  provide	  a	  more	  robust	  analysis	  to	  establish	  true	  phenotype.	  	  
	  
The	   contrasting	   effect	   on	   CXCL8	   release	   of	   RIP1	   knockdown	   and	   Pellino-­‐1	   knockdown	   on	  
poly(I:C)-­‐induced	  CXCL8	  release	  suggests	  a	  negative	  regulatory	  role	  for	  RIP1	  in	  TLR3	  signalling.	  
These	   data	   contrast	   published	   work	   highlighting	   RIP1	   as	   an	   essential	   mediator	   in	   TRIF-­‐
dependent	  NF-­‐κB	  signalling	  (Meylan	  et	  al.,	  2004).	  Nonetheless,	  there	   is	  culminating	  evidence	  
corroborating	   a	   negative	   regulatory	   role	   for	   RIP1.	   In	   support,	   RIP1	   has	   been	   shown	   to	  
negatively	  regulate	  TNFα-­‐activated	  non-­‐canonical	  NF-­‐κB	  signalling	  through	  TRAF2	  degradation,	  
NIK	  stabilization,	  IKKα	  phosphorylation	  and	  the	  processing	  of	  p100	  to	  generate	  p52	  (Kim	  et	  al.,	  
2011b).	  In	  RIG-­‐I	  signalling,	  RIP1	  also	  acts	  as	  a	  negative	  regulator	  of	  IRF3	  signalling	  through	  its	  
cleavage	  by	  caspase-­‐8	  (Rajput	  et	  al.,	  2011).	  	  
	  
Initially	   it	   was	   speculated	   that	   Pellino-­‐1’s	   mechanism	   of	   action	   might	   involve	   the	   negative	  
regulation	   of	   inhibitory	   functions	   of	   RIP1.	   Pellino-­‐1	   could	   exert	   its	   negative	   regulatory	   role	  
through	  the	  mediation	  of	  Lys-­‐48	  induced	  degradation	  of	  RIP1.	  This	  proposed	  hypothesis	  would	  
explain	   the	   spike	   in	   pro-­‐inflammatory	   cytokine	   CXCL8	   following	   RIP1	   knockdown	  due	   to	   the	  
removal	  of	   the	  NF-­‐κB	   inhibitory	   function	  of	  RIP1,	  whilst	  Pellino-­‐1	  knockdown	  would	  result	   in	  
the	  opposite	  effect	  due	  to	  removal	  of	  the	  regulator	  of	  the	  inhibitory	  RIP1.	  However,	  while	  this	  
theory	  explains	  the	  presence	  of	  constitutively	  expressed	  RIP1	  seen	  in	  unstimulated	  HBEpCs,	  it	  
does	  not	  explain	  the	   lack	  of	  RIP1	   inhibition	  following	  poly(I:C)	  stimulation,	  as	   it	  would	  follow	  
that	   Pellino-­‐1	   would	   induce	   Lys-­‐48	   linked	   degradation	   of	   RIP1.	   Furthermore,	   proteomic	  
analysis	  used	  to	  identify	  proteins	  with	  an	  affinity	  for	  Pellino-­‐1	  yielded	  no	  matches	  with	  RIP1	  at	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4	  or	  24	  hours	  post-­‐stimulation	  with	  poly(I:C)	   indicating	   further	  exploration	   into	  the	  action	  of	  
RIP1	  is	  required	  to	  determine	  the	  hypothesis.	  
	  
In	  addition	  to	   the	  regulation	  of	  canonical	  NF-­‐κB	  signalling,	  RIP1	  was	  originally	  described	  as	  a	  
regulator	  of	  apoptotic	  cell	  death	  in	  RIP1	  knockout	  mice	  (Kelliher	  et	  al.,	  1998).	  Viral	   infections	  
frequently	   result	   in	   apoptosis	   as	  part	  of	   the	  host	   cell’s	   viral	   defence.	   The	  activation	  of	   TRIF-­‐
dependent	  apoptosis	  is	  mediated	  at	  least	  in	  part	  by	  RIP1,	  FADD	  and	  caspase	  8	  (Numata	  et	  al.,	  
2011)	   (Estornes	   et	   al.,	   2012;	   McAllister	   et	   al.,	   2013).	   Both	   TLR3	   and	   RIP1	   are	   linked	   with	  
regulating	  virally-­‐induced	  apoptosis,	   it	  was	  therefore	  hypothesized	  that	  Pellino-­‐1	  may	  have	  a	  
role	  in	  apoptosis	  through	  the	  TLR3/Pellino-­‐1/RIP1	  interaction.	  
	  
Preliminary	  data	  measuring	  caspase-­‐8	  activity	  in	  Pellino-­‐1	  knockdown	  HBEpCs	  stimulated	  with	  
poly(I:C)	  showed	  increased	  caspase-­‐8	   levels	   in	  Pellino-­‐1	  knockdown	  samples	  when	  compared	  
to	  control.	  These	  data	  raise	  the	  possibility	  of	  a	  link	  between	  Pellino-­‐1	  and	  antiviral	  defence	  in	  
the	  form	  of	  cell	  death.	  Previously	  published	  work	  shows	  that	  the	  ubiquitination	  of	  RIP1	  by	  the	  
E3-­‐ubiquitin	   ligase	   called	   cellular	   inhibitor	   of	   apoptosis	   protein	   (cIAP)	   prevents	   it	   from	  
activating	   caspase-­‐8-­‐dependent	   extrinsic	   apoptotic	   pathway	   to	   TNF-­‐induced	   cell	   death	  
(Vanlangenakker	   et	   al.,	   2011).	  It	   is	   therefore	   possible	   that	   Pellino-­‐1	  may	   similarly	   serve	   as	   a	  
negative	  regulator	  of	  apoptosis	  via	  the	  polyubiquitination	  of	  RIP1	  in	  response	  to	  viral	  stimuli.	  
Further	   work	   into	   the	   action	   of	   Pellino-­‐1	   in	   virally	   induced	   apoptotic	   cell	   death	   would	   be	  
required	   to	   investigate	   the	  proposed	  mechanism,	   including	  characterization	  of	   the	  apoptotic	  
pathways	   involved	   in	  virally-­‐induced	  cell	  death.	  RV	  and	  poly(I:C)-­‐induced	  cell	  death	  could	  be	  
quantified	  by	   the	  use	  of	  Cell	   Titer-­‐glo	   luminescence	  assay.	   In	  addition,	   cell	   viability	   could	  be	  
determined	   by	   cell	   membrane	   integrity,	   and	   apoptosis	   by	   DNA	   fragmentation	   and	   TUNEL	  
staining.	  Survival	  can	  then	  be	  correlated	  with	  the	  activation	  of	  caspase-­‐3	  and	  caspase-­‐8.	  
Following	   the	   identification	   of	   occurring	   death	   pathways,	   key	   experiments	   can	   be	   repeated	  
with	  Pellino-­‐1	  knockdown	  to	  determine	  its	  involvement	  in	  the	  cell	  death	  and	  the	  consequences	  
on	  viral	  replication	  rates	  as	  measured	  by	  qPCR.	  
	  
5.7	  Pellino-­‐1	  in	  IFN	  signalling	  
	  
Data	   presented	   in	   this	   thesis	   indicates	   that	   Pellino-­‐1	   selectively	   regulates	   NF-­‐κB	   signalling	  
instead	   of	   IFN	   signalling.	   IFNβ	   mRNA	   expression	   was	   unaffected	   by	   poly(I:C)	   stimulation	  
following	   transient	  Pellino-­‐1	  knockdown.	  These	   results	   are	   supported	  by	   the	  unaltered	  CCL5	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secretion,	  an	  interferon-­‐stimulated	  gene,	  in	  primary	  epithelial	  cells	  from	  healthy	  controls	  and	  
patients	   with	   asthma	   in	   response	   to	   dsRNA	   (Bennett	   et	   al.,	   2012).	   Interestingly,	   IRF3	  
knockdown	   in	   HBEpCs	   result	   in	   a	   small	   reduction	   in	   Pellino-­‐1	   expression	   following	   poly(I:C)	  
stimulation.	  While	   these	  observations	  do	  not	   indicate	   IFN	   signalling	   is	   essential	   for	   Pellino-­‐1	  
expression,	   they	   do	   support	   a	   potential	   involvement,	   wherein	   IRF3	   activation	  may	   partially	  
regulate	   Pellino-­‐1	   activation.	   Indeed,	   the	   TBK1/IKKε	   complex	   have	   been	   identified	   as	  
mediators	  of	  Pellino-­‐1’s	  E3	  ligase	  activity	  in	  addition	  to	  the	  induction	  of	  the	  transcription	  of	  its	  
gene	  in	  a	  TLR3	  dependent	  manner	  (Smith	  et	  al.,	  2011).	  However,	  in	  contrast	  to	  data	  presented	  
in	  this	  thesis,	  IRF3	  knockout	  murine	  BMDMs	  resulted	  in	  the	  complete	  abolishment	  of	  Pellino-­‐1	  
upregulation	  by	  poly(I:C)	   (Smith	  et	  al.,	  2011).	  Again,	   these	  observations	  highlight	  differences	  
between	  mouse	  and	  humans	  in	  the	  regulation	  of	  Pellino-­‐1	  and	  its	  potential	  functional	  roles.	  
	  
Further	  contradicting	  findings	  came	  with	  the	  creation	  of	  the	  Pellino-­‐1	  knock-­‐in	  mouse	  with	  a	  
point	  mutation	  inhibiting	  its	  E3	  ubiquitin	  ligase	  activity	  (Enesa	  et	  al.,	  2012).	  Myeloid	  cells	  and	  
embryonic	   fibroblasts	   from	   these	   knock-­‐in	  mice	   showed	   a	   reduction	   in	   IFNβ	   expression	   and	  
secretion	  in	  response	  to	  poly(I:C).	  This	  reduction	  is	  due	  to	  the	  impaired	  interaction	  of	  IRF3	  with	  
the	  IFNβ	  promoter;	  to	  a	  lesser	  extent	  Pellino-­‐1	  also	  regulates	  the	  IFNβ	  positive	  feedback	  loop	  
wherein	  small	  amounts	  of	  IFNβ	  expressed	  following	  activation	  further	  amplify	  IFNβ	  production	  
through	  the	  JAK-­‐STAT	  pathway	  (Enesa	  et	  al.,	  2012).	  Recently	  findings	  also	  identified	  deformed	  
epidermal	   autoregulatory	   factor	   1	   homologue	   (DEAF1)	   as	   a	   Pellino-­‐1-­‐interacting	   protein	  
required	  for	  IFNβ	  transcription	  (Ordureau	  et	  al.,	  2013).	  	  
	  
The	  varied	  functional	  data	  for	  Pellino-­‐1	  in	  TRIF-­‐dependent	  signalling	  places	  Pellino-­‐1	  in	  distinct	  
arms	  of	   the	  pathway.	  While	  the	  use	  of	  Pellino-­‐1	  knockout	  mice	   indicate	  an	  essential	   role	   for	  
RIP1	   ubiquitination	   and	   resultant	   NF-­‐κB	   activation	   (Chang	   et	   al.,	   2009),	   the	   inhibition	   of	  
Pellino-­‐1’s	  E3	  ubiqutin	  ligase	  activity	  in	  knock-­‐in	  mice	  indicate	  a	  role	  in	  the	  recruitment	  of	  IRF3	  
to	  the	  IFNβ	  promoter	  (Enesa	  et	  al.,	  2012).	  It	  may	  be	  that	  variations	  reported	  on	  Pellino’1	  role	  
in	  IFNβ	  signalling	  is	  due	  to	  functional	  compensation	  by	  other	  members	  of	  the	  Pellino	  family	  in	  
Pellino-­‐1	  knockout	  mice	  (Moynagh,	  2014).	  However,	  as	  discussed	  in	  section	  5.6	  it	  is	  very	  likely	  
that	  the	  creation	  of	  the	  knock-­‐in	  model	  itself	  has	  had	  implications	  on	  the	  functionality	  of	  the	  
protein.	  Further	  evidence	   is	  required	  to	  support	  the	  depletion	  of	  the	  E3	   ligase	  activity	   in	  the	  
knock-­‐in	  model.	  Data	  in	  this	  thesis,	  supports	  the	  placement	  of	  Pellino-­‐1	  in	  the	  TRIF	  dependent	  
arm	  NF-­‐κB	  signalling.	  These	  data	  also	  potentially	  show	  substantial	  differences	  between	  human	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and	  mouse	  models,	  and	  reinforces	  the	  need	  to	  study	  primary	  cells	  from	  specific	  human	  organs	  
such	  as	  the	  lungs	  in	  order	  to	  understand	  roles	  in	  specific	  diseases	  in	  humans.	  
	  
5.8	  Pellino-­‐1	  potential	  binding	  partners:	  A20,	  TNIP1	  and	  TAX1BP1	  
Data	   presented	   in	   this	   thesis	   highlights	   substantial	   differences	   between	   human	   and	  mouse	  
models.	  Additionally,	  the	  role	  of	  Pellino-­‐1	  in	  regulating	  TLR3	  signalling	  through	  the	  interaction	  
with	  RIP1	  remains	  controversial.	  Proteomics	  analysis	  was	  therefore	  explored	  with	  the	  aim	  of	  
Identifying	  binding	  partners	  that	  would	  help	  clarify	  signalling.	  
Proteomic	  analysis	  identified	  multiple	  proteins	  that	  may	  have	  an	  affinity	  to	  Pellino-­‐1.	  A	  total	  of	  
334	   proteins	   were	   identified	   across	   both	   4	   hours	   and	   24	   hours	   stimulation	   with	   poly(I:C)	  
providing	  an	  extensive	  list	  of	  viable	  candidates	  for	  Pellino-­‐1	  binding.	  It	  is	  however	  important	  to	  
note	  that	  many	  of	  these	  proteins	  identified	  by	  mass-­‐spectrometry	  show	  equally	  high	  affinity	  to	  
our	  protein	  of	   interest	  Pellino-­‐1	  as	   the	   control	  mouse	   IgG2A	   suggesting	  non-­‐specific	  binding.	  
These	  data	  must	  therefore	  be	   interpreted	  with	  caution	  and	  serve	  only	  as	  a	  guide	  to	  possible	  
Pellino-­‐1	   targets	   requiring	   further	   confirmation	   with	   techniques	   such	   as	   protein	   complex-­‐
immunoprecipitation	  (Co-­‐IP),	  ligand	  binding	  assays,	  transient	  knockdowns	  or	  over-­‐expression.	  	  
Of	  the	  identified	  proteins,	  A20	  [also	  known	  as	  tumour	  necrosis	  factor,	  alpha-­‐induced	  protein	  3	  
(TNFAIP3)],	   TNFAIP3	   interacting	   protein	   (TNIP1)	   (also	   known	   as	   ABIN1)	   and	   Tax1-­‐binding	  
protein	  1	  (TAX1BP1)	  were	  of	  particular	  interest	  due	  to	  their	  involvement	  with	  NF-­‐κB	  signalling.	  
A20	  is	  a	  potent	  negative	  regulator	  of	  NF-­‐κB	  signalling	  wherein	  its	  knockdown	  results	  in	  chronic	  
multi-­‐organ	   inflammation	  and	  cell	  death	   in	  mice	   (Lee	  et	  al.,	  2012).	  A20	  displays	  a	  protective	  
role	  against	  both	  bacterial	  and	  viral	  infections	  (Reviewed	  in	  (Kelly	  et	  al.,	  2011)).	  A20	  has	  been	  
shown	   to	   attenuate	   NF-­‐κB	   activation	   in	   bronchial	   airway	   epithelial	   cells	   following	   infection	  
with	  H3N2	  and	  H1N1	   influenza	  virus	   (Onose	  et	  al.,	  2006).	  A20	  contains	  two	  ubiquitin-­‐editing	  
domains	   giving	   it	   both	   a	   deubiquitinating	   (DUB)	   and	   an	   E3	   ubiquitin	   ligase	   activity.	   A20	  
downregulates	  NF-­‐κB	  activity	   in	   the	  TNFR	  pathway	   through	   the	   cleavage	  of	   lysine	  63	   (K63)–
linked	   polyubiquitin	   chains	   on	   RIP1	   followed	   by	   the	   conjugation	   of	   lysine	   48	   (K48)–linked	  
polyubiquitin	  chains	  that	  target	  RIP1	  for	  degradation	  by	  the	  proteasome	  (Wertz	  et	  al.,	  2004).	  
A20	  also	  exerts	  its	  negative	  regulatory	  effects	  on	  TLR	  dependent	  NF-­‐κB	  signalling	  through	  the	  
deubiquitination	  of	  TRAF6	  (Boone	  et	  al.,	  2004).	  Furthermore,	  A20	  also	  uses	  multiple	  adaptors	  
to	  deubiquitinate	  specific	  signalling	  molecules.	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One	   of	   these	  many	   adaptors	   and	   interacting	   partners	   is	   TNIP1.	  While	   both	   A20	   and	   TNIP1	  
overexpression	  inhibits	  TNF,	  LPS	  and	  IL-­‐1	  induced	  NF-­‐κB	  activation	  in	  HEK293	  cells	  (Heyninck	  et	  
al.,	   1999),	   the	   inhibitory	   effect	   of	   TNIP1	   overexpression	   can	   be	   impaired	   by	   the	   RNA	  
interference	  of	  A20	  suggesting	  that	  TNIP1	  regulates	  NF-­‐κB	  activation	  through	  A20.	  Specifically,	  
TNIP1	  has	  been	  found	  to	  physically	  link	  A20	  to	  ubiquitinated	  IKKγ	  rendering	  it	  inactive	  through	  
A20-­‐mediated	  deubiquitination	  of	   IKKγ	   and	   leading	   to	  NF-­‐κB	   inhibition	   (Mauro	  et	   al.,	   2006).	  
Tandem	  affinity	  purification	  also	  revealed	  NFKB1	  and	  NFKB2	  as	  TNIP1	  interacting	  proteins,	  but	  
not	   their	   active	   components	   p52	   and	   p50	   (Bouwmeester	   et	   al.,	   2004).	   Additionally,	   the	  
interaction	  with	  NFKB2	  was	  dependent	  on	  NIK	  activation,	  however	  no	  functional	  significance	  
has	  yet	  been	  attributed	  to	  these	  interactions	  (Bouwmeester	  et	  al.,	  2004).	  	  
The	  overexpression	  of	  TNIP1	  also	  led	  to	  the	  discovery	  of	   its	  anti-­‐apoptotic	  activities,	  wherein	  
TNIP1	   prevents	   TNF-­‐induced	   apoptosis	   in	   cultured	   hepatocytes	   and	   in	   vivo	   (Wullaert	   et	   al.,	  
2005).	  While	   A20	   also	   displays	   anti-­‐apoptotic	   features,	   A20	   deficient	   cells	   still	   retain	   TNIP1-­‐
induced	   anti-­‐apoptotic	   effects	   suggesting	   these	   are	   A20-­‐independent	   functions.	   Moreover,	  
TNIP1	   inhibits	   caspase-­‐8	   recruitment	   to	   FADD,	   thus	   preventing	   caspase-­‐8	   cleavage	   and	  
apoptosis	  in	  response	  to	  TNF	  (Oshima	  et	  al.,	  2009).	  
Another	   A20	   adaptor	   displaying	   similar	   functions	   is	   ubiquitin-­‐binding-­‐domain-­‐containing	  
TAX1BP1.	  TAX1BP1	  similarly	  inhibits	  RIP1	  and	  TRAF6	  polyubiquitination	  via	  the	  recruitment	  of	  
ubiquitin-­‐editing	  A20	  (Iha	  et	  al.,	  2008).	   In	  addition,	  A20	  regulates	  antiviral	   immunity	  through	  
TAX1BP1,	   by	   disrupting	   Lys63-­‐ubiquitination	   of	   TBK1/IKKε	   in	   mouse	   embryonic	   fibroblasts	  
(Parvatiyar	  et	  al.,	  2010).	  
These	  data	  indicate	  a	  potentially	  novel	  mechanism	  of	  action	  for	  Pellino-­‐1,	  wherein	  it	  regulates	  
NF-­‐κB	  signalling	  through	  the	  negative	  regulator	  A20	  or	  its	  adaptor	  proteins	  TNIP1	  or	  TAX1BP1.	  
With	   epithelial	   cells	   from	   COPD	   patient	   airways	   showing	   increased	   levels	   of	   Pellino-­‐1	  
expression	   following	   viral	   stimulation,	   it	   is	   possible	   that	   Pellino-­‐1	   inhibits	   A20’s	   negative	  
regulatory	  functions	  and	  that	  through	  the	  manipulation	  of	  Pellino-­‐1	  expression	  could	  result	  in	  
decreased	   hallmark	   inflammatory	   response	   of	   COPD.	   These	   preliminary	   proteomics	   will	  
require	  confirmation	  with	  protein	  co-­‐immunoprecipitation	  (Co-­‐IP)	  and	  ligand	  binding	  assays	  to	  
determine	   their	   significance.	   If	   any	   of	   these	   targets	   are	   confirmed	   as	   Pellino-­‐1	   binding	  
partners,	   further	   investigations	   into	   the	   signalling	  molecules	   regulated	   by	   these	   in	   Pellino-­‐1	  
knockdown	  cells	  could	  help	  determine	  Pellino-­‐1’s	  regulation	  profile.	  The	  transient	  knockdown	  
of	  A20,	  TNIP1	  or	  TAX1BP1	  in	  Pellino-­‐1	  knockdown	  cells	  compared	  with	  control	  cells	  would	  also	  
help	   determine	   if	   the	   effects	   of	  A20	   knockdown	  are	  mediated	  by	   the	   targeting	   of	   Pellino-­‐1.	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Finally,	   the	   use	   of	   ubiquitin-­‐linkage	   specific	   antibodies	   will	   provide	   insight	   into	   the	   type	  
ubiquitin	  chains	  tagged	  by	  Pellino-­‐1.	  
	  
5.9	  Pellino-­‐1	  in	  MAPK	  signalling	  
	  
TLR3	  signalling	  following	  viral	  induction	  bifurcates	  downstream	  of	  TRIF	  (Figure	  1.1).	  While	  the	  
initiation	  of	  inflammatory	  signalling	  can	  lead	  to	  the	  phosphorylation	  of	  IRF3	  and	  the	  resulting	  
IFNβ,	  it	  can	  also	  lead	  to	  the	  activation	  of	  IKKs	  and	  MAP	  kinases	  and	  in	  turn	  the	  activation	  of	  NF-­‐
κB	  and	  AP-­‐1	  respectively	  (see	  section	  1.6.3).	  Coordinated	  activation	  of	  MAPKs	  has	  been	  shown	  
to	  regulate	  CXCL8	  expression	  in	  response	  to	  TNFα	  in	  airway	  epithelial	  cell	  line	  (Li	  et	  al.,	  2002).	  
Stabilization	  of	  CXCL8	  mRNA	  can	  also	  be	  controlled	  by	  p38	  (Hoffmann	  et	  al.,	  2002).	  As	  Pellino-­‐1	  
does	  not	  appear	  to	  elicit	   its	  effects	  through	  the	  degradation	  of	  IκBα,	  the	  rate-­‐limiting	  step	  of	  
canonical	  NF-­‐κB	   signalling,	   it	  was	   hypothesised	   that	   instead	  Pellino-­‐1	  may	  play	   a	   role	   in	   the	  
regulation	  and	  activation	  of	  MAPK	  as	  an	  alternative	  route	  to	  CXCL8	  transcription.	  
	  
AP-­‐1	  activation	  is	  mediated	  by	  MAP	  kinases	  such	  as	  JNK,	  ERK	  and	  p38	  (Kawai	  and	  Akira,	  2007).	  
Preliminary	  data	  suggested	  a	  role	  for	  Pellino-­‐1	  in	  the	  regulation	  of	  AP-­‐1	  in	  HBEpCs	  through	  p38	  
MAPK	  due	  to	  a	  measurable	  decrease	  in	  phospho	  p38	  activity	  in	  Pellino-­‐1	  knockdown	  samples.	  
These	  data	  contrast	  that	  from	  the	  Pellino-­‐1	  knock-­‐in	  mouse	  showing	  no	  deficiency	  in	  poly(I:C)-­‐
induced	  activation	  of	  MAP	  kinases	  in	  BMDM	  (Enesa	  et	  al.,	  2012).	  	  
	  
Further	  assessment	  of	  Pellino-­‐1	  involvement	  in	  AP-­‐1	  signalling	  was	  measured	  by	  the	  inhibition	  
of	   JNK,	   ERK	   and	   p38	   through	   their	   respective	   inhibitors	   SP600125,	   PD98059	   and	   SB203580.	  
Surprisingly,	   while	   JNK	   and	   p38	   inhibitors	   did	   not	   alter	   Pellino-­‐1	   expression	   in	   response	   to	  
poly(I:C),	  Pellino-­‐1	  mRNA	  and	  protein	  were	   inhibited	  by	  MEK1	   inhibitor	  PD98059	  and	  U0126	  
suggesting	  that	  Pellino-­‐1	  is	  regulated	  by	  ERK	  (demonstrated	  in	  Figure	  5.2).	  	  In	  addition,	  Pellino-­‐
1	  knockdown	  did	  not	  alter	  phospho	  ERK	  expression	  in	  HBEpCs	  at	  4	  or	  24	  hour	  post	  stimulation	  
with	  poly(I:C),	  in	  keeping	  with	  data	  from	  Jenson	  et	  al.	  whereby	  overexpression	  of	  Pellino-­‐2,	  but	  
not	  Pellino-­‐1,	  activated	  the	  ERK	  and	  JNK	  MAPK	  pathways	  (Jensen	  and	  Whitehead,	  2003a).	  To	  
add	   further	   insight	   into	   the	   role	   of	   MEK1	   in	   Pellino-­‐1	   regulation,	   it	   would	   be	   advisable	   to	  
continue	   determine	   the	   phosphorylation	   and/or	   activation	   of	   Pellino-­‐1	   E3	   ligase	   activity	   of	  
Pellino-­‐1	  following	  stimulation	  with	  poly(I:C)	  or	  RV.	  The	  phosphorylation	  of	  Pellino-­‐1	  by	  MEK1	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could	  be	  measured	  by	  mass	  spectrometry,	  and	  while	  the	  E3	  ligase	  activity	  will	  be	  determined	  
by	  a	  ubiquitination	  assay.	  	  	  
	  
	  
Figure	  5.2	  Possible	  mechanism	  for	  the	  regulation	  of	  Pellino-­‐1	  by	  ERK	  
This	   figure	  highlights	  a	  possible	  mechanism	  for	  the	  regulation	  of	  Pellino-­‐1	  by	  ERK	   in	  HBEpCs.	  
Upon	   TLR3	   activation,	   transcription	   factors	   such	   as	   NF-­‐κB	   and	  MAPKs	   are	   activated.	  MAPKs	  
form	   part	   of	   a	   protein	   kinase	   cascade	   consisting	   of	   at	   least	   three	   sequentially	   activated	  
enzymes	   resulting	   in	   the	   activation	   of	   ERK,	   p38s,	   and	   JNK/SAPKs.	   ERK	   is	   regulated	   by	   the	  




This	  thesis	  has	  investigated	  the	  regulation	  of	  Pellino-­‐1	  and	  its	  role	  in	  viral	   infection	  in	  human	  
bronchial	  airway	  epithelial	  cells.	  Data	  presented	  in	  this	  thesis	  showed	  that	  Pellino-­‐1	  expression	  
is	  upregulated	  in	  response	  to	  the	  TLR3	  agonist	  poly(I:C)	  in	  a	  TRIF-­‐dependent	  pathway	  in	  human	  
airway	  epithelial	  cells.	  	  These	  data	  resulted	  in	  the	  hypothesis	  that	  Pellino-­‐1	  may	  be	  selectively	  
mediating	   the	   TRIF-­‐dependent	  NF-­‐κB/MAPK	   pathway	   and	   not	   TLR3-­‐mediated	   IRF3	   and	   IFNβ	  
activation.	  
	  
In	   support	   of	   the	   hypothesis,	   the	   transient	   knockdown	   of	   Pellino-­‐1	   in	   airway	   epithelial	   cells	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IκBα	   degradation	   was	   not	   compromised	   which	   suggested	   that	   Pellino-­‐1	   may	   instead	   be	  
operating	   through	   the	   non-­‐canonical	   NF-­‐κB	   pathway.	   Preliminary	   data	   suggested	   Pellino-­‐1	  
negatively	   regulates	   the	   non-­‐canonical	   NF-­‐κB	   signalling	   through	   NFKB2.	   Additionally,	   the	  
transient	  knockdown	  of	  NFKB2	   in	  HBEpCs	  contrasted	   the	  phenotype	  of	  Pellino-­‐1	  knockdown	  
and	  in	  turn	  did	  not	  regulate	  Pellino-­‐1	  mRNA	  expression.	  It	  is	  therefore	  possible	  that	  following	  
viral	   infection	   in	   airway	   epithelial	   cells,	   TLR3	   activation	   culminates	   in	   the	   up-­‐regulation	   of	  
Pellino-­‐1	   leading	   to	   an	   increase	   in	   NFKB2	   expression,	   resulting	   in	   the	   suppression	   of	   NF-­‐κB	  
specific	  gene	  transcription.	  	  
	  
NFKB2	   expression	   was	   also	   quantified	   in	   epithelial	   cells	   isolated	   from	   diseased	   lung	   airway	  
epithelium	  of	  COPD	  patients	  then	  virally	  infected.	  Both	  Pellino-­‐1	  and	  NFKB2	  were	  significantly	  
expressed	  in	  these	  cells	  versus	  unstimulated	  control.	  Existing	  evidence	  supports	  NFKB2	  as	  the	  
first	   clear	   negative	   regulatory	  pathway	   that	  may	   limit	   ongoing	   TLR3	   signalling	   in	   a	  pathway-­‐
specific	   manner,	   and	   suggests	   that	   future	   exploration	   of	   non-­‐canonical	   NF-­‐κB	   signalling	   in	  
airways	  epithelial	  cells	  will	  be	   important	   in	  understanding	  how	  chronic	   inflammation	  may	  be	  
regulated	  in	  these	  cells.	  	  
	  
Proteomics	   analysis	   further	   identified	   a	   potentially	   novel	  mechanism	  of	   action	   for	   Pellino-­‐1,	  
wherein	   it	   regulates	   NF-­‐κB	   signalling	   through	   the	   negative	   regulator	   A20	   or	   its	   adaptor	  
proteins	  TNIP1	  or	  TAX1BP1.	  With	  epithelial	  cells	  from	  COPD	  patient	  airways	  showing	  increased	  
levels	   of	   Pellino-­‐1	   expression	   following	   viral	   stimulation,	   it	   is	   possible	   that	   Pellino-­‐1	   inhibits	  
A20’s	  negative	  regulatory	  functions	  and	  that	  through	  the	  manipulation	  of	  Pellino-­‐1	  expression	  
could	  result	  in	  decreased	  hallmark	  inflammatory	  response	  of	  COPD.	  
	  
In	  addition	  to	  the	  roles	  in	  non-­‐canonical	  NF-­‐κB	  signalling,	  the	  role	  of	  Pellino-­‐1	  in	  the	  regulation	  
and	  activation	  of	  MAPK	  as	  an	  alternative	  route	  to	  inflammatory	  regulation	  was	  also	  explored.	  
Preliminary	  data	  suggested	  a	  role	  for	  Pellino-­‐1	  in	  the	  regulation	  of	  AP-­‐1	  in	  HBEpCs	  through	  p38	  
MAPK.	  While	  assessment	  of	  the	  impact	  of	  the	  inhibition	  of	  the	  MAPKs	  on	  Pellino-­‐1	  expression	  
led	  to	  the	  novel	  discovery	  of	  ERK	  as	  a	  potential	  Pellino-­‐1	  regulator.	  	  
	  
A	   role	   for	   Pellino-­‐1	   in	   regulating	   TLR3	   signalling	   through	   the	   interaction	   with	   RIP1	   has	  
previously	  been	  identified	  but	  remains	  controversial.	  It	  was	  therefore	  hypothesised	  that	  if	  RIP1	  
were	   indeed	   a	   target	   of	   Pellino-­‐1	   then	   RIP1	   knockdown	   should	   recapitulate	   the	   Pellino-­‐1	  
knockdown	  phenotype.	   In	  contrast,	  RIP1	  knockdown	  significantly	   increased	  the	  inflammatory	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response	  in	  HBEpCs.	  Furthermore,	  proteomics	  analysis	  of	  Pellino-­‐1	  interacting	  proteins	  did	  not	  
identify	  RIP1	  as	  a	  Pellino-­‐1	  binding	  partner.	  However,	  Pellino-­‐1	  seems	  to	  have	  a	  regulatory	  role	  
in	  caspase-­‐8	  apoptosis,	  a	  RIP1	  dependent	  cell	  death	  mechanism.	   It	   is	   therefore	  possible	   that	  
Pellino-­‐1	  may	  similarly	  serve	  as	  a	  negative	  regulator	  of	  apoptosis	  via	  the	  polyubiquitination	  of	  
RIP1	  in	  response	  to	  viral	  stimuli.	  
	  
Data	   in	   this	   thesis	   clearly	   indicates	   that	   the	   ablation	   of	   Pellino-­‐1	   in	   human	   airway	   epithelial	  
cells	  results	  in	  a	  significant	  reduction	  in	  the	  TLR3-­‐induced	  activation	  of	  the	  NF-­‐κB	  induction	  of	  
cytokines	   such	  as	  CXCL8.	   This	  data	  has	  been	  aligned	  with	  existing	   findings	   adding	   value	  and	  
insight	  into	  the	  potential	  roles	  and	  mechanisms	  of	  Pellino-­‐1	  function	  in	  COPD	  and	  highlighted	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APPENDIX	  
	  
1.	  ELISA	  buffers	  composition 
	  
	  
Wash	  Buffer	  (pH	  7.2-­‐7.4)	  
	   Final	  Concentration	   Mass/	  Volume	  
NaCl	   0.5	  M	   292.2	  g	  
NaH2PO4	   2.5	  mM	   3	  g	  
Na2HPO4	   7.5	  mM	   10.7	  g	  
Tween®-­‐20	   0.1	  %	   10	  ml	  
Water	   	   To	  10	  litres	  
Coating	  Buffer	  (pH	  7.2-­‐7.4)	  
	   Final	  Concentration	   Mass/	  Volume	  
NaCl	   0.14	  M	   8.18	  g	  
KCl	   2.7	  mM	   0.2	  g	  
Na2HPO4	   8.1	  mM	   1.15	  g	  
KH2PO4.	   1.5	  mM	   0.2	  g	  
Water	   	   To	  1	  litre	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2.	  PCR	  buffers	  composition	  
	  
50	  x	  TAE	   	   	  
	   Final	  Concentration	   Mass	  /Volume	  	  
Tris	  Base	   1.67	  M	   242	  g	  
EDTA	   50	  mM	   37.2	  g	  
Glacial	  Acetic	  Acid	   	   57.1	  ml	  
Water	   	   To	  1	  litre	  
	  
3.	  Quantitative	  PCR	  primer-­‐probe	  sequences	  	  
	  
Target	   Type	   Sequence	  (5’-­‐3’)	  
RV1B	   Forward	   GTGAAGAGCCSCRTGTGCT	  	  
	   Reverse	   GCTSCAGGGTTAAGGTTAGCC	  	  
	   Probe	   TGAGTCCTCCGGCCCCTGAATG	  	  
IFNβ	   Forward	   CGCCGCATTGACCATCTA	  	  
	   Reverse	   CGCCGCATTGACCATCTA	  	  
	   Probe	   CGCCGCATTGACCATCTA	  	  
	  
4.	  Western	  Blotting	  
	  
Phosphatase	  Lysis	  Buffer	   	   	  
Reagent	   Concentration	   Mass/Volume	  
Tris	  Base	   50mM	   0.3	  g	  
Sodium	  Fluoride	   50	  mM	   0.1	  g	  
β-­‐glycerophosphate	   50	  mM	   0.54	  g	  
Sodium	  Orthovanadate	   10	  mM	   0.09	  g	  
Triton	  X-­‐100	   1%	   500	  μl	  
Water	   Up	  to	  50	  ml	   	  
PMSF	   1	  mM	  *Only	  add	  prior	  to	  use	   	  
Protease	  inhibitor	  cocktail	  III	   1:100	  *Only	  add	  prior	  to	  use	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Resolving	  Gel	   	   	  
Reagent	   10%	  (40-­‐120	  kDa)	   12%	  (15-­‐50	  kDa)	  
Distilled	  water	   5.9	  ml	   4.9	  ml	  
30%	  Acrylamide	   5	  ml	   6	  ml	  
1.5	  M	  Tris	  (pH	  8.8)	   3.8	  ml	   3.8	  ml	  
20%	  SDS	   75	  μl	   75	  μl	  
20%	  APS	   150	  μl	   150	  μl	  
TEMED	   6	  μl	   6	  μl	  
	  
Stacking	  Gel	   	  
Reagent	   5%	  
Distilled	  water	   2.8	  ml	  
30%	  Acrylamide	   830	  μl	  
1	  M	  Tris	  (pH	  6.8)	   1.26	  ml	  
20%	  SDS	   25	  μl	  
20%	  APS	   50	  μl	  
TEMED	   5	  μl	  
	  	  
10	  x	  SDS	  Running	  Buffer	   	   	  
Reagent	   Concentration	   Mass/Volume	  
Tris	   0.2	  M	   30.3	  g	  
Glycine	   1.92	  M	   144	  g	  
SDS	   20%	   10	  g	  
Water	   	   Make	  up	  to	  1	  L	  
	  
10	  X	  Transfer	  Buffer	   	   	  
Reagent	   Concentration	   Mass/Volume	  
Tris	   0.25	  M	   36.3	  g	  
Glycine	   2.4	  M	   181.25	  g	  
Water	   	   Make	  up	  to	  1	  L	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5.	  Full	  list	  of	  potential	  Pellino-­‐1	  interacting	  partners	  generated	  by	  mass	  spectometry	  
	  
Gene	  names	   Protein	  names	   Timepoint	  
A2M	   Alpha-­‐2-­‐macroglobulin	   4	  and	  24	  hour	  
ACAT1	   Acetyl-­‐CoA	  acetyltransferase,	  mitochondrial	   24	  hour	  
ACO2	   Aconitate	  hydratase,	  mitochondrial	   24	  hour	  
ACOT9	   Acyl-­‐coenzyme	  A	  thioesterase	  9,	  mitochondrial	   24	  hour	  
ACSL3	   Long-­‐chain-­‐fatty-­‐acid-­‐-­‐CoA	  ligase	  3	   4	  and	  24	  hour	  
ACTB	   Actin,	  cytoplasmic	  1;Actin,	  cytoplasmic	  1,	  N-­‐terminally	  processed	   24	  hour	  
ACTB;ACTG1	   Actin,	  cytoplasmic	  1,	  N-­‐terminally	  processed;	  Actin,	  cytoplasmic	  2,	  N-­‐
terminally	  processed	  
4	  hour	  
ACTBL2	   Beta-­‐actin-­‐like	  protein	  2	   4	  and	  24	  hour	  
ACTC1;ACTA1;ACTA2;ACTG2	   Actin,	  alpha	  cardiac	  muscle	  1;Actin,	  alpha	  skeletal	  muscle;Actin,	  aortic	  
smooth	  muscle;Actin,	  gamma-­‐enteric	  smooth	  muscle	  
4	  and	  24	  hour	  
AFP	   Alpha-­‐fetoprotein	   4	  and	  24	  hour	  
AGPS	   Alkyldihydroxyacetonephosphate	  synthase,	  peroxisomal	   24	  hour	  
AHCY	   Adenosylhomocysteinase	   4	  and	  24	  hour	  
AHNAK	   Neuroblast	  differentiation-­‐associated	  protein	  AHNAK	   4	  and	  24	  hour	  
AHSG	   Alpha-­‐2-­‐HS-­‐glycoprotein;Alpha-­‐2-­‐HS-­‐glycoprotein	  chain	  A;Alpha-­‐2-­‐HS-­‐
glycoprotein	  chain	  B	  
4	  and	  24	  hour	  
AIFM1	   Apoptosis-­‐inducing	  factor	  1,	  mitochondrial	   24	  hour	  
ALB	   Serum	  albumin	   4	  and	  24	  hour	  
ALDH1B1	   Aldehyde	  dehydrogenase	  X,	  mitochondrial	   24	  hour	  
ALDH2	   Aldehyde	  dehydrogenase,	  mitochondrial	   24	  hour	  
ALDH4A1	   Delta-­‐1-­‐pyrroline-­‐5-­‐carboxylate	  dehydrogenase,	  mitochondrial	   4	  and	  24	  hour	  
ALDH7A1	   Alpha-­‐aminoadipic	  semialdehyde	  dehydrogenase	   24	  hour	  
ALDOA	   Fructose-­‐bisphosphate	  aldolase	  A;Fructose-­‐bisphosphate	  aldolase	   4	  and	  24	  hour	  
ANXA1	   Annexin	  A1	   4	  hour	  
ANXA2;ANXA2P2	   Annexin	  A2;Annexin;Putative	  annexin	  A2-­‐like	  protein	   4	  and	  24	  hour	  
APOA1	   Apolipoprotein	  A-­‐I;Truncated	  apolipoprotein	  A-­‐I	   4	  hour	  
APOB	   Apolipoprotein	  B-­‐100;Apolipoprotein	  B-­‐48	   4	  and	  24	  hour	  
APOC3	   Apolipoprotein	  C-­‐III	   4	  and	  24	  hour	  
APOE	   Apolipoprotein	  E	   4	  and	  24	  hour	  
ARG1	   Arginase-­‐1	   4	  hour	  
ARGLU1	   Arginine	  and	  glutamate-­‐rich	  protein	  1	   4	  hour	  
ARL8A;ARL8B	   ADP-­‐ribosylation	  factor-­‐like	  protein	  8A;ADP-­‐ribosylation	  factor-­‐like	  protein	  
8B	  
24	  hour	  
ARPC4;ARPC4-­‐TTLL3	   Actin-­‐related	  protein	  2/3	  complex	  subunit	  4	   24	  hour	  
ARID1B	   AT-­‐rich	  interactive	  domain-­‐containing	  protein	  1B	   4	  hour	  
ATAD3A	   ATPase	  family	  AAA	  domain-­‐containing	  protein	  3A	   24	  hour	  
ATP1A1;ATP4A;ATP1A2;ATP1
A3	  
Sodium/potassium-­‐transporting	  ATPase	  subunit	  alpha-­‐1;Potassium-­‐
transporting	  ATPase	  alpha	  chain	  1;Sodium/potassium-­‐transporting	  ATPase	  
subunit	  alpha-­‐2;Sodium/potassium-­‐transporting	  ATPase	  subunit	  alpha-­‐3	  
4	  and	  24	  hour	  
ATP2A2	   Sarcoplasmic/endoplasmic	  reticulum	  calcium	  ATPase	  2	   4	  and	  24	  hour	  
ATP5A1	   ATP	  synthase	  subunit	  alpha,	  mitochondrial	   4	  and	  24	  hour	  
ATP5B	   ATP	  synthase	  subunit	  beta,	  mitochondrial;ATP	  synthase	  subunit	  beta	   4	  and	  24	  hour	  
ATP5C1	   ATP	  synthase	  subunit	  gamma,	  mitochondrial;ATP	  synthase	  gamma	  chain	   4	  and	  24	  hour	  
ATP5F1	   ATP	  synthase	  subunit	  b,	  mitochondrial	   4	  and	  24	  hour	  
ATP5J2;PTCD1	   ATP	  synthase	  subunit	  f,	  mitochondrial	   24	  hour	  
ATP5L	   ATP	  synthase	  subunit	  g,	  mitochondrial	   4	  and	  24	  hour	  
ATP5O	   ATP	  synthase	  subunit	  O,	  mitochondrial	   4	  and	  24	  hour	  
ATP6V1A	   V-­‐type	  proton	  ATPase	  catalytic	  subunit	  A	   24	  hour	  
BASP1	   Brain	  acid	  soluble	  protein	  1	   24	  hour	  
BCAP31	   B-­‐cell	  receptor-­‐associated	  protein	  31	   24	  hour	  
BCKDK	   [3-­‐methyl-­‐2-­‐oxobutanoate	  dehydrogenase	  [lipoamide]]	  kinase,	  
mitochondrial	  
24	  hour	  
BCL9L	   B-­‐cell	  CLL/lymphoma	  9-­‐like	  protein	   4	  hour	  
C3	   Complement	  C3	   4	  and	  24	  hour	  
C4A;C4B	   Complement	  C4-­‐A;Complement	  C4-­‐B	   4	  hour	  
C5	   Complement	  C5	   4	  hour	  
C9	   Complement	  component	  C9;Complement	  component	  C9a;Complement	   4	  hour	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component	  C9b	  
CACNA1D	   Voltage-­‐dependent	  L-­‐type	  calcium	  channel	  subunit	  alpha-­‐1D	   4	  hour	  
CALR	   Calreticulin	   24	  hour	  
CALML5	   Calmodulin-­‐like	  protein	  5	   4	  hour	  
CANX	   Calnexin	   24	  hour	  
CAPN2	   Calpain-­‐2	  catalytic	  subunit	   4	  hour	  
CAPZA2;CAPZA1	   F-­‐actin-­‐capping	  protein	  subunit	  alpha-­‐2;F-­‐actin-­‐capping	  protein	  subunit	  
alpha-­‐1	  
24	  hour	  
CASP14	   Caspase-­‐14;Caspase-­‐14	  subunit	  p19;Caspase-­‐14	  subunit	  p10	   4	  hour	  
CAT	   Catalase	   4	  and	  24	  hour	  
CBR4	   Carbonyl	  reductase	  family	  member	  4	   24	  hour	  
CCT3	   T-­‐complex	  protein	  1	  subunit	  gamma	   24	  hour	  
CCT8	   T-­‐complex	  protein	  1	  subunit	  theta	   24	  hour	  
CD63	   CD63	  antigen	   24	  hour	  
CDK11B;CDK11A;CDC2L2	   Cyclin-­‐dependent	  kinase	  11B;Cyclin-­‐dependent	  kinase	  11A	   4	  hour	  
CDKAL1	   Threonylcarbamoyladenosine	  tRNA	  methylthiotransferase	   4	  and	  24	  hour	  
CDRT15L2	   CMT1A	  duplicated	  region	  transcript	  15	  protein-­‐like	  protein	   24	  hour	  
CDSN	   Corneodesmosin	   4	  and	  24	  hour	  
CHTOP	   Chromatin	  target	  of	  PRMT1	  protein	   4	  and	  24	  hour	  
CKAP4	   Cytoskeleton-­‐associated	  protein	  4	   24	  hour	  
CLTC	   Clathrin	  heavy	  chain	  1	   24	  hour	  
COL1A1	   Collagen	  alpha-­‐1(I)	  chain	   4	  and	  24	  hour	  
COL1A2	   Collagen	  alpha-­‐2(I)	  chain	   4	  and	  24	  hour	  
COL3A1	   Collagen	  alpha-­‐1(III)	  chain	   4	  and	  24	  hour	  
COL8A1	   Collagen	  alpha-­‐1(VIII)	  chain;Vastatin	   24	  hour	  
COPS2	   	   4	  hour	  
CRNN	   Cornulin	   4	  hour	  
CSDA	   DNA-­‐binding	  protein	  A	   24	  hour	  
CSNK1A1;CSNK1A1L	   Casein	  kinase	  I	  isoform	  alpha;Casein	  kinase	  I	  isoform	  alpha-­‐like	   4	  hour	  
CSTA	   Cystatin-­‐A	   4	  and	  24	  hour	  
CSTB	   Cystatin-­‐B	   4	  hour	  
CTNNA1	   Catenin	  alpha-­‐1	   24	  hour	  
CTNND1	   Catenin	  delta-­‐1	   4	  hour	  
CTSB	   Cathepsin	  B;Cathepsin	  B	  light	  chain;Cathepsin	  B	  heavy	  chain	   24	  hour	  
CYB5R3	   NADH-­‐cytochrome	  b5	  reductase	  3;NADH-­‐cytochrome	  b5	  reductase	  3	  
membrane-­‐bound	  form;NADH-­‐cytochrome	  b5	  reductase	  3	  soluble	  form	  
24	  hour	  
CTSD	   Cathepsin	  D;Cathepsin	  D	  light	  chain;Cathepsin	  D	  heavy	  chain	   4	  hour	  
DBN1	   Drebrin	   4	  hour	  
DCD	   Dermcidin;Survival-­‐promoting	  peptide;DCD-­‐1	   4	  and	  24	  hour	  
DDB1	   DNA	  damage-­‐binding	  protein	  1	   24	  hour	  
DDOST	   Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  48	  kDa	  
subunit	  
4	  and	  24	  hour	  
DDX17;DDX5	   Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX17;Probable	  ATP-­‐dependent	  RNA	  
helicase	  DDX5	  
4	  and	  24	  hour	  
DDX47	   Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX47	   24	  hour	  
DDX5;DDX17	   Probable	  ATP-­‐dependent	  RNA	  helicase	  DDX5;Probable	  ATP-­‐dependent	  RNA	  
helicase	  DDX17	  
24	  hour	  
DECR1	   2,4-­‐dienoyl-­‐CoA	  reductase,	  mitochondrial	   24	  hour	  
DHCR7	   7-­‐dehydrocholesterol	  reductase	   	  
DHRS1	   Dehydrogenase/reductase	  SDR	  family	  member	  1	   24	  hour	  
DHRS4L1;DHRS4	   Putative	  dehydrogenase/reductase	  SDR	  family	  member	  4-­‐like	  
2;Dehydrogenase/reductase	  SDR	  family	  member	  4	  
24	  hour	  
DHX15	   Putative	  pre-­‐mRNA-­‐splicing	  factor	  ATP-­‐dependent	  RNA	  helicase	  DHX15	   4	  and	  24	  hour	  
DHX9	   ATP-­‐dependent	  RNA	  helicase	  A	   24	  hour	  
DLG5	   Disks	  large	  homolog	  5	   24	  hour	  
DLST	   Dihydrolipoyllysine-­‐residue	  succinyltransferase	  component	  of	  2-­‐oxoglutarate	  
dehydrogenase	  complex,	  mitochondrial	  
24	  hour	  
DSC1	   Desmocollin-­‐1	   4	  and	  24	  hour	  
DSC3	   Desmocollin-­‐3	   4	  hour	  
DSG1	   Desmoglein-­‐1	   4	  and	  24	  hour	  
DSP	   Desmoplakin	   4	  and	  24	  hour	  
EBP	   3-­‐beta-­‐hydroxysteroid-­‐Delta(8),Delta(7)-­‐isomerase	   4	  hour	  
ECM1	   Extracellular	  matrix	  protein	  1	   4	  hour	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EEF1A1;EEF1A1P5;EEF1A2	   Elongation	  factor	  1-­‐alpha	  1;Putative	  elongation	  factor	  1-­‐alpha-­‐like	  
3;Elongation	  factor	  1-­‐alpha	  2	  
4	  and	  24	  hour	  
EEF1G	   Elongation	  factor	  1-­‐gamma	   4	  and	  24	  hour	  
EEF2	   Elongation	  factor	  2	   24	  hour	  
EIF4A2;EIF4A1	   Eukaryotic	  initiation	  factor	  4A-­‐II;Eukaryotic	  initiation	  factor	  4A-­‐I	   24	  hour	  
EIF4A3	   Eukaryotic	  initiation	  factor	  4A-­‐III	   24	  hour	  
ELAVL1	   ELAV-­‐like	  protein	  1	   24	  hour	  
ENO1	   Alpha-­‐enolase	   4	  and	  24	  hour	  
ENO2	   Gamma-­‐enolase;Enolase	   4	  hour	  
EPHB2;EPHA6;EPHB3;EPHA7;
EPHB4;EPHA4;EPHB1;EPHA2	  
Ephrin	  type-­‐B	  receptor	  2;Ephrin	  type-­‐A	  receptor	  6;Ephrin	  type-­‐B	  receptor	  
3;Ephrin	  type-­‐A	  receptor	  7;Ephrin	  type-­‐B	  receptor	  4;Ephrin	  type-­‐A	  receptor	  
4;Ephrin	  type-­‐B	  receptor	  1;Ephrin	  type-­‐A	  receptor	  2	  
24	  hour	  
ERAP1	   Endoplasmic	  reticulum	  aminopeptidase	  1	   24	  hour	  
ERG	   Transcriptional	  regulator	  ERG	   4	  hour	  
ERH	   Enhancer	  of	  rudimentary	  homolog	   24	  hour	  
ERLIN1;ERLIN2	   Erlin-­‐1;Erlin-­‐2	   4	  and	  24	  hour	  
ERO1L	   ERO1-­‐like	  protein	  alpha	   24	  hour	  
ESYT1	   Extended	  synaptotagmin-­‐1	   24	  hour	  
ETFA	   Electron	  transfer	  flavoprotein	  subunit	  alpha,	  mitochondrial	   24	  hour	  
ETFB	   Electron	  transfer	  flavoprotein	  subunit	  beta	   24	  hour	  
ETHE1	   Protein	  ETHE1,	  mitochondrial	   24	  hour	  
F2	   Prothrombin;Activation	  peptide	  fragment	  1;Activation	  peptide	  fragment	  
2;Thrombin	  light	  chain;Thrombin	  heavy	  chain	  
4	  and	  24	  hour	  
F5	   Coagulation	  factor	  V;Coagulation	  factor	  V	  heavy	  chain;Coagulation	  factor	  V	  
light	  chain	  
24	  hour	  
FABP5	   Fatty	  acid-­‐binding	  protein,	  epidermal	   4	  and	  24	  hour	  
FADS2	   Fatty	  acid	  desaturase	  2	   24	  hour	  
FAF2	   FAS-­‐associated	  factor	  2	   24	  hour	  
FBL	   rRNA	  2-­‐O-­‐methyltransferase	  fibrillarin	   4	  and	  24	  hour	  
FBLN1	   Fibulin-­‐1	   24	  hour	  
FBLN1	   	   24	  hour	  
FDFT1	   Squalene	  synthase	   24	  hour	  
FLG	   Filaggrin	   4	  and	  24	  hour	  
FLG2	   Filaggrin-­‐2	   4	  and	  24	  hour	  
FLNA	   Filamin-­‐A	   4	  and	  24	  hour	  
FLNB	   Filamin-­‐B	   4	  and	  24	  hour	  
FN1	   Fibronectin;Anastellin;Ugl-­‐Y1;Ugl-­‐Y2;Ugl-­‐Y3	   4	  and	  24	  hour	  
FTH1	   Ferritin	  heavy	  chain;Ferritin	   4	  hour	  
FYTTD1	   UAP56-­‐interacting	  factor	   24	  hour	  
GAPDH	   Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	   4	  and	  24	  hour	  
GBP1	   Interferon-­‐induced	  guanylate-­‐binding	  protein	  1	   4	  and	  24	  hour	  
GC	   Vitamin	  D-­‐binding	  protein	   4	  hour	  
GGCT	   Gamma-­‐glutamylcyclotransferase	   24	  hour	  
GLS	   Glutaminase	  kidney	  isoform,	  mitochondrial	   24	  hour	  
GNAI3;GNAI2;GNAO1;GNAI1	   Guanine	  nucleotide-­‐binding	  protein	  G(k)	  subunit	  alpha;Guanine	  nucleotide-­‐
binding	  protein	  G(i)	  subunit	  alpha-­‐2;Guanine	  nucleotide-­‐binding	  protein	  G(o)	  
subunit	  alpha;Guanine	  nucleotide-­‐binding	  protein	  G(i)	  subunit	  alpha-­‐1	  
24	  hour	  
GNB1;GNB2;GNB4;GNB3	   Guanine	  nucleotide-­‐binding	  protein	  G(I)/G(S)/G(T)	  subunit	  beta-­‐1;Guanine	  
nucleotide-­‐binding	  protein	  G(I)/G(S)/G(T)	  subunit	  beta-­‐2;Guanine	  
nucleotide-­‐binding	  protein	  subunit	  beta-­‐4;Guanine	  nucleotide-­‐binding	  
protein	  G(I)/G(S)/G(T)	  subunit	  beta-­‐3	  
24	  hour	  
GNB2L1	   Guanine	  nucleotide-­‐binding	  protein	  subunit	  beta-­‐2-­‐like	  1	   4	  hour	  
GOT2	   Aspartate	  aminotransferase,	  mitochondrial;Aspartate	  aminotransferase	   24	  hour	  
GPD2	   Glycerol-­‐3-­‐phosphate	  dehydrogenase,	  mitochondrial	   24	  hour	  
GRN	   Granulins;Acrogranin;Paragranulin;Granulin-­‐1;Granulin-­‐2;Granulin-­‐
3;Granulin-­‐4;Granulin-­‐5;Granulin-­‐6;Granulin-­‐7	  
4	  and	  24	  hour	  
GSDMA	   Gasdermin-­‐A	   4	  hour	  
GSN	   Gelsolin	   24	  hour	  
GSTK1	   Glutathione	  S-­‐transferase	  kappa	  1	   24	  hour	  
GTF2I	   General	  transcription	  factor	  II-­‐I	   24	  hour	  






Histone	  H2A.x;Histone	  H2A	  type	  1-­‐A;Histone	  H2A	  type	  1-­‐B/E;Histone	  H2A	  
type	  1;Histone	  H2A	  type	  1-­‐D;Histone	  H2A	  type	  2-­‐A;Histone	  H2A	  type	  
3;Histone	  H2A	  type	  1-­‐C;Histone	  H2A	  type	  2-­‐B;Histone	  H2A	  type	  2-­‐C;Histone	  








Histone	  H2A.Z;Histone	  H2A.V;Histone	  H2A;Histone	  H2A.x;Histone	  H2A	  type	  
1-­‐A;Histone	  H2A	  type	  1-­‐B/E;Histone	  H2A	  type	  1;Histone	  H2A	  type	  1-­‐
D;Histone	  H2A	  type	  2-­‐A;Histone	  H2A	  type	  3;Histone	  H2A	  type	  2-­‐B;Histone	  
H2A	  type	  1-­‐C;Histone	  H2A	  type	  2-­‐C;Histone	  H2A.J;Histone	  H2A	  type	  1-­‐
H;Histone	  H2A	  type	  1-­‐J	  
24	  hour	  
HADHA	   Trifunctional	  enzyme	  subunit	  alpha,	  mitochondrial;Long-­‐chain	  enoyl-­‐CoA	  
hydratase;Long	  chain	  3-­‐hydroxyacyl-­‐CoA	  dehydrogenase	  
4	  and	  24	  hour	  
HADHB	   Trifunctional	  enzyme	  subunit	  beta,	  mitochondrial;3-­‐ketoacyl-­‐CoA	  thiolase	   24	  hour	  
HBA1;HBA2	   Hemoglobin	  subunit	  alpha	   4	  and	  24	  hour	  
HBB;HBD	   Hemoglobin	  subunit	  beta;LVV-­‐hemorphin-­‐7;Hemoglobin	  subunit	  delta	   4	  and	  24	  hour	  
HIST1H1B	   Histone	  H1.5	   4	  and	  24	  hour	  
HIST1H1C;HIST1H1D;HIST1H1
E	  
Histone	  H1.2;Histone	  H1.3;Histone	  H1.4	   4	  and	  24	  hour	  







Histone	  H2B;Histone	  H2B	  type	  1-­‐K;Histone	  H2B	  type	  F-­‐S;Histone	  H2B	  type	  1-­‐
D;Histone	  H2B	  type	  1-­‐C/E/F/G/I;Histone	  H2B	  type	  2-­‐F;Histone	  H2B	  type	  1-­‐
H;Histone	  H2B	  type	  1-­‐N;Histone	  H2B	  type	  1-­‐M;Histone	  H2B	  type	  1-­‐L;Histone	  
H2B	  type	  1-­‐J;Histone	  H2B	  type	  1-­‐O;Histone	  H2B	  type	  1-­‐B;Histone	  H2B	  type	  2-­‐
E;Histone	  H2B	  type	  3-­‐B;Histone	  H2B	  type	  1-­‐A	  
4	  and	  24	  hour	  
HK1	   Hexokinase-­‐1	   24	  hour	  
HLA-­‐A;HLA-­‐C;HLA-­‐H	   HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐68	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  A-­‐2	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  A-­‐3	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐24	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐32	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  A-­‐69	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  A-­‐11	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐30	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐31	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  A-­‐33	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  A-­‐25	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐23	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐26	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  A-­‐34	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  A-­‐43	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐66	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐74	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  A-­‐29	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  A-­‐80	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  Cw-­‐17	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  Cw-­‐16	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  Cw-­‐5	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  A-­‐1	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐36	  alpha	  
chain;Putative	  HLA	  class	  I	  histocompatibility	  antigen,	  alpha	  chain	  H	  
24	  hour	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HLA-­‐B	   HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐7	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐8	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐41	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐42	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐40	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐27	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐58	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐37	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐51	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐57	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐14	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐15	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐18	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐39	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐44	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐45	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐46	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐47	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐49	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐50	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐52	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐53	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐54	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐55	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐56	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐78	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐35	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐82	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐67	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐59	  alpha	  chain;HLA	  class	  I	  histocompatibility	  
antigen,	  B-­‐38	  alpha	  chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐13	  alpha	  
chain;HLA	  class	  I	  histocompatibility	  antigen,	  B-­‐48	  alpha	  chain;HLA	  class	  I	  
histocompatibility	  antigen,	  B-­‐81	  alpha	  chain	  
	  
HNRNPA0	   Heterogeneous	  nuclear	  ribonucleoprotein	  A0	   4	  and	  24	  hour	  
HNRNPA1	   Heterogeneous	  nuclear	  ribonucleoprotein	  A1	   24	  hour	  
HNRNPA2B1	   Heterogeneous	  nuclear	  ribonucleoproteins	  A2/B1	   4	  and	  24	  hour	  
HNRNPAB	   	   24	  hour	  
HNRNPC;HNRNPCL1	   Heterogeneous	  nuclear	  ribonucleoproteins	  C1/C2;Heterogeneous	  nuclear	  
ribonucleoprotein	  C-­‐like	  1	  
4	  and	  24	  hour	  
HNRNPH1;HNRNPF	   Heterogeneous	  nuclear	  ribonucleoprotein	  H;Heterogeneous	  nuclear	  
ribonucleoprotein	  H,	  N-­‐terminally	  processed;Heterogeneous	  nuclear	  
ribonucleoprotein	  F;Heterogeneous	  nuclear	  ribonucleoprotein	  F,	  N-­‐
terminally	  processed	  
4	  hour	  
HNRNPK	   Heterogeneous	  nuclear	  ribonucleoprotein	  K	   24	  hour	  
HNRNPL	   Heterogeneous	  nuclear	  ribonucleoprotein	  L	   	  
HNRNPM	   Heterogeneous	  nuclear	  ribonucleoprotein	  M	   4	  and	  24	  hour	  
HNRNPU	   Heterogeneous	  nuclear	  ribonucleoprotein	  U	   4	  and	  24	  hour	  
HNRNPUL2;hCG_2044799	   Heterogeneous	  nuclear	  ribonucleoprotein	  U-­‐like	  protein	  2	   24	  hour	  
HRNR	   Hornerin	   4	  and	  24	  hour	  
HSD17B10	   3-­‐hydroxyacyl-­‐CoA	  dehydrogenase	  type-­‐2	   24	  hour	  
HSD17B12	   Estradiol	  17-­‐beta-­‐dehydrogenase	  12	   	  
HSD17B4	   Peroxisomal	  multifunctional	  enzyme	  type	  2;(3R)-­‐hydroxyacyl-­‐CoA	  
dehydrogenase;Enoyl-­‐CoA	  hydratase	  2	  
24	  hour	  
HSP90AA1;HSP90AA2	   Heat	  shock	  protein	  HSP	  90-­‐alpha;Putative	  heat	  shock	  protein	  HSP	  90-­‐alpha	  
A2	  
4	  hour	  
HSP90AB1;HSP90AB3P	   Heat	  shock	  protein	  HSP	  90-­‐beta;Putative	  heat	  shock	  protein	  HSP	  90-­‐beta-­‐3	   4	  and	  24	  hour	  
HSP90AB2P	   Putative	  heat	  shock	  protein	  HSP	  90-­‐beta	  2	   4	  hour	  
HSP90B1	   Endoplasmin	   4	  and	  24	  hour	  
HSPA1A	   Heat	  shock	  70	  kDa	  protein	  1A/1B	   24	  hour	  
HSPA5	   78	  kDa	  glucose-­‐regulated	  protein	   4	  and	  24	  hour	  
HSPA6;HSPA7;HSPA1A;HSPA
1L;HSPA8	  
Heat	  shock	  70	  kDa	  protein	  6;Putative	  heat	  shock	  70	  kDa	  protein	  7;Heat	  shock	  
70	  kDa	  protein	  1A/1B;Heat	  shock	  70	  kDa	  protein	  1-­‐like	  
4	  and	  24	  hour	  
HSPA8;HSPA2	   Heat	  shock	  cognate	  71	  kDa	  protein;Heat	  shock-­‐related	  70	  kDa	  protein	  2	   4	  and	  24	  hour	  
HSPA9	   Stress-­‐70	  protein,	  mitochondrial	   4	  and	  24	  hour	  
HSPB1	   Heat	  shock	  protein	  beta-­‐1	   4	  and	  24	  hour	  
HSPD1	   60	  kDa	  heat	  shock	  protein,	  mitochondrial	   4	  and	  24	  hour	  
HSPE1	   10	  kDa	  heat	  shock	  protein,	  mitochondrial	   24	  hour	  
HYOU1	   Hypoxia	  up-­‐regulated	  protein	  1	   24	  hour	  
IARS	   Isoleucine-­‐-­‐tRNA	  ligase,	  cytoplasmic	   24	  hour	  
IDH2	   Isocitrate	  dehydrogenase	  [NADP],	  mitochondrial;Isocitrate	  dehydrogenase	  
[NADP]	  
4	  hour	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IGHG1	   Ig	  gamma-­‐1	  chain	  C	  region	   4	  and	  24	  hour	  
IGHG4;IGHG3	   Ig	  gamma-­‐4	  chain	  C	  region;Ig	  gamma-­‐3	  chain	  C	  region	   4	  and	  24	  hour	  
IGKC	   Ig	  kappa	  chain	  C	  region	   4	  and	  24	  hour	  
IGLC2;IGLC3;IGLC6;IGLC1	   Ig	  lambda-­‐2	  chain	  C	  regions;Ig	  lambda-­‐3	  chain	  C	  regions;Ig	  lambda-­‐6	  chain	  C	  
region;Ig	  lambda-­‐1	  chain	  C	  regions	  
4	  and	  24	  hour	  
IGLL5	   Immunoglobulin	  lambda-­‐like	  polypeptide	  5	   4	  and	  24	  hour	  
IL1R1	   Interleukin-­‐1	  receptor	  type	  1;Interleukin-­‐1	  receptor	  type	  1,	  membrane	  
form;Interleukin-­‐1	  receptor	  type	  1,	  soluble	  form	  
24	  hour	  
IMMT	   Mitochondrial	  inner	  membrane	  protein	   24	  hour	  
ITIH2	   Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H2	   4	  and	  24	  hour	  
ITIH3	   Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H3	   24	  hour	  
ITIH4	   Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H4;70	  kDa	  inter-­‐alpha-­‐trypsin	  
inhibitor	  heavy	  chain	  H4;35	  kDa	  inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H4	  
4	  and	  24	  hour	  
JUP	   Junction	  plakoglobin	   4	  and	  24	  hour	  
KAT5	   Histone	  acetyltransferase	  KAT5	   24	  hour	  
KIF14	   Kinesin-­‐like	  protein	  KIF14	   4	  hour	  
KPRP	   Keratinocyte	  proline-­‐rich	  protein	   24	  hour	  
LAD1	   Ladinin-­‐1	   24	  hour	  
LAMA3	   Laminin	  subunit	  alpha-­‐3	   24	  hour	  
LAMB3	   Laminin	  subunit	  beta-­‐3	   4	  and	  24	  hour	  
LAMC2	   Laminin	  subunit	  gamma-­‐2	   4	  and	  24	  hour	  
LAMP1	   Lysosome-­‐associated	  membrane	  glycoprotein	  1	   4	  hour	  
LDHA	   L-­‐lactate	  dehydrogenase	  A	  chain	   4	  and	  24	  hour	  
LDHB	   L-­‐lactate	  dehydrogenase	  B	  chain;L-­‐lactate	  dehydrogenase	   4	  hour	  
LGALS3BP	   Galectin-­‐3-­‐binding	  protein	   24	  hour	  
LGALS7	   Galectin-­‐7	   	  
LGALS9	   Galectin-­‐9	   24	  hour	  
LMNA	   Prelamin-­‐A/C;Lamin-­‐A/C	   4	  and	  24	  hour	  
LRRC73	   Leucine-­‐rich	  repeat-­‐containing	  protein	  73	   4	  hour	  
LRPPRC	   Leucine-­‐rich	  PPR	  motif-­‐containing	  protein,	  mitochondrial	   24	  hour	  
LTF	   Lactotransferrin;Kaliocin-­‐1;Lactoferroxin-­‐A;Lactoferroxin-­‐B;Lactoferroxin-­‐C	   4	  and	  24	  hour	  
LUC7L2;LUC7L	   Putative	  RNA-­‐binding	  protein	  Luc7-­‐like	  2;Putative	  RNA-­‐binding	  protein	  Luc7-­‐
like	  1	  
4	  hour	  
LUC7L3	   Luc7-­‐like	  protein	  3	   4	  and	  24	  hour	  
LYZ	   Lysozyme	  C	   4	  hour	  
MBOAT7	   Lysophospholipid	  acyltransferase	  7	   24	  hour	  
MDH1	   Malate	  dehydrogenase,	  cytoplasmic;Malate	  dehydrogenase	   24	  hour	  
MDH2	   Malate	  dehydrogenase,	  mitochondrial;Malate	  dehydrogenase	   4	  and	  24	  hour	  
MGST1	   Microsomal	  glutathione	  S-­‐transferase	  1	   4	  and	  24	  hour	  
MGST3	   Microsomal	  glutathione	  S-­‐transferase	  3	   4	  hour	  
MMTAG2	   Multiple	  myeloma	  tumor-­‐associated	  protein	  2	   4	  hour	  
MON1A	   Vacuolar	  fusion	  protein	  MON1	  homolog	  A	   24	  hour	  
MRPL14	   39S	  ribosomal	  protein	  L14,	  mitochondrial	   4	  and	  24	  hour	  
MRPL2	   39S	  ribosomal	  protein	  L2,	  mitochondrial	   24	  hour	  
MRPL22	   39S	  ribosomal	  protein	  L22,	  mitochondrial	   24	  hour	  
MRPL37	   39S	  ribosomal	  protein	  L37,	  mitochondrial	   24	  hour	  
MRPL9	   39S	  ribosomal	  protein	  L9,	  mitochondrial	   4	  and	  24	  hour	  
MRPS11	   28S	  ribosomal	  protein	  S11,	  mitochondrial	   24	  hour	  
MRPS18A	   28S	  ribosomal	  protein	  S18a,	  mitochondrial	   24	  hour	  
MRPS21	   28S	  ribosomal	  protein	  S21,	  mitochondrial	   24	  hour	  
MSMO1	   Methylsterol	  monooxygenase	  1	   24	  hour	  
MTMR4	   Myotubularin-­‐related	  protein	  4	   24	  hour	  
MYH9	   Myosin-­‐9	   4	  and	  24	  hour	  
MYL12B;MYL12A	   Myosin	  regulatory	  light	  chain	  12B;Myosin	  regulatory	  light	  chain	  12A	   24	  hour	  
MYO1B	   Unconventional	  myosin-­‐Ib	   4	  and	  24	  hour	  
MYOF	   Myoferlin	   24	  hour	  
NARS2	   Probable	  asparagine-­‐-­‐tRNA	  ligase,	  mitochondrial	   24	  hour	  
NCL	   Nucleolin	   4	  and	  24	  hour	  
NCLN	   Nicalin	   24	  hour	  
NHP2L1	   NHP2-­‐like	  protein	  1	   24	  hour	  
NNT	   NAD(P)	  transhydrogenase,	  mitochondrial	   24	  hour	  
NOP56;NOL5A	   Nucleolar	  protein	  56	   24	  hour	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OAT	   Ornithine	  aminotransferase,	  mitochondrial;Ornithine	  aminotransferase,	  
hepatic	  form;Ornithine	  aminotransferase,	  renal	  form	  
4	  and	  24	  hour	  
OCIAD2	   OCIA	  domain-­‐containing	  protein	  2	   4	  hour	  
OSBPL10	   Oxysterol-­‐binding	  protein-­‐related	  protein	  10;Oxysterol-­‐binding	  protein	   4	  hour	  
OXA1L	   Mitochondrial	  inner	  membrane	  protein	  OXA1L	   24	  hour	  
P4HB	   Protein	  disulfide-­‐isomerase	   4	  and	  24	  hour	  
PCBP3;PCBP2;PCBP1	   Poly(rC)-­‐binding	  protein	  3;Poly(rC)-­‐binding	  protein	  2;Poly(rC)-­‐binding	  protein	  
1	  
4	  and	  24	  hour	  
PCK2	   Phosphoenolpyruvate	  carboxykinase	  [GTP],	  mitochondrial	   4	  and	  24	  hour	  
PDHA1	   Pyruvate	  dehydrogenase	  E1	  component	  subunit	  alpha,	  somatic	  form,	  
mitochondrial	  
24	  hour	  
PDHB	   Pyruvate	  dehydrogenase	  E1	  component	  subunit	  beta,	  mitochondrial	   4	  and	  24	  hour	  
PDIA3	   Protein	  disulfide-­‐isomerase	  A3;Thioredoxin	   4	  and	  24	  hour	  
PDIA4	   Protein	  disulfide-­‐isomerase	  A4	   24	  hour	  
PDIA6	   Protein	  disulfide-­‐isomerase	  A6	   4	  and	  24	  hour	  
PELI1	   E3	  ubiquitin-­‐protein	  ligase	  pellino	  homolog	  1	   4	  and	  24	  hour	  
PGK1	   Phosphoglycerate	  kinase	  1;Phosphoglycerate	  kinase	   4	  and	  24	  hour	  
PHB	   Prohibitin	   4	  and	  24	  hour	  
PHB2	   Prohibitin-­‐2	   24	  hour	  
PKM2	   Pyruvate	  kinase	  isozymes	  M1/M2;Pyruvate	  kinase	   4	  and	  24	  hour	  
PKP1	   Plakophilin-­‐1	   4	  and	  24	  hour	  
PKP3	   Plakophilin-­‐3	   4	  hour	  
PLAA	   Phospholipase	  A-­‐2-­‐activating	  protein	   4	  hour	  
PLEC	   Plectin	   4	  hour	  
PLG	   Plasminogen;Plasmin	  heavy	  chain	  A;Activation	  peptide;Angiostatin;Plasmin	  
heavy	  chain	  A,	  short	  form;Plasmin	  light	  chain	  B	  
24	  hour	  
PLOD2	   Procollagen-­‐lysine,2-­‐oxoglutarate	  5-­‐dioxygenase	  2	   24	  hour	  
POF1B	   Protein	  POF1B	   4	  and	  24	  hour	  
PPA2	   Inorganic	  pyrophosphatase	  2,	  mitochondrial	   24	  hour	  
PPIB	   Peptidyl-­‐prolyl	  cis-­‐trans	  isomerase	  B	   4	  and	  24	  hour	  
PRDX1;PRDX4	   Peroxiredoxin-­‐1;Peroxiredoxin-­‐4	   4	  and	  24	  hour	  
PRDX2	   Peroxiredoxin-­‐2	   4	  hour	  
PRDX3	   Thioredoxin-­‐dependent	  peroxide	  reductase,	  mitochondrial	   24	  hour	  
PRDX4	   Peroxiredoxin-­‐4	   24	  hour	  
PRKDC	   DNA-­‐dependent	  protein	  kinase	  catalytic	  subunit	   24	  hour	  
PRPF40A	   Pre-­‐mRNA-­‐processing	  factor	  40	  homolog	  A	   24	  hour	  
PRSS3	   Trypsin-­‐3	   4	  and	  24	  hour	  
PSMB5	   Proteasome	  subunit	  beta	  type-­‐5	   24	  hour	  
PSMC1	   26S	  protease	  regulatory	  subunit	  4	   24	  hour	  
PTBP3;PTBP1	   Polypyrimidine	  tract-­‐binding	  protein	  3;Polypyrimidine	  tract-­‐binding	  protein	  1	   24	  hour	  
PTCD1;ATP5J2	   ATP	  synthase	  subunit	  f,	  mitochondrial	   4	  hour	  
PUF60	   Poly(U)-­‐binding-­‐splicing	  factor	  PUF60	   4	  and	  24	  hour	  
PYGL	   Glycogen	  phosphorylase,	  liver	  form	   4	  hour	  
PZP	   Pregnancy	  zone	  protein	   4	  and	  24	  hour	  
RAB10	   Ras-­‐related	  protein	  Rab-­‐10	   4	  and	  24	  hour	  
RAB11B;RAB11A	   Ras-­‐related	  protein	  Rab-­‐11B;Ras-­‐related	  protein	  Rab-­‐11A	   4	  and	  24	  hour	  
RAB14	   Ras-­‐related	  protein	  Rab-­‐14	   4	  and	  24	  hour	  
RAB1A;RAB1C;RAB1B	   Ras-­‐related	  protein	  Rab-­‐1A;Putative	  Ras-­‐related	  protein	  Rab-­‐1C;Ras-­‐related	  
protein	  Rab-­‐1B	  
4	  and	  24	  hour	  
RAB21	   Ras-­‐related	  protein	  Rab-­‐21	   4	  and	  24	  hour	  
RAB2A;RAB2B	   Ras-­‐related	  protein	  Rab-­‐2A;Ras-­‐related	  protein	  Rab-­‐2B	   4	  and	  24	  hour	  
RAB5B;RAB5A	   Ras-­‐related	  protein	  Rab-­‐5B;Ras-­‐related	  protein	  Rab-­‐5A	   24	  hour	  
RAB5C	   Ras-­‐related	  protein	  Rab-­‐5C	   4	  and	  24	  hour	  
RAB6A	   Ras-­‐related	  protein	  Rab-­‐6A	   24	  hour	  
RAB7A	   Ras-­‐related	  protein	  Rab-­‐7a	   4	  and	  24	  hour	  
RAB8A	   Ras-­‐related	  protein	  Rab-­‐8A	   24	  hour	  
RAC2;RAC3;RAC1	   Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  2;Ras-­‐related	  C3	  botulinum	  toxin	  
substrate	  3;Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  1	  
24	  hour	  
RALY	   RNA-­‐binding	  protein	  Raly	   4	  hour	  
RAP1B;RAP1A	   Ras-­‐related	  protein	  Rap-­‐1b;Ras-­‐related	  protein	  Rap-­‐1A	   24	  hour	  
RAP2C;RAP2A;RAP2B	   Ras-­‐related	  protein	  Rap-­‐2c;Ras-­‐related	  protein	  Rap-­‐2a;Ras-­‐related	  protein	  
Rap-­‐2b	  
24	  hour	  
RBM14	   RNA-­‐binding	  protein	  14	   4	  and	  24	  hour	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RBM25	   RNA-­‐binding	  protein	  25	   4	  hour	  
RBM39	   RNA-­‐binding	  protein	  39	   4	  and	  24	  hour	  
RDH11	   Retinol	  dehydrogenase	  11	   24	  hour	  
RER1	   Protein	  RER1	   24	  hour	  
RG9MTD1	   Mitochondrial	  ribonuclease	  P	  protein	  1	   24	  hour	  
RHOA;RHOC	   Transforming	  protein	  RhoA;Rho-­‐related	  GTP-­‐binding	  protein	  RhoC	   24	  hour	  
RHOC;RHOA	   Rho-­‐related	  GTP-­‐binding	  protein	  RhoC;Transforming	  protein	  RhoA	   4	  hour	  
RPL11	   60S	  ribosomal	  protein	  L11	   4	  and	  24	  hour	  
RPL12	   60S	  ribosomal	  protein	  L12	   4	  and	  24	  hour	  
RPL13	   60S	  ribosomal	  protein	  L13	   4	  and	  24	  hour	  
RPL14	   60S	  ribosomal	  protein	  L14	   4	  and	  24	  hour	  
RPL18	   60S	  ribosomal	  protein	  L18	   24	  hour	  
RPL18A	   60S	  ribosomal	  protein	  L18a	   4	  and	  24	  hour	  
RPL21	   60S	  ribosomal	  protein	  L21	   4	  and	  24	  hour	  
RPL23	   60S	  ribosomal	  protein	  L23	   4	  hour	  
RPL24	   60S	  ribosomal	  protein	  L24	   4	  hour	  
RPL26;RPL26L1	   60S	  ribosomal	  protein	  L26;60S	  ribosomal	  protein	  L26-­‐like	  1	   4	  and	  24	  hour	  
RPL27	   60S	  ribosomal	  protein	  L27	   4	  hour	  
RPL27A	   60S	  ribosomal	  protein	  L27a	   4	  and	  24	  hour	  
RPL28	   60S	  ribosomal	  protein	  L28	   4	  and	  24	  hour	  
RPL29	   60S	  ribosomal	  protein	  L29	   4	  and	  24	  hour	  
RPL3	   60S	  ribosomal	  protein	  L3	   4	  and	  24	  hour	  
RPL30	   60S	  ribosomal	  protein	  L30	   4	  hour	  
RPL34	   60S	  ribosomal	  protein	  L34	   4	  hour	  
RPL35	   60S	  ribosomal	  protein	  L35	   4	  and	  24	  hour	  
RPL35A	   60S	  ribosomal	  protein	  L35a	   4	  and	  24	  hour	  
RPL36AL;RPL36A	   60S	  ribosomal	  protein	  L36a-­‐like;60S	  ribosomal	  protein	  L36a	   4	  hour	  
RPL37A;RPL37L	   60S	  ribosomal	  protein	  L37a;Putative	  60S	  ribosomal	  protein	  L37a-­‐like	   4	  hour	  
RPL38	   60S	  ribosomal	  protein	  L38	   4	  and	  24	  hour	  
RPL4	   60S	  ribosomal	  protein	  L4	   4	  and	  24	  hour	  
RPL7	   60S	  ribosomal	  protein	  L7	   4	  and	  24	  hour	  
RPL8	   60S	  ribosomal	  protein	  L8	   4	  hour	  
RPL9	   60S	  ribosomal	  protein	  L9	   4	  and	  24	  hour	  
RPLP0;RPLP0P6	   60S	  acidic	  ribosomal	  protein	  P0;60S	  acidic	  ribosomal	  protein	  P0-­‐like	   4	  and	  24	  hour	  
RPN1	   Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  1	   4	  and	  24	  hour	  
RPN2	   Dolichyl-­‐diphosphooligosaccharide-­‐-­‐protein	  glycosyltransferase	  subunit	  2	   4	  and	  24	  hour	  
RPRD2	   Regulation	  of	  nuclear	  pre-­‐mRNA	  domain-­‐containing	  protein	  2	   24	  hour	  
RPS13	   40S	  ribosomal	  protein	  S13	   4	  and	  24	  hour	  
RPS14	   40S	  ribosomal	  protein	  S14	   4	  and	  24	  hour	  
RPS16	   40S	  ribosomal	  protein	  S16	   4	  and	  24	  hour	  
RPS18	   40S	  ribosomal	  protein	  S18	   4	  and	  24	  hour	  
RPS19	   40S	  ribosomal	  protein	  S19	   4	  hour	  
RPS19BP1	   Active	  regulator	  of	  SIRT1	   24	  hour	  
RPS20	   40S	  ribosomal	  protein	  S20	   4	  and	  24	  hour	  
RPS23	   40S	  ribosomal	  protein	  S23	   4	  and	  24	  hour	  
RPS25	   40S	  ribosomal	  protein	  S25	   24	  hour	  
RPS3	   40S	  ribosomal	  protein	  S3	   24	  hour	  
RPS4X;RPS4Y1	   40S	  ribosomal	  protein	  S4,	  X	  isoform;40S	  ribosomal	  protein	  S4,	  Y	  isoform	  1	   4	  and	  24	  hour	  
RPS8	   40S	  ribosomal	  protein	  S8	   4	  hour	  
RPS9	   40S	  ribosomal	  protein	  S9	   4	  and	  24	  hour	  
RPSAP58;RPSA	   40S	  ribosomal	  protein	  SA	   24	  hour	  
RRP1B	   Ribosomal	  RNA	  processing	  protein	  1	  homolog	  B	   24	  hour	  
RTN4	   Reticulon-­‐4	   4	  and	  24	  hour	  
RYK	   Tyrosine-­‐protein	  kinase	  RYK	   24	  hour	  
S100A14	   Protein	  S100-­‐A14	   24	  hour	  
S100A16	   Protein	  S100-­‐A16	   24	  hour	  
S100A7	   Protein	  S100-­‐A7	   4	  hour	  
S100A9	   Protein	  S100-­‐A9	   4	  hour	  
SBSN	   Suprabasin	   4	  and	  24	  hour	  
SCAMP3	   Secretory	  carrier-­‐associated	  membrane	  protein	  3	   24	  hour	  
SCP2	   Non-­‐specific	  lipid-­‐transfer	  protein	   24	  hour	  
SEC61B	   Protein	  transport	  protein	  Sec61	  subunit	  beta	   24	  hour	  
SEMG2;SEMG1	   Semenogelin-­‐2;Semenogelin-­‐1;Alpha-­‐inhibin-­‐92;Alpha-­‐inhibin-­‐31;Seminal	   4	  hour	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basic	  protein	  
SERPINA7	   Thyroxine-­‐binding	  globulin	   4	  and	  24	  hour	  
SERPINB12	   Serpin	  B12	   4	  and	  24	  hour	  
SERPINB3;SERPINB4	   Serpin	  B3;Serpin	  B4	   4	  and	  24	  hour	  
SERPINC1	   Antithrombin-­‐III	   4	  hour	  
SERPINF1	   Pigment	  epithelium-­‐derived	  factor	   4	  and	  24	  hour	  
SERPINF2	   Alpha-­‐2-­‐antiplasmin	   4	  hour	  
SERPINH1	   Serpin	  H1	   4	  and	  24	  hour	  
SF3B3	   Splicing	  factor	  3B	  subunit	  3	   	  
SFPQ	   Splicing	  factor,	  proline-­‐	  and	  glutamine-­‐rich	   4	  and	  24	  hour	  
SFXN1	   Sideroflexin-­‐1	   4	  and	  24	  hour	  
SHMT2	   Serine	  hydroxymethyltransferase,	  mitochondrial;Serine	  
hydroxymethyltransferase	  
24	  hour	  
SLC16A1	   Monocarboxylate	  transporter	  1	   24	  hour	  
SLC16A3	   Monocarboxylate	  transporter	  4	   24	  hour	  
SLC25A1	   Tricarboxylate	  transport	  protein,	  mitochondrial	   4	  and	  24	  hour	  
SLC25A11	   Mitochondrial	  2-­‐oxoglutarate/malate	  carrier	  protein	   4	  and	  24	  hour	  
SLC25A13;SLC25A12	   Calcium-­‐binding	  mitochondrial	  carrier	  protein	  Aralar2;Calcium-­‐binding	  
mitochondrial	  carrier	  protein	  Aralar1	  
24	  hour	  
SLC25A24	   Calcium-­‐binding	  mitochondrial	  carrier	  protein	  SCaMC-­‐1	   24	  hour	  
SLC25A3	   Phosphate	  carrier	  protein,	  mitochondrial	   4	  and	  24	  hour	  
SLC25A5	   ADP/ATP	  translocase	  2	   4	  and	  24	  hour	  
SLC25A6;SLC25A4	   ADP/ATP	  translocase	  3;ADP/ATP	  translocase	  1	   4	  and	  24	  hour	  
SLC2A1	   Solute	  carrier	  family	  2,	  facilitated	  glucose	  transporter	  member	  1	   4	  and	  24	  hour	  
SLC35E1	   Solute	  carrier	  family	  35	  member	  E1	   24	  hour	  
SLC3A2	   4F2	  cell-­‐surface	  antigen	  heavy	  chain	   4	  and	  24	  hour	  
SLC7A5	   Large	  neutral	  amino	  acids	  transporter	  small	  subunit	  1	   4	  and	  24	  hour	  
SNRPD1	   Small	  nuclear	  ribonucleoprotein	  Sm	  D1	   4	  hour	  
SNRPD2	   Small	  nuclear	  ribonucleoprotein	  Sm	  D2	   24	  hour	  
SOD2	   Superoxide	  dismutase	  [Mn],	  mitochondrial;Superoxide	  dismutase	   24	  hour	  
SPAG17	   Sperm-­‐associated	  antigen	  17	   4	  hour	  
SPRR3	   Small	  proline-­‐rich	  protein	  3	   4	  hour	  
SQRDL	   Sulfide:quinone	  oxidoreductase,	  mitochondrial	   4	  and	  24	  hour	  
SQSTM1	   Sequestosome-­‐1	   4	  hour	  
SRRM1	   Serine/arginine	  repetitive	  matrix	  protein	  1	   4	  hour	  
SSR4	   Translocon-­‐associated	  protein	  subunit	  delta	   24	  hour	  
SRSF4;SRSF6;SRSF5	   Serine/arginine-­‐rich	  splicing	  factor	  4;Serine/arginine-­‐rich	  splicing	  factor	  
6;Serine/arginine-­‐rich	  splicing	  factor	  5	  
4	  hour	  
STOM	   Erythrocyte	  band	  7	  integral	  membrane	  protein	   4	  and	  24	  hour	  
SUCLA2	   Succinyl-­‐CoA	  ligase	  [ADP-­‐forming]	  subunit	  beta,	  mitochondrial	   24	  hour	  
SUCLG1	   Succinyl-­‐CoA	  ligase	  [ADP/GDP-­‐forming]	  subunit	  alpha,	  mitochondrial	   24	  hour	  
TAP1	   Antigen	  peptide	  transporter	  1	   24	  hour	  
TAP2	   Antigen	  peptide	  transporter	  2	   24	  hour	  
TARDBP	   TAR	  DNA-­‐binding	  protein	  43	   24	  hour	  
TAX1BP1	   Tax1-­‐binding	  protein	  1	   4	  hour	  
TBRG4	   Protein	  TBRG4	   24	  hour	  
TCOF1	   Treacle	  protein	   4	  hour	  
TENC1	   Tensin-­‐like	  C1	  domain-­‐containing	  phosphatase	   4	  and	  24	  hour	  
TF	   Serotransferrin	   	  
TGM1	   Protein-­‐glutamine	  gamma-­‐glutamyltransferase	  K	   24	  hour	  
TGM3	   Protein-­‐glutamine	  gamma-­‐glutamyltransferase	  E;Protein-­‐glutamine	  gamma-­‐
glutamyltransferase	  E	  50	  kDa	  catalytic	  chain;Protein-­‐glutamine	  gamma-­‐
glutamyltransferase	  E	  27	  kDa	  non-­‐catalytic	  chain	  
4	  and	  24	  hour	  
THBS1	   Thrombospondin-­‐1	   4	  and	  24	  hour	  
THRAP3	   Thyroid	  hormone	  receptor-­‐associated	  protein	  3	   24	  hour	  
TICAM1	   TIR	  domain-­‐containing	  adapter	  molecule	  1	   4	  hour	  
TIMM50	   Mitochondrial	  import	  inner	  membrane	  translocase	  subunit	  TIM50	   24	  hour	  
TM9SF1;CHMP4A	   Charged	  multivesicular	  body	  protein	  4a	   4	  hour	  
TM9SF3	   Transmembrane	  9	  superfamily	  member	  3	   24	  hour	  
TMED10	   Transmembrane	  emp24	  domain-­‐containing	  protein	  10	   4	  hour	  
TMED2	   Transmembrane	  emp24	  domain-­‐containing	  protein	  2	   24	  hour	  
TMEM165	   Transmembrane	  protein	  165	   24	  hour	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TMEM33	   Transmembrane	  protein	  33	   24	  hour	  
TMF1	   TATA	  element	  modulatory	  factor	   24	  hour	  
TNFAIP3	   Tumor	  necrosis	  factor	  alpha-­‐induced	  protein	  3	   4	  and	  24	  hour	  
TNIP1	   TNFAIP3-­‐interacting	  protein	  1	   4	  and	  24	  hour	  
TOMM40	   Mitochondrial	  import	  receptor	  subunit	  TOM40	  homolog	   24	  hour	  
TOR1AIP1	   Torsin-­‐1A-­‐interacting	  protein	  1	   24	  hour	  
TPI1	   Triosephosphate	  isomerase	   4	  and	  24	  hour	  
TRAP1	   Heat	  shock	  protein	  75	  kDa,	  mitochondrial	   24	  hour	  
TREX1	   Three	  prime	  repair	  exonuclease	  1	   24	  hour	  
TRIM21	   E3	  ubiquitin-­‐protein	  ligase	  TRIM21	   24	  hour	  
TRIM39;TRIM39R	   Tripartite	  motif-­‐containing	  protein	  39	   24	  hour	  
TRIM65	   Tripartite	  motif-­‐containing	  protein	  65	   4	  hour	  
TRY6;PRSS1;PRSS2	   Putative	  trypsin-­‐6;Trypsin-­‐1;Alpha-­‐trypsin	  chain	  1;Alpha-­‐trypsin	  chain	  
2;Trypsin-­‐2	  
4	  hour	  
TUBA1B;TUBA4A	   Tubulin	  alpha-­‐1B	  chain;Tubulin	  alpha-­‐4A	  chain	   4	  and	  24	  hour	  
TUBB;TUBB4B;TUBB2A;TUBB
2B;TUBB3	  
Tubulin	  beta	  chain;Tubulin	  beta-­‐4B	  chain;Tubulin	  beta-­‐2A	  chain;Tubulin	  
beta-­‐2B	  chain;Tubulin	  beta-­‐3	  chain	  
4	  and	  24	  hour	  
TUFM	   Elongation	  factor	  Tu,	  mitochondrial	   4	  and	  24	  hour	  
U2AF1	   Splicing	  factor	  U2AF	  35	  kDa	  subunit	   4	  and	  24	  hour	  
U2AF2	   Splicing	  factor	  U2AF	  65	  kDa	  subunit	   4	  hour	  
UBA52	   Ubiquitin-­‐60S	  ribosomal	  protein	  L40;Ubiquitin;60S	  ribosomal	  protein	  L40	   4	  hour	  
UBC;UBB;RPS27A;UBA52	   Polyubiquitin-­‐C;Ubiquitin;Polyubiquitin-­‐B;Ubiquitin;Ubiquitin-­‐40S	  ribosomal	  
protein	  S27a;Ubiquitin;40S	  ribosomal	  protein	  S27a;Ubiquitin-­‐60S	  ribosomal	  
protein	  L40;Ubiquitin;60S	  ribosomal	  protein	  L40	  
24	  hour	  
UBE3B	   Ubiquitin-­‐protein	  ligase	  E3B	   24	  hour	  
UQCRC1	   Cytochrome	  b-­‐c1	  complex	  subunit	  1,	  mitochondrial	   24	  hour	  
UQCRC2	   Cytochrome	  b-­‐c1	  complex	  subunit	  2,	  mitochondrial	   4	  and	  24	  hour	  
VANGL1	   Vang-­‐like	  protein	  1	   4	  hour	  
VDAC1	   Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  1	   4	  and	  24	  hour	  
VDAC2	   Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  2	   4	  and	  24	  hour	  
VDAC3	   Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  3	   4	  and	  24	  hour	  
VIM	   Vimentin	   4	  hour	  
VTN	   Vitronectin;Vitronectin	  V65	  subunit;Vitronectin	  V10	  subunit;Somatomedin-­‐B	   4	  and	  24	  hour	  
XP32	   Skin-­‐specific	  protein	  32	   4	  hour	  
YBX1	   Nuclease-­‐sensitive	  element-­‐binding	  protein	  1	   24	  hour	  
YIF1A	   Protein	  YIF1A	   24	  hour	  
YWHAZ;YWHAE;SFN;YWHAG;
YWHAB;YWHAH;YWHAQ	  
14-­‐3-­‐3	  protein	  zeta/delta;14-­‐3-­‐3	  protein	  epsilon;14-­‐3-­‐3	  protein	  sigma;14-­‐3-­‐3	  
protein	  gamma;14-­‐3-­‐3	  protein	  gamma,	  N-­‐terminally	  processed;14-­‐3-­‐3	  
protein	  beta/alpha;14-­‐3-­‐3	  protein	  beta/alpha,	  N-­‐terminally	  processed;14-­‐3-­‐3	  
protein	  eta;14-­‐3-­‐3	  protein	  theta	  
4	  and	  24	  hour	  
ZNF280A	   Zinc	  finger	  protein	  280A	   4	  hour	  
ZNF355P	   Putative	  zinc	  finger	  protein	  355P	   4	  hour	  
	   Ig	  kappa	  chain	  V-­‐III	  region	  HAH;Ig	  kappa	  chain	  V-­‐III	  region	  HIC;Ig	  kappa	  chain	  
V-­‐III	  region	  SIE;Ig	  kappa	  chain	  V-­‐III	  region	  Ti;Ig	  kappa	  chain	  V-­‐III	  region	  
WOL;Ig	  kappa	  chain	  V-­‐III	  region	  GOL	  
24	  hour	  
	   Ig	  heavy	  chain	  V-­‐II	  region	  OU	   4	  and	  24	  hour	  
	   Ig	  kappa	  chain	  V-­‐II	  region	  RPMI	  6410;Ig	  kappa	  chain	  V-­‐II	  region	  GM607;Ig	  
kappa	  chain	  V-­‐II	  region	  Cum;Ig	  kappa	  chain	  V-­‐II	  region	  TEW	  
4	  hour	  
	   Ig	  kappa	  chain	  V-­‐III	  region	  HAH;Ig	  kappa	  chain	  V-­‐III	  region	  WOL;Ig	  kappa	  
chain	  V-­‐I	  region	  AG;Ig	  kappa	  chain	  V-­‐I	  region	  Ka	  
4	  hour	  
	   Ig	  kappa	  chain	  V-­‐III	  region	  NG9	   4	  and	  24	  hour	  
	  	   Ig	  kappa	  chain	  V-­‐II	  region	  RPMI	  6410;Ig	  kappa	  chain	  V-­‐II	  region	  GM607;Ig	  
kappa	  chain	  V-­‐II	  region	  Cum;Ig	  kappa	  chain	  V-­‐II	  region	  TEW	  
24	  hour	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